



Uploading 11.str



chain nodes :

19 20 21 22 23 24 25 26 28

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

chain bonds :

1-23 10-22 13-28 14-21 16-19 17-24 18-20 24-25 24-26

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 8-11 9-10 9-14 11-12 12-13
12-15 13-14 13-18 15-16 16-17 17-18

exact/norm bonds :



1-2 1-6 1-23 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 8-11 9-10 9-14 10-22
11-12 12-13 12-15 13-14 13-18 13-28 14-21 15-16 16-17 16-19 17-18 17-24
18-20 24-25
24-26

G1:C,O,S,N

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:CLASS
20:CLASS 21:CLASS
22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS 28:CLASS

Uploading 15.str



10692764

chain nodes :

19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

chain bonds :

1-23 4-31 10-22 13-27 14-21 15-28 16-19 17-24 18-20 24-25 24-26 28-29
28-30 31-32 32-33

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 8-11 9-10 9-14 11-12 12-13
12-15 13-14 13-18 15-16 16-17 17-18

exact/norm bonds :

1-23 4-31 5-7 6-10 7-8 8-9 8-11 9-10 9-14 10-22 11-12 12-13 12-15 13-14

13-18 13-27 14-21 15-16 15-28 16-17 16-19 17-18 18-20 24-25 24-26 28-29
28-30 31-32

32-33

exact bonds :

17-24

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom

11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:CLASS


20:CLASS 21:CLASS

22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS 27:CLASS 28:CLASS 29:CLASS

30:CLASS 31:CLASS

32:CLASS 33:CLASS

Uploading 18.str



chain nodes :

19 20 21 22 23 24 25 26 27 28 29 30 31 32

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

chain bonds :

1-23 7-31 7-32 10-22 13-27 14-21 15-28 16-19 17-24 18-20 24-25 24-26
28-29 28-30

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 8-11 9-10 9-14 11-12 12-13
12-15 13-14 13-18 15-16 16-17 17-18

exact/norm bonds :

10692764

1-23 5-7 6-10 7-8 7-31 7-32 8-9 8-11 9-10 9-14 10-22 11-12 12-13 12-15
13-14 13-18 13-27 14-21 15-16 15-28 16-17 16-19 17-18 18-20 24-25 24-26
28-29 28-30

exact bonds :

17-24


normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:CLASS
20:CLASS 21:CLASS
22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS 27:CLASS 28:CLASS 29:CLASS
30:CLASS 31:CLASS
32:CLASS

Uploading l26.str



chain nodes :

19 20 21 22 23 24 25 26 27 28 29 30 31 32

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

chain bonds :

1-23 7-31 7-32 10-22 13-27 14-21 15-28 16-19 17-24 18-20 24-25 24-26
28-29 28-30

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 8-11 9-10 9-14 11-12 12-13
12-15 13-14 13-18 15-16 16-17 17-18

exact/norm bonds :

1-23 5-7 6-10 7-8 7-31 8-9 8-11 9-10 9-14 10-22 11-12 12-13 12-15 13-14
13-18 13-27 14-21 15-16 15-28 16-17 16-19 17-18 18-20 24-25 24-26

exact bonds :

7-32 17-24 28-29 28-30

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:CLASS


10692764

20:CLASS 21:CLASS
22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS 27:CLASS 28:CLASS 29:CLASS
30:CLASS 31:CLASS
32:CLASS

*****INVENTOR RESULTS *****

=> d que 195

L1 STR




G1 C,O,S,N

Structure attributes must be viewed using STN Express query preparation.

L3 9270 SEA FILE=REGISTRY SSS FUL L1


L5 STR



Structure attributes must be viewed using STN Express query preparation.


L7 66 SEA FILE=REGISTRY SUB=L3 SSS FUL L5

L8 STR



Structure attributes must be viewed using STN Express query preparation.

L10	1047	SEA FILE=REGISTRY SUB=L3	SSS FUL L8	
L11	18	SEA FILE=HCAPLUS ABB=ON	PLU=ON L7	
L12	14	SEA FILE=HCAPLUS ABB=ON	PLU=ON L11 AND (AY<2003 OR PY<2003 OR PRY<2003)	
L13	28687	SEA FILE=HCAPLUS ABB=ON	PLU=ON L10	
L14	1	SEA FILE=HCAPLUS ABB=ON	PLU=ON L12 AND ((RNA OR RIBONUCLEIC ACID?) (L) (MODULAT?))	
L15	1	SEA FILE=HCAPLUS ABB=ON	PLU=ON L12 AND (RNA OR RIBONUCLEIC ACID?)	
L16	1	SEA FILE=HCAPLUS ABB=ON	PLU=ON (L14 OR L15)	
L17	14	SEA FILE=HCAPLUS ABB=ON	PLU=ON (L12 OR L16)	
L18	15	SEA FILE=HCAPLUS ABB=ON	PLU=ON L7 (L) (THU OR PKT OR PAC OR BAC OR DMA)/RL	
L19	13	SEA FILE=HCAPLUS ABB=ON	PLU=ON L18 AND (AY<2003 OR PY<2003 OR PRY<2003)	
L20	14	SEA FILE=HCAPLUS ABB=ON	PLU=ON (L17 OR L19)	
L21	18	SEA FILE=HCAPLUS ABB=ON	PLU=ON L13 AND ((RNA OR RIBONUCLEIC ACID?) (L) (MODULAT?))	
L22	7	SEA FILE=HCAPLUS ABB=ON	PLU=ON L21 AND (AY<2003 OR PY<2003 OR PRY<2003)	
L26		STR		



Structure attributes must be viewed using STN Express query preparation.

L28	493	SEA FILE=REGISTRY SUB=L3	SSS FUL L26	
L30	5922	SEA FILE=HCAPLUS ABB=ON	PLU=ON L28 (L) (THU OR PKT OR PAC OR	

		BAC OR DMA)/RL		
L31	3	SEA FILE=HCAPLUS ABB=ON	PLU=ON	L30 AND ((RNA OR RIBONUCLEIC ACID?) (L) (MODULAT?))
L32	155	SEA FILE=HCAPLUS ABB=ON	PLU=ON	L30 AND (RNA OR RIBONUCLEIC ACID?)
L33	116	SEA FILE=HCAPLUS ABB=ON	PLU=ON	L32 AND (AY<2003 OR PY<2003 OR PRY<2003)
L34	7	SEA FILE=HCAPLUS ABB=ON	PLU=ON	(L22 OR L31)
L35	22	SEA FILE=HCAPLUS ABB=ON	PLU=ON	L33 AND (?DISEASE? OR ?DISORDER? OR ?INFECTION? OR ?DYSFUNCTION?)
L36	28	SEA FILE=HCAPLUS ABB=ON	PLU=ON	(L34 OR L35)
L37	28	SEA FILE=HCAPLUS ABB=ON	PLU=ON	(L36 OR L22)
L38	5	SEA FILE=HCAPLUS ABB=ON	PLU=ON	DTMR
L39	9535	SEA FILE=HCAPLUS ABB=ON	PLU=ON	"NERVOUS SYSTEM, DISEASE (L) DEGENERATION"+OLD/CT
L40	54794	SEA FILE=HCAPLUS ABB=ON	PLU=ON	"HUMAN IMMUNODEFICIENCY VIRUS"+OLD,NT/CT
L41	44073	SEA FILE=HCAPLUS ABB=ON	PLU=ON	"HUMAN IMMUNODEFICIENCY VIRUS 1"+OLD/CT
L42	20700	SEA FILE=HCAPLUS ABB=ON	PLU=ON	"AIDS (DISEASE)" +OLD/CT
L43	885	SEA FILE=HCAPLUS ABB=ON	PLU=ON	"WEST NILE VIRUS"+OLD/CT
L44	271	SEA FILE=HCAPLUS ABB=ON	PLU=ON	"POTATO LEAFROLL VIRUS"+OLD/CT
L45	13196	SEA FILE=HCAPLUS ABB=ON	PLU=ON	"INFLUENZA VIRUS"+OLD,NT/CT
L46	5	SEA FILE=HCAPLUS ABB=ON	PLU=ON	"INFECTION (L) MENINGOPNEUMONITIS"+OLD/CT
L47	5	SEA FILE=HCAPLUS ABB=ON	PLU=ON	"LUNG, DISEASE (L) MENINGOPNEUMONITIS"+OLD/CT
L48	1669	SEA FILE=HCAPLUS ABB=ON	PLU=ON	"RABIES VIRUS"+OLD/CT
L49	87393	SEA FILE=HCAPLUS ABB=ON	PLU=ON	(L38 OR L39 OR L40 OR L41 OR L42 OR L43 OR L44 OR L45 OR L46 OR L47 OR L48)
L50	25	SEA FILE=HCAPLUS ABB=ON	PLU=ON	L33 AND (CANCER? OR TUMOR? OR TUMOUR? OR LEUKEMIA? OR SARCOMA? OR MYELOMA? OR MELANOMA? OR ASTHMA? OR ARTHRITIS? OR ANEMIA? OR ALZHEIMER? OR HUNTINGTON? OR OARTIC ANEURYSM? OR DIABETES? OR ISCHEMIA? OR HYPERLIPIDEMIA ? OR OBESITY?)
L51	10	SEA FILE=HCAPLUS ABB=ON	PLU=ON	L33 AND L49
L52	26	SEA FILE=HCAPLUS ABB=ON	PLU=ON	(L50 OR L51)
L53	39	SEA FILE=HCAPLUS ABB=ON	PLU=ON	(L52 OR L37)
L54	6	SEA FILE=HCAPLUS ABB=ON	PLU=ON	L20 AND (CANCER? OR TUMOR? OR TUMOUR? OR LEUKEMIA? OR SARCOMA? OR MYELOMA? OR MELANOMA? OR ASTHMA? OR ARTHRITIS? OR ANEMIA? OR ALZHEIMER? OR HUNTINGTON? OR OARTIC ANEURYSM? OR DIABETES? OR ISCHEMIA? OR HYPERLIPIDEMIA ? OR OBESITY?)
L55	2	SEA FILE=HCAPLUS ABB=ON	PLU=ON	L20 AND L49
L56	14	SEA FILE=HCAPLUS ABB=ON	PLU=ON	(L54 OR L55 OR L20)
L57	9813	SEA FILE=HCAPLUS ABB=ON	PLU=ON	L3 (L) (THU OR PKT OR PAC OR BAC OR DMA)/RL
L58	951	SEA FILE=HCAPLUS ABB=ON	PLU=ON	L57 AND (CANCER? OR TUMOR? OR TUMOUR? OR LEUKEMIA? OR SARCOMA? OR MYELOMA? OR MELANOMA? OR ASTHMA? OR ARTHRITIS? OR ANEMIA? OR ALZHEIMER? OR HUNTINGTON? OR OARTIC ANEURYSM? OR DIABETES? OR ISCHEMIA? OR HYPERLIPIDEMIA ? OR OBESITY?)
L59	155	SEA FILE=HCAPLUS ABB=ON	PLU=ON	L57 AND L49
L60	93	SEA FILE=HCAPLUS ABB=ON	PLU=ON	L58 AND L59
L61	57	SEA FILE=HCAPLUS ABB=ON	PLU=ON	L60 AND (AY<2003 OR PY<2003 OR PRY<2003)
L64	9	SEA FILE=HCAPLUS ABB=ON	PLU=ON	L53 AND L61
L65	30	SEA FILE=HCAPLUS ABB=ON	PLU=ON	L53 AND (AY<2002 OR PY<2002 OR PRY<2002)

L66 6 SEA FILE=HCAPLUS ABB=ON PLU=ON L65 AND L61
 L67 7 SEA FILE=HCAPLUS ABB=ON PLU=ON L65 AND L49
 L68 7 SEA FILE=HCAPLUS ABB=ON PLU=ON (L66 OR L67)
 L69 10 SEA FILE=HCAPLUS ABB=ON PLU=ON (L64 OR L68)
 L70 17 SEA FILE=HCAPLUS ABB=ON PLU=ON (L34 OR L69)
 L71 25 SEA FILE=HCAPLUS ABB=ON PLU=ON L33 AND (CANCER? OR TUMOR? OR
 TUMOUR? OR LEUKEMIA? OR SARCOMA? OR MYELOMA? OR MELANOMA? OR
 ASTHMA? OR ARTHRITIS? OR ANEMIA? OR ALZHEIMER? OR HUNTINGTON?
 OR OARTIC ANEURYSM? OR DIABETES? OR ISCHEMIA? OR HYPERLIPIDEMIA
 ? OR OBESITY?)
 L72 10 SEA FILE=HCAPLUS ABB=ON PLU=ON L33 AND L49
 L73 26 SEA FILE=HCAPLUS ABB=ON PLU=ON (L71 OR L72)
 L74 33 SEA FILE=HCAPLUS ABB=ON PLU=ON (L70 OR L73)
 L79 33 SEA FILE=HCAPLUS ABB=ON PLU=ON (L31 OR L34 OR L74)
 L80 10 SEA FILE=HCAPLUS ABB=ON PLU=ON L79 AND L49
 L81 26 SEA FILE=HCAPLUS ABB=ON PLU=ON L79 AND (CANCER? OR TUMOR? OR
 TUMOUR? OR LEUKEMIA? OR SARCOMA? OR MYELOMA? OR MELANOMA? OR
 ASTHMA? OR ARTHRITIS? OR ANEMIA? OR ALZHEIMER? OR HUNTINGTON?
 OR OARTIC ANEURYSM? OR DIABETES? OR ISCHEMIA? OR HYPERLIPIDEMIA
 ? OR OBESITY?)
 L82 27 SEA FILE=HCAPLUS ABB=ON PLU=ON (L80 OR L81)
 L83 33 SEA FILE=HCAPLUS ABB=ON PLU=ON (L82 OR L31 OR L34)
 L84 536 SEA FILE=HCAPLUS ABB=ON PLU=ON ("LEVY S"/AU OR "LEVY S B"/AU
 OR "LEVY STUARD B"/AU OR "LEVY STUART"/AU OR "LEVY STUART
 B"/AU)
 L85 93 SEA FILE=HCAPLUS ABB=ON PLU=ON ("DRAPER M"/AU OR "DRAPER M
 A"/AU OR "DRAPER M D"/AU OR "DRAPER M H"/AU OR "DRAPER M P"/AU
 OR "DRAPER M R"/AU OR "DRAPER M S"/AU OR "DRAPER M W"/AU OR
 "DRAPER MICHAEL"/AU OR "DRAPER MICHAEL D"/AU OR "DRAPER
 MICHAEL DAVID"/AU OR "DRAPER MICHAEL L"/AU OR "DRAPER MICHAEL
 P"/AU OR "DRAPER MICHAEL PRESTON"/AU OR "DRAPER MICHAEL W"/AU
 OR "DRAPER MICHAEL WILLIAM"/AU)
 L86 282 SEA FILE=HCAPLUS ABB=ON PLU=ON ("NELSON M"/AU OR "NELSON M
 L"/AU OR "NELSON MARC"/AU OR "NELSON MARK"/AU OR "NELSON MARK
 L"/AU OR "NELSON MARK LESLIE"/AU OR "NELSON MARK LOGE"/AU OR
 "NELSON MARK LOUIS"/AU)
 L87 2640 SEA FILE=HCAPLUS ABB=ON PLU=ON ("JONES FUNIYO ICHII"/AU OR
 "JONES FURMAN M JR"/AU OR "JONES G"/AU OR "JONES G A"/AU OR
 "JONES G A C"/AU OR "JONES G A D"/AU OR "JONES G ALEXANDER"/AU
 OR "JONES G ALUN"/AU OR "JONES G ARNOLD"/AU OR "JONES G B"/AU
 OR "JONES G C"/AU OR "JONES G C H"/AU OR "JONES G C JR"/AU OR
 "JONES G C W"/AU OR "JONES G CARLETON"/AU OR "JONES G CECIL"/AU
 OR "JONES G D"/AU OR "JONES G D D"/AU OR "JONES G D GLYNNE"/AU
 OR "JONES G D O"/AU OR "JONES G DENYS GLYNNE"/AU OR "JONES G
 DOUGLAS"/AU OR "JONES G E"/AU OR "JONES G E G"/AU OR "JONES G
 E JR"/AU OR "JONES G E M"/AU OR "JONES G E S"/AU OR "JONES G E
 SEEGAR"/AU OR "JONES G F"/AU OR "JONES G F C"/AU OR "JONES G
 G"/AU OR "JONES G GARY"/AU OR "JONES G H"/AU OR "JONES G H
 G"/AU OR "JONES G H GETHIN"/AU OR "JONES G H S"/AU OR "JONES G
 HOWARD"/AU OR "JONES G I"/AU OR "JONES G I L"/AU OR "JONES G
 II"/AU OR "JONES G IVOR"/AU OR "JONES G J"/AU OR "JONES G J
 L"/AU OR "JONES G J R"/AU OR "JONES G JR"/AU OR "JONES G K"/AU
 OR "JONES G KEMPSON"/AU OR "JONES G L"/AU OR "JONES G LL"/AU
 OR "JONES G LLOYD"/AU OR "JONES G M"/AU OR "JONES G M D B"/AU
 OR "JONES G M JR"/AU OR "JONES G M M"/AU OR "JONES G M T"/AU
 OR "JONES G M THELWALL"/AU OR "JONES G MARK"/AU OR "JONES G
 MARY"/AU OR "JONES G MELVILL"/AU OR "JONES G NELSON"/AU OR
 "JONES G O"/AU OR "JONES G O L"/AU OR "JONES G P"/AU OR "JONES
 G P D"/AU OR "JONES G P GLYNNE"/AU OR "JONES G PARRY"/AU OR
 "JONES G PAUL"/AU OR "JONES G R"/AU OR "JONES G R D"/AU OR

"JONES G R F"/AU OR "JONES G R H"/AU OR "JONES G R JR"/AU OR
 "JONES G R N"/AU OR "JONES G ROBERT N"/AU OR "JONES G S"/AU OR
 "JONES G S JR"/AU OR "JONES G SANFORD"/AU OR "JONES G SCOTT"/AU
 OR "JONES G T"/AU OR "JONES G V"/AU OR "JONES G W"/AU OR
 "JONES G WENDELL"/AU)

L88 381 SEA FILE=HCAPLUS ABB=ON PLU=ON ("JONES GRAHAM"/AU OR "JONES
 GRAHAM A"/AU OR "JONES GRAHAM ALFRED"/AU OR "JONES GRAHAM
 ANTHONY"/AU OR "JONES GRAHAM B"/AU OR "JONES GRAHAM C"/AU OR
 "JONES GRAHAM D"/AU OR "JONES GRAHAM E"/AU OR "JONES GRAHAM
 ELGIN"/AU OR "JONES GRAHAM H"/AU OR "JONES GRAHAM HARRIES"/AU
 OR "JONES GRAHAM HOWARD"/AU OR "JONES GRAHAM HUGH"/AU OR
 "JONES GRAHAM J"/AU OR "JONES GRAHAM K"/AU OR "JONES GRAHAM
 L"/AU OR "JONES GRAHAM LLOYD"/AU OR "JONES GRAHAM LONGDEN"/AU
 OR "JONES GRAHAM P"/AU OR "JONES GRAHAM PETER"/AU OR "JONES
 GRAHAM R"/AU OR "JONES GRAHAM R D"/AU OR "JONES GRAHAM
 ROGER"/AU OR "JONES GRAHAM ROSS DALLAS"/AU OR "JONES GRAHAM
 STEWART"/AU OR "JONES GRAHAM TREVOR"/AU)

L89 3 SEA FILE=HCAPLUS ABB=ON PLU=ON L84 AND L85 AND L86 AND (L87
 OR L88)

L90 113 SEA FILE=HCAPLUS ABB=ON PLU=ON (L84 OR L85 OR L86 OR L87 OR
 L88) AND L3

L91 94 SEA FILE=HCAPLUS ABB=ON PLU=ON (L84 OR L85 OR L86 OR L87 OR
 L88) AND (L7 OR L10)

L92 3 SEA FILE=HCAPLUS ABB=ON PLU=ON (L90 OR L91) AND L49

L93 11 SEA FILE=HCAPLUS ABB=ON PLU=ON (L90 OR L91) AND (CANCER? OR
 TUMOR? OR TUMOUR? OR LEUKEMIA? OR SARCOMA? OR MYELOMA? OR
 MELANOMA? OR ASTHMA? OR ARTHRITIS? OR ANEMIA? OR ALZHEIMER? OR
 HUNTINGTON? OR OARTIC ANEURYSM? OR DIABETES? OR ISCHEMIA? OR
 HYPERLIPIDEMIA? OR OBESITY?)

L94 15 SEA FILE=HCAPLUS ABB=ON PLU=ON (L89 OR L92 OR L93)

L95 6 SEA FILE=HCAPLUS ABB=ON PLU=ON L94 NOT (L56 OR L83)

=> d que 1107

L96 6383 SEA LEVY S?/AU

L97 480 SEA DRAPER M?/AU

L98 8358 SEA NELSON M?/AU

L99 16184 SEA JONES G?/AU

L100 7 SEA L96 AND L97 AND L98 AND L99

L102 536 SEA (L96 OR L97 OR L98 OR L99) AND TETRACYCLINE?

L103 40 SEA L102 AND (RNA OR RIBONUCLEIC ACID?)

L104 43 SEA (L100 OR L103) AND (AY<2003 OR PY<2003 OR PRY<2003)

L105 26 DUP REM L104 (17 DUPLICATES REMOVED)

L106 6 SEA L105 AND (CANCER? OR TUMOR? OR TUMOUR? OR LEUKEMIA? OR
 SARCOMA? OR MYELOMA? OR MELANOMA? OR ASTHMA? OR ARTHRITIS? OR
 ANEMIA? OR ALZHEIMER? OR HUNTINGTON? OR OARTIC ANEURYSM? OR
 DIABETES? OR ISCHEMIA? OR HYPERLIPIDEMIA? OR OBESITY? OR
 VIRUS?)

L107 9 SEA (L100 OR L106)

=> dup rem 195,1107

FILE 'HCAPLUS' ENTERED AT 17:03:22 ON 11 APR 2007
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 17:03:22 ON 11 APR 2007
 Copyright (c) 2007 The Thomson Corporation

10692764

FILE 'WPIX' ENTERED AT 17:03:22 ON 11 APR 2007
COPYRIGHT (C) 2007 THE THOMSON CORPORATION
PROCESSING COMPLETED FOR L95
PROCESSING COMPLETED FOR L107
L108 12 DUP REM L95 L107 (3 DUPLICATES REMOVED)
ANSWERS '1-9' FROM FILE HCAPLUS
ANSWERS '10-11' FROM FILE BIOSIS
ANSWER '12' FROM FILE WPIX

=> d ibib abs retable l108 tot

L108 ANSWER 1 OF 12 HCAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 1
ACCESSION NUMBER: 2004:633439 HCAPLUS Full-text
DOCUMENT NUMBER: 141:167771
TITLE: Tetracycline compounds having target therapeutic activities
INVENTOR(S): *Levy, Stuart B.; Draper, Michael; Nelson, Mark L.; Jones, Graham*
PATENT ASSIGNEE(S): Paratek Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 277 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004064728	A2	20040805	WO 2004-US1036	20040116
WO 2004064728	A3	20041216		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI				
US 2006194773	A1	20060831	US 2004-996119	20041122 <--
PRIORITY APPLN. INFO.:			US 2003-441141P	P 20030116
			US 2001-305546P	P 20010713 <--
			US 2002-395741P	P 20020712 <--
			US 2002-196010	A2 20020715 <--
			US 2004-759484	B1 20040116

OTHER SOURCE(S): MARPAT 141:167771
AB Methods and compds. for treating diseases, e.g. inflammation process-associated states, with tetracycline compds. having a target therapeutic activity are described. Preparation of selected tetracycline compds. is described.

L108 ANSWER 2 OF 12 HCAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 2
ACCESSION NUMBER: 2004:371068 HCAPLUS Full-text
DOCUMENT NUMBER: 140:386057
TITLE: Methods of using substituted *tetracycline* compounds to modulate *RNA*, and therapeutic use
INVENTOR(S): *Levy, Stuart B.; Draper, Michael; Jones, Graham; Nelson, Mark L.*
PATENT ASSIGNEE(S): Paratek Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 124 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004038000	A2	20040506	WO 2003-US33926	20031024 <--
WO 2004038000	A3	20041111		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2503446	A1	20040506	CA 2003-2503446	20031024 <--
AU 2003287217	A1	20040513	AU 2003-287217	20031024 <--
US 2004214800	A1	20041028	US 2003-692764	20031024 <--
EP 1562608	A2	20050817	EP 2003-781397	20031024 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006503897	T	20060202	JP 2004-547164	20031024 <--
PRIORITY APPLN. INFO.:			US 2002-421248P	P 20021024 <--
			WO 2003-US33926	W 20031024

OTHER SOURCE(S): MARPAT 140:386057

AB A method for modulating *RNA* with *tetracycline* compds. is described. The invention also discloses a method for treating a subject for a disorder treatable by modulation of *RNA* or by modulation of *RNA* in combination with a second agent. Compound preparation is also described.

L108 ANSWER 3 OF 12 HCAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 3

ACCESSION NUMBER: 2003:57866 HCAPLUS Full-text

DOCUMENT NUMBER: 138:117673

TITLE: Tetracycline compounds having target therapeutic activities

INVENTOR(S): Levy, Stuart B.; Draper, Michael; Nelson, Mark L.; Jones, Graham

PATENT ASSIGNEE(S): Paratek Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 158 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003005971	A2	20030123	WO 2002-US22451	20020715 <--
WO 2003005971	A3	20031127		
WO 2003005971	A8	20040506		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,				

10692764

KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
 FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF,
 CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2002318238 A1 20030129 AU 2002-318238 20020715 <--
 US 2004063674 A1 20040401 US 2002-196010 20020715 <--
 EP 1408987 A2 20040421 EP 2002-748169 20020715 <--

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK


JP 2004537544 T 20041216 JP 2003-511780 20020715 <--
 US 2006194773 A1 20060831 US 2004-996119 20041122 <--

PRIORITY APPLN. INFO.:
 US 2001-305546P P 20010713 <--
 US 2002-395741P P 20020712 <--
 US 2002-196010 A2 20020715 <--
 WO 2002-US22451 W 20020715 <--
 US 2003-441141P P 20030116
 US 2004-759484 B1 20040116

OTHER SOURCE(S): MARPAT 138:117673
 AB Methods and compds. for treating a variety of diseases with tetracycline
 compds. having a target therapeutic activity are described, as is compound
 preparation

L108 ANSWER 4 OF 12 HCAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2006:792973 HCAPLUS Full-text
 DOCUMENT NUMBER: 145:230464
 TITLE: Preparation of 11a,12-derivatives of tetracycline
 compounds
 INVENTOR(S): **Nelson, Mark L.**; Ismail, Mohamed Y.;
 Berniac, Joel
 PATENT ASSIGNEE(S): Paratek Pharmaceuticals, Inc., USA
 SOURCE: PCT Int. Appl., 60pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006084265	A1	20060810	WO 2006-US4233	20060206
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 2006281717	A1	20061214	US 2006-348608	20060206
PRIORITY APPLN. INFO.:			US 2005-650031P	P 20050204
OTHER SOURCE(S):			MARPAT 145:230464	
GI				



I

AB The preparation of 11a,12-dehydrotetracycline compds. I [R1 = H, alkyl, alkenyl, aryl, amido, etc.; R2 = H, alkyl, alkynyl, amino, etc.; R3, R10, R12 = H, alkyl, aryl, CH2Ph, arylalkyl, prodrug moiety; R4, R21 = alkyl, alkenyl, alkynyl, etc.; R5, R22 = OH, H, alkanoyl, alkaroyl, etc.; R7 = H, halo, NO2, alkenyl, etc.; R8 = H, alkylamino, heterocyclyl, acyl, etc.; R9 = H, halo, NO2, alkoxy, etc.; R23, R24 = H, alkyl, alkylthio, aryl, etc.; Q = double bond when R2 and R20 are absent; single bond when R2 and R20 are H, alkyl, halo, aryl, etc.] are described. For example, treating doxycycline with NaBH4 gave 12-dehydrodoxycycline. The compds. are claimed as therapeutic agents treating a variety of conditions including **cancer**, inflammation, and infectious conditions.

RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Ashley, R	2003			US 2003195174 A1	
Ashley, R	2004			US 2004002481 A1	HCAPLUS
Levy, S	2002			US 2002115644 A1	HCAPLUS
Paratek Pharmaceuticals	2004			WO 2004006850 A	HCAPLUS

L108 ANSWER 5 OF 12 HCAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2005:696869 HCAPLUS Full-text

DOCUMENT NUMBER: 143:172684

TITLE: Preparation of aromatic A-ring derivatives of
 tetracycline compounds

INVENTOR(S): **Nelson, Mark L.**

PATENT ASSIGNEE(S): Paratek Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 58 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005070878	A1	20050804	WO 2005-US4793	20050118
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,				
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,				
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,				
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,				
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,				
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,				
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,				
EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,				

10692764

RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
MR, NE, SN, TD, TG

CA 2553510 A1 20050804 CA 2005-2553510 20050118
US 2006003971 A1 20060105 US 2005-39230 20050118
EP 1716101 A1 20061102 EP 2005-723098 20050118


R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK,
BA, HR, IS, YU

PRIORITY APPLN. INFO.:

US 2004-537228P P 20040115
US 2004-558907P P 20040401
US 2004-622720P P 20041027
WO 2005-US4793 W 20050118

OTHER SOURCE(S): CASREACT 143:172684; MARPAT 143:172684

GI



AB Aromatized A-ring derivs. of tetracycline compds., such as I [R5 = H, OH; R7 = H, NMe2; R9 = H, CH2NHCH2CMe3], were prepared for use in antibiotic pharmaceutical compns. which are claimed for use in the treatment of bacterial, viral, fungal and parasitic infections and for treatment of multiple sclerosis. Thus, minocycline dihydrochloride was treated with AcOH and H2SO4 overnight followed by treatment of the reaction solution with HCl and thionyl chloride to give aromatized minocycline derivative I (R5 = R9 = H, R7 = NMe2). The prepared tetracyclines were assayed for inhibitory activity against E. coli, S aureus and Enterococcus sp.

RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Blackwood, R	1966			US 3250810 A	HCAPLUS
McCormick, J	1968	90	7127	JOURNAL OF THE AMERI	HCAPLUS
Rennhard, H	1962			US 3043876 A	HCAPLUS
Stephens, C	1963			US 3081346 A	HCAPLUS

L108 ANSWER 6 OF 12 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:60256 HCAPLUS Full-text

DOCUMENT NUMBER: 140:93847

TITLE: Preparation of 3-, 10-, and 12a-substituted
tetracycline compounds for the treatment of
tetracycline responsive states

INVENTOR(S): **Nelson, Mark L.**; Ismail, Mohamed Y.;
Bandarage, Upul; Sizensky, Emmanuelle; Chen, Jackson

PATENT ASSIGNEE(S): Paratek Pharmaceuticals, Inc, USA

SOURCE: PCT Int. Appl., 43 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004006850	A2	20040122	WO 2003-US21992	20030714
WO 2004006850	A3	20040415		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2492273	A1	20040122	CA 2003-2492273	20030714
AU 2003261161	A1	20040202	AU 2003-261161	20030714
EP 1534300	A2	20050601	EP 2003-764630	20030714
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005533115	T	20051104	JP 2004-521799	20030714
CN 1700922	A	20051123	CN 2003-821180	20030714
IN 2005CN00168	A	20070330	IN 2005-CN168	20050211
US 2005288262	A1	20051229	US 2005-69197	20050228
PRIORITY APPLN. INFO.:			US 2002-395696P	P 20020712
			US 2003-619653	B1 20030714
			WO 2003-US21992	W 20030714
			US 2004-853537	B1 20040524
OTHER SOURCE(S):		MARPAT 140:93847		
GI				




AB The present invention pertains to novel 3, 10, and/or 12a-substituted tetracycline compds. of formula I [X = (substituted) CHMe, (substituted) CH₂, S, (substituted) NH, O; R₁ = (substituted) OH, (substituted) NH₂; R₂ = (substituted) CONH₂, CN; R₃, R₁₀, R₁₁ = H, alkyl, aryl, aralkyl, Ac, alkylcarbonyl, etc.; R₄, R₆ = H, NH₂, alkyl, OH, halo, etc.; R₅ = H, OH, SH, alkanoyl, aroyl, etc.; R₇-R₉ = H, OH, halo, SH, nitro, alkyl, alkoxy, etc.]. These tetracycline compds. can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compds. in general, such as blocking tetracycline efflux and modulation of gene expression.

DOCUMENT NUMBER: 139:100974
 TITLE: Preparation of 4-dedimethylamino (substituted) tetracycline compounds for treating tetracycline responsive states
 INVENTOR(S): Nelson, Mark L.; Ohemeng, Kwasi
 PATENT ASSIGNEE(S): Paratek Pharmaceuticals, Inc., USA
 SOURCE: PCT Int. Appl., 181 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003057169	A2	20030717	WO 2003-US336	20030106
WO 2003057169	A3	20031204		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003235759	A1	20030724	AU 2003-235759	20030106
US 2004157806	A1	20040812	US 2003-337914	20030106
US 7056902	B2	20060606		
EP 1474380	A2	20041110	EP 2003-729351	20030106
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005514410	T	20050519	JP 2003-557528	20030106
US 2006089336	A1	20060427	US 2005-283571	20051118
PRIORITY APPLN. INFO.:				
			US 2002-346929P	P 20020108
			US 2002-346930P	P 20020108
			US 2002-346956P	P 20020108
			US 2002-347065P	P 20020108
			US 2002-367049P	P 20020321
			US 2003-337914	A1 20030106
			WO 2003-US336	W 20030106

OTHER SOURCE(S): MARPAT 139:100974
 GI



AB The present invention pertains, at least in part, to novel substituted 4-dedimethylamino tetracycline compds. of formula I [X = (substituted) CHCH₃,

(substituted) CH₂, S, (substituted) NH, O, etc.; R₁, R₂ = H, alkyl, alkoxy, alkylthio, arylalkyl, aryl, etc.; R₂, R₃, R₁₀-R₁₂ = H, prodrug moiety; R₄, R₅ = H, alkyl, OH, halo, etc.; R₄R₅ = O; R₆ = H, OH, SH, alkanoyl, aroyl, aryl, heteroaryl, alkyl, alkoxy, etc.; R₇ = NO₂, alkyl, aryl, alkoxy, alkylthio, amino, etc.; R₈ = H, OH, halo, thiol, alkyl, aryl, etc.; R₉ = H, NO₂, alkyl, aryl, alkoxy, alkylthio, etc.]. These tetracycline compds. can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compds. in general, such as blocking tetracycline efflux and modulation of gene expression.

L108 ANSWER 8 OF 12 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:89242 HCAPLUS Full-text

DOCUMENT NUMBER: 139:239920

TITLE: The effect of treatment on radiological progression in rheumatoid arthritis: a systematic review of randomized placebo-controlled trials

AUTHOR(S): Jones, G.; Halbert, J.; Crotty, M.; Shanahan, E. M.; Batterham, M.; Ahern, M.

CORPORATE SOURCE: Dept. of Rehabilitation and Adged Care, Flinders University, Bedford Park, 5042, Australia

SOURCE: Rheumatology (Oxford, United Kingdom) (2003), 42(1), 6-13

CODEN: RUMAFK; ISSN: 1462-0324

PUBLISHER: Oxford University Press

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Objective was to undertake a systematic review of randomized placebo-controlled trials to assess and rank the efficacy of pharmacol. interventions in preventing radiol. progression of rheumatoid arthritis. The two outcome measures were the weighted standardized mean difference and the odds of progression of x-ray scores pooled as close to 12 mo as possible to minimize heterogeneity. A total of 38 trials were identified. Of these, 13 were excluded, leaving data on 3907 subjects. Infliximab, cyclosporin, sulfasalazine, leflunomide, methotrexate, parenteral gold, corticosteroids, auranofin and interleukin 1 receptor antagonist were statistically better than placebo in terms of change in erosion scores. All agents were equivalent statistically, with the exception of infliximab (which was superior to the last five agents). There were similar findings for the odds of progression, with the exception of auranofin (P=0.06) and the infliximab-methotrexate comparison (P=0.07). Other agents did not reach statistical significance in either outcome measure. With the exception of the antimalarials, the magnitude of the effect was consistent with the effect seen in short-term disease activity trials. There is published evidence which supports the efficacy of nine agents in decreasing radiol. progression in rheumatoid arthritis.

RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
=====	=====	=====	=====	=====	=====
Anon	1997			Cochrane collaborati	
Bathon, J	2000	343	1586	N Engl J Med	HCAPLUS
Bluhm, G	1997	24	1295	J Rheumatol	HCAPLUS
Borg, G	1988	15	1747	J Rheumatol	MEDLINE
Bresnihan, B	1998	41	2196	Arthritis Rheum	HCAPLUS
Capell, H	1986	45	705	Ann Rheum Dis	MEDLINE
Cochran, W	1954	10	101	Biometrics	
Cohen, J	1988		21	Statistical power an	
Cooperating Clinics	1973	16	353	Arthritis Rheum	

Cooperating Clinics	1970	283	883	N Engl J Med	
Davis, M	1991	30	451	Br J Rheumatol	MEDLINE
Eberhardt, K	1996	14	625	Clin Exp Rheum	MEDLINE
Egglemeijer, F	1996	39	396	Arthritis Rheum	
Empire Rheumatism Council	1957	16	277	Ann Rheum Dis	
Empire Rheumatism Council	1961	20	315	Ann Rheum Dis	
Felson, D	1990	33	1449	Arthritis Rheum	MEDLINE
Forre, O	1994	37	1506	Arthritis Rheum	MEDLINE
Freedman, A	1960	19	243	Ann Rheum Dis	MEDLINE
Glennas, A	1997	36	870	Br J Rheumatol	HCAPLUS
Gofton, J	1984	11	768	J Rheumatol	MEDLINE
Goldsmith, C	1993	20	575	J Rheumatol	MEDLINE
Goronzy, J	1997		155	Primer on the rheuma	
Hamilton, E	1962	5	502	Arthritis Rheum	MEDLINE
Hannonen, P	1993	36	1501	Arthritis Rheum	MEDLINE
Hansen, T	1990	301	268	Br Med J	MEDLINE
Hedges, L	1985		33	Statistical methods	
Iannuzzi, L	1983	309	1023	N Engl J Med	MEDLINE
Joint Committee of the	1959	18	173	Ann Rheum Dis	
Jones, G	1997	36	95	Br J Rheumatol	MEDLINE
Kerstens, P	2000	27	1148	J Rheumatol	HCAPLUS
Kirwan, J	1995	333	142	New Engl J Med	MEDLINE
Larsen, A	1977	18	481	Acta Radiol Diagn	MEDLINE
Lidsky, M	1973	16	148	Arthritis Rheum	MEDLINE
Liebling, M	1981	94	21	Ann Intern Med	MEDLINE
Lipsky, P	2000	343	1594	N Engl J Med	HCAPLUS
Maccagno, A	1994	23	211	Scand J Rheumatol	MEDLINE
Multicentre Trial group	1973	1	275	Lancet	
Popert, A	1961	20	18	Ann Rheum Dis	MEDLINE
Ralston, S	1989	48	396	Ann Rheum Dis	MEDLINE
Rosenthal, R	1979	86	638	Psychol Bull	
Schned, E	1997		6	Primer on the rheuma	
Scott, D	1989	28	128	Br J Rheumatol	MEDLINE
Sharp, J	1971	14	706	Arthritis Rheum	MEDLINE
Shiokawa, Y	1977	20	1464	Arthritis Rheum	MEDLINE
Sigler, J	1974	80	21	Ann Intern Med	MEDLINE
Sileghem, A	1992	51	761	Ann Rheum Dis	MEDLINE
Smolen, J	1999	353	259	Lancet	HCAPLUS
Smyth, C	1975	135	789	Arch Intern Med	MEDLINE
Strand, V	1999	159	2542	Arch Intern Med	HCAPLUS
The HERA Study Group	1995	98	156	Am J Med	
Townes, A	1976	19	563	Arthritis Rheum	MEDLINE
Van Gestel, A	1995	34	347	Br J Rheumatol	MEDLINE
Wendt, T	1999	4	442	Eur J Med Res	HCAPLUS
Williams, H	1988	31	702	Arthritis Rheum	MEDLINE
Willkens, R	1996	44	64	J Rheumatol Suppl	HCAPLUS
Wilson, A	1992	156	173	Med J Aust	MEDLINE

L108 ANSWER 9 OF 12 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:545493 HCAPLUS Full-text

DOCUMENT NUMBER: 135:117208

TITLE: Tetracycline compounds, their, and their use
preparation for treatment of Cryptosporidium
parvum-related disorders

INVENTOR(S): *Levy, Stuart B.; Nelson, Mark L.*

PATENT ASSIGNEE(S): Trustees of Tufts College, USA

SOURCE: PCT Int. Appl., 37 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 10

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001052858	A1	20010726	WO 2001-US2093	20010123
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2397863	A1	20010726	CA 2001-2397863	20010123
US 2002115644	A1	20020822	US 2001-768189	20010123
US 6833365	B2	20041221		
EP 1263442	A1	20021211	EP 2001-903210	20010123
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003523963	T	20030812	JP 2001-552905	20010123
US 2002128237	A1	20020912	US 2001-882273	20010615
US 2004224927	A1	20041111	US 2004-820456	20040407
US 2005215532	A1	20050929	US 2004-982728	20041104
US 7202235	B2	20070410		
US 2006234988	A1	20061019	US 2006-453326	20060614
PRIORITY APPLN. INFO.:				
			US 2000-178519P	P 20000124
			US 1999-234847	A 19990122
			US 1999-154701P	P 19990914
			US 2000-212139P	P 20000616
			WO 2000-US16672	W 20000616
			US 2001-768189	A1 20010123
			WO 2001-US2093	W 20010123
			US 2001-882273	B1 20010615
			US 2004-820456	B1 20040407

OTHER SOURCE(S): MARPAT 135:117208

AB Methods and pharmaceutical compns. for treating *Cryptosporidium parvum*-related disorders in a mammal are disclosed. Several tetracycline compds. are prepared (e.g. 13-(Phenylthio)-5-hydroxy-6- α - deoxytetracycline), which are useful for treating *Cryptosporidium parvum*-related disorders.

RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Armson	1999	178	227	FEMS Microbiology Le	HCAPLUS
Brites, C	1991	24	117	Revista da Sociedade	MEDLINE
Fayer	1993	79	553	J of Parasitology	HCAPLUS
Levy	1999			WO 9937306 A	HCAPLUS
Rogalski, W	1977			US 4024272 A	HCAPLUS
Tufts College	1993			WO 9308806 A	HCAPLUS

L108 ANSWER 10 OF 12 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN

ACCESSION NUMBER: 2002:234112 BIOSIS Full-text

DOCUMENT NUMBER: PREV200200234112

TITLE: *Tetracyclines* in the control of gene expression in eukaryotes.

AUTHOR(S): Gossen, Manfred [Reprint author]; Bujard, Hermann

CORPORATE SOURCE: Max-Delbruck-Centrum, Robert-Rossle-Str. 10, D-13125,

SOURCE: Berlin-Buch, Germany
Nelson, M.; Hillen, W.; Greenwald, R. A. (2001) pp. 139-157. Tetracyclines in biology, chemistry and medicine. print.
 Publisher: Birkhaeuser Boston, 675 Massachusetts Avenue, Cambridge, MA, 02139, USA; Birkhaeuser Verlag, CH-4001, Basel, Switzerland.
 ISBN: 3-7643-6282-0 (cloth).
 DOCUMENT TYPE: Book
 Book; (Book Chapter)
 LANGUAGE: English
 ENTRY DATE: Entered STN: 10 Apr 2002
 Last Updated on STN: 10 Apr 2002

L108 ANSWER 11 OF 12 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN

ACCESSION NUMBER: 2002:234113 BIOSIS Full-text
 DOCUMENT NUMBER: PREV200200234113
 TITLE: **Tetracycline**-regulated gene expression to study oncogenes in vivo.
 AUTHOR(S): Kudlow, Jeffrey E. [Reprint author]
 CORPORATE SOURCE: Department of Medicine/Endocrinology, University of alabama at Birmingham, 1808 7th Avenue South, Rm 756, Birmingham, AL, 35294-0012, USA
 SOURCE: **Nelson, M.**; Hillen, W.; Greenwald, R. A. (2001) pp. 159-175. Tetracyclines in biology, chemistry and medicine. print.
 Publisher: Birkhaeuser Boston, 675 Massachusetts Avenue, Cambridge, MA, 02139, USA; Birkhaeuser Verlag, CH-4001, Basel, Switzerland.
 ISBN: 3-7643-6282-0 (cloth).
 DOCUMENT TYPE: Book
 Book; (Book Chapter)
 LANGUAGE: English
 ENTRY DATE: Entered STN: 10 Apr 2002
 Last Updated on STN: 10 Apr 2002

L108 ANSWER 12 OF 12 WPIX COPYRIGHT 2007 THE THOMSON CORP on STN
 ACCESSION NUMBER: 2004-314834 [29] WPIX
 CROSS REFERENCE: 2003-256330; 2004-604107
 DOC. NO. CPI: C2004-119438 [29]
 TITLE: Treating disease, particularly inflammatory process associated state e.g. lung disorders, **diabetes**, **ischemia**, metastasis, bone mass disorder and neurological disorders comprises administering tetracycline compound
 DERWENT CLASS: B05
 INVENTOR: **DRAPER M**; **JONES G**; **LEVY S B**
 ; **NELSON M L**
 PATENT ASSIGNEE: (DRAP-I) DRAPER M; (JONE-I) JONES G; (LEVY-I) LEVY S B;
 (NELS-I) NELSON M L
 COUNTRY COUNT: 1

PATENT INFO ABBR.:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC
US 20040063674	A1	20040401	(200429)*	EN	378	[0]

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
US 20040063674	A1 Provisional	US 2001-305546P	20010713
US 20040063674	A1 Provisional	US 2002-395741P	20020712
US 20040063674	A1	US 2002-196010	20020715

PRIORITY APPLN. INFO: US 2002-196010 20020715
 US 2001-305546P 20010713
 US 2002-395741P 20020712

AN 2004-314834 [29] WPIX

CR 2003-256330; 2004-604107

AB US 20040063674 A1 UPAB: 20050528

NOVELTY - Treating disease comprises administering a tetracycline compound (I) having a target therapeutic activity for the state.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the following:

(1) a composition (C1) comprising (I) in combination with another agent (A1); and

(2) a packaged composition (C2) comprising (I) and directions for its use.

ACTIVITY - Antiinflammatory; Respiratory-Gen.; Antiasthmatic; CNS-Gen.; Antiarteriosclerotic; Osteopathic; Ophthalmological; Antidiabetic; Vasotropic; Antimalarial; Cytostatic; Neuroprotective; Antiarthritic; Antirheumatic; Nootropic; Antiparkinsonian; Antiulcer; Anticonvulsant; Neuroleptic; Hypotension; Hypnotic; Antidepressant; Antimanic; Tranquillizer; Antimigraine; Cerebroprotective; Vulnerary; Muscular-Gen.; Dermatological; Gastrointestinal-Gen.; Hepatotropic; Virucide.

Test details are described but no results given.

MECHANISM OF ACTION - Protein glycosylation inhibitor; vascular aneurysm formation inhibitor; Angiogenesis inhibitor; Tumor metastasis inhibitor.

USE - Used for treating inflammatory process associated state including matrix metalloproteinase (MMP) (MMP-1 to MMP-20) and nitric oxide associated states, particularly inflammatory disorders, lung disorders (e.g. *asthma*, cystic fibrosis, emphysema, acute lung injury and bronchitis), adult respiratory distress syndrome, acute respiratory distress syndrome, aortic or vascular aneurysms, arteriosclerosis, atherosclerosis, bone or cartilage degradation, bronchiectasis, chronic obstructive pulmonary disease, corneal ulceration, *diabetes* (e.g. juvenile *diabetes* or *diabetes* mellitus), diabetic complications, diabetic ulcers, dry eye, *ischemia*, restenosis, malaria, metastasis, multiple sclerosis, bone mass disorder (e.g. osteoarthritis, osteoporosis, osteosarcoma, osteomyelitis and periodontitis), rheumatoid arthritis, neurological disorders (e.g. *Alzheimer's* disease, dementia related to *Alzheimer's* disease, Parkinson's disease, Lewy diffuse body disease, senile dementia, *Huntington's* disease, Gilles de la Tourette's syndrome, Amyotrophic lateral sclerosis (ALS), progressive supranuclear palsy, epilepsy, Creutzfeldt-Jakob disease, autonomic function disorder, hypertension, sleep disorder, neuropsychiatric disorder, depression, schizophrenia, schizoaffective disorder, Korsakoff's psychosis, mania, anxiety disorder, phobic disorder, learning disorder, memory disorder, amnesia, age related memory loss, attention deficit disorder, dysthymic disorder, major depressive disorder, mania, obsessive-compulsive disorder, psychoactive substance use disorders, anxiety, panic disorder, bipolar affective disorder, BP-1, migraine, traumatic brain injury, spinal cord trauma, motor neuron disease, and nerve damage), senescence, skin and eye diseases, stroke, tissue wounds, *cancer* (e.g. tumor growth, tumor invasion, carcinoma, *sarcoma*), ulcerative colitis, hepatitis, sinusitis, and vascular stroke, and for preventing vascular aneurysm formation and inducing the regression of the aneurysm in vascular tissue (e.g. artery) and for decreasing angiogenesis (all claimed).

10692764


ADVANTAGE - (I) Exhibit antibacterial or antiinfective activity, but also selectivity for the disease being treated, and eliminate the side effects associated with the prior art.

*****REFERENCES GEARED TOWARDS QUERY FOR CLAIM 57 *****

=> d que 156

L1

STR



G1 C,O,S,N


Structure attributes must be viewed using STN Express query preparation.

L3

9270 SEA FILE=REGISTRY SSS FUL L1

L5

STR



Structure attributes must be viewed using STN Express query preparation.

L7	66	SEA FILE=REGISTRY SUB=L3 SSS FUL L5
L11	18	SEA FILE=HCAPLUS ABB=ON PLU=ON L7
L12	14	SEA FILE=HCAPLUS ABB=ON PLU=ON L11 AND (AY<2003 OR PY<2003 OR PRY<2003)
L14	1	SEA FILE=HCAPLUS ABB=ON PLU=ON L12 AND ((RNA OR RIBONUCLEIC ACID?) (L) (MODULAT?))
L15	1	SEA FILE=HCAPLUS ABB=ON PLU=ON L12 AND (RNA OR RIBONUCLEIC ACID?)
L16	1	SEA FILE=HCAPLUS ABB=ON PLU=ON (L14 OR L15)
L17	14	SEA FILE=HCAPLUS ABB=ON PLU=ON (L12 OR L16)
L18	15	SEA FILE=HCAPLUS ABB=ON PLU=ON L7 (L) (THU OR PKT OR PAC OR BAC OR DMA)/RL
L19	13	SEA FILE=HCAPLUS ABB=ON PLU=ON L18 AND (AY<2003 OR PY<2003 OR PRY<2003)
L20	14	SEA FILE=HCAPLUS ABB=ON PLU=ON (L17 OR L19)
L38	5	SEA FILE=HCAPLUS ABB=ON PLU=ON DTMR
L39	9535	SEA FILE=HCAPLUS ABB=ON PLU=ON "NERVOUS SYSTEM, DISEASE (L) DEGENERATION"+OLD/CT
L40	54794	SEA FILE=HCAPLUS ABB=ON PLU=ON "HUMAN IMMUNODEFICIENCY VIRUS"+OLD,NT/CT
L41	44073	SEA FILE=HCAPLUS ABB=ON PLU=ON "HUMAN IMMUNODEFICIENCY VIRUS 1"+OLD/CT
L42	20700	SEA FILE=HCAPLUS ABB=ON PLU=ON "AIDS (DISEASE)" +OLD/CT
L43	885	SEA FILE=HCAPLUS ABB=ON PLU=ON "WEST NILE VIRUS"+OLD/CT
L44	271	SEA FILE=HCAPLUS ABB=ON PLU=ON "POTATO LEAFROLL VIRUS"+OLD/CT
L45	13196	SEA FILE=HCAPLUS ABB=ON PLU=ON "INFLUENZA VIRUS"+OLD,NT/CT
L46	5	SEA FILE=HCAPLUS ABB=ON PLU=ON "INFECTION (L) MENINGOPNEUMONITIS"+OLD/CT
L47	5	SEA FILE=HCAPLUS ABB=ON PLU=ON "LUNG, DISEASE (L) MENINGOPNEUMONITIS"+OLD/CT
L48	1669	SEA FILE=HCAPLUS ABB=ON PLU=ON "RABIES VIRUS"+OLD/CT
L49	87393	SEA FILE=HCAPLUS ABB=ON PLU=ON (L38 OR L39 OR L40 OR L41 OR L42 OR L43 OR L44 OR L45 OR L46 OR L47 OR L48)
L54	6	SEA FILE=HCAPLUS ABB=ON PLU=ON L20 AND (CANCER? OR TUMOR? OR TUMOUR? OR LEUKEMIA? OR SARCOMA? OR MYELOMA? OR MELANOMA? OR ASTHMA? OR ARTHRITIS? OR ANEMIA? OR ALZHEIMER? OR HUNTINGTON? OR OARTIC ANEURYSM? OR DIABETES? OR ISCHEMIA? OR HYPERLIPIDEMIA ? OR OBESITY?)
L55	2	SEA FILE=HCAPLUS ABB=ON PLU=ON L20 AND L49
L56	14	SEA FILE=HCAPLUS ABB=ON PLU=ON (L54 OR L55 OR L20)

=> d ibib abs hitstr hitind retable l56 tot

L56 ANSWER 1 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2004:1036703 HCAPLUS Full-text
 DOCUMENT NUMBER: 141:420412
 TITLE: Substituted tetracycline compounds for the treatment
 of malaria
 INVENTOR(S): Draper, Michael; Nelson, Mark L.
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 590 pp., Cont.-in-part of U.S.
 Ser. No. 128,990, abandoned.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004242548	A1	20041202	US 2003-692563	20031024 <--
US 2004092490	A1	20040513	US 2002-128990	20020424 <--
PRIORITY APPLN. INFO.:			US 2001-286193P	P 20010424 <--
			US 2002-128990	B2 20020424 <--
			US 2002-421259P	P 20021024 <--

OTHER SOURCE(S): MARPAT 141:420412

AB The invention provides a method for treating or preventing malaria in a subject. The method includes administering an effective amount of a substituted tetracycline compound, such that malaria is treated or prevented. In one aspect, the invention relates to pharmaceutical compns. which include an effective amount of a tetracycline compound to treat malaria in a subject and a pharmaceutically acceptable carrier. The substituted tetracycline compds. of the invention can be used to in combination with one or more antimalarial compds. or can be used to treat or prevent malaria which is resistant to one or more other antimalarial compds. Preparation of e.g. sancycline derivs. is described.


IT 53108-41-1 389625-03-0 459809-44-0
 460071-69-6 460073-37-4 460073-70-5
 460073-72-7 460073-74-9 460074-19-5
 473972-91-7 488815-54-9 488815-55-0
 488815-56-1 488815-58-3 488815-63-0
 488817-32-9 488818-13-9 488818-17-3
 488818-20-8 488818-21-9 488818-27-5
 488818-31-1 488818-45-7 488818-60-6
 488818-63-9 488818-82-2 488819-02-9
 488819-08-5 488819-19-8 488820-15-1
 488820-27-5 601454-95-9 601454-98-2
 601454-99-3 685832-62-6 685834-76-8
 685859-28-3

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (substituted tetracycline compds. for treatment of malaria)

RN 53108-41-1 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-7-[(dimethylamino)methyl]-
 1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-,
 [4S-(4 α ,4a α ,5a α ,12a α)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 389625-03-0 HCAPLUS

CN Carbamic acid, [[(6aS,10S,10aS,11aR)-8-(aminocarbonyl)-10-(dimethylamino)-5,6a,7,10,10a,11,11a,12-octahydro-4,6,6a,9-tetrahydroxy-5,7-dioxo-1-naphthacenyl]methyl]-, 2,2-dimethylpropyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 459809-44-0 HCAPLUS

CN 3-Pyridinecarboxamide, N-[[[(6aS,10S,10aS,11aR)-8-(aminocarbonyl)-10-(dimethylamino)-3-(1,1-dimethylethyl)-5,6a,7,10,10a,11,11a,12-octahydro-4,6,6a,9-tetrahydroxy-5,7-dioxo-1-naphthacenyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 460071-69-6 HCAPLUS

CN Carbamic acid, [[(6aS,10S,10aS,11aR)-8-(aminocarbonyl)-10-(dimethylamino)-5,6a,7,10,10a,11,11a,12-octahydro-4,6,6a,9-tetrahydroxy-5,7-dioxo-1-naphthacenyl]methyl]-, 2-methylpropyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 460073-37-4 HCAPLUS

CN 2-Naphthacenecarboxamide, 7-[[bis(2-methylpropyl)amino]methyl]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 460073-70-5 HCAPLUS

CN 2-Naphthacenecarboxamide, 7-[[bis(2,2-dimethoxyethyl)amino]methyl]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 460073-72-7 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-7-[[[(1-methyl-1H-pyrrol-2-yl)methyl]amino]methyl]-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 460073-74-9 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-7-[[[(1H-pyrrol-2-ylmethyl)amino]methyl]-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 460074-19-5 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-7,9-bis[[[(2,2-dimethylpropyl)amino]methyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 473972-91-7 HCAPLUS

10692764

CN 2-Pyridinecarboxamide, N-[[[(6aS,10S,10aS,11aR)-8-(aminocarbonyl)-10-(dimethylamino)-3-(1,1-dimethylethyl)-5,6a,7,10,10a,11,11a,12-octahydro-4,6,6a,9-tetrahydroxy-5,7-dioxo-1-naphthacenyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 488815-54-9 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-7-[[[(2,2-dimethylpropyl)amino]methyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 488815-55-0 HCAPLUS

CN 2-Naphthacenecarboxamide, 7-[(diethylamino)methyl]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 488815-56-1 HCAPLUS

CN 2-Naphthacenecarboxamide, 7-[[bis(cyclopropylmethyl)amino]methyl]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 488815-58-3 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-7-[[[(2-methylbutyl)amino]methyl]-1,11-dioxo-, (4S,4aS,5aR,12aS)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 488815-63-0 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-7-[[[(2-methylpropyl)amino]methyl]-1,11-dioxo-, (4S,4aS,5aR,12aS)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 488817-32-9 HCAPLUS

CN 1,8-Naphthacenedicarboxamide, 10-(dimethylamino)-5,6a,7,10,10a,11,11a,12-octahydro-4,6,6a,9,11-pentahydroxy-N1,N1,12-trimethyl-5,7-dioxo-, (6aS,10S,10aR,11S,11aR,12R) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 488818-13-9 HCAPLUS

CN 4-Pyrimidinecarboxamide, N-[[[(6aS,10S,10aR,11aR)-8-(aminocarbonyl)-10-(dimethylamino)-5,6a,7,10,10a,11,11a,12-octahydro-4,6,6a,9-tetrahydroxy-5,7-dioxo-1-naphthacenyl]methyl]-1,6-dihydro-6-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 488818-17-3 HCAPLUS

CN 4-Pyridinecarboxamide, N-[[[(6aS,10S,10aR,11aR)-8-(aminocarbonyl)-10-(dimethylamino)-5,6a,7,10,10a,11,11a,12-octahydro-4,6,6a,9-tetrahydroxy-5,7-dioxo-1-naphthacenyl]methyl]-, 1-oxide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 488818-20-8 HCAPLUS

CN 4-Isoxazolecarboxamide, N-[[[(6aS,10S,10aS,11aR)-8-(aminocarbonyl)-10-(dimethylamino)-5,6a,7,10,10a,11,11a,12-octahydro-4,6,6a,9-tetrahydroxy-5,7-dioxo-1-naphthacenyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 488818-21-9 HCAPLUS

CN 3-Pyridinecarboxamide, N-[[[(6aS,10S,10aS,11aR)-8-(aminocarbonyl)-10-(dimethylamino)-5,6a,7,10,10a,11,11a,12-octahydro-4,6,6a,9-tetrahydroxy-5,7-dioxo-1-naphthacenyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 488818-27-5 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-7-[[[(1-methylethyl)amino]methyl]-1,11-dioxo-, (4S,4aS,5aR,12aS) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 488818-31-1 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-7-[[[(1-oxido-4-pyridinyl)methyl]amino]methyl]-1,11-dioxo-, (4S,4aS,5aR,12aS) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 488818-45-7 HCAPLUS

CN 1,8-Naphthacenedicarboxamide, 10-(dimethylamino)-5,6a,7,10,10a,11,11a,12-octahydro-4,6,6a,9-tetrahydroxy-N1,N1-dimethyl-5,7-dioxo-, (6aS,10S,10aS,11aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 488818-60-6 HCAPLUS

CN 4-Morpholinecarboxamide, N-[[[(6aS,10S,10aS,11aR)-8-(aminocarbonyl)-10-(dimethylamino)-3-ethynyl-5,6a,7,10,10a,11,11a,12-octahydro-4,6,6a,9-tetrahydroxy-5,7-dioxo-1-naphthacenyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 488818-63-9 HCAPLUS

CN 4-Morpholinecarboxamide, N-[[[(6aS,10S,10aS,11aR)-8-(aminocarbonyl)-10-(dimethylamino)-3-ethyl-5,6a,7,10,10a,11,11a,12-octahydro-4,6,6a,9-tetrahydroxy-5,7-dioxo-1-naphthacenyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 488818-82-2 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-7-[[[(2-fluoro-1-methylethyl)amino]methyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 488819-02-9 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-7-[[[(4-fluorophenyl)methyl]amino]methyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 488819-08-5 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-7-[[[(phenylmethyl)amino]methyl]-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 488819-19-8 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-7-[[[(2,2-dimethylpropyl)amino]methyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-[(methylthio)methyl]-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI)

(CA INDEX NAME)


Absolute stereochemistry.



RN 488820-15-1 HCAPLUS

CN 2-Naphthacenecarboxamide, 7-[(acetylamino)methyl]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 488820-27-5 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-7-[[[(2,2-dimethyl-1-oxopropyl)amino]methyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 601454-95-9 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-7-[[[(4-fluorophenyl)methyl]amino]methyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4R,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 601454-98-2 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-7-[[(phenylmethyl) amino]methyl]-, (4R,4aS,5aR,12aS) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 601454-99-3 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-7,9-bis[[(2,2-dimethylpropyl) amino]methyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4aS,5aR,12aS) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 685832-62-6 HCAPLUS

CN 2-Naphthacenecarboxamide, 7-[[(cyanomethyl) amino]methyl]-4-(dimethylamino)-

10692764

1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-,
(4S,4aS,5aR,12aS) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 685834-76-8 HCAPLUS

CN 4-Morpholinecarboxamide, N-[[[(6aS,10S,10aS,11aR)-8-(aminocarbonyl)-3-(chloroethynyl)-10-(dimethylamino)-5,6a,7,10,10a,11,11a,12-octahydro-4,6,6a,9-tetrahydroxy-5,7-dioxo-1-naphthacenyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 685859-28-3 HCAPLUS

CN 2-Naphthacenecarboxamide, 7-[[[(2-cyanoethyl)amino]methyl]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IC ICM A61K031-65
 INCL 514152000
 CC 1-5 (Pharmacology)
 Section cross-reference(s): 26, 63
 IT **Anemia** (disease)
 Antibacterial agents
 Antimalarials
 Antimicrobial agents
 Antipyretics
 Combination chemotherapy
 Drug delivery systems
 Drug interactions
 Fever and Hyperthermia
 Gram-positive bacteria
 Headache
 Human
 Malaria
 Plasmodium falciparum
 Plasmodium malariae
 Plasmodium ovale
 Plasmodium vivax
 Prophylaxis
 (substituted tetracycline compds. for treatment of malaria)
 IT 60-54-8 60-54-8D, Tetracycline, derivs. 79-57-2 127-33-3 564-25-0
 808-26-4 914-00-1 1665-56-1 2444-65-7 3242-03-3 4495-20-9
 4497-07-8 5585-59-1 5874-95-3 5995-55-1 10118-89-5 10118-90-8
 10236-47-2 15866-90-7 16145-05-4 19109-13-8 31642-30-5
 35689-63-5 35689-65-7 53108-40-0 53108-41-1 53173-80-1
 59046-79-6 73351-16-3 82336-02-5 113164-67-3 115207-75-5
 120793-45-5 146253-71-6 146253-75-0 146278-01-5 146278-02-6
 146278-03-7 149934-16-7 149934-19-0 151922-17-7 153621-68-2
 155819-14-0 155819-18-4 161321-34-2 161452-37-5 186759-47-7
 186759-49-9 186759-51-3 186759-53-5 186759-55-7 186759-61-5
 220620-09-7 233585-94-9 233585-95-0 233585-96-1 233585-97-2
 233586-02-2 233586-03-3 233586-04-4 233586-06-6 233586-08-8
 233586-09-9 233586-10-2 233586-11-3 233586-12-4 263760-96-9
 263760-98-1 263760-99-2 263761-01-9 263761-02-0 263761-08-6
 295356-11-5 295356-13-7 295356-16-0 295356-17-1 330627-21-9
 330627-22-0 330627-23-1 330627-24-2 330627-26-4 330627-29-7
 330627-31-1 330627-32-2 344771-54-6 351336-92-0 351336-94-2
 365276-98-8 365276-99-9 365277-00-5 365277-01-6 365277-02-7
 365277-03-8 365277-04-9 365277-05-0 365277-06-1 365277-07-2
 365277-08-3 365277-11-8 365277-12-9 365277-13-0 365277-14-1
 365277-16-3 365277-19-6 365277-20-9 365277-21-0 365277-23-2
 365277-24-3 365277-26-5 365277-28-7 365277-29-8 365277-33-4
 365277-34-5 365277-35-6 365277-36-7 365277-37-8 365277-38-9
 365277-39-0 365277-40-3 365277-41-4 365277-42-5 365277-43-6
 365277-44-7 365277-45-8 365277-47-0 365277-48-1 365277-49-2
 365277-50-5 365277-51-6 365277-52-7 365277-54-9 365277-55-0
 365277-56-1 365277-57-2 365277-58-3 365277-59-4 365277-60-7
 365277-61-8 365277-62-9 365277-63-0 365277-64-1 365277-65-2
 365277-66-3 365277-88-9 374748-06-8 380435-62-1 380435-63-2
 380435-65-4 380435-74-5 380435-76-7 380435-88-1 389081-55-4
 389081-56-5 389081-57-6 389081-58-7 389081-59-8 389081-60-1
 389081-61-2 389081-62-3 389081-64-5 389081-65-6 389081-66-7
 389081-67-8 389081-68-9 389081-69-0 389081-71-4 389081-73-6
 389081-74-7 389081-75-8 389081-76-9 389081-77-0 389081-78-1
 389081-79-2 389081-80-5 389081-85-0 389139-10-0 389139-12-2
 389139-15-5 389139-16-6 389139-17-7 389139-18-8 389139-19-9

389139-20-2	389139-21-3	389139-22-4	389139-23-5	389139-24-6
389139-25-7	389139-26-8	389139-27-9	389139-28-0	389139-29-1
389139-30-4	389139-31-5	389139-32-6	389139-33-7	389139-34-8
389139-35-9	389139-36-0	389139-37-1	389139-38-2	389139-39-3
389139-41-7	389139-42-8	389139-43-9	389139-44-0	389139-45-1
389139-46-2	389139-47-3	389139-48-4	389139-49-5	389139-50-8
389139-51-9	389139-52-0	389139-53-1	389139-54-2	389139-55-3
389139-56-4	389139-57-5	389139-58-6	389139-59-7	389139-60-0
389139-61-1	389139-62-2	389139-63-3	389139-64-4	389139-65-5
389139-66-6	389139-67-7	389139-68-8	389139-69-9	389139-70-2
389139-71-3	389139-72-4	389139-73-5	389139-74-6	

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(substituted tetracycline compds. for treatment of malaria)

IT	389139-75-7	389139-76-8	389139-78-0	389139-79-1	389139-80-4
	389139-81-5	389139-82-6	389139-83-7	389139-85-9	389139-86-0
	389139-87-1	389139-88-2	389139-89-3	389139-90-6	389139-91-7
	389139-93-9	389139-94-0	389139-96-2	389139-97-3	389139-98-4
	389139-99-5	389140-00-5	389140-01-6	389140-02-7	389140-03-8
	389140-06-1	389570-43-8	389570-46-1	389570-48-3	389570-49-4
	389570-50-7	389570-51-8	389570-52-9	389570-53-0	389570-54-1
	389623-72-7	389623-74-9	389623-77-2	389623-80-7	389623-82-9
	389623-86-3	389623-88-5	389623-89-6	389623-90-9	389623-91-0
	389623-93-2	389623-95-4	389623-96-5	389623-97-6	389623-98-7
	389623-99-8	389624-01-5	389624-03-7	389624-04-8	389624-05-9
	389624-06-0	389624-07-1	389624-08-2	389624-09-3	389624-11-7
	389624-12-8	389624-13-9	389624-14-0	389624-15-1	389624-16-2
	389624-18-4	389624-19-5	389624-20-8	389624-21-9	389624-22-0
	389624-23-1	389624-24-2	389624-26-4	389624-27-5	389624-28-6
	389624-29-7	389624-30-0	389624-31-1	389624-32-2	389624-33-3
	389624-34-4	389624-35-5	389624-36-6	389624-37-7	389624-38-8
	389624-39-9	389624-40-2	389624-41-3	389624-42-4	389624-43-5
	389624-44-6	389624-45-7	389624-46-8	389624-47-9	389624-48-0
	389624-49-1	389624-51-5	389624-52-6	389624-53-7	389624-54-8
	389624-55-9	389624-56-0	389624-57-1	389624-59-3	389624-60-6
	389624-61-7	389624-62-8	389624-63-9	389624-64-0	389624-65-1
	389624-66-2	389624-67-3	389624-68-4	389624-69-5	389624-70-8
	389624-71-9	389624-72-0	389624-73-1	389624-74-2	389624-75-3
	389624-76-4	389624-77-5	389624-78-6	389624-79-7	389624-80-0
	389624-81-1	389624-82-2	389624-83-3	389624-84-4	389624-85-5
	389624-86-6	389624-87-7	389624-88-8	389624-89-9	389624-90-2
	389624-91-3	389624-92-4	389624-93-5	389624-94-6	389624-95-7
	389624-96-8	389624-97-9	389624-98-0	389624-99-1	389625-00-7
	389625-01-8	389625-02-9	389625-03-0	389625-04-1	
	389625-05-2	389625-06-3	389625-07-4	389625-09-6	389625-10-9
	389625-11-0	389625-12-1	439217-57-9	439217-59-1	459425-79-7
	459425-80-0	459425-96-8	459426-11-0	459809-42-8	459809-43-9
	459809-44-0	459809-45-1	459809-46-2	459809-47-3	
	459809-48-4	459809-49-5	459809-50-8	459809-51-9	459809-52-0
	459809-53-1	459809-54-2	459809-55-3	459809-57-5	459809-58-6
	459809-59-7	459809-61-1	459809-63-3	459809-65-5	459809-66-6
	459809-67-7	459809-68-8	459809-70-2	459809-74-6	459809-76-8
	459809-77-9	459809-79-1	459809-81-5	459809-82-6	459809-86-0
	459809-88-2	459809-91-7	459809-92-8	459809-95-1	459809-96-2
	459809-97-3	459809-98-4	459809-99-5	459810-00-5	459810-01-6
	459810-02-7	459810-03-8	459810-04-9	459810-06-1	459810-07-2
	459810-08-3	459810-09-4	460068-27-3	460068-29-5	460068-30-8
	460068-31-9	460068-32-0	460068-33-1	460068-34-2	460068-35-3
	460068-36-4	460068-38-6	460068-39-7	460068-40-0	460068-41-1
	460068-42-2	460068-43-3	460068-44-4	460068-45-5	460068-46-6

460068-47-7 460068-48-8 460068-49-9 460068-50-2 460068-51-3

460068-52-4 460068-53-5 460068-54-6

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(substituted tetracycline compds. for treatment of malaria)

IT 460068-55-7 460068-57-9 460068-58-0 460068-59-1 460068-60-4
 460068-61-5 460068-62-6 460068-63-7 460068-64-8 460068-65-9
 460068-66-0 460068-67-1 460068-68-2 460068-69-3 460068-70-6
 460068-71-7 460068-72-8 460068-73-9 460068-74-0 460068-75-1
 460068-76-2 460068-77-3 460068-78-4 460068-79-5 460068-80-8
 460068-81-9 460068-82-0 460068-84-2 460068-85-3 460068-86-4
 460068-87-5 460068-88-6 460068-90-0 460068-92-2 460068-93-3
 460068-94-4 460068-95-5 460068-96-6 460068-97-7 460068-99-9
 460069-34-5 460069-38-9 460069-65-2 460069-70-9 460069-89-0
 460070-96-9 460070-02-4 460070-03-5 460070-53-5 460070-61-5
 460070-66-0 460070-73-9 460070-76-2 460070-79-5 460070-92-2
 460070-95-5 460071-02-7 460071-04-9 460071-06-1 460071-09-4
 460071-12-9 460071-14-1 460071-17-4 460071-19-6 460071-29-8
 460071-33-4 460071-37-8 460071-66-3 460071-69-6
 460071-80-1 460071-83-4 460071-87-8 460071-89-0 460071-91-4
 460071-93-6 460071-97-0 460071-99-2 460072-01-9 460072-03-1
 460072-05-3 460072-07-5 460072-09-7 460072-10-0 460072-12-2
 460072-15-5 460072-17-7 460072-19-9 460072-21-3 460072-25-7
 460072-28-0 460072-29-1 460072-30-4 460072-31-5 460072-33-7
 460072-36-0 460072-40-6 460072-43-9 460072-45-1 460072-47-3
 460072-49-5 460072-59-7 460072-63-3 460072-65-5 460072-70-2
 460072-73-5 460072-75-7 460072-78-0 460072-82-6 460072-86-0
 460072-89-3 460072-91-7 460072-93-9 460073-01-2 460073-03-4
 460073-05-6 460073-07-8 460073-09-0 460073-11-4 460073-15-8
 460073-17-0 460073-21-6 460073-22-7 460073-23-8 460073-25-0
 460073-27-2 460073-29-4 460073-31-8 460073-35-2 460073-37-4
 460073-40-9 460073-41-0 460073-43-2 460073-45-4 460073-47-6
 460073-49-8 460073-51-2 460073-53-4 460073-55-6 460073-58-9
 460073-62-5 460073-64-7 460073-68-1 460073-70-5
 460073-72-7 460073-74-9 460073-76-1 460073-78-3
 460073-80-7 460073-82-9 460073-84-1 460073-86-3 460073-88-5
 460073-90-9 460073-92-1 460073-94-3 460073-96-5 460073-98-7
 460074-00-4 460074-02-6 460074-04-8 460074-06-0 460074-09-3
 460074-11-7 460074-13-9 460074-15-1 460074-19-5
 460074-21-9 460074-23-1 460074-26-4 460074-28-6 460074-30-0
 460074-34-4 460074-36-6 460074-38-8 460074-40-2 460074-42-4
 460074-44-6 460074-46-8 460074-48-0 460074-50-4 460074-52-6
 460074-54-8 460074-56-0 460074-58-2 460074-60-6 460074-62-8
 460074-64-0 460074-66-2 460074-68-4 460074-69-5 460074-71-9
 460074-73-1 460074-75-3 460074-77-5 460074-79-7 460074-81-1
 460074-83-3 460074-85-5 460074-87-7 460074-89-9 460074-91-3
 460074-93-5 460074-95-7 460074-97-9 460074-99-1 460075-04-1
 460075-06-3 460075-08-5 460075-12-1 460075-14-3 460075-62-1
 460076-23-7 460082-77-3 460082-87-5 460082-89-7 460082-90-0
 460082-91-1 473972-91-7 473973-13-6 473973-20-5
 473973-34-1 473973-37-4 473973-41-0 473973-62-5 473973-64-7
 473973-86-3 473973-96-5 473974-12-8 473974-75-3 473974-76-4
 473974-77-5 473974-79-7 473974-80-0 473974-81-1 473974-82-2
 473974-83-3

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(substituted tetracycline compds. for treatment of malaria)

IT 473974-84-4 473974-85-5 488815-44-7 488815-46-9 488815-47-0
 488815-49-2 488815-52-7 488815-53-8 488815-54-9
 488815-55-0 488815-56-1 488815-57-2

488815-58-3	488815-59-4	488815-60-7	488815-61-8	
488815-62-9	488815-63-0	488815-64-1	488815-65-2	
488815-66-3	488815-68-5	488815-69-6	488815-71-0	488815-72-1
488815-73-2	488815-74-3	488815-75-4	488815-76-5	488815-77-6
488815-78-7	488815-80-1	488815-82-3	488815-89-0	488815-93-6
488815-98-1	488816-00-8	488816-13-3	488816-16-6	488816-18-8
488816-19-9	488816-26-8	488816-37-1	488816-39-3	488816-42-8
488816-54-2	488816-64-4	488816-65-5	488816-70-2	488816-71-3
488816-73-5	488816-75-7	488816-82-6	488816-88-2	488816-92-8
488816-93-9	488816-98-4	488817-01-2	488817-06-7	488817-11-4
488817-13-6	488817-14-7	488817-15-8	488817-16-9	488817-17-0
488817-18-1	488817-19-2	488817-20-5	488817-21-6	488817-22-7
488817-23-8	488817-24-9	488817-25-0	488817-26-1	488817-27-2
488817-28-3	488817-29-4	488817-30-7	488817-31-8	488817-32-9
488817-33-0	488817-35-2	488817-36-3	488817-37-4	488817-38-5
488817-39-6	488817-41-0	488817-42-1	488817-44-3	488817-45-4
488817-46-5	488817-47-6	488817-48-7	488817-49-8	488817-50-1
488817-51-2	488817-52-3	488817-53-4	488817-54-5	488817-55-6
488817-56-7	488817-57-8	488817-58-9	488817-59-0	488817-60-3
488817-61-4	488817-62-5	488817-63-6	488817-64-7	488817-65-8
488817-67-0	488817-68-1	488817-73-8	488817-75-0	488817-76-1
488817-79-4	488817-80-7	488817-82-9	488817-89-6	488817-91-0
488817-92-1	488817-94-3	488817-95-4	488817-96-5	488817-97-6
488818-04-8	488818-06-0	488818-07-1	488818-08-2	488818-10-6
488818-11-7	488818-12-8	488818-13-9	488818-14-0	
488818-16-2	488818-17-3	488818-18-4	488818-19-5	
488818-20-8	488818-21-9	488818-23-1	488818-25-3	
488818-27-5	488818-28-6	488818-29-7	488818-30-0	
488818-31-1	488818-32-2	488818-33-3	488818-34-4	
488818-35-5	488818-36-6	488818-37-7	488818-38-8	488818-39-9
488818-40-2	488818-41-3	488818-42-4	488818-43-5	488818-44-6
488818-45-7	488818-46-8	488818-47-9	488818-48-0	
488818-49-1	488818-50-4	488818-51-5	488818-52-6	488818-53-7
488818-54-8	488818-55-9	488818-56-0	488818-57-1	488818-58-2
488818-59-3	488818-60-6	488818-61-7	488818-63-9	
488818-64-0	488818-65-1	488818-66-2	488818-67-3	488818-68-4
488818-69-5	488818-70-8	488818-71-9	488818-72-0	488818-73-1
488818-74-2	488818-75-3	488818-76-4	488818-77-5	488818-78-6
488818-79-7	488818-80-0	488818-81-1	488818-82-2	
488818-83-3	488818-84-4	488818-85-5	488818-86-6	488818-87-7
488818-88-8	488818-89-9	488818-90-2	488818-91-3	488818-92-4
488818-93-5	488818-94-6	488818-95-7	488818-97-9	488818-98-0
488818-99-1	488819-00-7	488819-01-8	488819-02-9	
488819-03-0	488819-04-1	488819-05-2	488819-06-3	488819-07-4
488819-08-5	488819-14-3	488819-16-5	488819-17-6	
488819-18-7	488819-19-8	488819-20-1	488819-21-2	
488819-22-3	488819-23-4	488819-24-5	488819-25-6	488819-26-7
488819-27-8	488819-28-9			

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(substituted tetracycline compds. for treatment of malaria)

IT	488819-29-0	488819-30-3	488819-31-4	488819-32-5	488819-33-6
	488819-34-7	488819-35-8	488819-36-9	488819-37-0	488819-38-1
	488819-39-2	488819-40-5	488819-41-6	488819-42-7	488819-43-8
	488819-44-9	488819-45-0	488819-46-1	488819-47-2	488819-48-3
	488819-49-4	488819-50-7	488819-52-9	488819-53-0	488819-54-1
	488819-55-2	488819-56-3	488819-57-4	488819-58-5	488819-59-6
	488819-60-9	488819-61-0	488819-62-1	488819-63-2	488819-64-3
	488819-65-4	488819-66-5	488819-67-6	488819-68-7	488819-69-8
	488819-70-1	488819-71-2	488819-72-3	488819-73-4	488819-74-5

488819-75-6	488819-76-7	488819-77-8	488819-78-9	488819-79-0
488819-80-3	488819-82-5	488819-84-7	488819-85-8	488819-86-9
488819-87-0	488819-88-1	488819-89-2	488819-90-5	488819-91-6
488819-92-7	488819-93-8	488819-94-9	488819-95-0	488819-96-1
488819-97-2	488819-98-3	488819-99-4	488820-00-4	488820-01-5
488820-02-6	488820-03-7	488820-04-8	488820-05-9	488820-06-0
488820-07-1	488820-09-3	488820-10-6	488820-11-7	488820-12-8
488820-13-9	488820-14-0	488820-15-1	488820-16-2	
488820-17-3	488820-18-4	488820-19-5	488820-20-8	488820-21-9
488820-22-0	488820-23-1	488820-24-2	488820-25-3	488820-26-4
488820-27-5	488820-28-6	488820-29-7	488820-30-0	
488820-31-1	488820-32-2	488820-33-3	488820-34-4	488820-43-5
488820-48-0	577795-55-2	577795-64-3	601454-79-9	601454-80-2
601454-82-4	601454-85-7	601454-92-6	601454-95-9	
601454-97-1	601454-98-2	601454-99-3	601455-02-1	
601455-03-2	601455-04-3	601455-05-4	601455-07-6	601455-09-8
601455-11-2	601455-12-3	601455-13-4	601455-15-6	601455-16-7
601455-17-8	601455-18-9	601455-19-0	601455-20-3	601455-21-4
601455-22-5	601455-23-6	601455-24-7	601455-25-8	601455-26-9
601455-27-0	601455-29-2	601455-30-5	601455-31-6	601455-32-7
601455-33-8	601455-34-9	601455-35-0	601455-36-1	601455-37-2
601455-38-3	601455-39-4	601455-41-8	601455-42-9	601455-43-0
601455-44-1	601455-45-2	601455-46-3	601455-47-4	601455-49-6
601455-50-9	601455-52-1	601455-53-2	601455-54-3	601455-55-4
601455-56-5	601455-57-6	601455-58-7	601455-60-1	601455-62-3
601455-63-4	601455-65-6	601455-66-7	601455-67-8	601455-68-9
601455-69-0	601455-71-4	601455-72-5	601455-73-6	601455-75-8
601455-76-9	601455-77-0	601455-78-1	601455-79-2	601455-80-5
601455-81-6	601455-83-8	601455-84-9	601455-85-0	601455-86-1
601455-87-2	601455-89-4	601455-90-7	601455-91-8	601455-92-9
601455-95-2	601470-72-8	607400-44-2	607400-46-4	607400-50-0
607400-72-6	607401-16-1	607401-26-3	607401-28-5	607401-38-7
607401-41-2	607401-43-4	607401-45-6	607401-48-9	607401-54-7
607401-57-0	607401-59-2	607401-63-8	607401-65-0	607401-67-2
607401-69-4	607401-71-8	607401-73-0	607401-75-2	607401-77-4
607401-79-6	607401-81-0	607401-83-2	607401-86-5	607401-98-9
607402-03-9	607402-08-4	607402-10-8	607402-12-0	607402-14-2
607402-16-4	607402-18-6	607402-20-0	607402-22-2	607402-24-4
607402-28-8	607402-58-4	607402-71-1	607402-72-2	607402-73-3

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(substituted tetracycline compds. for treatment of malaria)

IT	607402-74-4	607402-75-5	607402-76-6	607402-77-7	607402-79-9
	607402-80-2	607402-81-3	607402-82-4	607402-83-5	607402-84-6
	607402-85-7	607738-53-4	644995-53-9	685831-46-3	685831-47-4
	685831-48-5	685831-49-6	685831-50-9	685831-51-0	685831-52-1
	685832-62-6	685832-63-7	685832-64-8	685832-65-9	
	685832-66-0	685832-68-2	685832-71-7	685832-75-1	685832-82-0
	685832-83-1	685832-84-2	685832-85-3	685832-86-4	685832-87-5
	685832-88-6	685832-89-7	685832-90-0	685832-91-1	685832-92-2
	685832-93-3	685832-94-4	685832-95-5	685832-96-6	685832-97-7
	685832-98-8	685832-99-9	685833-00-5	685833-01-6	685833-02-7
	685833-03-8	685833-04-9	685833-05-0	685833-06-1	685833-07-2
	685833-08-3	685833-09-4	685833-10-7	685833-11-8	685833-12-9
	685833-13-0	685833-14-1	685833-15-2	685833-16-3	685833-17-4
	685833-18-5	685833-19-6	685833-20-9	685833-21-0	685833-22-1
	685833-23-2	685833-24-3	685833-25-4	685833-26-5	685833-27-6
	685833-28-7	685833-29-8	685833-30-1	685833-31-2	685833-32-3
	685833-33-4	685833-34-5	685833-35-6	685833-36-7	685833-37-8
	685833-38-9	685833-39-0	685833-40-3	685833-41-4	685833-42-5

685833-43-6	685833-44-7	685833-45-8	685833-46-9	685833-47-0
685833-48-1	685833-49-2	685833-50-5	685833-51-6	685833-52-7
685833-53-8	685833-54-9	685833-55-0	685833-56-1	685833-57-2
685833-66-3	685833-68-5	685833-69-6	685833-82-3	685834-60-0
685834-61-1	685834-62-2	685834-63-3	685834-71-3	685834-72-4
685834-74-6	685834-75-7	685834-76-8	685834-77-9	
685834-83-7	685834-85-9	685834-88-2	685834-89-3	685834-91-7
685834-92-8	685834-93-9	685859-06-7	685859-07-8	685859-08-9
685859-09-0	685859-10-3	685859-11-4	685859-12-5	685859-14-7
685859-18-1	685859-19-2	685859-20-5	685859-21-6	685859-24-9
685859-28-3	685859-34-1	685859-35-2	685860-95-1	
685860-96-2	685860-97-3	685860-98-4	685860-99-5	685861-00-1
685861-04-5	685861-07-8	685862-44-6	685881-89-4	685881-91-8

RL: PAC (Pharmacological activity); THU (Therapeutic

use); BIOL (Biological study); USES (Uses)

(substituted tetracycline compds. for treatment of malaria)

L56 ANSWER 2 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:633439 HCAPLUS Full-text

DOCUMENT NUMBER: 141:167771

TITLE: Tetracycline compounds having target therapeutic activities

INVENTOR(S): Levy, Stuart B.; Draper, Michael; Nelson, Mark L.; Jones, Graham

PATENT ASSIGNEE(S): Paratek Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 277 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004064728	A2	20040805	WO 2004-US1036	20040116
WO 2004064728	A3	20041216		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NA, NI				
US 2006194773	A1	20060831	US 2004-996119	20041122 <--
PRIORITY APPLN. INFO.:			US 2003-441141P	P 20030116
			US 2001-305546P	P 20010713 <--
			US 2002-395741P	P 20020712 <--
			US 2002-196010	A2 20020715 <--
			US 2004-759484	B1 20040116

OTHER SOURCE(S): MARPAT 141:167771

AB Methods and compds. for treating diseases, e.g. inflammation process-associated states, with tetracycline compds. having a target therapeutic activity are described. Preparation of selected tetracycline compds. is described.

IT 53108-41-1 459809-44-0 460071-69-6
 460073-37-4 460073-70-5 460073-72-7
 460073-74-9 460074-19-5 488815-54-9
 488815-55-0 488815-56-1 488815-63-0
 488817-32-9 488818-13-9 488818-17-3
 488818-20-8 488818-21-9 488818-27-5
 488818-31-1 488818-45-7 488818-60-6
 488818-63-9 488818-82-2 488819-02-9
 488819-08-5 488819-19-8 488820-15-1

488820-27-5 601454-83-5 601454-96-0

731030-71-0


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(tetracycline compds. with target therapeutic activities)

RN 53108-41-1 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-7-[(dimethylamino)methyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, [4S-(4a,4aa,5aa,12aa)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 459809-44-0 HCAPLUS

CN 3-Pyridinecarboxamide, N-[[[(6aS,10S,10aS,11aR)-8-(aminocarbonyl)-10-(dimethylamino)-3-(1,1-dimethylethyl)-5,6a,7,10,10a,11,11a,12-octahydro-4,6,6a,9-tetrahydroxy-5,7-dioxo-1-naphthacenyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 460071-69-6 HCAPLUS

CN Carbamic acid, [[[(6aS,10S,10aS,11aR)-8-(aminocarbonyl)-10-(dimethylamino)-5,6a,7,10,10a,11,11a,12-octahydro-4,6,6a,9-tetrahydroxy-5,7-dioxo-1-naphthacenyl]methyl]-, 2-methylpropyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 460073-37-4 HCAPLUS

CN 2-Naphthacenecarboxamide, 7-[[bis(2-methylpropyl)amino]methyl]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 460073-70-5 HCAPLUS

CN 2-Naphthacenecarboxamide, 7-[[bis(2,2-dimethoxyethyl)amino]methyl]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 460073-72-7 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-7-[[[(1-methyl-1H-pyrrol-2-yl)methyl]amino]methyl]-1,11-dioxo-, (4S,4aS,5aR,12aS)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 460073-74-9 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-7-[[[(1H-pyrrol-2-ylmethyl)amino]methyl]-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 460074-19-5 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-7,9-bis[[[(2,2-dimethylpropyl)amino]methyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 488815-54-9 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-7-[[[(2,2-dimethylpropyl)amino]methyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-

10692764

tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 488815-55-0 HCAPLUS

CN 2-Naphthacenecarboxamide, 7-[(diethylamino)methyl]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 488815-56-1 HCAPLUS

CN 2-Naphthacenecarboxamide, 7-[[bis(cyclopropylmethyl)amino]methyl]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 488815-63-0 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-7-[[[(2-methylpropyl)amino]methyl]-1,11-dioxo-, (4S,4aS,5aR,12aS) - (9CI) (CA INDEX NAME)

10692764

(4S,4aS,5aR,12aS) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 488817-32-9 HCAPLUS

CN 1,8-Naphthacenedicarboxamide, 10-(dimethylamino)-5,6a,7,10,10a,11,11a,12-octahydro-4,6,6a,9,11-pentahydroxy-N1,N1,12-trimethyl-5,7-dioxo-, (6aS,10S,10aR,11S,11aR,12R) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 488818-13-9 HCAPLUS

CN 4-Pyrimidinecarboxamide, N-[[(6aS,10S,10aR,11aR) -8-(aminocarbonyl) -10-(dimethylamino) -5,6a,7,10,10a,11,11a,12-octahydro-4,6,6a,9-tetrahydroxy-5,7-dioxo-1-naphthacenyl]methyl] -1,6-dihydro-6-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 488818-17-3 HCAPLUS

CN 4-Pyridinecarboxamide, N-[[(6aS,10S,10aR,11aR) -8-(aminocarbonyl) -10-(dimethylamino) -5,6a,7,10,10a,11,11a,12-octahydro-4,6,6a,9-tetrahydroxy-

10692764

5,7-dioxo-1-naphthacenyl]methyl]-, 1-oxide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 488818-20-8 HCAPLUS

CN 4-Isoxazolecarboxamide, N-[[[(6aS,10S,10aS,11aR)-8-(aminocarbonyl)-10-(dimethylamino)-5,6a,7,10,10a,11,11a,12-octahydro-4,6,6a,9-tetrahydroxy-5,7-dioxo-1-naphthacenyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 488818-21-9 HCAPLUS

CN 3-Pyridinecarboxamide, N-[[[(6aS,10S,10aS,11aR)-8-(aminocarbonyl)-10-(dimethylamino)-5,6a,7,10,10a,11,11a,12-octahydro-4,6,6a,9-tetrahydroxy-5,7-dioxo-1-naphthacenyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 488818-27-5 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-7-[[[(1-methylethyl)amino]methyl]-1,11-dioxo-, (4S,4aS,5aR,12aS) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 488818-31-1 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-7-[[[(1-oxido-4-pyridinyl)methyl]amino]methyl]-1,11-dioxo-, (4S,4aS,5aR,12aS) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 488818-45-7 HCAPLUS

CN 1,8-Naphthacenedicarboxamide, 10-(dimethylamino)-5,6a,7,10,10a,11,11a,12-octahydro-4,6,6a,9-tetrahydroxy-N1,N1-dimethyl-5,7-dioxo-, (4S,4aS,5aR,12aS) - (9CI) (CA INDEX NAME)

10692764

(6aS,10S,10aS,11aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 488818-60-6 HCAPLUS

CN 4-Morpholinecarboxamide, N-[[[(6aS,10S,10aS,11aR)-8-(aminocarbonyl)-10-(dimethylamino)-3-ethynyl-5,6a,7,10,10a,11,11a,12-octahydro-4,6,6a,9-tetrahydroxy-5,7-dioxo-1-naphthacenyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 488818-63-9 HCAPLUS

CN 4-Morpholinecarboxamide, N-[[[(6aS,10S,10aS,11aR)-8-(aminocarbonyl)-10-(dimethylamino)-3-ethyl-5,6a,7,10,10a,11,11a,12-octahydro-4,6,6a,9-tetrahydroxy-5,7-dioxo-1-naphthacenyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 488818-82-2 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-7-[[[(2-fluoro-1-methylethyl)amino]methyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 488819-02-9 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-7-[[[(4-fluorophenyl)methyl]amino]methyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 488819-08-5 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-7-[[[(phenylmethyl)amino]methyl]-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 488819-19-8 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-7-[[[(2,2-dimethylpropyl)amino]methyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-[(methylthio)methyl]-1,11-dioxo-, (4S,4aS,5aR,12aS)-(9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 488820-15-1 HCAPLUS

CN 2-Naphthacenecarboxamide, 7-[(acetylamino)methyl]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 488820-27-5 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-7-[[[(2,2-dimethyl-1-oxopropyl)amino]methyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 601454-83-5 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-7-[[[(1-methylpropyl)amino]methyl]-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 601454-96-0 HCAPLUS

CN 4-Morpholinecarboxamide, N-[[[(6aS,10R,10aS,11aR)-8-(aminocarbonyl)-10-(dimethylamino)-3-ethynyl-5,6a,7,10,10a,11,11a,12-octahydro-4,6,6a,9-tetrahydroxy-5,7-dioxo-1-naphthacenyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 731030-71-0 HCAPLUS

CN 2-Naphthacenecarboxamide, 7-[[[bis(dimethoxymethyl)amino]methyl]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IC ICM A61K
 CC 1-7 (Pharmacology)
 Section cross-reference(s): 26
 IT Nervous system, disease
 (*Huntington's* chorea; tetracycline compds. with target
 therapeutic activities)
 IT Tumor necrosis factors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (TNF- α antagonists; tetracycline compds. with target therapeutic
 activities)
 IT Diabetes mellitus
 (and diabetic complications; tetracycline compds. with target
 therapeutic activities)
 IT Autoimmune disease
 (insulin-dependent *diabetes* mellitus; tetracycline compds.
 with target therapeutic activities)
 IT Diabetes mellitus
 (insulin-dependent; tetracycline compds. with target therapeutic
 activities)
 IT Bone, neoplasm
 Sarcoma
 (osteosarcoma; tetracycline compds. with target therapeutic activities)
 IT Adhesion, biological
 Aging, animal
 Alzheimer's disease
 Amnesia
 Aneurysm
 Angiogenesis
 Angiogenesis inhibitors
 Anti-Alzheimer's agents
 Anti-infective agents
 Anti-inflammatory agents
 Anti-ischemic agents
 Antiartherosclerotics
 Antiarthritics
 Antiasthmatics
 Antibacterial agents
 Antibiotics
 Anticonvulsants
 Antidepressants
 Antidiabetic agents
 Antihypertensives
 Antimalarials
 Antimigraine agents

Antioxidants
 Antiparkinsonian agents
 Antipsychotics
 Antirheumatic agents
 Antitumor agents
 Antiulcer agents
 Antiviral agents
 Anxiety
 Anxiolytics
 Arteriosclerosis
 Asthma
 Atherosclerosis
 Calcium channel blockers
 Carcinoma
 Cardiovascular agents
 Cell migration
 Chemotherapy
 Cognition enhancers
 Combination chemotherapy
 Cystic fibrosis
 Drug delivery systems
 Emphysema
 Epilepsy
 Escherichia coli
 Eye, disease
 Fungicides
 Gastrointestinal agents
 Ginkgo biloba
 Hepatitis
 Human
 Hypertension
 Infection
 Inflammation
 Ischemia
 Learning disorders
 Macrophage
 Malaria
 Memory disorders
 Mental and behavioral disorders
 Mitochondria
 Multiple sclerosis
 Neoplasm
 Nervous system, disease
 Nervous system agents
 Opioid antagonists
 Osteoarthritis
 Osteomyelitis
 Parasitocides
 Parkinson's disease
 Psychotropics
 Radiotherapy
 Rheumatoid arthritis
 Sarcoma
 Schizophrenia
 Skin, disease
 Sleep disorders
 Sodium channel blockers
 Staphylococcus aureus
 Ulcer
 Wernicke-Korsakoff syndrome

Wound

Wound healing promoters

(tetracycline compds. with target therapeutic activities)

IT 50-81-7, Vitamin C, biological studies 53-03-2, Prednisone 60-54-8D, Tetracycline, derivs. 302-79-4, Retinoic acid 303-98-0, Coenzyme Q10 987-78-0, CDP-choline 1134-47-0, Baclofen 1406-18-4, Vitamin E 1645-21-2 1665-56-1 1744-22-5, Riluzole 2444-65-7 2763-96-4, Muscimol 3219-99-6 3242-03-3 4495-20-9 4497-07-8 4497-08-9 4656-99-9 5679-02-7 5874-95-3 5995-55-1 7518-17-4 7782-49-2, Selenium, biological studies 10118-89-5 10118-92-0 11096-26-7, Erythropoietin 11103-57-4, Vitamin A 14206-58-7 14297-93-9 14611-51-9, Selegiline 15866-90-7 16145-05-4 24290-70-8 31642-30-5 31981-85-8 35689-63-5 35689-65-7 53108-40-0 **53108-41-1** 53173-80-1 57828-26-9, Lipoic acid 59046-79-6 60142-96-3, Gabapentin 77901-56-5 84057-84-1, Lamotrigine 88828-25-5 112924-45-5, Dexanabinol 115207-75-5 120793-45-5 128298-28-2, Remacemide 146253-71-6 146253-75-0 146278-01-5 146278-02-6 146278-03-7 149934-16-7 149934-19-0 151922-17-7 153621-68-2 155819-14-0 155819-18-4 161320-33-8 161321-34-2 161452-36-4 180002-76-0 186759-47-7 186759-49-9 186759-51-3 186759-53-5 186759-55-7 186759-61-5 220620-09-7 233585-95-0 233585-96-1 233585-97-2 233586-02-2 233586-03-3 233586-04-4 233586-06-6 233586-07-7 233586-08-8 233586-09-9 233586-10-2 233586-11-3 233586-12-4 233586-16-8 263258-27-1 263258-30-6 263258-33-9 263258-38-4 263258-83-9 263258-85-1 263258-86-2 263258-87-3 263258-89-5 263259-00-3 263760-96-9 263760-98-1 263761-01-9 263761-02-0 263761-08-6 269724-94-9 269724-95-0 269725-01-1 269725-54-4 295356-11-5 295356-12-6 295356-13-7 295356-16-0 295356-17-1 330627-21-9 330627-22-0 330627-23-1 330627-24-2 330627-26-4 330627-27-5 330627-32-2 344771-54-6 351336-92-0 351336-94-2 365276-98-8 365276-99-9 365277-00-5 365277-01-6 365277-02-7 365277-03-8 365277-04-9 365277-05-0 365277-06-1 365277-08-3 365277-11-8 365277-12-9 365277-13-0 365277-14-1 365277-19-6 365277-20-9 365277-21-0 365277-22-1 365277-23-2 365277-24-3 365277-26-5 365277-28-7 365277-29-8 365277-34-5 365277-35-6 365277-36-7 365277-37-8 365277-38-9 365277-39-0 365277-40-3 365277-41-4 365277-42-5 365277-43-6 365277-44-7 365277-45-8 365277-46-9 365277-47-0 365277-49-2 365277-50-5 365277-51-6 365277-52-7 365277-53-8 365277-54-9 365277-55-0 365277-57-2 365277-58-3 365277-59-4 365277-60-7 365277-61-8 365277-62-9 365277-63-0 365277-64-1 365277-65-2 365277-66-3 365277-88-9 374748-06-8 380435-62-1 380435-65-4 380435-76-7 380435-88-1 389081-55-4 389081-56-5 389081-58-7 389081-60-1 389081-61-2 389081-62-3 389081-63-4 389081-65-6 389081-66-7 389081-67-8 389081-68-9 389081-69-0 389081-71-4 389081-72-5 389081-73-6 389081-74-7 389081-75-8 389081-76-9 389081-77-0 389081-78-1 389081-79-2 389081-80-5 389081-85-0 389139-10-0 389139-12-2 389139-15-5 389139-16-6 389139-17-7 389139-18-8 389139-20-2 389139-22-4 389139-23-5 389139-24-6 389139-25-7 389139-26-8 389139-27-9 389139-28-0 389139-29-1 389139-31-5 389139-32-6 389139-34-8 389139-35-9 389139-36-0 389139-37-1 389139-38-2 389139-39-3 389139-40-6 389139-41-7 389139-42-8 389139-43-9 389139-44-0 389139-45-1 389139-46-2 389139-47-3 389139-48-4

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(tetracycline compds. with target therapeutic activities)

IT 389139-49-5 389139-51-9 389139-52-0 389139-53-1 389139-54-2 389139-55-3 389139-56-4 389139-57-5 389139-58-6 389139-59-7 389139-60-0 389139-61-1 389139-62-2 389139-63-3 389139-65-5 389139-67-7 389139-68-8 389139-69-9 389139-70-2 389139-71-3

389139-72-4	389139-73-5	389139-74-6	389139-75-7	389139-76-8
389139-79-1	389139-80-4	389139-81-5	389139-82-6	389139-83-7
389139-85-9	389139-86-0	389139-87-1	389139-88-2	389139-89-3
389139-90-6	389139-91-7	389139-92-8	389139-93-9	389139-94-0
389139-96-2	389139-98-4	389139-99-5	389140-00-5	389140-01-6
389140-03-8	389140-04-9	389140-06-1	389570-43-8	389570-46-1
389570-49-4	389570-50-7	389570-51-8	389570-52-9	389570-53-0
389570-54-1	389623-72-7	389623-80-7	389623-82-9	389623-86-3
389623-88-5	389623-89-6	389623-93-2	389623-95-4	389623-96-5
389623-97-6	389623-98-7	389623-99-8	389624-01-5	389624-02-6
389624-03-7	389624-04-8	389624-05-9	389624-07-1	389624-08-2
389624-09-3	389624-12-8	389624-13-9	389624-14-0	389624-15-1
389624-18-4	389624-20-8	389624-21-9	389624-22-0	389624-23-1
389624-24-2	389624-26-4	389624-27-5	389624-28-6	389624-29-7
389624-30-0	389624-32-2	389624-33-3	389624-34-4	389624-35-5
389624-36-6	389624-38-8	389624-39-9	389624-41-3	389624-43-5
389624-44-6	389624-45-7	389624-49-1	389624-51-5	389624-52-6
389624-54-8	389624-55-9	389624-56-0	389624-57-1	389624-59-3
389624-62-8	389624-63-9	389624-66-2	389624-67-3	389624-68-4
389624-69-5	389624-71-9	389624-73-1	389624-75-3	389624-76-4
389624-77-5	389624-79-7	389624-81-1	389624-84-4	389624-85-5
389624-86-6	389624-87-7	389624-88-8	389624-90-2	389624-91-3
389624-92-4	389624-93-5	389624-97-9	389624-98-0	389625-00-7
389625-01-8	389625-02-9	389625-05-2	389625-06-3	389625-07-4
389625-07-4	389625-09-6	389625-09-6	389625-10-9	389625-11-0
389625-12-1	439217-57-9	439217-59-1	459425-79-7	459425-80-0
459425-96-8	459426-11-0	459809-42-8	459809-43-9	459809-44-0
459809-45-1	459809-46-2	459809-47-3	459809-50-8	459809-51-9
459809-53-1	459809-54-2	459809-55-3	459809-56-4	459809-57-5
459809-58-6	459809-59-7	459809-61-1	459809-63-3	459809-65-5
459809-66-6	459809-67-7	459809-68-8	459809-70-2	459809-72-4
459809-74-6	459809-76-8	459809-77-9	459809-79-1	459809-81-5
459809-82-6	459809-86-0	459809-88-2	459809-91-7	459809-92-8
459809-93-9	459809-94-0	459809-95-1	459809-96-2	459809-97-3
459809-98-4	459810-00-5	459810-01-6	459810-02-7	459810-03-8
459810-04-9	459810-05-0	459810-06-1	459810-07-2	459810-09-4
460068-26-2	460068-27-3	460068-29-5	460068-30-8	460068-31-9
460068-32-0	460068-33-1	460068-34-2	460068-35-3	460068-36-4
460068-38-6	460068-39-7	460068-40-0	460068-41-1	460068-42-2
460068-43-3	460068-44-4	460068-45-5	460068-46-6	460068-47-7
460068-48-8	460068-49-9	460068-50-2	460068-51-3	460068-52-4
460068-53-5	460068-54-6	460068-55-7	460068-57-9	460068-58-0
460068-59-1	460068-60-4	460068-62-6	460068-63-7	460068-64-8
460068-65-9				

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(tetracycline compds. with target therapeutic activities)

IT	460068-66-0	460068-67-1	460068-68-2	460068-69-3	460068-70-6
	460068-71-7	460068-72-8	460068-73-9	460068-74-0	460068-75-1
	460068-76-2	460068-77-3	460068-78-4	460068-79-5	460068-80-8
	460068-81-9	460068-82-0	460068-83-1	460068-84-2	460068-85-3
	460068-86-4	460068-87-5	460068-88-6	460068-90-0	460068-92-2
	460068-93-3	460068-94-4	460068-95-5	460068-96-6	460068-97-7
	460068-99-9	460069-34-5	460069-38-9	460069-65-2	460069-70-9
	460069-89-0	460069-96-9	460070-02-4	460070-53-5	460070-61-5
	460070-66-0	460070-73-9	460070-76-2	460070-79-5	460070-92-2
	460070-95-5	460071-02-7	460071-04-9	460071-06-1	460071-09-4
	460071-12-9	460071-14-1	460071-17-4	460071-19-6	460071-29-8
	460071-31-2	460071-33-4	460071-66-3	460071-69-6	
	460071-80-1	460071-83-4	460071-87-8	460071-89-0	460071-91-4

460071-93-6	460071-97-0	460071-99-2	460072-01-9	460072-03-1
460072-05-3	460072-07-5	460072-09-7	460072-10-0	460072-12-2
460072-15-5	460072-17-7	460072-19-9	460072-21-3	460072-25-7
460072-28-0	460072-29-1	460072-30-4	460072-31-5	460072-33-7
460072-36-0	460072-38-2	460072-40-6	460072-43-9	460072-45-1
460072-47-3	460072-49-5	460072-53-1	460072-55-3	460072-57-5
460072-59-7	460072-61-1	460072-63-3	460072-65-5	460072-70-2
460072-73-5	460072-75-7	460072-78-0	460072-82-6	460072-86-0
460072-89-3	460072-91-7	460072-93-9	460072-99-5	460073-01-2
460073-03-4	460073-05-6	460073-07-8	460073-07-8	460073-09-0
460073-11-4	460073-15-8	460073-17-0	460073-21-6	460073-22-7
460073-23-8	460073-25-0	460073-27-2	460073-29-4	460073-31-8
460073-33-0	460073-35-2	460073-37-4	460073-40-9	
460073-41-0	460073-43-2	460073-45-4	460073-47-6	460073-49-8
460073-51-2	460073-53-4	460073-55-6	460073-58-9	460073-60-3
460073-62-5	460073-64-7	460073-68-1	460073-70-5	
460073-72-7	460073-74-9	460073-76-1	460073-78-3	
460073-80-7	460073-82-9	460073-84-1	460073-86-3	460073-88-5
460073-90-9	460073-92-1	460073-94-3	460073-96-5	460074-00-4
460074-02-6	460074-04-8	460074-06-0	460074-09-3	460074-09-3
460074-11-7	460074-13-9	460074-15-1	460074-17-3	460074-19-5
460074-21-9	460074-23-1	460074-26-4	460074-28-6	460074-30-0
460074-32-2	460074-34-4	460074-36-6	460074-38-8	460074-40-2
460074-42-4	460074-44-6	460074-46-8	460074-48-0	460074-50-4
460074-52-6	460074-54-8	460074-56-0	460074-58-2	460074-60-6
460074-62-8	460074-64-0	460074-66-2	460074-68-4	460074-69-5
460074-71-9	460074-73-1	460074-75-3	460074-77-5	460074-79-7
460074-81-1	460074-85-5	460074-87-7	460074-89-9	460074-91-3
460074-93-5	460074-95-7	460074-97-9	460074-99-1	460075-04-1
460075-06-3	460075-08-5	460075-12-1	460075-14-3	460075-62-1
460076-23-7	460082-61-5	460082-62-6	460082-77-3	460082-87-5
460082-89-7	460082-90-0	470661-76-8	473718-07-9	473973-13-6
473973-20-5	473973-34-1	473973-37-4	473973-41-0	473973-62-5
473973-64-7	473973-86-3	473973-96-5	473974-12-8	473974-75-3
473974-76-4	473974-77-5	473974-79-7	473974-80-0	473974-81-1

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(tetracycline compds. with target therapeutic activities)

IT	473974-82-2	473974-83-3	473974-84-4	473974-85-5	488815-52-7
	488815-53-8	488815-54-9	488815-55-0		
	488815-56-1	488815-57-2	488815-59-4	488815-60-7	
	488815-61-8	488815-62-9	488815-63-0	488815-64-1	
	488815-65-2	488815-66-3	488815-67-4	488815-68-5	488815-69-6
	488815-70-9	488815-71-0	488815-72-1	488815-73-2	488815-74-3
	488815-75-4	488815-76-5	488815-77-6	488815-78-7	488815-79-8
	488815-80-1	488815-82-3	488815-89-0	488815-93-6	488815-98-1
	488816-00-8	488816-09-7	488816-13-3	488816-16-6	488816-18-8
	488816-19-9	488816-26-8	488816-37-1	488816-39-3	488816-42-8
	488816-54-2	488816-55-3	488816-58-6	488816-59-7	488816-64-4
	488816-65-5	488816-70-2	488816-71-3	488816-73-5	488816-75-7
	488816-82-6	488816-86-0	488816-88-2	488816-92-8	488816-93-9
	488816-98-4	488817-01-2	488817-06-7	488817-11-4	488817-13-6
	488817-14-7	488817-15-8	488817-16-9	488817-17-0	488817-18-1
	488817-19-2	488817-20-5	488817-21-6	488817-22-7	488817-23-8
	488817-24-9	488817-25-0	488817-26-1	488817-27-2	488817-28-3
	488817-29-4	488817-30-7	488817-31-8	488817-32-9	
	488817-33-0	488817-34-1	488817-35-2	488817-36-3	488817-37-4
	488817-38-5	488817-39-6	488817-40-9	488817-41-0	488817-42-1
	488817-43-2	488817-44-3	488817-45-4	488817-46-5	488817-47-6
	488817-48-7	488817-49-8	488817-50-1	488817-51-2	488817-52-3

488817-53-4	488817-54-5	488817-55-6	488817-56-7	488817-57-8
488817-58-9	488817-59-0	488817-60-3	488817-61-4	488817-62-5
488817-63-6	488817-64-7	488817-65-8	488817-66-9	488817-67-0
488817-68-1	488817-69-2	488817-70-5	488817-71-6	488817-72-7
488817-73-8	488817-74-9	488817-75-0	488817-76-1	488817-77-2
488817-78-3	488817-79-4	488817-80-7	488817-81-8	488817-82-9
488817-89-6	488817-91-0	488817-92-1	488817-93-2	488817-94-3
488817-95-4	488817-96-5	488817-97-6	488817-98-7	488817-99-8
488818-00-4	488818-01-5	488818-02-6	488818-03-7	488818-04-8
488818-05-9	488818-06-0	488818-07-1	488818-08-2	488818-09-3
488818-10-6	488818-11-7	488818-12-8	488818-13-9	
488818-14-0	488818-15-1	488818-16-2	488818-17-3	
488818-18-4	488818-19-5	488818-20-8	488818-21-9	
488818-22-0	488818-23-1	488818-24-2	488818-25-3	488818-26-4
488818-27-5	488818-28-6	488818-29-7	488818-30-0	
488818-31-1	488818-32-2	488818-33-3	488818-34-4	
488818-35-5	488818-36-6	488818-37-7	488818-38-8	488818-39-9
488818-40-2	488818-41-3	488818-42-4	488818-43-5	488818-44-6
488818-45-7	488818-46-8	488818-47-9	488818-48-0	
488818-49-1	488818-50-4	488818-51-5	488818-52-6	488818-53-7
488818-54-8	488818-55-9	488818-56-0	488818-57-1	488818-58-2
488818-59-3	488818-60-6	488818-61-7	488818-63-9	
488818-64-0	488818-65-1	488818-66-2	488818-67-3	488818-68-4
488818-69-5	488818-70-8	488818-71-9	488818-72-0	488818-73-1
488818-74-2	488818-75-3	488818-76-4	488818-77-5	488818-78-6
488818-79-7	488818-80-0	488818-81-1	488818-82-2	
488818-83-3	488818-84-4	488818-85-5	488818-86-6	488818-87-7
488818-88-8	488818-89-9	488818-90-2	488818-91-3	

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(tetracycline compds. with target therapeutic activities)

IT	488818-92-4	488818-93-5	488818-94-6	488818-95-7	488818-96-8
	488818-97-9	488818-98-0	488818-99-1	488819-00-7	488819-01-8
	488819-02-9	488819-03-0	488819-04-1	488819-05-2	
	488819-06-3	488819-07-4	488819-08-5	488819-14-3	
	488819-15-4	488819-16-5	488819-17-6	488819-18-7	488819-19-8
	488819-20-1	488819-21-2	488819-22-3	488819-23-4	488819-24-5
	488819-25-6	488819-26-7	488819-27-8	488819-28-9	488819-29-0
	488819-30-3	488819-31-4	488819-32-5	488819-33-6	488819-34-7
	488819-35-8	488819-36-9	488819-37-0	488819-38-1	488819-39-2
	488819-40-5	488819-41-6	488819-42-7	488819-43-8	488819-44-9
	488819-45-0	488819-46-1	488819-47-2	488819-48-3	488819-49-4
	488819-50-7	488819-51-8	488819-52-9	488819-53-0	488819-54-1
	488819-55-2	488819-56-3	488819-57-4	488819-58-5	488819-59-6
	488819-60-9	488819-61-0	488819-62-1	488819-63-2	488819-64-3
	488819-65-4	488819-66-5	488819-67-6	488819-68-7	488819-69-8
	488819-70-1	488819-71-2	488819-72-3	488819-73-4	488819-74-5
	488819-75-6	488819-76-7	488819-77-8	488819-78-9	488819-79-0
	488819-80-3	488819-81-4	488819-82-5	488819-83-6	488819-84-7
	488819-85-8	488819-86-9	488819-87-0	488819-88-1	488819-89-2
	488819-90-5	488819-91-6	488819-92-7	488819-93-8	488819-94-9
	488819-95-0	488819-96-1	488819-97-2	488819-98-3	488819-99-4
	488820-00-4	488820-01-5	488820-02-6	488820-03-7	488820-04-8
	488820-05-9	488820-06-0	488820-07-1	488820-08-2	488820-09-3
	488820-10-6	488820-11-7	488820-12-8	488820-13-9	488820-14-0
	488820-15-1	488820-16-2	488820-17-3	488820-18-4	
	488820-19-5	488820-20-8	488820-21-9	488820-22-0	488820-23-1
	488820-24-2	488820-25-3	488820-26-4	488820-27-5	
	488820-28-6	488820-29-7	488820-30-0	488820-31-1	488820-32-2
	488820-33-3	488820-34-4	488820-42-4	488820-43-5	488820-45-7

488820-46-8	488820-47-9	488820-48-0	488820-49-1	488820-50-4
488821-84-7	511269-36-6	511269-46-8	558468-21-6	558468-22-7
558468-23-8	558468-25-0	558468-26-1	558468-27-2	558468-28-3
558468-29-4	558468-30-7	558468-31-8	558468-32-9	558468-34-1
558468-35-2	558468-36-3	558468-43-2	558468-44-3	558468-45-4
558468-46-5	558468-47-6	558468-50-1	558468-51-2	558468-52-3
558468-53-4	558468-54-5	558468-55-6	558468-56-7	558468-57-8
558468-58-9	558468-59-0	558468-63-6	558468-64-7	558468-65-8
558468-66-9	558468-67-0	558468-69-2	558468-70-5	558468-71-6
558468-72-7	558468-73-8	558468-73-8	558468-74-9	558468-75-0
558468-77-2	558468-78-3	558468-80-7	558468-81-8	558468-82-9
558468-88-5	558468-89-6	558468-90-9	558468-92-1	558468-93-2
558468-94-3	558468-95-4	558468-96-5	558468-97-6	558468-98-7
558468-99-8	558469-00-4	558469-01-5	558469-02-6	558469-03-7
558469-04-8	558469-05-9	558469-06-0	558469-07-1	558469-08-2
558469-09-3	558469-10-6	558469-11-7	558469-12-8	558469-13-9
558469-14-0	558469-15-1	558469-16-2	558469-17-3	558469-18-4
558469-19-5	558469-20-8	558469-21-9	558469-22-0	558469-23-1
558469-24-2	558469-25-3	558469-26-4	558469-27-5	558469-28-6

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(tetracycline compds. with target therapeutic activities)

IT	558469-29-7	558469-30-0	558469-31-1	558469-32-2	558469-33-3
	558469-34-4	558469-35-5	558469-36-6	558469-37-7	558469-38-8
	558469-40-2	558469-41-3	558469-42-4	558469-43-5	558469-44-6
	558469-46-8	558469-47-9	558469-48-0	558469-49-1	558469-50-4
	558469-51-5	558469-52-6	558469-53-7	558469-55-9	558469-56-0
	558469-57-1	558469-60-6	558469-61-7	558469-62-8	558469-63-9
	558469-64-0	558469-67-3	558469-68-4	558469-69-5	558469-71-9
	558469-72-0	558469-76-4	558469-79-7	558469-80-0	558469-81-1
	577795-55-2	601454-83-5	601454-96-0	601455-03-2	
	601455-04-3	601455-05-4	601455-07-6	601455-08-7	601455-09-8
	601455-11-2	601455-12-3	601455-14-5	601455-15-6	601455-18-9
	601455-20-3	601455-21-4	601455-22-5	601455-23-6	601455-25-8
	601455-26-9	601455-27-0	601455-29-2	601455-30-5	601455-31-6
	601455-32-7	601455-34-9	601455-35-0	601455-36-1	601455-37-2
	601455-38-3	601455-39-4	601455-41-8	601455-42-9	601455-43-0
	601455-44-1	601455-45-2	601455-46-3	601455-48-5	601455-50-9
	601455-53-2	601455-54-3	601455-71-4	601455-73-6	601455-90-7
	601455-92-9	607399-77-9	607399-86-0	607400-33-9	607400-40-8
	607400-72-6	607401-13-8	607401-18-3	607401-22-9	607401-28-5
	607401-48-9	607401-50-3	607401-52-5	607401-54-7	607401-57-0
	607401-59-2	607401-61-6	607401-63-8	607401-65-0	607401-67-2
	607401-69-4	607401-71-8	607401-73-0	607401-75-2	607401-77-4
	607401-79-6	607401-81-0	607401-83-2	607401-86-5	607401-98-9
	607402-01-7	607402-03-9	607402-06-2	607402-08-4	607402-10-8
	607402-12-0	607402-14-2	607402-16-4	607402-18-6	607402-20-0
	607402-22-2	607402-24-4	607402-26-6	607402-28-8	607402-31-3
	607402-71-1	607402-73-3	607402-74-4	607402-75-5	607402-76-6
	607402-77-7	607402-79-9	607402-80-2	607402-81-3	616874-81-8
	629597-96-2	685832-83-1	685832-90-0	685832-93-3	685833-08-3
	685833-25-4	685833-45-8	685833-53-8	685833-54-9	685833-56-1
	685833-66-3	685833-68-5	685862-44-6	731019-87-7	731019-88-8
	731019-89-9	731019-90-2	731019-91-3	731019-92-4	731019-93-5
	731019-94-6	731019-95-7	731019-96-8	731019-97-9	731019-98-0
	731019-99-1	731020-00-1	731020-01-2	731020-02-3	731020-03-4
	731020-04-5	731020-05-6	731020-06-7	731020-07-8	731020-08-9
	731020-09-0	731020-10-3	731020-11-4	731020-12-5	731020-13-6
	731020-14-7	731020-15-8	731020-16-9	731020-17-0	731020-18-1
	731020-19-2	731020-20-5	731020-21-6	731020-22-7	731020-23-8

731020-24-9	731020-25-0	731020-26-1	731020-27-2	731020-28-3
731020-29-4	731020-30-7	731020-31-8	731020-32-9	731020-33-0
731020-34-1	731020-35-2	731020-36-3	731020-37-4	731020-38-5
731020-39-6	731020-40-9	731020-41-0	731020-42-1	731020-43-2
731020-44-3	731020-45-4	731020-46-5	731020-47-6	731020-48-7
731020-49-8	731020-50-1	731020-51-2	731020-52-3	731020-53-4
731020-54-5	731020-55-6	731020-56-7	731020-57-8	731020-58-9
731020-59-0	731020-60-3	731020-61-4	731020-62-5	731020-63-6
731020-64-7	731020-65-8	731020-66-9	731020-67-0	731020-69-2
731020-70-5	731020-71-6			

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(tetracycline compds. with target therapeutic activities)

IT	731030-35-6	731030-36-7	731030-37-8	731030-38-9	731030-39-0
	731030-40-3	731030-41-4	731030-42-5	731030-43-6	731030-44-7
	731030-45-8	731030-46-9	731030-47-0	731030-48-1	731030-49-2
	731030-50-5	731030-51-6	731030-52-7	731030-53-8	731030-54-9
	731030-55-0	731030-56-1	731030-57-2	731030-58-3	731030-59-4
	731030-60-7	731030-61-8	731030-62-9	731030-64-1	731030-66-3
	731030-67-4	731030-68-5	731030-69-6	731030-70-9	731030-71-0
	731030-72-1	731030-73-2	731030-74-3	731030-75-4	731030-76-5
	731030-77-6	731030-78-7	731030-79-8	731030-80-1	731030-81-2
	731030-82-3	731030-83-4	731030-84-5	731030-85-6	731030-86-7
	731030-87-8	731030-88-9	731030-89-0	731030-90-3	731030-91-4
	731030-92-5	731030-93-6	731030-94-7	731030-95-8	732993-66-7

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(tetracycline compds. with target therapeutic activities)

L56 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:371069 HCAPLUS Full-text

DOCUMENT NUMBER: 140:386006

TITLE: Substituted tetracycline compounds for the treatment of malaria

INVENTOR(S): Draper, Michael; Nelson, Mark L.

PATENT ASSIGNEE(S): Paratek Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 161 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004038001	A2	20040506	WO 2003-US33927	20031024 <--
WO 2004038001	A3	20041111		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2502464	A1	20040506	CA 2003-2502464	20031024 <--
AU 2003287218	A1	20040513	AU 2003-287218	20031024 <--
EP 1556007	A2	20050727	EP 2003-781398	20031024 <--

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

JP 2006503898 T 20060202 JP 2004-547165 20031024 <--
PRIORITY APPLN. INFO.: US 2002-421259P P 20021024 <--
WO 2003-US33927 W 20031024

OTHER SOURCE(S): MARPAT 140:386006

AB The invention provides a method for treating or preventing malaria in a subject. The method includes administering to the subject an effective amount of a substituted tetracycline compound, such that malaria is treated or prevented. In one aspect, the invention relates to pharmaceutical compns. which include an effective amount of a tetracycline compound to treat malaria in a subject and a pharmaceutically acceptable carrier. The substituted tetracycline compds. of the invention can be used to in combination with one or more antimalarial compds. or can be used to treat or prevent malaria which is resistant to one or more other antimalarial compds. Compound preparation is described.


IT 53108-41-1 389625-03-0 459809-44-0
460071-69-6 460073-37-4 460073-70-5
460073-72-7 460073-74-9 460074-19-5
473972-91-7 488815-54-9 488815-55-0
488815-56-1 488815-58-3 488815-63-0
488817-32-9 488818-13-9 488818-17-3
488818-20-8 488818-21-9 488818-27-5
488818-31-1 488818-45-7 488818-60-6
488818-63-9 488818-82-2 488819-02-9
488819-08-5 488819-19-8 488820-15-1
488820-27-5 601454-95-9 601454-98-2
601454-99-3 685832-62-6 685834-76-8
685859-28-3

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tetracycline derivs. for malaria treatment)

RN 53108-41-1 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-7-[(dimethylamino)methyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, [4S-(4 α ,4a α ,5a α ,12a α)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 389625-03-0 HCAPLUS

CN Carbamic acid, [[[6aS,10S,10aS,11aR)-8-(aminocarbonyl)-10-(dimethylamino)-5,6a,7,10,10a,11,11a,12-octahydro-4,6,6a,9-tetrahydroxy-5,7-dioxo-1-naphthacenyl]methyl]-, 2,2-dimethylpropyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 459809-44-0 HCAPLUS

CN 3-Pyridinecarboxamide, N-[[[(6aS,10S,10aS,11aR)-8-(aminocarbonyl)-10-(dimethylamino)-3-(1,1-dimethylethyl)-5,6a,7,10,10a,11,11a,12-octahydro-4,6,6a,9-tetrahydroxy-5,7-dioxo-1-naphthacenyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 460071-69-6 HCAPLUS

CN Carbamic acid, [[[(6aS,10S,10aS,11aR)-8-(aminocarbonyl)-10-(dimethylamino)-5,6a,7,10,10a,11,11a,12-octahydro-4,6,6a,9-tetrahydroxy-5,7-dioxo-1-naphthacenyl]methyl]-, 2-methylpropyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 460073-37-4 HCAPLUS

CN 2-Naphthacenecarboxamide, 7-[[bis(2-methylpropyl)amino]methyl]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 460073-70-5 HCAPLUS

CN 2-Naphthacenecarboxamide, 7-[[bis(2,2-dimethoxyethyl)amino]methyl]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 460073-72-7 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-7-[[[(1-methyl-1H-pyrrol-2-yl)methyl]amino]methyl]-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 460073-74-9 HCAPLUS

10692764

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-7-[[[(1H-pyrrol-2-ylmethyl)amino]methyl]-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 460074-19-5 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-7,9-bis[[[(2,2-dimethylpropyl)amino]methyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 473972-91-7 HCAPLUS

CN 2-Pyridinecarboxamide, N-[[[(6aS,10S,10aS,11aR)-8-(aminocarbonyl)-10-(dimethylamino)-3-(1,1-dimethylethyl)-5,6a,7,10,10a,11,11a,12-octahydro-4,6,6a,9-tetrahydroxy-5,7-dioxo-1-naphthacenyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 488815-54-9 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-7-[[[(2,2-dimethylpropyl)amino]methyl]]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 488815-55-0 HCAPLUS

CN 2-Naphthacenecarboxamide, 7-[(diethylamino)methyl]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 488815-56-1 HCAPLUS

CN 2-Naphthacenecarboxamide, 7-[[bis(cyclopropylmethyl)amino]methyl]]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 488815-58-3 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-7-[[[(2-methylbutyl)amino]methyl]-1,11-dioxo-, (4S,4aS,5aR,12aS) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 488815-63-0 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-7-[[[(2-methylpropyl)amino]methyl]-1,11-dioxo-, (4S,4aS,5aR,12aS) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 488817-32-9 HCAPLUS

CN 1,8-Naphthacenedicarboxamide, 10-(dimethylamino)-5,6a,7,10,10a,11,11a,12-octahydro-4,6,6a,9,11-pentahydroxy-N1,N1,12-trimethyl-5,7-dioxo-, (6aS,10S,10aR,11S,11aR,12R) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 488818-13-9 HCAPLUS

CN 4-Pyrimidinecarboxamide, N-[[[(6aS,10S,10aS,11aR)-8-(aminocarbonyl)-10-(dimethylamino)-5,6a,7,10,10a,11,11a,12-octahydro-4,6,6a,9-tetrahydroxy-5,7-dioxo-1-naphthacenyl]methyl]-1,6-dihydro-6-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 488818-17-3 HCAPLUS

CN 4-Pyridinecarboxamide, N-[[[(6aS,10S,10aS,11aR)-8-(aminocarbonyl)-10-(dimethylamino)-5,6a,7,10,10a,11,11a,12-octahydro-4,6,6a,9-tetrahydroxy-5,7-dioxo-1-naphthacenyl]methyl]-, 1-oxide (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 488818-20-8 HCAPLUS

CN 4-Isoxazolecarboxamide, N-[[[(6aS,10S,10aS,11aR)-8-(aminocarbonyl)-10-

10692764

(dimethylamino)-5,6a,7,10,10a,11,11a,12-octahydro-4,6,6a,9-tetrahydroxy-5,7-dioxo-1-naphthacenyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 488818-21-9 HCAPLUS

CN 3-Pyridinecarboxamide, N-[[[(6aS,10S,10aS,11aR)-8-(aminocarbonyl)-10-(dimethylamino)-5,6a,7,10,10a,11,11a,12-octahydro-4,6,6a,9-tetrahydroxy-5,7-dioxo-1-naphthacenyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 488818-27-5 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-7-[[[(1-methylethyl)amino]methyl]-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 488818-31-1 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-7-[[[(1-oxido-4-pyridinyl)methyl]amino]methyl]-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 488818-45-7 HCAPLUS

CN 1,8-Naphthacenedicarboxamide, 10-(dimethylamino)-5,6a,7,10,10a,11,11a,12-octahydro-4,6,6a,9-tetrahydroxy-N1,N1-dimethyl-5,7-dioxo-, (6aS,10S,10aS,11aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 488818-60-6 HCAPLUS

CN 4-Morpholinecarboxamide, N-[[[(6aS,10S,10aS,11aR)-8-(aminocarbonyl)-10-(dimethylamino)-3-ethynyl-5,6a,7,10,10a,11,11a,12-octahydro-4,6,6a,9-tetrahydroxy-5,7-dioxo-1-naphthacenyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 488818-63-9 HCAPLUS

CN 4-Morpholinecarboxamide, N-[[[(6aS,10S,10aS,11aR)-8-(aminocarbonyl)-10-(dimethylamino)-3-ethyl-5,6a,7,10,10a,11,11a,12-octahydro-4,6,6a,9-tetrahydroxy-5,7-dioxo-1-naphthacenyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 488818-82-2 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-7-[[[(2-fluoro-1-methylethyl)amino]methyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 488819-02-9 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-7-[[[(4-

10692764

fluorophenyl)methyl]amino]methyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 488819-08-5 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-7-[[[(phenylmethyl)amino]methyl]-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 488819-19-8 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-7-[[[(2,2-dimethylpropyl)amino]methyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-[(methylthio)methyl]-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 488820-15-1 HCAPLUS

CN 2-Naphthacenecarboxamide, 7-[(acetylamino)methyl]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 488820-27-5 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-7-[[[(2,2-dimethyl-1-oxopropyl)amino]methyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 601454-95-9 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-7-[[[(4-fluorophenyl)methyl]amino]methyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4R,4aS,5aR,12aS) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 601454-98-2 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-7-[(phenylmethyl)amino]methyl-, (4R,4aS,5aR,12aS) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 601454-99-3 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-7,9-bis[[(2,2-dimethylpropyl)amino]methyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4aS,5aR,12aS) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 685832-62-6 HCAPLUS

CN 2-Naphthacenecarboxamide, 7-[(cyanomethyl)amino]methyl-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 685834-76-8 HCAPLUS

CN 4-Morpholinecarboxamide, N-[[[(6aS,10S,10aS,11aR)-8-(aminocarbonyl)-3-(chloroethynyl)-10-(dimethylamino)-5,6a,7,10,10a,11,11a,12-octahydro-4,6,6a,9-tetrahydroxy-5,7-dioxo-1-naphthacenyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 685859-28-3 HCAPLUS

CN 2-Naphthacenecarboxamide, 7-[[[(2-cyanoethyl)amino]methyl]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IC ICM C12N

CC 1-5 (Pharmacology)

Section cross-reference(s): 25, 63

IT **Anemia** (disease)
 Antimalarials
 Antimicrobial agents
 Antipyretics
 Drug delivery systems
 Drug interactions
 Drug resistance
 Fever and Hyperthermia
 Headache
 Human
 Malaria
 Plasmodium (malarial genus)
 Plasmodium falciparum
 Plasmodium malariae
 Plasmodium ovale
 Plasmodium vivax
 (tetracycline derivs. for malaria treatment)

IT 60-54-8 79-57-2 127-33-3 564-25-0 808-26-4 914-00-1 1665-56-1
 2444-65-7 3242-03-3 4495-20-9 4497-07-8 5585-59-1 5874-95-3
 5995-55-1 10118-89-5 10118-90-8 10236-47-2 15866-90-7 16145-05-4
 19109-13-8 31642-30-5 35689-63-5 35689-65-7 53108-40-0
 53108-41-1 53173-80-1 59046-79-6 73351-16-3 82336-02-5
 113164-67-3 115207-75-5 120793-45-5 146253-71-6 146253-75-0
 146278-01-5 146278-02-6 146278-03-7 149934-16-7 149934-19-0
 151922-17-7 153621-68-2 155819-14-0 155819-18-4 161321-34-2
 161452-37-5 186759-47-7 186759-49-9 186759-51-3 186759-53-5
 186759-55-7 186759-61-5 220620-09-7 233585-94-9 233585-95-0
 233585-96-1 233585-97-2 233586-02-2 233586-03-3 233586-04-4
 233586-06-6 233586-08-8 233586-09-9 233586-10-2 233586-11-3
 233586-12-4 263760-96-9 263760-98-1 263760-99-2 263761-01-9
 263761-02-0 263761-08-6 295356-11-5 295356-13-7 295356-16-0
 295356-17-1 330627-21-9 330627-22-0 330627-23-1 330627-24-2
 330627-26-4 330627-29-7 330627-31-1 330627-32-2 344771-54-6
 351336-92-0 351336-94-2 365276-98-8 365276-99-9 365277-00-5
 365277-01-6 365277-02-7 365277-03-8 365277-04-9 365277-05-0
 365277-06-1 365277-07-2 365277-08-3 365277-11-8 365277-12-9
 365277-13-0 365277-14-1 365277-16-3 365277-19-6 365277-20-9
 365277-21-0 365277-23-2 365277-24-3 365277-26-5 365277-28-7
 365277-29-8 365277-33-4 365277-34-5 365277-35-6 365277-36-7
 365277-37-8 365277-38-9 365277-39-0 365277-40-3 365277-41-4
 365277-42-5 365277-43-6 365277-44-7 365277-45-8 365277-47-0
 365277-48-1 365277-49-2 365277-50-5 365277-51-6 365277-52-7
 365277-54-9 365277-55-0 365277-56-1 365277-57-2 365277-58-3
 365277-59-4 365277-60-7 365277-61-8 365277-62-9 365277-63-0
 365277-64-1 365277-65-2 365277-66-3 365277-88-9 374748-06-8
 380435-62-1 380435-63-2 380435-65-4 380435-74-5 380435-76-7
 380435-88-1 389081-55-4 389081-56-5 389081-57-6 389081-58-7
 389081-59-8 389081-60-1 389081-61-2 389081-62-3 389081-64-5
 389081-65-6 389081-66-7 389081-67-8 389081-68-9 389081-69-0
 389081-71-4 389081-73-6 389081-74-7 389081-75-8 389081-76-9
 389081-77-0 389081-78-1 389081-79-2 389081-80-5 389081-85-0
 389139-10-0 389139-12-2 389139-15-5 389139-16-6 389139-17-7
 389139-18-8 389139-19-9 389139-20-2 389139-21-3 389139-22-4
 389139-23-5 389139-24-6 389139-25-7 389139-26-8 389139-27-9
 389139-28-0 389139-29-1 389139-30-4 389139-31-5 389139-32-6
 389139-33-7 389139-34-8 389139-35-9 389139-36-0 389139-37-1
 389139-38-2 389139-39-3 389139-41-7 389139-42-8 389139-43-9
 389139-44-0 389139-45-1 389139-46-2 389139-47-3 389139-48-4
 389139-49-5 389139-50-8 389139-51-9 389139-52-0 389139-53-1

10692764

389139-54-2	389139-55-3	389139-56-4	389139-57-5	389139-58-6
389139-59-7	389139-60-0	389139-61-1	389139-62-2	389139-63-3
389139-64-4	389139-65-5	389139-66-6	389139-67-7	389139-68-8
389139-69-9	389139-70-2	389139-71-3	389139-72-4	389139-73-5
389139-74-6	389139-75-7			

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tetracycline derivs. for malaria treatment)

IT	389139-76-8	389139-78-0	389139-79-1	389139-80-4	389139-81-5
	389139-82-6	389139-83-7	389139-85-9	389139-86-0	389139-87-1
	389139-88-2	389139-89-3	389139-90-6	389139-91-7	389139-93-9
	389139-94-0	389139-96-2	389139-97-3	389139-98-4	389139-99-5
	389140-00-5	389140-01-6	389140-02-7	389140-03-8	389140-06-1
	389570-43-8	389570-46-1	389570-48-3	389570-49-4	389570-50-7
	389570-51-8	389570-52-9	389570-53-0	389570-54-1	389623-72-7
	389623-74-9	389623-77-2	389623-80-7	389623-82-9	389623-86-3
	389623-88-5	389623-89-6	389623-90-9	389623-91-0	389623-93-2
	389623-95-4	389623-96-5	389623-97-6	389623-98-7	389623-99-8
	389624-01-5	389624-03-7	389624-04-8	389624-05-9	389624-06-0
	389624-07-1	389624-08-2	389624-09-3	389624-11-7	389624-12-8
	389624-13-9	389624-14-0	389624-15-1	389624-16-2	389624-18-4
	389624-19-5	389624-20-8	389624-21-9	389624-22-0	389624-23-1
	389624-24-2	389624-26-4	389624-27-5	389624-28-6	389624-29-7
	389624-30-0	389624-31-1	389624-32-2	389624-33-3	389624-34-4
	389624-35-5	389624-36-6	389624-37-7	389624-38-8	389624-39-9
	389624-40-2	389624-41-3	389624-42-4	389624-43-5	389624-44-6
	389624-45-7	389624-46-8	389624-47-9	389624-48-0	389624-49-1
	389624-51-5	389624-52-6	389624-53-7	389624-54-8	389624-55-9
	389624-56-0	389624-57-1	389624-59-3	389624-60-6	389624-61-7
	389624-62-8	389624-63-9	389624-64-0	389624-65-1	389624-66-2
	389624-67-3	389624-68-4	389624-69-5	389624-70-8	389624-71-9
	389624-72-0	389624-73-1	389624-74-2	389624-75-3	389624-76-4
	389624-77-5	389624-78-6	389624-79-7	389624-80-0	389624-81-1
	389624-82-2	389624-83-3	389624-84-4	389624-85-5	389624-86-6
	389624-87-7	389624-88-8	389624-89-9	389624-90-2	389624-91-3
	389624-92-4	389624-93-5	389624-94-6	389624-95-7	389624-96-8
	389624-97-9	389624-98-0	389624-99-1	389625-00-7	389625-01-8
	389625-02-9	389625-03-0	389625-04-1	389625-05-2	
	389625-06-3	389625-07-4	389625-09-6	389625-10-9	389625-11-0
	389625-12-1	439217-57-9	439217-59-1	459425-79-7	459425-80-0
	459425-96-8	459426-11-0	459809-42-8	459809-43-9	459809-44-0
	459809-45-1	459809-46-2	459809-47-3	459809-48-4	459809-49-5
	459809-50-8	459809-51-9	459809-52-0	459809-53-1	459809-54-2
	459809-55-3	459809-57-5	459809-58-6	459809-59-7	459809-61-1
	459809-63-3	459809-65-5	459809-66-6	459809-67-7	459809-68-8
	459809-70-2	459809-74-6	459809-76-8	459809-77-9	459809-79-1
	459809-81-5	459809-82-6	459809-86-0	459809-88-2	459809-91-7
	459809-92-8	459809-95-1	459809-96-2	459809-97-3	459809-98-4
	459809-99-5	459810-00-5	459810-01-6	459810-02-7	459810-03-8
	459810-04-9	459810-06-1	459810-07-2	459810-08-3	459810-09-4
	460068-27-3	460068-29-5	460068-30-8	460068-31-9	460068-32-0
	460068-33-1	460068-34-2	460068-35-3	460068-36-4	460068-38-6
	460068-39-7	460068-40-0	460068-41-1	460068-42-2	460068-43-3
	460068-44-4	460068-45-5	460068-46-6	460068-47-7	460068-48-8
	460068-49-9	460068-50-2	460068-51-3	460068-52-4	460068-53-5
	460068-54-6	460068-55-7			

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tetracycline derivs. for malaria treatment)

IT	460068-57-9	460068-58-0	460068-59-1	460068-60-4	460068-61-5
----	-------------	-------------	-------------	-------------	-------------

460068-62-6	460068-63-7	460068-64-8	460068-65-9	460068-66-0
460068-67-1	460068-68-2	460068-69-3	460068-70-6	460068-71-7
460068-72-8	460068-73-9	460068-74-0	460068-75-1	460068-76-2
460068-77-3	460068-78-4	460068-79-5	460068-80-8	460068-81-9
460068-82-0	460068-84-2	460068-85-3	460068-86-4	460068-87-5
460068-88-6	460068-90-0	460068-92-2	460068-93-3	460068-94-4
460068-95-5	460068-96-6	460068-97-7	460068-99-9	460069-34-5
460069-38-9	460069-65-2	460069-70-9	460069-89-0	460069-96-9
460070-02-4	460070-03-5	460070-53-5	460070-61-5	460070-66-0
460070-73-9	460070-76-2	460070-79-5	460070-92-2	460070-95-5
460071-02-7	460071-04-9	460071-06-1	460071-09-4	460071-12-9
460071-14-1	460071-17-4	460071-19-6	460071-29-8	460071-33-4
460071-37-8	460071-66-3	460071-69-6	460071-80-1	
460071-83-4	460071-87-8	460071-89-0	460071-91-4	460071-93-6
460071-97-0	460071-99-2	460072-01-9	460072-03-1	460072-05-3
460072-07-5	460072-09-7	460072-10-0	460072-12-2	460072-15-5
460072-17-7	460072-19-9	460072-21-3	460072-25-7	460072-28-0
460072-29-1	460072-30-4	460072-31-5	460072-33-7	460072-36-0
460072-40-6	460072-43-9	460072-45-1	460072-47-3	460072-49-5
460072-59-7	460072-63-3	460072-65-5	460072-70-2	460072-73-5
460072-75-7	460072-78-0	460072-82-6	460072-86-0	460072-89-3
460072-91-7	460072-93-9	460073-01-2	460073-03-4	460073-05-6
460073-07-8	460073-09-0	460073-11-4	460073-15-8	460073-17-0
460073-21-6	460073-22-7	460073-23-8	460073-25-0	460073-27-2
460073-29-4	460073-31-8	460073-35-2	460073-37-4	
460073-40-9	460073-41-0	460073-43-2	460073-45-4	460073-47-6
460073-49-8	460073-51-2	460073-53-4	460073-55-6	460073-58-9
460073-62-5	460073-64-7	460073-68-1	460073-70-5	
460073-72-7	460073-74-9	460073-76-1	460073-78-3	
460073-80-7	460073-82-9	460073-84-1	460073-86-3	460073-88-5
460073-90-9	460073-92-1	460073-94-3	460073-96-5	460073-98-7
460074-00-4	460074-02-6	460074-04-8	460074-06-0	460074-09-3
460074-11-7	460074-13-9	460074-15-1	460074-19-5	
460074-21-9	460074-23-1	460074-26-4	460074-28-6	460074-30-0
460074-34-4	460074-36-6	460074-38-8	460074-40-2	460074-42-4
460074-44-6	460074-46-8	460074-48-0	460074-50-4	460074-52-6
460074-54-8	460074-56-0	460074-58-2	460074-60-6	460074-62-8
460074-64-0	460074-66-2	460074-68-4	460074-69-5	460074-71-9
460074-73-1	460074-75-3	460074-77-5	460074-79-7	460074-81-1
460074-83-3	460074-85-5	460074-87-7	460074-89-9	460074-91-3
460074-93-5	460074-95-7	460074-97-9	460074-99-1	460075-04-1
460075-06-3	460075-08-5	460075-12-1	460075-14-3	460075-62-1
460076-23-7	460082-77-3	460082-87-5	460082-89-7	460082-90-0
460082-91-1	473972-91-7	473973-13-6	473973-20-5	
473973-34-1	473973-37-4	473973-41-0	473973-62-5	473973-64-7
473973-86-3	473973-96-5	473974-12-8	473974-75-3	473974-76-4
473974-77-5	473974-79-7	473974-80-0	473974-81-1	473974-82-2
473974-83-3	473974-84-4			

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tetracycline derivs. for malaria treatment)

IT	473974-85-5	488815-44-7	488815-46-9	488815-47-0	488815-49-2
	488815-52-7	488815-53-8	488815-54-9	488815-55-0	
	488815-56-1	488815-57-2	488815-58-3	488815-59-4	
	488815-60-7	488815-61-8	488815-62-9	488815-63-0	
	488815-64-1	488815-65-2	488815-66-3	488815-68-5	488815-69-6
	488815-71-0	488815-72-1	488815-73-2	488815-74-3	488815-75-4
	488815-76-5	488815-77-6	488815-78-7	488815-80-1	488815-82-3
	488815-89-0	488815-93-6	488815-98-1	488816-00-8	488816-13-3
	488816-16-6	488816-18-8	488816-19-9	488816-26-8	488816-37-1

488816-39-3	488816-42-8	488816-54-2	488816-64-4	488816-65-5
488816-70-2	488816-71-3	488816-73-5	488816-75-7	488816-82-6
488816-88-2	488816-92-8	488816-93-9	488816-98-4	488817-01-2
488817-06-7	488817-11-4	488817-13-6	488817-14-7	488817-15-8
488817-16-9	488817-17-0	488817-18-1	488817-19-2	488817-20-5
488817-21-6	488817-22-7	488817-23-8	488817-24-9	488817-25-0
488817-26-1	488817-27-2	488817-28-3	488817-29-4	488817-30-7
488817-31-8	488817-32-9	488817-33-0	488817-35-2	
488817-36-3	488817-37-4	488817-38-5	488817-39-6	488817-41-0
488817-42-1	488817-44-3	488817-45-4	488817-46-5	488817-47-6
488817-48-7	488817-49-8	488817-50-1	488817-51-2	488817-52-3
488817-53-4	488817-54-5	488817-55-6	488817-56-7	488817-57-8
488817-58-9	488817-59-0	488817-60-3	488817-61-4	488817-62-5
488817-63-6	488817-64-7	488817-65-8	488817-67-0	488817-68-1
488817-73-8	488817-75-0	488817-76-1	488817-79-4	488817-80-7
488817-82-9	488817-89-6	488817-91-0	488817-92-1	488817-94-3
488817-95-4	488817-96-5	488817-97-6	488818-04-8	488818-06-0
488818-07-1	488818-08-2	488818-10-6	488818-11-7	488818-12-8
488818-13-9	488818-14-0	488818-16-2	488818-17-3	
488818-18-4	488818-19-5	488818-20-8	488818-21-9	
488818-23-1	488818-25-3	488818-27-5	488818-28-6	
488818-29-7	488818-30-0	488818-31-1	488818-32-2	
488818-33-3	488818-34-4	488818-35-5	488818-36-6	488818-37-7
488818-38-8	488818-39-9	488818-40-2	488818-41-3	488818-42-4
488818-43-5	488818-44-6	488818-45-7	488818-46-8	
488818-47-9	488818-48-0	488818-49-1	488818-50-4	488818-51-5
488818-52-6	488818-53-7	488818-54-8	488818-55-9	488818-56-0
488818-57-1	488818-58-2	488818-59-3	488818-60-6	
488818-61-7	488818-63-9	488818-64-0	488818-65-1	
488818-66-2	488818-67-3	488818-68-4	488818-69-5	488818-70-8
488818-71-9	488818-72-0	488818-73-1	488818-74-2	488818-75-3
488818-76-4	488818-77-5	488818-78-6	488818-79-7	488818-80-0
488818-81-1	488818-82-2	488818-83-3	488818-84-4	
488818-85-5	488818-86-6	488818-87-7	488818-88-8	488818-89-9
488818-90-2	488818-91-3	488818-92-4	488818-93-5	488818-94-6
488818-95-7	488818-97-9	488818-98-0	488818-99-1	488819-00-7
488819-01-8	488819-02-9	488819-03-0	488819-04-1	
488819-05-2	488819-06-3	488819-07-4	488819-08-5	
488819-14-3	488819-16-5	488819-17-6	488819-18-7	488819-19-8
488819-20-1	488819-21-2	488819-22-3	488819-23-4	488819-24-5
488819-25-6	488819-26-7	488819-27-8	488819-28-9	488819-29-0
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
(tetracycline derivs. for malaria treatment)				
IT	488819-30-3	488819-31-4	488819-32-5	488819-33-6
	488819-35-8	488819-36-9	488819-37-0	488819-38-1
	488819-40-5	488819-41-6	488819-42-7	488819-43-8
	488819-45-0	488819-46-1	488819-47-2	488819-48-3
	488819-50-7	488819-52-9	488819-53-0	488819-54-1
	488819-56-3	488819-57-4	488819-58-5	488819-59-6
	488819-61-0	488819-62-1	488819-63-2	488819-64-3
	488819-66-5	488819-67-6	488819-68-7	488819-69-8
	488819-71-2	488819-72-3	488819-73-4	488819-74-5
	488819-76-7	488819-77-8	488819-78-9	488819-79-0
	488819-82-5	488819-84-7	488819-85-8	488819-86-9
	488819-88-1	488819-89-2	488819-90-5	488819-91-6
	488819-93-8	488819-94-9	488819-95-0	488819-96-1
	488819-98-3	488819-99-4	488820-00-4	488820-01-5
	488820-03-7	488820-04-8	488820-05-9	488820-06-0
	488820-09-3	488820-10-6	488820-11-7	488820-12-8
				488820-13-9

488820-14-0	488820-15-1	488820-16-2	488820-17-3	
488820-18-4	488820-19-5	488820-20-8	488820-21-9	488820-22-0
488820-23-1	488820-24-2	488820-25-3	488820-26-4	488820-27-5
488820-28-6	488820-29-7	488820-30-0	488820-31-1	488820-32-2
488820-33-3	488820-34-4	488820-43-5	488820-48-0	577795-55-2
577795-64-3	601454-79-9	601454-80-2	601454-82-4	601454-85-7
601454-92-6	601454-95-9	601454-97-1	601454-98-2	
601454-99-3	601455-02-1	601455-03-2	601455-04-3	
601455-05-4	601455-07-6	601455-09-8	601455-11-2	601455-12-3
601455-13-4	601455-15-6	601455-16-7	601455-17-8	601455-18-9
601455-19-0	601455-20-3	601455-21-4	601455-22-5	601455-23-6
601455-24-7	601455-25-8	601455-26-9	601455-27-0	601455-29-2
601455-30-5	601455-31-6	601455-32-7	601455-33-8	601455-34-9
601455-35-0	601455-36-1	601455-37-2	601455-38-3	601455-39-4
601455-41-8	601455-42-9	601455-43-0	601455-44-1	601455-45-2
601455-46-3	601455-47-4	601455-49-6	601455-50-9	601455-52-1
601455-53-2	601455-54-3	601455-55-4	601455-56-5	601455-57-6
601455-58-7	601455-60-1	601455-62-3	601455-63-4	601455-65-6
601455-66-7	601455-67-8	601455-68-9	601455-69-0	601455-71-4
601455-72-5	601455-73-6	601455-75-8	601455-76-9	601455-77-0
601455-78-1	601455-79-2	601455-80-5	601455-81-6	601455-83-8
601455-84-9	601455-85-0	601455-86-1	601455-87-2	601455-89-4
601455-90-7	601455-91-8	601455-92-9	601455-95-2	601470-72-8
607400-44-2	607400-46-4	607400-50-0	607400-72-6	607401-16-1
607401-26-3	607401-28-5	607401-38-7	607401-41-2	607401-43-4
607401-45-6	607401-48-9	607401-54-7	607401-57-0	607401-59-2
607401-63-8	607401-65-0	607401-67-2	607401-69-4	607401-71-8
607401-73-0	607401-75-2	607401-77-4	607401-79-6	607401-81-0
607401-83-2	607401-86-5	607401-98-9	607402-03-9	607402-08-4
607402-10-8	607402-12-0	607402-14-2	607402-16-4	607402-18-6
607402-20-0	607402-22-2	607402-24-4	607402-28-8	607402-58-4
607402-71-1	607402-72-2	607402-73-3	607402-74-4	

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tetracycline derivs. for malaria treatment)

IT	607402-75-5	607402-76-6	607402-77-7	607402-79-9	607402-80-2
	607402-81-3	607402-82-4	607402-83-5	607402-84-6	607402-85-7
	607738-53-4	644995-53-9	685831-46-3	685831-47-4	685831-48-5
	685831-49-6	685831-50-9	685831-51-0	685831-52-1	685832-62-6
	685832-63-7	685832-64-8	685832-65-9	685832-66-0	685832-68-2
	685832-71-7	685832-75-1	685832-82-0	685832-83-1	685832-84-2
	685832-85-3	685832-86-4	685832-87-5	685832-88-6	685832-89-7
	685832-90-0	685832-91-1	685832-92-2	685832-93-3	685832-94-4
	685832-95-5	685832-96-6	685832-97-7	685832-98-8	685832-99-9
	685833-00-5	685833-01-6	685833-02-7	685833-03-8	685833-04-9
	685833-05-0	685833-06-1	685833-07-2	685833-08-3	685833-09-4
	685833-10-7	685833-11-8	685833-12-9	685833-13-0	685833-14-1
	685833-15-2	685833-16-3	685833-17-4	685833-18-5	685833-19-6
	685833-20-9	685833-21-0	685833-22-1	685833-23-2	685833-24-3
	685833-25-4	685833-26-5	685833-27-6	685833-28-7	685833-29-8
	685833-30-1	685833-31-2	685833-32-3	685833-33-4	685833-34-5
	685833-35-6	685833-36-7	685833-37-8	685833-38-9	685833-39-0
	685833-40-3	685833-41-4	685833-42-5	685833-43-6	685833-44-7
	685833-45-8	685833-46-9	685833-47-0	685833-48-1	685833-49-2
	685833-50-5	685833-51-6	685833-52-7	685833-53-8	685833-54-9
	685833-55-0	685833-56-1	685833-57-2	685833-66-3	685833-68-5
	685833-69-6	685833-82-3	685834-60-0	685834-61-1	685834-62-2
	685834-63-3	685834-71-3	685834-72-4	685834-74-6	685834-75-7
	685834-76-8	685834-77-9	685834-83-7	685834-85-9	
	685834-88-2	685834-89-3	685834-91-7	685834-92-8	685834-93-9

685859-06-7 685859-07-8 685859-08-9 685859-09-0 685859-10-3
 685859-11-4 685859-12-5 685859-14-7 685859-18-1 685859-19-2
 685859-20-5 685859-21-6 685859-24-9 685859-28-3
 685859-34-1 685859-35-2 685860-95-1 685860-96-2 685860-97-3
 685860-98-4 685860-99-5 685861-00-1 685861-04-5 685861-07-8
 685862-44-6 685881-89-4 685881-91-8

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (tetracycline derivs. for malaria treatment)

L56 ANSWER 4 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:371068 HCAPLUS Full-text

DOCUMENT NUMBER: 140:386057

TITLE: Methods of using substituted tetracycline compounds to modulate RNA, and therapeutic use

INVENTOR(S): Levy, Stuart B.; Draper, Michael; Jones, Graham; Nelson, Mark L.

PATENT ASSIGNEE(S): Paratek Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 124 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004038000	A2	20040506	WO 2003-US33926	20031024 <--
WO 2004038000	A3	20041111		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2503446	A1	20040506	CA 2003-2503446	20031024 <--
AU 2003287217	A1	20040513	AU 2003-287217	20031024 <--
US 2004214800	A1	20041028	US 2003-692764	20031024 <--
EP 1562608	A2	20050817	EP 2003-781397	20031024 <--
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
JP 2006503897	T	20060202	JP 2004-547164	20031024 <--
PRIORITY APPLN. INFO.:			US 2002-421248P	P 20021024 <--
			WO 2003-US33926	W 20031024

OTHER SOURCE(S): MARPAT 140:386057

AB A method for modulating RNA with tetracycline compds. is described. The invention also discloses a method for treating a subject for a disorder treatable by modulation of RNA or by modulation of RNA in combination with a second agent. Compound preparation is also described.

IT 53108-41-1 389625-03-0 459809-44-0
 460071-69-6 460073-37-4 460073-70-5
 460073-72-7 460073-74-9 460074-19-5
 488815-54-9 488815-55-0 488815-56-1
 488815-58-3 488815-63-0 488817-32-9
 488818-13-9 488818-17-3 488818-20-8
 488818-21-9 488818-27-5 488818-31-1

10692764

488818-45-7 488818-60-6 488818-63-9
488818-82-2 488819-02-9 488819-08-5
488819-19-8 488820-15-1 488820-27-5
601454-95-9 601454-98-2 685832-62-6
685859-28-3


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(RNA-modulating substituted tetracycline compds., and therapeutic use)

RN 53108-41-1 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-7-[(dimethylamino)methyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, [4S-(4 α ,4a α ,5a α ,12a α)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 389625-03-0 HCAPLUS

CN Carbamic acid, [[[6aS,10S,10aS,11aR)-8-(aminocarbonyl)-10-(dimethylamino)-5,6a,7,10,10a,11,11a,12-octahydro-4,6,6a,9-tetrahydroxy-5,7-dioxo-1-naphthacenyl]methyl]-, 2,2-dimethylpropyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 459809-44-0 HCAPLUS

CN 3-Pyridinecarboxamide, N-[[[(6aS,10S,10aS,11aR)-8-(aminocarbonyl)-10-(dimethylamino)-3-(1,1-dimethylethyl)-5,6a,7,10,10a,11,11a,12-octahydro-4,6,6a,9-tetrahydroxy-5,7-dioxo-1-naphthacenyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 460071-69-6 HCAPLUS

CN Carbamic acid, [[(6aS,10S,10aS,11aR)-8-(aminocarbonyl)-10-(dimethylamino)-5,6a,7,10,10a,11,11a,12-octahydro-4,6,6a,9-tetrahydroxy-5,7-dioxo-1-naphthacenyl]methyl]-, 2-methylpropyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 460073-37-4 HCAPLUS

CN 2-Naphthacenecarboxamide, 7-[[bis(2-methylpropyl)amino]methyl]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 460073-70-5 HCAPLUS

CN 2-Naphthacenecarboxamide, 7-[[bis(2,2-dimethoxyethyl)amino]methyl]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 460073-72-7 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-7-[[[(1-methyl-1H-pyrrol-2-yl)methyl]amino]methyl]-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 460073-74-9 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-7-[[[(1H-pyrrol-2-yl)methyl]amino]methyl]-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10692764

RN 460074-19-5 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-7,9-bis[[(2,2-dimethylpropyl)amino]methyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 488815-54-9 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-7-[[[(2,2-dimethylpropyl)amino]methyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 488815-55-0 HCAPLUS

CN 2-Naphthacenecarboxamide, 7-[(diethylamino)methyl]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 488815-56-1 HCAPLUS

CN 2-Naphthacenecarboxamide, 7-[[bis(cyclopropylmethyl)amino]methyl]-4-

10692764

(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 488815-58-3 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-7-[[(2-methylbutyl) amino]methyl]-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 488815-63-0 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-7-[[(2-methylpropyl) amino]methyl]-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 488817-32-9 HCAPLUS

CN 1,8-Naphthacenedicarboxamide, 10-(dimethylamino)-5,6a,7,10,10a,11,11a,12-

10692764

octahydro-4,6,6a,9,11-pentahydroxy-N1,N1,12-trimethyl-5,7-dioxo-,
(6aS,10S,10aR,11S,11aR,12R) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 488818-13-9 HCAPLUS

CN 4-Pyrimidinecarboxamide, N-[[[(6aS,10S,10aR,11aR)-8-(aminocarbonyl)-10-(dimethylamino)-5,6a,7,10,10a,11,11a,12-octahydro-4,6,6a,9-tetrahydroxy-5,7-dioxo-1-naphthacenyl]methyl]-1,6-dihydro-6-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 488818-17-3 HCAPLUS

CN 4-Pyridinecarboxamide, N-[[[(6aS,10S,10aR,11aR)-8-(aminocarbonyl)-10-(dimethylamino)-5,6a,7,10,10a,11,11a,12-octahydro-4,6,6a,9-tetrahydroxy-5,7-dioxo-1-naphthacenyl]methyl]-, 1-oxide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 488818-20-8 HCAPLUS

CN 4-Isoxazolecarboxamide, N-[[[(6aS,10S,10aS,11aR)-8-(aminocarbonyl)-10-(dimethylamino)-5,6a,7,10,10a,11,11a,12-octahydro-4,6,6a,9-tetrahydroxy-5,7-dioxo-1-naphthacenyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 488818-21-9 HCAPLUS

CN 3-Pyridinecarboxamide, N-[[[(6aS,10S,10aS,11aR)-8-(aminocarbonyl)-10-(dimethylamino)-5,6a,7,10,10a,11,11a,12-octahydro-4,6,6a,9-tetrahydroxy-5,7-dioxo-1-naphthacenyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 488818-27-5 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-7-[[[(1-methylethyl)amino]methyl]-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 488818-31-1 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-7-[[[(1-oxido-4-pyridinyl)methyl]amino]methyl]-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 488818-45-7 HCAPLUS

CN 1,8-Naphthacenedicarboxamide, 10-(dimethylamino)-5,6a,7,10,10a,11,11a,12-octahydro-4,6,6a,9-tetrahydroxy-N1,N1-dimethyl-5,7-dioxo-, (6aS,10S,10aS,11aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 488818-60-6 HCAPLUS

CN 4-Morpholinecarboxamide, N-[[[(6aS,10S,10aS,11aR)-8-(aminocarbonyl)-10-(dimethylamino)-3-ethynyl-5,6a,7,10,10a,11,11a,12-octahydro-4,6,6a,9-tetrahydroxy-5,7-dioxo-1-naphthacenyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 488818-63-9 HCAPLUS

CN 4-Morpholinecarboxamide, N-[[[(6aS,10S,10aS,11aR)-8-(aminocarbonyl)-10-(dimethylamino)-3-ethyl-5,6a,7,10,10a,11,11a,12-octahydro-4,6,6a,9-tetrahydroxy-5,7-dioxo-1-naphthacenyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 488818-82-2 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-7-[[[(2-fluoro-1-methylethyl)amino]methyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 488819-02-9 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-7-[[[(4-

10692764

fluorophenyl)methyl]amino]methyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 488819-08-5 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-7-[[(phenylmethyl) amino]methyl]-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 488819-19-8 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-7-[[(2,2-dimethylpropyl) amino]methyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-[(methylthio)methyl]-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 488820-15-1 HCAPLUS

CN 2-Naphthacenecarboxamide, 7-[(acetylamino)methyl]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 488820-27-5 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-7-[[[(2,2-dimethyl-1-oxopropyl)amino]methyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 601454-95-9 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-7-[[[(4-fluorophenyl)methyl]amino]methyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4R,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 601454-98-2 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-7-[[(phenylmethyl) amino]methyl]-, (4R,4aS,5aR,12aS)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 685832-62-6 HCAPLUS

CN 2-Naphthacenecarboxamide, 7-[[(cyanomethyl) amino]methyl]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 685859-28-3 HCAPLUS

CN 2-Naphthacenecarboxamide, 7-[[(2-cyanoethyl) amino]methyl]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



IC ICM C12N
 CC 1-12 (Pharmacology)
 Section cross-reference(s): 25
 ST tetracycline compd prepn *RNA modulation* therapeutic
 IT Animals
 Drug screening
 Embryophyta
 Human
 Macrophage
 Plants
 RNA splicing
 Translation, genetic
 Virus
 (*RNA-modulating* substituted tetracycline compds.,
 and therapeutic use)
 IT Heterogeneous nuclear ribonucleoproteins
 Proteins
 RNA
 Ribosomal proteins
 mRNA
 rRNA
 tRNA
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (*RNA-modulating* substituted tetracycline compds.,
 and therapeutic use)
 IT Tetracyclines
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (*RNA-modulating* substituted tetracycline compds.,
 and therapeutic use)
 IT Biological transport
 (intracellular; *RNA-modulating* substituted
 tetracycline compds., and therapeutic use)
 IT Cell nucleus
 (nuclear *RNA*; *RNA-modulating* substituted
 tetracycline compds., and therapeutic use)
 IT *RNA*
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (nuclear; *RNA-modulating* substituted tetracycline
 compds., and therapeutic use)
 IT *RNA*
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (small nuclear; *RNA-modulating* substituted
 tetracycline compds., and therapeutic use)
 IT Ribonucleoproteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (snRNP (small nuclear ribonucleoprotein); **RNA-**
modulating substituted tetracycline compds., and therapeutic
 use)

IT 9055-11-2, Endonuclease 501433-35-8, Inducible nitric oxide synthase

RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (**RNA-modulating** substituted tetracycline compds.,
 and therapeutic use)

IT 60-54-8 60-54-8D, Tetracycline, derivs. 79-57-2 127-33-3 564-25-0
 808-26-4 1665-56-1 2444-65-7 3242-03-3 4497-07-8 5585-59-1
 5874-95-3 5995-55-1 10118-89-5 10118-90-8 16145-05-4 24290-70-8
 31642-30-5 35689-63-5 35689-65-7 53108-40-0 **53108-41-1**
 53173-80-1 59046-79-6 77901-56-5 115207-75-5 120793-45-5
 146253-71-6 146253-75-0 146278-01-5 146278-02-6 146278-03-7
 149934-16-7 149934-19-0 151922-17-7 153621-68-2 155819-14-0
 155819-18-4 161320-33-8 161321-34-2 161452-36-4 186759-47-7
 186759-49-9 186759-51-3 186759-53-5 186759-55-7 186759-61-5
 220620-09-7 233585-94-9 233585-95-0 233585-96-1 233585-97-2
 233586-02-2 233586-03-3 233586-04-4 233586-06-6 233586-07-7
 233586-08-8 233586-09-9 233586-10-2 233586-11-3 233586-12-4
 233586-16-8 263760-96-9 263760-98-1 263761-01-9 263761-02-0
 263761-08-6 295356-11-5 295356-12-6 295356-13-7 295356-16-0
 295356-17-1 330627-21-9 330627-22-0 330627-23-1 330627-24-2
 330627-26-4 330627-27-5 330627-29-7 330627-31-1 330627-32-2
 344771-54-6 351336-92-0 351336-94-2 365276-98-8 365276-99-9
 365277-00-5 365277-01-6 365277-02-7 365277-03-8 365277-04-9
 365277-05-0 365277-06-1 365277-08-3 365277-11-8 365277-12-9
 365277-13-0 365277-14-1 365277-19-6 365277-20-9 365277-21-0
 365277-22-1 365277-23-2 365277-24-3 365277-26-5 365277-28-7
 365277-29-8 365277-34-5 365277-35-6 365277-36-7 365277-37-8
 365277-38-9 365277-39-0 365277-40-3 365277-41-4 365277-42-5
 365277-43-6 365277-44-7 365277-45-8 365277-46-9 365277-47-0
 365277-49-2 365277-51-6 365277-52-7 365277-53-8 365277-54-9
 365277-55-0 365277-57-2 365277-58-3 365277-59-4 365277-60-7
 365277-61-8 365277-62-9 365277-63-0 365277-64-1 365277-65-2
 365277-66-3 365277-88-9 374748-06-8 380435-62-1 380435-65-4
 380435-74-5 380435-76-7 380435-88-1 389081-55-4 389081-56-5
 389081-58-7 389081-60-1 389081-61-2 389081-62-3 389081-63-4
 389081-65-6 389081-66-7 389081-67-8 389081-68-9 389081-69-0
 389081-71-4 389081-72-5 389081-73-6 389081-74-7 389081-75-8
 389081-76-9 389081-77-0 389081-78-1 389081-79-2 389081-80-5
 389081-85-0 389139-10-0 389139-12-2 389139-15-5 389139-16-6
 389139-17-7 389139-18-8 389139-19-9 389139-20-2 389139-21-3
 389139-22-4 389139-23-5 389139-24-6 389139-25-7 389139-26-8
 389139-27-9 389139-28-0 389139-29-1 389139-30-4 389139-31-5
 389139-32-6 389139-33-7 389139-34-8 389139-35-9 389139-36-0
 389139-37-1 389139-38-2 389139-39-3 389139-40-6 389139-41-7
 389139-42-8 389139-43-9 389139-44-0 389139-45-1 389139-46-2
 389139-47-3 389139-48-4 389139-49-5 389139-51-9 389139-52-0
 389139-53-1 389139-54-2 389139-56-4 389139-57-5 389139-58-6
 389139-59-7 389139-60-0 389139-61-1 389139-62-2 389139-63-3
 389139-64-4 389139-65-5 389139-66-6 389139-67-7 389139-68-8
 389139-69-9 389139-70-2 389139-71-3 389139-72-4 389139-73-5
 389139-74-6 389139-75-7 389139-78-0 389139-79-1 389139-80-4
 389139-81-5 389139-82-6 389139-83-7 389139-85-9

RL: **PAC (Pharmacological activity); THU (Therapeutic**
use); BIOL (Biological study); USES (Uses)
 (**RNA-modulating** substituted tetracycline compds.,
 and therapeutic use)

IT 389139-86-0 389139-87-1 389139-88-2 389139-89-3 389139-90-6

389139-91-7	389139-93-9	389139-94-0	389139-96-2	389139-97-3
389139-98-4	389139-99-5	389140-00-5	389140-01-6	389140-03-8
389140-04-9	389140-06-1	389570-43-8	389570-46-1	389570-49-4
389570-50-7	389570-51-8	389570-52-9	389570-53-0	389570-54-1
389623-72-7	389623-77-2	389623-80-7	389623-82-9	389623-86-3
389623-88-5	389623-89-6	389623-90-9	389623-93-2	389623-95-4
389623-96-5	389623-97-6	389623-98-7	389623-99-8	389624-01-5
389624-03-7	389624-04-8	389624-05-9	389624-06-0	389624-07-1
389624-08-2	389624-09-3	389624-11-7	389624-12-8	389624-13-9
389624-14-0	389624-15-1	389624-16-2	389624-18-4	389624-19-5
389624-20-8	389624-21-9	389624-22-0	389624-23-1	389624-24-2
389624-26-4	389624-27-5	389624-28-6	389624-29-7	389624-30-0
389624-31-1	389624-32-2	389624-33-3	389624-34-4	389624-35-5
389624-36-6	389624-37-7	389624-38-8	389624-39-9	389624-41-3
389624-42-4	389624-43-5	389624-44-6	389624-45-7	389624-46-8
389624-47-9	389624-48-0	389624-49-1	389624-51-5	389624-52-6
389624-53-7	389624-54-8	389624-55-9	389624-56-0	389624-57-1
389624-59-3	389624-60-6	389624-61-7	389624-62-8	389624-63-9
389624-64-0	389624-65-1	389624-66-2	389624-67-3	389624-68-4
389624-69-5	389624-70-8	389624-71-9	389624-72-0	389624-73-1
389624-74-2	389624-75-3	389624-76-4	389624-77-5	389624-78-6
389624-79-7	389624-80-0	389624-81-1	389624-82-2	389624-84-4
389624-85-5	389624-86-6	389624-87-7	389624-88-8	389624-90-2
389624-91-3	389624-92-4	389624-93-5	389624-94-6	389624-96-8
389624-97-9	389624-98-0	389625-00-7	389625-01-8	389625-02-9
389625-03-0	389625-04-1	389625-05-2	389625-06-3	
389625-07-4	389625-09-6	389625-10-9	389625-11-0	389625-12-1
439217-57-9	439217-59-1	459425-79-7	459425-80-0	459425-96-8
459426-11-0	459809-42-8	459809-43-9	459809-44-0	
459809-45-1	459809-46-2	459809-47-3	459809-48-4	459809-49-5
459809-50-8	459809-51-9	459809-52-0	459809-53-1	459809-54-2
459809-55-3	459809-56-4	459809-57-5	459809-58-6	459809-59-7
459809-61-1	459809-63-3	459809-65-5	459809-66-6	459809-67-7
459809-68-8	459809-70-2	459809-72-4	459809-74-6	459809-76-8
459809-77-9	459809-79-1	459809-81-5	459809-82-6	459809-86-0
459809-88-2	459809-91-7	459809-92-8	459809-93-9	459809-94-0
459809-95-1	459809-97-3	459809-98-4	459810-00-5	459810-02-7
459810-03-8	459810-04-9	459810-06-1	459810-07-2	460068-26-2
460068-27-3	460068-29-5	460068-30-8	460068-31-9	460068-32-0
460068-33-1	460068-34-2	460068-35-3	460068-36-4	460068-38-6
460068-39-7	460068-40-0	460068-41-1	460068-42-2	460068-43-3
460068-44-4	460068-45-5	460068-46-6	460068-47-7	460068-48-8
460068-49-9	460068-50-2	460068-51-3	460068-52-4	460068-53-5
460068-54-6	460068-55-7	460068-57-9	460068-58-0	460068-59-1
460068-60-4	460068-61-5	460068-62-6	460068-63-7	460068-64-8
460068-65-9	460068-66-0	460068-67-1	460068-68-2	460068-69-3
460068-70-6	460068-71-7	460068-72-8		

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(RNA-modulating substituted tetracycline compds., and therapeutic use)

IT	460068-73-9	460068-74-0	460068-75-1	460068-76-2	460068-77-3
	460068-78-4	460068-79-5	460068-80-8	460068-81-9	460068-82-0
	460068-83-1	460068-84-2	460068-85-3	460068-86-4	460068-87-5
	460068-88-6	460068-90-0	460068-92-2	460068-93-3	460068-94-4
	460068-95-5	460068-96-6	460068-97-7	460068-99-9	460069-34-5
	460069-38-9	460069-65-2	460069-70-9	460069-89-0	460070-02-4
	460070-53-5	460070-61-5	460070-66-0	460070-73-9	460070-76-2
	460070-79-5	460070-92-2	460070-95-5	460071-02-7	460071-04-9
	460071-06-1	460071-09-4	460071-12-9	460071-14-1	460071-17-4

460071-19-6	460071-29-8	460071-31-2	460071-33-4	460071-66-3
460071-69-6	460071-80-1	460071-83-4	460071-87-8	
460071-89-0	460071-91-4	460071-93-6	460071-97-0	460071-99-2
460072-01-9	460072-03-1	460072-05-3	460072-07-5	460072-09-7
460072-10-0	460072-12-2	460072-15-5	460072-17-7	460072-19-9
460072-21-3	460072-25-7	460072-28-0	460072-29-1	460072-30-4
460072-31-5	460072-33-7	460072-36-0	460072-38-2	460072-40-6
460072-43-9	460072-45-1	460072-47-3	460072-49-5	460072-63-3
460072-65-5	460072-70-2	460072-73-5	460072-75-7	460072-78-0
460072-82-6	460072-86-0	460072-89-3	460072-91-7	460072-93-9
460072-99-5	460073-01-2	460073-03-4	460073-05-6	460073-07-8
460073-09-0	460073-11-4	460073-15-8	460073-17-0	460073-21-6
460073-22-7	460073-23-8	460073-25-0	460073-27-2	460073-29-4
460073-31-8	460073-35-2	460073-37-4	460073-40-9	
460073-41-0	460073-43-2	460073-45-4	460073-47-6	460073-49-8
460073-51-2	460073-55-6	460073-58-9	460073-60-3	460073-62-5
460073-64-7	460073-68-1	460073-70-5	460073-72-7	
460073-74-9	460073-76-1	460073-78-3	460073-80-7	
460073-82-9	460073-84-1	460073-86-3	460073-88-5	460073-90-9
460073-92-1	460073-94-3	460073-96-5	460073-98-7	460074-00-4
460074-02-6	460074-04-8	460074-09-3	460074-09-3	460074-11-7
460074-13-9	460074-19-5	460074-21-9	460074-23-1	
460074-26-4	460074-28-6	460074-30-0	460074-34-4	460074-36-6
460074-38-8	460074-40-2	460074-42-4	460074-44-6	460074-46-8
460074-48-0	460074-50-4	460074-52-6	460074-54-8	460074-56-0
460074-58-2	460074-60-6	460074-62-8	460074-64-0	460074-66-2
460074-68-4	460074-69-5	460074-71-9	460074-73-1	460074-75-3
460074-77-5	460074-79-7	460074-81-1	460074-85-5	460074-87-7
460074-89-9	460074-91-3	460074-93-5	460074-95-7	460074-97-9
460074-99-1	460075-04-1	460075-06-3	460075-08-5	460075-12-1
460075-14-3	460075-62-1	460076-23-7	460082-87-5	460082-89-7
460082-90-0	460082-91-1	473973-13-6	473973-20-5	473973-34-1
473973-37-4	473973-41-0	473973-62-5	473973-64-7	473973-86-3
473973-96-5	473974-12-8	473974-75-3	473974-76-4	473974-77-5
473974-79-7	473974-80-0	473974-81-1	473974-82-2	473974-83-3
473974-84-4	473974-85-5	488815-52-7	488815-53-8	488815-54-9
488815-55-0	488815-56-1	488815-57-2		
488815-58-3	488815-59-4	488815-60-7	488815-61-8	
488815-62-9	488815-63-0	488815-64-1	488815-65-2	
488815-66-3	488815-67-4	488815-68-5	488815-69-6	488815-70-9

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(RNA-modulating substituted tetracycline compds.,
and therapeutic use)

IT	488815-71-0	488815-72-1	488815-73-2	488815-74-3	488815-75-4
	488815-76-5	488815-77-6	488815-78-7	488815-79-8	488815-80-1
	488815-82-3	488815-89-0	488815-93-6	488815-98-1	488816-00-8
	488816-09-7	488816-13-3	488816-16-6	488816-18-8	488816-19-9
	488816-26-8	488816-37-1	488816-39-3	488816-42-8	488816-54-2
	488816-55-3	488816-58-6	488816-59-7	488816-64-4	488816-65-5
	488816-70-2	488816-71-3	488816-73-5	488816-75-7	488816-82-6
	488816-86-0	488816-88-2	488816-92-8	488816-93-9	488816-98-4
	488817-01-2	488817-06-7	488817-11-4	488817-13-6	488817-14-7
	488817-15-8	488817-16-9	488817-17-0	488817-18-1	488817-19-2
	488817-20-5	488817-21-6	488817-22-7	488817-23-8	488817-24-9
	488817-25-0	488817-26-1	488817-27-2	488817-28-3	488817-29-4
	488817-30-7	488817-31-8	488817-32-9	488817-33-0	
	488817-34-1	488817-35-2	488817-36-3	488817-37-4	488817-38-5
	488817-39-6	488817-40-9	488817-41-0	488817-42-1	488817-43-2
	488817-44-3	488817-45-4	488817-46-5	488817-47-6	488817-48-7

488817-49-8	488817-50-1	488817-51-2	488817-52-3	488817-53-4
488817-54-5	488817-55-6	488817-56-7	488817-57-8	488817-58-9
488817-59-0	488817-60-3	488817-61-4	488817-62-5	488817-63-6
488817-64-7	488817-65-8	488817-66-9	488817-67-0	488817-68-1
488817-69-2	488817-70-5	488817-71-6	488817-72-7	488817-73-8
488817-74-9	488817-75-0	488817-76-1	488817-77-2	488817-78-3
488817-79-4	488817-80-7	488817-81-8	488817-82-9	488817-89-6
488817-91-0	488817-92-1	488817-93-2	488817-94-3	488817-95-4
488817-96-5	488817-97-6	488817-98-7	488817-99-8	488818-00-4
488818-01-5	488818-02-6	488818-03-7	488818-04-8	488818-05-9
488818-06-0	488818-07-1	488818-08-2	488818-09-3	488818-10-6
488818-11-7	488818-12-8	488818-13-9	488818-14-0	
488818-15-1	488818-16-2	488818-17-3	488818-18-4	
488818-19-5	488818-20-8	488818-21-9	488818-22-0	
488818-23-1	488818-24-2	488818-25-3	488818-26-4	488818-27-5
488818-28-6	488818-29-7	488818-30-0	488818-31-1	
488818-32-2	488818-33-3	488818-34-4	488818-35-5	488818-36-6
488818-37-7	488818-38-8	488818-39-9	488818-40-2	488818-41-3
488818-42-4	488818-43-5	488818-44-6	488818-45-7	
488818-46-8	488818-47-9	488818-48-0	488818-49-1	488818-50-4
488818-51-5	488818-52-6	488818-53-7	488818-54-8	488818-55-9
488818-56-0	488818-57-1	488818-58-2	488818-59-3	488818-60-6
488818-61-7	488818-63-9	488818-64-0	488818-65-1	
488818-66-2	488818-67-3	488818-68-4	488818-69-5	488818-70-8
488818-71-9	488818-72-0	488818-73-1	488818-74-2	488818-75-3
488818-76-4	488818-77-5	488818-78-6	488818-79-7	488818-80-0
488818-81-1	488818-82-2	488818-83-3	488818-84-4	
488818-85-5	488818-86-6	488818-87-7	488818-88-8	488818-89-9
488818-90-2	488818-91-3	488818-92-4	488818-93-5	488818-94-6
488818-95-7	488818-96-8	488818-97-9	488818-98-0	488818-99-1
488819-00-7	488819-01-8	488819-02-9	488819-03-0	
488819-04-1	488819-05-2	488819-06-3	488819-07-4	488819-08-5
488819-14-3	488819-15-4	488819-16-5	488819-17-6	488819-18-7

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(RNA-modulating substituted tetracycline compds., and therapeutic use)

IT	488819-19-8	488819-20-1	488819-21-2	488819-22-3	
	488819-23-4	488819-24-5	488819-25-6	488819-26-7	488819-27-8
	488819-28-9	488819-29-0	488819-30-3	488819-31-4	488819-32-5
	488819-33-6	488819-34-7	488819-35-8	488819-36-9	488819-37-0
	488819-38-1	488819-39-2	488819-40-5	488819-41-6	488819-42-7
	488819-43-8	488819-44-9	488819-45-0	488819-46-1	488819-47-2
	488819-48-3	488819-49-4	488819-50-7	488819-51-8	488819-52-9
	488819-53-0	488819-54-1	488819-55-2	488819-56-3	488819-57-4
	488819-58-5	488819-59-6	488819-60-9	488819-61-0	488819-62-1
	488819-63-2	488819-64-3	488819-65-4	488819-66-5	488819-67-6
	488819-68-7	488819-69-8	488819-70-1	488819-71-2	488819-72-3
	488819-73-4	488819-74-5	488819-75-6	488819-76-7	488819-77-8
	488819-78-9	488819-79-0	488819-80-3	488819-81-4	488819-82-5
	488819-83-6	488819-84-7	488819-85-8	488819-86-9	488819-87-0
	488819-88-1	488819-89-2	488819-90-5	488819-91-6	488819-92-7
	488819-93-8	488819-94-9	488819-95-0	488819-96-1	488819-97-2
	488819-98-3	488819-99-4	488820-00-4	488820-01-5	488820-02-6
	488820-03-7	488820-04-8	488820-05-9	488820-06-0	488820-07-1
	488820-08-2	488820-09-3	488820-10-6	488820-11-7	488820-12-8
	488820-13-9	488820-14-0	488820-15-1	488820-16-2	
	488820-17-3	488820-18-4	488820-19-5	488820-20-8	488820-21-9
	488820-22-0	488820-23-1	488820-24-2	488820-25-3	488820-26-4
	488820-27-5	488820-28-6	488820-29-7	488820-30-0	

488820-31-1	488820-32-2	488820-33-3	488820-34-4	488820-48-0
488820-49-1	488821-84-7	577795-55-2	601454-79-9	601454-80-2
601454-82-4	601454-85-7	601454-92-6	601454-95-9	
601454-97-1	601454-98-2	601455-02-1	601455-03-2	
601455-04-3	601455-05-4	601455-07-6	601455-09-8	601455-11-2
601455-12-3	601455-13-4	601455-15-6	601455-16-7	601455-17-8
601455-18-9	601455-19-0	601455-20-3	601455-21-4	601455-22-5
601455-23-6	601455-24-7	601455-25-8	601455-26-9	601455-27-0
601455-29-2	601455-30-5	601455-31-6	601455-32-7	601455-33-8
601455-34-9	601455-35-0	601455-36-1	601455-37-2	601455-38-3
601455-39-4	601455-41-8	601455-42-9	601455-43-0	601455-44-1
601455-45-2	601455-46-3	601455-47-4	607400-44-2	607400-46-4
607400-50-0	607400-72-6	607401-48-9	607401-54-7	607401-57-0
607401-59-2	607401-63-8	607401-65-0	607401-67-2	607401-69-4
607401-71-8	607401-73-0	607401-75-2	607401-77-4	607401-79-6
607401-81-0	607401-83-2	607401-98-9	607402-03-9	607402-08-4
607402-10-8	607402-12-0	607402-14-2	607402-16-4	607402-18-6
607402-20-0	607402-22-2	607402-24-4	607402-28-8	607402-58-4
607402-73-3	607402-74-4	607402-75-5	607402-76-6	607402-77-7
607402-79-9	607402-80-2	607402-81-3	607402-82-4	607402-83-5
607402-84-6	607402-85-7	644995-53-9	685831-50-9	685831-51-0
685831-52-1	685832-62-6	685832-63-7	685832-64-8	
685832-65-9	685832-66-0	685832-68-2	685832-71-7	685832-75-1
685832-82-0	685832-83-1	685832-84-2	685832-85-3	685832-86-4
685832-87-5	685832-88-6	685832-89-7	685832-90-0	685832-91-1
685832-92-2	685832-93-3			

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(RNA-modulating substituted tetracycline compds., and therapeutic use)

IT	685832-94-4	685832-95-5	685832-96-6	685832-97-7	685832-98-8
	685832-99-9	685833-00-5	685833-01-6	685833-02-7	685833-03-8
	685833-04-9	685833-05-0	685833-06-1	685833-07-2	685833-08-3
	685833-09-4	685833-10-7	685833-11-8	685833-12-9	685833-13-0
	685833-14-1	685833-15-2	685833-16-3	685833-17-4	685833-18-5
	685833-19-6	685833-20-9	685833-21-0	685833-22-1	685833-23-2
	685833-24-3	685833-25-4	685833-26-5	685833-27-6	685833-28-7
	685833-29-8	685833-30-1	685833-31-2	685833-32-3	685833-33-4
	685833-34-5	685833-35-6	685833-36-7	685833-37-8	685833-38-9
	685833-39-0	685833-40-3	685833-41-4	685833-42-5	685833-43-6
	685833-44-7	685833-45-8	685833-46-9	685833-47-0	685833-48-1
	685833-49-2	685833-50-5	685833-51-6	685833-52-7	685833-53-8
	685833-54-9	685833-55-0	685833-56-1	685833-57-2	685833-66-3
	685833-68-5	685859-06-7	685859-07-8	685859-08-9	685859-09-0
	685859-10-3	685859-11-4	685859-12-5	685859-14-7	685859-18-1
	685859-19-2	685859-20-5	685859-21-6	685859-24-9	685859-28-3
	685859-34-1	685859-35-2			

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(RNA-modulating substituted tetracycline compds., and therapeutic use)

IT	98-80-6, Phenylboronic acid	1066-54-2, Trimethylsilylacetylene
	1679-18-1, 4-Chlorophenylboronic acid	1765-93-1, 4-Fluorophenylboronic acid
	14047-29-1, p-Carboxyphenylboronic acid	35037-73-1, 4-Trifluoromethoxyphenylisocyanate
		59046-78-5

RL: RCT (Reactant); RACT (Reactant or reagent)

(RNA-modulating substituted tetracycline compds., and therapeutic use)

IT	113164-67-3P, 7-Iodosancycline	263761-05-3P, 7-Ethynylsancycline
----	--------------------------------	-----------------------------------

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

(Reactant or reagent)

(RNA-modulating substituted tetracycline compds.,
and therapeutic use)IT 263760-99-2P, 7-(4-Chlorophenyl)sancycline 389140-02-7P 685831-49-6P
686290-41-5PRL: SPN (Synthetic preparation); PREP (Preparation)
(RNA-modulating substituted tetracycline compds.,
and therapeutic use)

L56 ANSWER 5 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:777531 HCAPLUS Full-text

DOCUMENT NUMBER: 139:292094

TITLE: Preparation of substituted tetracycline compounds for
the treatment of bacterial infections and neoplasmsINVENTOR(S): Nelson, Mark L.; Ohemeng, Kwasi; Frechette, Roger;
Abato, Paul; Assefa, Haregewein; Bandarage, Upul;
Berniac, Joel; Bhatia, Beena; Chen, Jackson; Ismail,
Mohamed Y.; Kim, Oak A.; Mathews, Jude; McIntyre,
Laura; Nihlawi, Mohammed; Pearson, Andre; Reddy,
Laxma; Sheahan, Paul; Sizensky, Emmanuelle; Tourigny,
Justin; Verma, Atul K.; Viski, Peter; Warchol, Tadeusz
PATENT ASSIGNEE(S): Paratek Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 118 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003079984	A2	20031002	WO 2003-US8324	20030318 <--
WO 2003079984	A3	20040910		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2479877	A1	20031002	CA 2003-2479877	20030318 <--
AU 2003218243	A1	20031008	AU 2003-218243	20030318 <--
EP 1503981	A2	20050209	EP 2003-714236	20030318 <--
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
JP 2005520846	T	20050714	JP 2003-577816	20030318 <--
CN 1653037	A	20050810	CN 2003-810965	20030318 <--
US 2005038002	A1	20050217	US 2003-740961	20031218 <--
PRIORITY APPLN. INFO.:			US 2002-366915P	P 20020321 <--
			US 2002-367045P	P 20020321 <--
			US 2002-367048P	P 20020321 <--
			US 2002-395468P	P 20020712 <--
			US 2003-440305P	P 20030114
			US 2003-391903	B1 20030318
			WO 2003-US8324	W 20030318

OTHER SOURCE(S): MARPAT 139:292094

GI



I

AB Novel substituted tetracycline compds. of formula I [X = (substituted) CH, S, (substituted) NH, O; R1, R2 = H, alkyl, arylalkyl, aryl, heterocyclic, heteroarom.; R4 = (substituted) NH₂, alkyl, aryl, OH, halo, H; R5 = OH, H, SH, alkanoyl, aroyl, alkyl, alkoxy, alkylthio, etc.; R7 = NO₂, heterocyclic, alkyl, aminoalkyl, aryl, alkoxy, etc.; R8, R9 = H, OH, halo, SH, nitro, alkyl, aryl, alkoxy, alkylamino, etc.; R3, R10, R11, R12 = H, prodrug moiety] are prepared. These tetracycline compds. can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compds. in general, such as blocking tetracycline efflux and modulation of gene expression. Thus, 7-phenylsancycline was prepared in 2 steps from sancycline and phenylboronic acid.

IT 488818-45-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation);

THU (Therapeutic use); BIOL (Biological study); PREP


(Preparation); USES (Uses)

(preparation of tetracycline compds. for the treatment of bacterial infections and neoplasms)

RN 488818-45-7 HCAPLUS

CN 1,8-Naphthacenedicarboxamide, 10-(dimethylamino)-5,6a,7,10,10a,11,11a,12-octahydro-4,6,6a,9-tetrahydroxy-N1,N1-dimethyl-5,7-dioxo-, (6aS,10S,10aS,11aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IC ICM A61K

CC 26-6 (Biomolecules and Their Synthetic Analogs)

Section cross-reference(s): 1, 30, 63

IT	5874-95-3P	10118-89-5P	53108-40-0P	155819-14-0P	155819-18-4P
	263760-96-9P	344771-54-6P	365277-49-2P	380435-88-1P	389139-31-5P
	389140-02-7P	439217-57-9P	439217-59-1P	459425-96-8P	459809-54-2P
	459809-68-8P	460068-62-6P	460069-96-9P	460071-12-9P	460072-45-1P
	460073-29-4P	460073-45-4P	460073-47-6P	460073-49-8P	460073-51-2P

460073-55-6P	460073-58-9P	460073-60-3P	460073-62-5P	460073-64-7P
460073-68-1P	460073-76-1P	460073-80-7P	460073-82-9P	460073-84-1P
460073-86-3P	460073-90-9P	460073-92-1P	460073-94-3P	460073-96-5P
460074-04-8P	460074-06-0P	460074-13-9P	460074-34-4P	460074-36-6P
460074-38-8P	460074-42-4P	460074-44-6P	460074-46-8P	460074-48-0P
460074-50-4P	460074-52-6P	460074-54-8P	460074-58-2P	460074-60-6P
460074-64-0P	460074-66-2P	460074-68-4P	460074-69-5P	460074-71-9P
460074-75-3P	460074-77-5P	460074-79-7P	460074-81-1P	460074-85-5P
460074-87-7P	460074-89-9P	460074-91-3P	460074-93-5P	460074-95-7P
460074-97-9P	460074-99-1P	460075-04-1P	460075-08-5P	460075-12-1P
460075-14-3P	460082-90-0P	460082-91-1P	473973-41-0P	473974-85-5P
488815-53-8P	488815-59-4P	488815-60-7P	488815-62-9P	488818-18-4P
488818-23-1P	488818-24-2P	488818-25-3P	488818-28-6P	488818-29-7P
488818-33-3P	488818-35-5P	488818-36-6P	488818-38-8P	488818-39-9P
488818-40-2P	488818-42-4P	488818-43-5P	488818-45-7P	
488818-46-8P	488818-48-0P	488818-49-1P	488818-53-7P	488818-58-2P
488818-66-2P	488818-70-8P	488818-71-9P	488818-73-1P	488818-74-2P
488818-76-4P	488818-80-0P	488818-81-1P	488818-83-3P	488818-84-4P
488818-85-5P	488818-87-7P	488818-88-8P	488818-90-2P	488818-94-6P
488818-99-1P	488819-00-7P	488819-01-8P	488819-03-0P	488819-04-1P
488819-06-3P	488819-14-3P	488819-17-6P	488819-18-7P	488819-20-1P
488819-21-2P	488819-23-4P	488819-24-5P	488819-26-7P	488819-27-8P
488819-31-4P	488819-34-7P	488819-35-8P	488819-36-9P	488819-41-6P
488819-42-7P	488819-43-8P	488819-49-4P	488819-52-9P	488819-56-3P
488819-58-5P	488819-60-9P	488819-67-6P	488819-68-7P	488819-69-8P
488819-70-1P	488819-72-3P	488819-76-7P	488819-77-8P	488819-88-1P
488819-94-9P	488820-00-4P	488820-09-3P	488820-13-9P	488820-18-4P
488820-20-8P	488820-26-4P	488820-28-6P	488820-32-2P	577795-55-2P
601455-03-2P	607399-66-6P	607399-77-9P	607399-86-0P	607400-10-2P
607400-33-9P	607400-40-8P	607400-44-2P	607400-46-4P	607400-50-0P
607400-65-7P	607400-72-6P	607401-03-6P	607401-06-9P	607401-13-8P
607401-16-1P	607401-18-3P	607401-20-7P	607401-22-9P	607401-26-3P
607401-28-5P	607401-38-7P	607401-41-2P	607401-43-4P	607401-45-6P
607401-48-9P	607401-50-3P	607401-52-5P	607401-54-7P	607401-57-0P
607401-59-2P	607401-61-6P	607401-63-8P	607401-65-0P	607401-67-2P
607401-69-4P	607401-71-8P	607401-73-0P	607401-75-2P	607401-77-4P
607401-79-6P	607401-81-0P	607401-83-2P	607401-86-5P	607401-98-9P
607402-01-7P	607402-03-9P	607402-06-2P	607402-08-4P	607402-10-8P
607402-12-0P	607402-14-2P	607402-16-4P	607402-18-6P	607402-20-0P
607402-22-2P	607402-24-4P	607402-26-6P	607402-28-8P	607402-31-3P
607402-58-4P	607402-69-7P	607402-70-0P	607402-71-1P	607402-72-2P
607402-73-3P	607402-74-4P	607402-75-5P	607402-76-6P	607402-77-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation);

THU (Therapeutic use); BIOL (Biological study); PREP

(Preparation); USES (Uses)

(preparation of tetracycline compds. for the treatment of bacterial infections and neoplasms)

L56 ANSWER 6 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:777530 HCAPLUS Full-text

DOCUMENT NUMBER: 139:292093

TITLE: Methods of preparing substituted tetracyclines with transition metal-based chemistries

INVENTOR(S): Nelson, Mark L.; Rennie, Glen; Koza, Darrell J.

PATENT ASSIGNEE(S): Trustees of Tufts College, USA

SOURCE: PCT Int. Appl., 41 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 10

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003079983	A2	20031002	WO 2003-US8323	20030318 <--
WO 2003079983	A3	20041111		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2002128237	A1	20020912	US 2001-882273	20010615 <--
AU 2003218242	A1	20031008	AU 2003-218242	20030318 <--
US 2004224927	A1	20041111	US 2004-820456	20040407 <--
US 2005187198	A1	20050825	US 2004-4559	20041203 <--
US 2006234988	A1	20061019	US 2006-453326	20060614 <--
PRIORITY APPLN. INFO.:			US 2002-367050P	P 20020321 <--
			US 1999-154701P	P 19990914 <--
			US 2000-212139P	P 20000616 <--
			WO 2000-US16672	W 20000616 <--
			US 2000-232091P	P 20000912 <--
			US 2000-660598	A2 20000913 <--
			US 2001-882273	B1 20010615 <--
			US 2003-391923	B1 20030318
			WO 2003-US8323	W 20030318
			US 2004-765233	B1 20040126
			US 2004-820456	B1 20040407

OTHER SOURCE(S): MARPAT 139:292093
GI



AB The present invention relates to novel chemistries which allow for heretofore unobtainable substituted tetracycline compds. which exhibit significant activity in tetracycline responsive states. The methods disclosed herein utilize reactive tetracycline-based precursor compds., reactive organic substituent precursors and transition metal catalysts under conditions such that a tetracycline compound substituted with the desired organic substituent is formed. In one embodiment of the invention, a substituted tetracycline compound may be prepared by combining a reactive tetracycline-based precursor compound such as an arene tetracycline diazonium salt, and a reactive organic substituent precursor, e.g., alkenes, substituted alkenes, vinyl monomers, aroms. and heteroaroms., in the presence of a transition metal catalyst, such as palladium acetate, under conditions such that a tetracycline compound substituted with the organic substituent is formed. Such compds. may optionally act as intermediates for making other compds., e.g., hydrogenation

of unsatd. groups on the substituent. Thus, I was prepared from 9-diazoniumdoxycycline (preparation given) using palladium acetate catalyst, and was found to have antibacterial activity.

IT 488818-45-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation);

THU (Therapeutic use); BIOL (Biological study); PREP


(Preparation); USES (Uses)

(preparation of antibacterial tetracyclines using transition metal catalysts)

RN 488818-45-7 HCAPLUS

CN 1,8-Naphthacenedicarboxamide, 10-(dimethylamino)-5,6a,7,10,10a,11,11a,12-octahydro-4,6,6a,9-tetrahydroxy-N1,N1-dimethyl-5,7-dioxo-, (6aS,10S,10aS,11aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IC ICM A61K

CC 26-6 (Biomolecules and Their Synthetic Analogs)

Section cross-reference(s): 1, 30

IT 263760-98-1P 263760-99-2P 263761-01-9P 263761-03-1P 330627-22-0P
330627-23-1P 330627-26-4P 330627-27-5P 330627-32-2P 344771-54-6P
389081-61-2P 389081-77-0P 389081-82-7P 460073-51-2P 460074-13-9P
460074-42-4P 473973-41-0P 488818-28-6P 488818-45-7P
607738-51-2P 607738-52-3P 607738-53-4P 607738-54-5P 607738-55-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation);

THU (Therapeutic use); BIOL (Biological study); PREP

(Preparation); USES (Uses)

(preparation of antibacterial tetracyclines using transition metal catalysts)

L56 ANSWER 7 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:737533 HCAPLUS Full-text

DOCUMENT NUMBER: 139:261089

TITLE: Preparation of aminomethyl substituted tetracycline compounds for treating tetracycline responsive states

INVENTOR(S): Nelson, Mark L.; Ohemeng, Kwasi; Frechette, Roger; Ismail, Mohamed Y.; McIntyre, Laura; Bowser, Todd

PATENT ASSIGNEE(S): Paratek Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 51 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003075857	A2	20030918	WO 2003-US7229	20030310 <--

WO 2003075857

A3

20040205

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2478335 A1 20030918 CA 2003-2478335 20030310 <--

AU 2003220123 A1 20030922 AU 2003-220123 20030310 <--

EP 1482926 A2 20041208 EP 2003-716416 20030310 <--

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

CN 1649582 A 20050803 CN 2003-809979 20030310 <--

JP 2005526754 T 20050908 JP 2003-574133 20030310 <--

US 2005026875 A1 20050203 US 2003-737361 20031215 <--

US 2005026876 A1 20050203 US 2004-786881 20040224 <--

IN 2004CN02212 A 20070330 IN 2004-CN2212 20041004 <--

PRIORITY APPLN. INFO.: US 2002-362654P P 20020308 <--

US 2002-395495P P 20020712 <--

US 2001-275621P P 20010313 <--

US 2001-895857 A2 20010629 <--


US 2003-384855 B1 20030310

WO 2003-US7229 W 20030310

US 2003-412656 B1 20030410

OTHER SOURCE(S): MARPAT 139:261089

GI



I

AB The present invention pertains, at least in part, to aminomethyl substituted tetracycline compds., such as I [J1, J2 = H, aryl, sulfonyl, acyl; J3, J4 = H, alkyl, halo; X = (substituted) CHCH3, (substituted) CH2, S, (substituted) NR6, O; R1, R2 = H, alkyl, alkoxy, alkylthio, arylalkyl, aryl; R2, R3, R10-R12 = H, prodrug moiety; R4, R5 = H, alkyl, OH, halo, amino; R6 = H, alkyl, OH, halo, alkoxy, alkylthio, arylalkyl, aryl; R8 = H, OH, halo, thiol, alkyl, aryl; R9 = H, NO2, alkyl, aryl, alkoxy, alkylthio, amino], and pharmaceutically acceptable salts, esters, and prodrugs thereof. Tetracycline compds. were tested for their antibacterial efficacy (no data). These tetracycline compds. can be used to treat numerous tetracycline responsive states, such as bacterial infections, cancer, a lung injury, an eye disorder, neurol. disorder or stroke.

IT 460073-37-4P 460073-72-7P 460073-74-9P

488815-56-1P 488818-17-3P 488818-20-8P

488818-21-9P 488818-31-1P 488818-63-9P
 488820-15-1P 488820-27-5P 601454-73-3P
 601454-81-3P 601454-83-5P 601454-84-6P
 601454-86-8P 601454-88-0P 601454-91-5P
 601454-93-7P 601454-94-8P 601454-95-9P
 601454-96-0P 601454-98-2P 601454-99-3P
 601455-00-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation);

THU (Therapeutic use); BIOL (Biological study); PREP


(Preparation); USES (Uses)

(preparation of aminomethyl substituted tetracycline compds. for treating tetracycline responsive states)

RN 460073-37-4 HCAPLUS

CN 2-Naphthacenecarboxamide, 7-[[bis(2-methylpropyl)amino]methyl]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 460073-72-7 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-7-[[[(1-methyl-1H-pyrrol-2-yl)methyl]amino]methyl]-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 460073-74-9 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-7-[[[(1H-pyrrol-2-yl)methyl]amino]methyl]-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 488815-56-1 HCAPLUS

CN 2-Naphthacenecarboxamide, 7-[[bis(cyclopropylmethyl)amino]methyl]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 488818-17-3 HCAPLUS

CN 4-Pyridinecarboxamide, N-[[[(6aS,10S,10aS,11aR)-8-(aminocarbonyl)-10-(dimethylamino)-5,6a,7,10,10a,11,11a,12-octahydro-4,6,6a,9-tetrahydroxy-5,7-dioxo-1-naphthacenyl]methyl]-, 1-oxide (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 488818-20-8 HCAPLUS

10692764

CN 4-Isoxazolecarboxamide, N-[[[(6aS,10S,10aS,11aR)-8-(aminocarbonyl)-10-(dimethylamino)-5,6a,7,10,10a,11,11a,12-octahydro-4,6,6a,9-tetrahydroxy-5,7-dioxo-1-naphthacenyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 488818-21-9 HCAPLUS

CN 3-Pyridinecarboxamide, N-[[[(6aS,10S,10aS,11aR)-8-(aminocarbonyl)-10-(dimethylamino)-5,6a,7,10,10a,11,11a,12-octahydro-4,6,6a,9-tetrahydroxy-5,7-dioxo-1-naphthacenyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 488818-31-1 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-7-[[[(1-oxido-4-pyridinyl)methyl]amino]methyl]-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 488818-63-9 HCAPLUS

CN 4-Morpholinecarboxamide, N-[[[(6aS,10S,10aS,11aR)-8-(aminocarbonyl)-10-(dimethylamino)-3-ethyl-5,6a,7,10,10a,11,11a,12-octahydro-4,6,6a,9-tetrahydroxy-5,7-dioxo-1-naphthacenyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 488820-15-1 HCAPLUS

CN 2-Naphthacenecarboxamide, 7-[(acetylamino)methyl]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 488820-27-5 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-7-[[[(2,2-dimethyl-1-oxopropyl)amino]methyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-

10692764

tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 601454-73-3 HCAPLUS

CN 2-Naphthacenecarboxamide, 7-[[bis(2,2-dimethoxyethyl)amino]methyl]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, dihydrochloride, (4aS,5aR,12aS) - (9CI) (CA INDEX NAME),

Absolute stereochemistry.




● 2 HCl

RN 601454-81-3 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-7-[[2,2-dimethylpropyl]amino]methyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4aS,5aR,12aS) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 601454-83-5 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-7-[[(1-methylpropyl) amino]methyl]-1,11-dioxo-, (4S,4aS,5aR,12aS) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 601454-84-6 HCAPLUS

CN 2-Naphthacenecarboxamide, 7-[[bis(2,2-dimethoxyethyl) amino]methyl]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4R,4aS,5aR,12aS) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 601454-86-8 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-7-[(dimethylamino)methyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4R,4aS,5aR,12aS) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 601454-88-0 HCAPLUS

CN 2-Naphthacenecarboxamide, 7-[(diethylamino)methyl]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4R,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 601454-91-5 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-7-[[[(1-methylethyl)amino]methyl]-1,11-dioxo-, (4aS,5aR,12aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 601454-93-7 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-7-[[[(2-methylpropyl)amino]methyl]-1,11-dioxo-, (4aS,5aR,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 601454-94-8 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-7-[[[(2-fluoro-1-methylethyl)amino]methyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-

10692764

tetrahydroxy-1,11-dioxo-, (4aS,5aR,12aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 601454-95-9 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-7-[[[(4-fluorophenyl)methyl]amino]methyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4R,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 601454-96-0 HCAPLUS

CN 4-Morpholinecarboxamide, N-[[[(6aS,10R,10aS,11aR)-8-(aminocarbonyl)-10-(dimethylamino)-3-ethynyl-5,6a,7,10,10a,11,11a,12-octahydro-4,6,6a,9-tetrahydroxy-5,7-dioxo-1-naphthacenyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 601454-98-2 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-7-[[(phenylmethyl) amino]methyl]-, (4R,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 601454-99-3 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-7,9-bis[[(2,2-dimethylpropyl) amino]methyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4aS,5aR,12aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 601455-00-9 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-7-[[(2,2-dimethylpropyl) amino]methyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-[(methylthio)methyl]-1,11-dioxo-, (4aS,5aR,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IC ICM A61K
 CC 26-6 (Biomolecules and Their Synthetic Analogs)
 Section cross-reference(s): 1, 10, 63
 ST tetracycline methylamino prepn bacterial infection treatment;
cancer treatment tetracycline methylamino prepn
 IT Neoplasm
 (treatment; preparation of aminomethyl substituted tetracycline compds. for
 treating **cancer** associated with tetracycline responsive states)

IT 459810-07-2P 460073-21-6P 460073-31-8P **460073-37-4P**
 460073-40-9P 460073-41-0P 460073-43-2P **460073-72-7P**
460073-74-9P 460073-78-3P 460073-88-5P 460074-09-3P
 460074-11-7P 460074-23-1P 460074-26-4P 460074-34-4P 460076-23-7P
 473973-37-4P 473974-81-1P 473974-82-2P 473974-84-4P
488815-56-1P 488815-57-2P **488818-17-3P**
488818-20-8P **488818-21-9P** **488818-31-1P**
 488818-34-4P 488818-37-7P 488818-41-3P 488818-47-9P 488818-51-5P
 488818-54-8P 488818-56-0P 488818-59-3P **488818-63-9P**
 488818-65-1P 488818-72-0P 488818-74-2P 488818-75-3P 488818-77-5P
 488818-79-7P 488818-91-3P 488818-95-7P 488819-05-2P 488819-07-4P
 488819-16-5P 488819-38-1P 488819-44-9P 488819-45-0P 488819-53-0P
 488819-55-2P 488819-57-4P 488819-64-3P 488819-65-4P 488819-75-6P
 488819-79-0P 488819-86-9P 488819-87-0P 488819-89-2P 488819-90-5P
 488819-92-7P 488819-93-8P 488819-98-3P 488819-99-4P 488820-00-4P
 488820-01-5P 488820-02-6P 488820-03-7P 488820-10-6P 488820-11-7P
 488820-14-0P **488820-15-1P** 488820-16-2P 488820-19-5P
 488820-21-9P 488820-22-0P 488820-24-2P **488820-27-5P**
 488820-29-7P 488820-30-0P 488820-34-4P 601454-70-0P 601454-71-1P
 601454-72-2P **601454-73-3P** 601454-74-4P 601454-75-5P
 601454-76-6P 601454-77-7P 601454-78-8P 601454-79-9P 601454-80-2P
601454-81-3P 601454-82-4P **601454-83-5P**
601454-84-6P 601454-85-7P **601454-86-8P** 601454-87-9P
601454-88-0P 601454-89-1P 601454-90-4P **601454-91-5P**
 601454-92-6P **601454-93-7P** **601454-94-8P**
601454-95-9P **601454-96-0P** 601454-97-1P
601454-98-2P **601454-99-3P** **601455-00-9P**
 601455-01-0P 601455-02-1P 601455-03-2P 601455-04-3P 601455-05-4P
 601455-06-5P 601455-07-6P 601455-08-7P 601455-09-8P 601455-10-1P
 601455-11-2P 601455-12-3P 601455-13-4P 601455-14-5P 601455-15-6P
 601455-16-7P 601455-17-8P 601455-18-9P 601455-19-0P 601455-20-3P
 601455-21-4P 601455-22-5P 601455-23-6P 601455-24-7P 601455-25-8P
 601455-26-9P 601455-27-0P 601455-28-1P 601455-29-2P 601455-30-5P
 601455-31-6P 601455-32-7P 601455-33-8P 601455-34-9P 601455-35-0P
 601455-36-1P 601455-37-2P 601455-38-3P 601455-39-4P 601455-41-8P
 601455-42-9P 601455-43-0P 601455-44-1P 601455-45-2P 601455-46-3P
 601455-47-4P 601455-48-5P 601455-49-6P 601455-50-9P 601455-51-0P
 601455-52-1P 601455-53-2P 601455-54-3P 601455-55-4P 601455-56-5P
 601455-57-6P 601455-58-7P 601455-59-8P 601455-60-1P 601455-61-2P
 601455-62-3P 601455-63-4P 601455-64-5P 601455-65-6P 601455-66-7P
 601455-67-8P 601455-68-9P 601455-69-0P 601455-70-3P 601455-71-4P
 601455-72-5P 601455-73-6P 601455-74-7P 601455-75-8P 601455-76-9P
 601455-77-0P 601455-78-1P 601455-79-2P 601455-80-5P 601455-81-6P
 601455-82-7P 601455-83-8P 601455-84-9P 601455-85-0P 601455-86-1P
 601455-87-2P 601455-88-3P 601455-89-4P 601455-90-7P 601455-91-8P
 601455-92-9P 601455-93-0P 601455-97-4P 601455-98-5P 601455-99-6P
 601456-00-2P 601456-01-3P 601456-02-4P 601456-03-5P 601470-72-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation);
 THU (Therapeutic use); BIOL (Biological study); PREP

(Preparation); USES (Uses)

(preparation of aminomethyl substituted tetracycline compds. for treating tetracycline responsive states)

L56 ANSWER 8 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:57866 HCAPLUS Full-text

DOCUMENT NUMBER: 138:117673

TITLE: Tetracycline compounds having target therapeutic activities

INVENTOR(S): Levy, Stuart B.; Draper, Michael; Nelson, Mark L.; Jones, Graham

PATENT ASSIGNEE(S): Paratek Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 158 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003005971	A2	20030123	WO 2002-US22451	20020715 <--
WO 2003005971	A3	20031127		
WO 2003005971	A8	20040506		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002318238	A1	20030129	AU 2002-318238	20020715 <--
US 2004063674	A1	20040401	US 2002-196010	20020715 <--
EP 1408987	A2	20040421	EP 2002-748169	20020715 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
JP 2004537544	T	20041216	JP 2003-511780	20020715 <--
US 2006194773	A1	20060831	US 2004-996119	20041122 <--
PRIORITY APPLN. INFO.:				
			US 2001-305546P	P 20010713 <--
			US 2002-395741P	P 20020712 <--
			US 2002-196010	A2 20020715 <--
			WO 2002-US22451	W 20020715 <--
			US 2003-441141P	P 20030116
			US 2004-759484	B1 20040116

OTHER SOURCE(S): MARPAT 138:117673

AB Methods and compds. for treating a variety of diseases with tetracycline compds. having a target therapeutic activity are described, as is compound preparation

IT 53108-41-1 389625-03-0 459809-44-0
 460071-69-6 460073-37-4 460073-70-5
 460073-72-7 460073-74-9 460074-19-5
 488815-54-9 488815-55-0 488815-56-1
 488815-58-3 488815-63-0 488817-32-9
 488818-13-9 488818-17-3 488818-20-8
 488818-21-9 488818-27-5 488818-31-1
 488818-45-7 488818-60-6 488818-63-9
 488818-82-2 488819-02-9 488819-08-5

488819-19-8 488820-15-1 488820-27-5

RL: PAC (Pharmacological activity); THU (Therapeutic


use); BIOL (Biological study); USES (Uses)

(tetracycline compds. with target therapeutic activities)

RN 53108-41-1 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-7-[(dimethylamino)methyl]-
1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-,
[4S-(4 α ,4a α ,5a α ,12a α)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 389625-03-0 HCAPLUS

CN Carbamic acid, [[[6aS,10S,10aS,11aR)-8-(aminocarbonyl)-10-(dimethylamino)-
5,6a,7,10,10a,11,11a,12-octahydro-4,6,6a,9-tetrahydroxy-5,7-dioxo-1-
naphthacenyl]methyl]-, 2,2-dimethylpropyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 459809-44-0 HCAPLUS

CN 3-Pyridinecarboxamide, N-[[[(6aS,10S,10aS,11aR)-8-(aminocarbonyl)-10-
(dimethylamino)-3-(1,1-dimethylethyl)-5,6a,7,10,10a,11,11a,12-octahydro-
4,6,6a,9-tetrahydroxy-5,7-dioxo-1-naphthacenyl]methyl]- (9CI) (CA INDEX
NAME)


Absolute stereochemistry.



RN 460071-69-6 HCAPLUS

CN Carbamic acid, [[(6aS,10S,10aS,11aR)-8-(aminocarbonyl)-10-(dimethylamino)-5,6a,7,10,10a,11,11a,12-octahydro-4,6,6a,9-tetrahydroxy-5,7-dioxo-1-naphthacenyl]methyl]-, 2-methylpropyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 460073-37-4 HCAPLUS

CN 2-Naphthacenecarboxamide, 7-[[bis(2-methylpropyl)amino]methyl]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 460073-70-5 HCAPLUS

CN 2-Naphthacenecarboxamide, 7-[[bis(2,2-dimethoxyethyl)amino]methyl]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 460073-72-7 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-7-[[[(1-methyl-1H-pyrrol-2-yl)methyl]amino]methyl]-1,11-dioxo-, (4S,4aS,5aR,12aS) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 460073-74-9 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-7-[[[(1H-pyrrol-2-yl)methyl]amino]methyl]-, (4S,4aS,5aR,12aS) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10692764

RN 460074-19-5 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-7,9-bis[[(2,2-dimethylpropyl)amino]methyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 488815-54-9 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-7-[[[(2,2-dimethylpropyl)amino]methyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 488815-55-0 HCAPLUS

CN 2-Naphthacenecarboxamide, 7-[(diethylamino)methyl]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 488815-56-1 HCAPLUS

CN 2-Naphthacenecarboxamide, 7-[[bis(cyclopropylmethyl)amino]methyl]-4-

10692764

(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 488815-58-3 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-7-[[(2-methylbutyl) amino]methyl]-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 488815-63-0 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-7-[[(2-methylpropyl) amino]methyl]-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 488817-32-9 HCAPLUS

CN 1,8-Naphthacenedicarboxamide, 10-(dimethylamino)-5,6a,7,10,10a,11,11a,12-

10692764

octahydro-4,6,6a,9,11-pentahydroxy-N1,N1,12-trimethyl-5,7-dioxo-,
(6aS,10S,10aR,11S,11aR,12R) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 488818-13-9 HCAPLUS

CN 4-Pyrimidinecarboxamide, N-[[[(6aS,10S,10aR,11aR)-8-(aminocarbonyl)-10-(dimethylamino)-5,6a,7,10,10a,11,11a,12-octahydro-4,6,6a,9-tetrahydroxy-5,7-dioxo-1-naphthacenyl]methyl]-1,6-dihydro-6-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 488818-17-3 HCAPLUS

CN 4-Pyridinecarboxamide, N-[[[(6aS,10S,10aR,11aR)-8-(aminocarbonyl)-10-(dimethylamino)-5,6a,7,10,10a,11,11a,12-octahydro-4,6,6a,9-tetrahydroxy-5,7-dioxo-1-naphthacenyl]methyl]-, 1-oxide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 488818-20-8 HCAPLUS

CN 4-Isoxazolecarboxamide, N-[[[(6aS,10S,10aS,11aR)-8-(aminocarbonyl)-10-(dimethylamino)-5,6a,7,10,10a,11,11a,12-octahydro-4,6,6a,9-tetrahydroxy-5,7-dioxo-1-naphthacenyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 488818-21-9 HCAPLUS

CN 3-Pyridinecarboxamide, N-[[[(6aS,10S,10aS,11aR)-8-(aminocarbonyl)-10-(dimethylamino)-5,6a,7,10,10a,11,11a,12-octahydro-4,6,6a,9-tetrahydroxy-5,7-dioxo-1-naphthacenyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 488818-27-5 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-7-[[[(1-methylethyl)amino]methyl]-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 488818-31-1 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-7-[[[(1-oxido-4-pyridinyl)methyl]amino]methyl]-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 488818-45-7 HCAPLUS

CN 1,8-Naphthacenedicarboxamide, 10-(dimethylamino)-5,6a,7,10,10a,11,11a,12-octahydro-4,6,6a,9-tetrahydroxy-N1,N1-dimethyl-5,7-dioxo-, (6aS,10S,10aS,11aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 488818-60-6 HCAPLUS

CN 4-Morpholinecarboxamide, N-[[[(6aS,10S,10aS,11aR)-8-(aminocarbonyl)-10-(dimethylamino)-3-ethynyl-5,6a,7,10,10a,11,11a,12-octahydro-4,6,6a,9-tetrahydroxy-5,7-dioxo-1-naphthacenyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 488818-63-9 HCAPLUS

CN 4-Morpholinecarboxamide, N-[[[(6aS,10S,10aS,11aR)-8-(aminocarbonyl)-10-(dimethylamino)-3-ethyl-5,6a,7,10,10a,11,11a,12-octahydro-4,6,6a,9-tetrahydroxy-5,7-dioxo-1-naphthacenyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 488818-82-2 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-7-[[[(2-fluoro-1-methylethyl)amino]methyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 488819-02-9 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-7-[[[(4-(2-fluoro-1-methylethyl)amino]methyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)

10692764

fluorophenyl)methyl]amino]methyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 488819-08-5 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-7-[[[(phenylmethyl)amino]methyl]-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 488819-19-8 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-7-[[[(2,2-dimethylpropyl)amino]methyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-[(methylthio)methyl]-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 488820-15-1 HCAPLUS

CN 2-Naphthacenecarboxamide, 7-[(acetylamino)methyl]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 488820-27-5 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-7-[[[(2,2-dimethyl-1-oxopropyl)amino]methyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IC ICM A61K

CC 1-12 (Pharmacology)

Section cross-reference(s): 26

IT Nervous system, disease

(*Huntington's* chorea; tetracycline compds. with target therapeutic activities)

IT Mental and behavioral disorders

(dementia, *Alzheimer's* disease-related; tetracycline compds. with target therapeutic activities)

IT Autoimmune disease

(insulin-dependent *diabetes* mellitus; tetracycline compds. with target therapeutic activities)

IT *Diabetes* mellitus

(insulin-dependent; tetracycline compds. with target therapeutic activities)

IT Bone, neoplasm

Sarcoma

(osteosarcoma; tetracycline compds. with target therapeutic activities)

IT Aging, animal

Alzheimer's disease

Amnesia
 Aneurysm
 Angiogenesis
 Angiogenesis inhibitors
 Anti-*Alzheimer's* agents
 Anti-inflammatory agents
 Anti-ischemic agents
 Antiarteriosclerotics
 Antiarthritics
 Antiasthmatics
 Antibacterial agents
 Anticonvulsants
 Antidepressants
 Antidiabetic agents
 Antihypertensives
 Antimalarials
 Antimigraine agents
 Antipsychotics
 Antirheumatic agents
 Antitumor agents
 Antiviral agents
 Anxiety
 Anxiolytics
 Arteriosclerosis
 Asthma
 Atherosclerosis
 Autoimmune disease
 Carcinoma
 Cardiovascular agents
 Cognition enhancers
 Cystic fibrosis
 Diabetes mellitus
 Drug delivery systems
 Emphysema
 Epilepsy
 Escherichia coli
 Eye, disease
 Fungicides
 Gastrointestinal agents
 Hepatitis
 Human
 Hypertension
 Inflammation
 Ischemia
 Learning disorders
 Lung, disease
 Macrophage
 Malaria
 Mental and behavioral disorders
 Multiple sclerosis
 Neoplasm
 Nervous system, disease
 Nervous system agents
 Osteoarthritis
 Osteomyelitis
 Osteoporosis
 Parasitocides
 Psychotropics
 Rheumatoid *arthritis*
 Sarcoma

Schizophrenia
 Skin, disease
 Sleep disorders
 Staphylococcus aureus
 Wernicke-Korsakoff syndrome
 Wound healing promoters

(tetracycline compds. with target therapeutic activities)

IT Tumor necrosis factors

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(α , antagonists; tetracycline compds. with target therapeutic activities, and use with other agents)

IT 60-54-8 60-54-8D, Tetracycline, derivs. 127-33-3 564-25-0 914-00-1
 2444-65-7 3242-03-3 4497-07-8 5874-95-3 5995-55-1 10118-89-5
 16145-05-4 24290-70-8 31642-30-5 35689-63-5 35689-65-7
 53108-41-1 53173-80-1 59046-79-6 77901-56-5 115207-75-5
 120793-45-5 146253-71-6 146253-75-0 146278-01-5 146278-02-6
 146278-03-7 149934-16-7 149934-19-0 151922-17-7 153621-68-2
 161320-33-8 161321-34-2 161452-36-4 186759-47-7 186759-49-9
 186759-51-3 186759-53-5 186759-55-7 186759-61-5 220620-09-7
 233585-94-9 233585-95-0 233585-96-1 233585-97-2 233586-02-2
 233586-03-3 233586-04-4 233586-06-6 233586-07-7 233586-08-8
 233586-09-9 233586-10-2 233586-11-3 233586-12-4 233586-16-8
 263760-96-9 263760-98-1 263761-01-9 263761-02-0 263761-08-6
 295356-11-5 295356-12-6 295356-13-7 295356-16-0 295356-17-1
 330627-21-9 330627-22-0 330627-23-1 330627-24-2 330627-26-4
 330627-27-5 330627-32-2 344771-54-6 351336-92-0 351336-94-2
 365276-98-8 365276-99-9 365277-00-5 365277-01-6 365277-02-7
 365277-03-8 365277-04-9 365277-05-0 365277-06-1 365277-08-3
 365277-11-8 365277-12-9 365277-13-0 365277-14-1 365277-16-3
 365277-19-6 365277-20-9 365277-21-0 365277-22-1 365277-23-2
 365277-24-3 365277-26-5 365277-28-7 365277-29-8 365277-34-5
 365277-35-6 365277-36-7 365277-37-8 365277-38-9 365277-39-0
 365277-40-3 365277-41-4 365277-42-5 365277-43-6 365277-44-7
 365277-45-8 365277-46-9 365277-47-0 365277-48-1 365277-49-2
 365277-50-5 365277-51-6 365277-52-7 365277-53-8 365277-54-9
 365277-55-0 365277-56-1 365277-57-2 365277-58-3 365277-59-4
 365277-60-7 365277-61-8 365277-62-9 365277-63-0 365277-64-1
 365277-65-2 365277-66-3 365277-88-9 374748-06-8 380435-62-1
 380435-63-2 380435-65-4 380435-76-7 380435-88-1 389081-55-4
 389081-56-5 389081-58-7 389081-60-1 389081-61-2 389081-62-3
 389081-63-4 389081-64-5 389081-65-6 389081-66-7 389081-67-8
 389081-68-9 389081-69-0 389081-71-4 389081-72-5 389081-73-6
 389081-74-7 389081-75-8 389081-76-9 389081-77-0 389081-78-1
 389081-79-2 389081-80-5 389081-85-0 389139-10-0 389139-12-2
 389139-15-5 389139-16-6 389139-17-7 389139-18-8 389139-19-9
 389139-20-2 389139-21-3 389139-22-4 389139-23-5 389139-24-6
 389139-25-7 389139-26-8 389139-27-9 389139-28-0 389139-29-1
 389139-31-5 389139-32-6 389139-33-7 389139-34-8 389139-35-9
 389139-36-0 389139-37-1 389139-38-2 389139-39-3 389139-40-6
 389139-41-7 389139-42-8 389139-43-9 389139-44-0 389139-45-1
 389139-46-2 389139-47-3 389139-48-4 389139-49-5 389139-51-9
 389139-52-0 389139-53-1 389139-54-2 389139-55-3 389139-56-4
 389139-57-5 389139-58-6 389139-59-7 389139-60-0 389139-61-1
 389139-62-2 389139-63-3 389139-64-4 389139-65-5 389139-66-6
 389139-67-7 389139-68-8 389139-69-9 389139-70-2 389139-71-3
 389139-72-4 389139-73-5 389139-74-6 389139-75-7 389139-78-0
 389139-79-1 389139-80-4 389139-81-5 389139-82-6 389139-83-7
 389139-85-9 389139-86-0 389139-87-1 389139-88-2 389139-89-3

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(tetracycline compds. with target therapeutic activities)

IT	389139-90-6	389139-91-7	389139-92-8	389139-93-9	389139-94-0
	389139-95-1	389139-96-2	389139-97-3	389139-98-4	389139-99-5
	389140-00-5	389140-01-6	389140-02-7	389140-03-8	389140-04-9
	389140-06-1	389570-43-8	389570-46-1	389570-49-4	389570-50-7
	389570-51-8	389570-52-9	389570-53-0	389570-54-1	389623-72-7
	389623-77-2	389623-80-7	389623-82-9	389623-86-3	389623-88-5
	389623-89-6	389623-91-0	389623-93-2	389623-95-4	389623-96-5
	389623-97-6	389623-98-7	389623-99-8	389624-01-5	389624-02-6
	389624-03-7	389624-04-8	389624-05-9	389624-08-2	389624-09-3
	389624-12-8	389624-13-9	389624-14-0	389624-15-1	389624-18-4
	389624-20-8	389624-21-9	389624-22-0	389624-23-1	389624-24-2
	389624-26-4	389624-27-5	389624-28-6	389624-29-7	389624-30-0
	389624-31-1	389624-32-2	389624-33-3	389624-34-4	389624-35-5
	389624-36-6	389624-37-7	389624-38-8	389624-39-9	389624-40-2
	389624-41-3	389624-43-5	389624-44-6	389624-45-7	389624-46-8
	389624-51-5	389624-52-6	389624-54-8	389624-55-9	389624-56-0
	389624-57-1	389624-59-3	389624-62-8	389624-63-9	389624-66-2
	389624-67-3	389624-68-4	389624-69-5	389624-70-8	389624-71-9
	389624-72-0	389624-73-1	389624-75-3	389624-76-4	389624-77-5
	389624-78-6	389624-79-7	389624-80-0	389624-81-1	389624-82-2
	389624-83-3	389624-84-4	389624-85-5	389624-86-6	389624-87-7
	389624-88-8	389624-89-9	389624-90-2	389624-91-3	389624-92-4
	389624-93-5	389624-94-6	389624-95-7	389624-97-9	389624-98-0
	389624-99-1	389625-00-7	389625-01-8	389625-02-9	389625-03-0
	389625-04-1	389625-05-2	389625-06-3	389625-07-4	389625-07-4
	389625-09-6	389625-09-6	389625-10-9	389625-11-0	389625-12-1
	439217-57-9	439217-59-1	459425-79-7	459425-80-0	459425-96-8
	459426-11-0	459809-42-8	459809-43-9	459809-44-0	
	459809-45-1	459809-46-2	459809-47-3	459809-48-4	459809-49-5
	459809-50-8	459809-51-9	459809-52-0	459809-53-1	459809-54-2
	459809-55-3	459809-56-4	459809-57-5	459809-58-6	459809-59-7
	459809-61-1	459809-63-3	459809-65-5	459809-66-6	459809-67-7
	459809-68-8	459809-70-2	459809-72-4	459809-74-6	459809-76-8
	459809-77-9	459809-79-1	459809-81-5	459809-82-6	459809-86-0
	459809-88-2	459809-91-7	459809-92-8	459809-93-9	459809-94-0
	459809-95-1	459809-96-2	459809-97-3	459809-98-4	459810-00-5
	459810-01-6	459810-02-7	459810-03-8	459810-04-9	459810-06-1
	459810-07-2	459810-09-4	460068-26-2	460068-27-3	460068-29-5
	460068-30-8	460068-31-9	460068-33-1	460068-34-2	460068-35-3
	460068-36-4	460068-38-6	460068-39-7	460068-40-0	460068-41-1
	460068-43-3	460068-44-4	460068-45-5	460068-46-6	460068-47-7
	460068-48-8	460068-49-9	460068-50-2	460068-51-3	460068-52-4
	460068-53-5	460068-54-6	460068-55-7	460068-57-9	460068-58-0
	460068-59-1	460068-60-4	460068-63-7	460068-64-8	460068-65-9
	460068-66-0	460068-67-1	460068-68-2	460068-69-3	460068-70-6
	460068-71-7	460068-72-8	460068-73-9	460068-74-0	460068-75-1
	460068-76-2	460068-77-3	460068-78-4	460068-79-5	460068-80-8
	460068-81-9	460068-82-0			

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(tetracycline compds. with target therapeutic activities)

IT	460068-83-1	460068-84-2	460068-85-3	460068-86-4	460068-87-5
	460068-88-6	460068-90-0	460068-92-2	460068-93-3	460068-94-4
	460068-95-5	460068-96-6	460068-97-7	460068-99-9	460069-34-5
	460069-38-9	460069-65-2	460069-70-9	460069-89-0	460069-96-9
	460070-02-4	460070-03-5	460070-53-5	460070-61-5	460070-66-0
	460070-73-9	460070-76-2	460070-79-5	460070-92-2	460070-95-5
	460071-02-7	460071-04-9	460071-06-1	460071-09-4	460071-12-9
	460071-14-1	460071-17-4	460071-19-6	460071-29-8	460071-31-2

460071-33-4	460071-37-8	460071-66-3	460071-69-6	
460071-80-1	460071-83-4	460071-83-4	460071-87-8	460071-89-0
460071-91-4	460071-93-6	460071-97-0	460071-99-2	460072-01-9
460072-03-1	460072-05-3	460072-07-5	460072-09-7	460072-10-0
460072-12-2	460072-15-5	460072-17-7	460072-19-9	460072-21-3
460072-25-7	460072-28-0	460072-29-1	460072-30-4	460072-31-5
460072-33-7	460072-36-0	460072-38-2	460072-40-6	460072-43-9
460072-45-1	460072-47-3	460072-49-5	460072-61-1	460072-63-3
460072-65-5	460072-70-2	460072-73-5	460072-75-7	460072-78-0
460072-82-6	460072-86-0	460072-89-3	460072-91-7	460072-93-9
460072-99-5	460073-01-2	460073-03-4	460073-05-6	460073-07-8
460073-09-0	460073-11-4	460073-15-8	460073-17-0	460073-21-6
460073-22-7	460073-23-8	460073-25-0	460073-27-2	460073-29-4
460073-31-8	460073-33-0	460073-35-2	460073-37-4	
460073-40-9	460073-41-0	460073-43-2	460073-45-4	460073-47-6
460073-49-8	460073-51-2	460073-55-6	460073-58-9	460073-60-3
460073-62-5	460073-64-7	460073-68-1	460073-70-5	
460073-72-7	460073-74-9	460073-76-1	460073-78-3	
460073-80-7	460073-82-9	460073-84-1	460073-86-3	460073-88-5
460073-90-9	460073-92-1	460073-94-3	460073-96-5	460074-00-4
460074-02-6	460074-04-8	460074-06-0	460074-09-3	460074-11-7
460074-13-9	460074-17-3	460074-19-5	460074-21-9	
460074-23-1	460074-26-4	460074-28-6	460074-30-0	460074-32-2
460074-34-4	460074-36-6	460074-38-8	460074-40-2	460074-42-4
460074-44-6	460074-46-8	460074-48-0	460074-50-4	460074-52-6
460074-54-8	460074-56-0	460074-58-2	460074-60-6	460074-62-8
460074-64-0	460074-66-2	460074-68-4	460074-69-5	460074-71-9
460074-73-1	460074-75-3	460074-77-5	460074-79-7	460074-81-1
460074-85-5	460074-87-7	460074-89-9	460074-91-3	460074-93-5
460074-95-7	460074-97-9	460074-99-1	460075-04-1	460075-06-3
460075-08-5	460075-12-1	460075-14-3	460075-62-1	460076-23-7
460082-87-5	460082-89-7	460082-90-0	473973-13-6	473973-20-5
473973-34-1	473973-37-4	473973-41-0	473973-62-5	473973-64-7
473973-86-3	473973-96-5	473974-12-8	473974-75-3	473974-76-4
473974-77-5	473974-79-7	473974-80-0	473974-81-1	473974-82-2
473974-83-3	473974-84-4	473974-85-5	488815-44-7	488815-45-8
488815-46-9	488815-47-0	488815-48-1	488815-49-2	488815-52-7
488815-53-8	488815-54-9	488815-55-0		
488815-56-1	488815-57-2	488815-58-3	488815-59-4	
488815-60-7	488815-61-8	488815-62-9	488815-63-0	
488815-64-1	488815-65-2	488815-66-3	488815-67-4	488815-68-5

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(tetracycline compds. with target therapeutic activities)

IT	488815-69-6	488815-70-9	488815-71-0	488815-72-1	488815-73-2
	488815-74-3	488815-75-4	488815-76-5	488815-77-6	488815-78-7
	488815-79-8	488815-80-1	488815-82-3	488815-89-0	488815-93-6
	488815-98-1	488816-00-8	488816-09-7	488816-13-3	488816-16-6
	488816-18-8	488816-19-9	488816-26-8	488816-37-1	488816-39-3
	488816-42-8	488816-54-2	488816-55-3	488816-58-6	488816-59-7
	488816-64-4	488816-65-5	488816-70-2	488816-71-3	488816-73-5
	488816-75-7	488816-82-6	488816-86-0	488816-88-2	488816-92-8
	488816-93-9	488816-98-4	488817-01-2	488817-06-7	488817-11-4
	488817-13-6	488817-14-7	488817-15-8	488817-16-9	488817-17-0
	488817-18-1	488817-19-2	488817-20-5	488817-21-6	488817-22-7
	488817-23-8	488817-24-9	488817-25-0	488817-26-1	488817-27-2
	488817-28-3	488817-29-4	488817-30-7	488817-31-8	488817-32-9
	488817-33-0	488817-34-1	488817-35-2	488817-36-3	488817-37-4
	488817-38-5	488817-39-6	488817-40-9	488817-41-0	488817-42-1
	488817-43-2	488817-44-3	488817-45-4	488817-46-5	488817-47-6

488817-48-7	488817-49-8	488817-50-1	488817-51-2	488817-52-3
488817-53-4	488817-54-5	488817-55-6	488817-56-7	488817-57-8
488817-58-9	488817-59-0	488817-60-3	488817-61-4	488817-62-5
488817-63-6	488817-64-7	488817-65-8	488817-66-9	488817-67-0
488817-68-1	488817-69-2	488817-70-5	488817-71-6	488817-72-7
488817-73-8	488817-74-9	488817-75-0	488817-76-1	488817-77-2
488817-78-3	488817-79-4	488817-80-7	488817-81-8	488817-82-9
488817-89-6	488817-91-0	488817-92-1	488817-93-2	488817-94-3
488817-95-4	488817-96-5	488817-97-6	488817-98-7	488817-99-8
488818-00-4	488818-01-5	488818-02-6	488818-03-7	488818-04-8
488818-05-9	488818-06-0	488818-07-1	488818-08-2	488818-09-3
488818-10-6	488818-11-7	488818-12-8	488818-13-9	
488818-14-0	488818-15-1	488818-16-2	488818-17-3	
488818-18-4	488818-19-5	488818-20-8	488818-21-9	
488818-22-0	488818-23-1	488818-24-2	488818-25-3	488818-26-4
488818-27-5	488818-28-6	488818-29-7	488818-30-0	
488818-31-1	488818-32-2	488818-33-3	488818-34-4	
488818-35-5	488818-36-6	488818-37-7	488818-38-8	488818-39-9
488818-40-2	488818-41-3	488818-42-4	488818-43-5	488818-44-6
488818-45-7	488818-46-8	488818-47-9	488818-48-0	
488818-49-1	488818-50-4	488818-51-5	488818-52-6	488818-53-7
488818-54-8	488818-55-9	488818-56-0	488818-57-1	488818-58-2
488818-59-3	488818-60-6	488818-61-7	488818-63-9	
488818-64-0	488818-65-1	488818-66-2	488818-67-3	488818-68-4
488818-69-5	488818-70-8	488818-71-9	488818-72-0	488818-73-1
488818-74-2	488818-75-3	488818-76-4	488818-77-5	488818-78-6
488818-79-7	488818-80-0	488818-81-1	488818-82-2	
488818-83-3	488818-84-4	488818-85-5	488818-86-6	488818-87-7
488818-88-8	488818-89-9	488818-90-2	488818-91-3	488818-92-4
488818-93-5	488818-94-6	488818-95-7	488818-96-8	488818-97-9
488818-98-0	488818-99-1	488819-00-7	488819-01-8	488819-02-9
488819-03-0	488819-04-1	488819-05-2	488819-06-3	488819-07-4
488819-08-5	488819-14-3	488819-15-4	488819-16-5	

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(tetracycline compds. with target therapeutic activities)

IT	488819-17-6	488819-18-7	488819-19-8	488819-20-1	
	488819-21-2	488819-22-3	488819-23-4	488819-24-5	488819-25-6
	488819-26-7	488819-27-8	488819-28-9	488819-29-0	488819-30-3
	488819-31-4	488819-32-5	488819-33-6	488819-34-7	488819-35-8
	488819-36-9	488819-37-0	488819-38-1	488819-39-2	488819-40-5
	488819-41-6	488819-42-7	488819-43-8	488819-44-9	488819-45-0
	488819-46-1	488819-47-2	488819-48-3	488819-49-4	488819-50-7
	488819-51-8	488819-52-9	488819-53-0	488819-54-1	488819-55-2
	488819-56-3	488819-57-4	488819-58-5	488819-59-6	488819-60-9
	488819-61-0	488819-62-1	488819-63-2	488819-64-3	488819-65-4
	488819-66-5	488819-67-6	488819-68-7	488819-69-8	488819-70-1
	488819-71-2	488819-72-3	488819-73-4	488819-74-5	488819-75-6
	488819-76-7	488819-77-8	488819-78-9	488819-79-0	488819-80-3
	488819-81-4	488819-82-5	488819-83-6	488819-84-7	488819-85-8
	488819-86-9	488819-87-0	488819-88-1	488819-89-2	488819-90-5
	488819-91-6	488819-92-7	488819-93-8	488819-94-9	488819-95-0
	488819-96-1	488819-97-2	488819-98-3	488819-99-4	488820-00-4
	488820-01-5	488820-02-6	488820-03-7	488820-04-8	488820-05-9
	488820-06-0	488820-07-1	488820-08-2	488820-09-3	488820-10-6
	488820-11-7	488820-12-8	488820-13-9	488820-14-0	488820-15-1
	488820-16-2	488820-17-3	488820-18-4	488820-19-5	488820-20-8
	488820-21-9	488820-22-0	488820-23-1	488820-24-2	488820-25-3
	488820-26-4	488820-27-5	488820-28-6	488820-29-7	
	488820-30-0	488820-31-1	488820-32-2	488820-33-3	488820-34-4

488820-42-4 488820-43-5 488820-45-7 488820-46-8 488820-47-9
 488820-48-0 488820-49-1 488820-50-4 488821-84-7
 RL: PAC (Pharmacological activity); THU (Therapeutic
 use); BIOL (Biological study); USES (Uses)
 (tetracycline compds. with target therapeutic activities)

L56 ANSWER 9 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2002:832571 HCAPLUS Full-text
 DOCUMENT NUMBER: 137:333118
 TITLE: Substituted tetracycline compounds for the treatment
 of malaria
 INVENTOR(S): Draper, Michael; Nelson, Mark L.; Frechette, Roger
 PATENT ASSIGNEE(S): Paratek Pharmaceuticals, Inc., USA
 SOURCE: PCT Int. Appl., 89 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002085303	A2	20021031	WO 2002-US12935	20020424 <--
WO 2002085303	A3	20030515		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2444899	A1	20021031	CA 2002-2444899	20020424 <--
EP 1399414	A2	20040324	EP 2002-723955	20020424 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004529927	T	20040930	JP 2002-582879	20020424 <--
PRIORITY APPLN. INFO.:			US 2001-286193P	P 20010424 <--
			WO 2002-US12935	W 20020424 <--

OTHER SOURCE(S): MARPAT 137:333118

AB The invention provides a method for treating or preventing malaria in a subject. The method includes administering to the subject an effective amount of a substituted tetracycline compound, such that malaria is treated or prevented. In one aspect, the invention provides pharmaceutical compns. which include an effective amount of a tetracycline compound to treat malaria in a subject and a pharmaceutically acceptable carrier. The substituted tetracycline compds. of the invention can be used in combination with one or more antimalarial compds. or can be used to treat or prevent malaria which is resistant to one or more other antimalarial compds. Compound preparation is described.

IT 459809-44-0 460074-19-5 473972-91-7


RL: PAC (Pharmacological activity); THU (Therapeutic
 use); BIOL (Biological study); USES (Uses)

(Substituted tetracycline compds. for the treatment of malaria)

RN 459809-44-0 HCAPLUS

CN 3-Pyridinecarboxamide, N-[[[(6aS,10S,10aS,11aR)-8-(aminocarbonyl)-10-(dimethylamino)-3-(1,1-dimethylethyl)-5,6a,7,10,10a,11,11a,12-octahydro-4,6,6a,9-tetrahydroxy-5,7-dioxo-1-naphthacenyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 460074-19-5 HCAPLUS

CN 2-Naphthacene-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 473972-91-7 HCAPLUS

CN 2-Pyridinecarboxamide, N-[[[(6aS,10S,10aS,11aR)-8-(aminocarbonyl)-10-(dimethylamino)-3-(1,1-dimethylethyl)-5,6a,7,10,10a,11,11a,12-octahydro-4,6,6a,9-tetrahydroxy-5,7-dioxo-1-naphthacenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IC ICM A61K
 CC 1-5 (Pharmacology)
 Section cross-reference(s): 25, 63
 IT **Anemia** (disease)
 Fever and Hyperthermia
 (supplementary compound for treatment of; Substituted tetracycline
 compds. for the treatment of malaria)



IT 60-54-8 60-54-8D, Tetracycline, derivs. 79-57-2 127-33-3 564-25-0
 808-26-4 914-00-1 10118-90-8 31642-30-5 35689-65-7 146253-75-0
 146278-03-7 151922-17-7 186759-47-7 186759-51-3 186759-53-5
 201849-42-5 233585-95-0 233586-04-4 233586-06-6 233586-09-9
 263760-98-1 263761-02-0 263761-08-6 330627-24-2 344771-54-6
 351336-94-2 365277-01-6 365277-22-1 365277-23-2 365277-28-7
 365277-29-8 365277-38-9 365277-45-8 365277-47-0 365277-51-6
 365277-55-0 365277-56-1 365277-57-2 365277-59-4 365277-60-7
 365277-63-0 365277-66-3 374748-06-8 380435-62-1 380435-63-2
 380435-65-4 380435-76-7 389081-56-5 389081-58-7 389081-61-2
 389081-62-3 389081-64-5 389081-77-0 389081-85-0 389139-10-0
 389139-12-2 389139-16-6 389139-19-9 389139-20-2 389139-21-3
 389139-22-4 389139-23-5 389139-24-6 389139-27-9 389139-28-0
 389139-30-4 389139-33-7 389139-41-7 389139-43-9 389139-44-0
 389139-45-1 389139-46-2 389139-48-4 389139-49-5 389139-50-8
 389139-51-9 389139-52-0 389139-53-1 389139-54-2 389139-55-3
 389139-58-6 389139-62-2 389139-63-3 389139-64-4 389139-65-5
 389139-67-7 389139-68-8 389139-78-0 389139-81-5 389139-86-0
 389139-91-7 389139-93-9 389140-00-5 389623-72-7 389623-77-2
 389623-80-7 389623-82-9 389623-88-5 389623-89-6 389623-90-9
 389623-91-0 389623-93-2 389623-95-4 389623-96-5 389623-97-6
 389623-99-8 389624-00-4 389624-01-5 389624-02-6 389624-03-7
 389624-04-8 389624-05-9 389624-06-0 389624-07-1 389624-08-2
 389624-09-3 389624-10-6 389624-11-7 389624-12-8 389624-14-0
 389624-15-1 389624-16-2 389624-18-4 389624-19-5 389624-20-8
 389624-21-9 389624-22-0 389624-23-1 389624-24-2 389624-26-4
 389624-27-5 389624-28-6 389624-30-0 389624-32-2 389624-33-3
 389624-35-5 389624-36-6 389624-37-7 389624-38-8 389624-39-9
 389624-40-2 389624-41-3 389624-42-4 389624-43-5 389624-51-5
 389624-55-9 389624-62-8 389624-73-1 389624-74-2 389624-75-3
 389624-81-1 389624-83-3 389624-85-5 389624-95-7 389624-96-8
 389624-97-9 389624-99-1 459809-44-0 459809-46-2
 459809-53-1 459809-67-7 459809-72-4 459809-99-5 459810-00-5
 459810-03-8 459810-06-1 460068-29-5 460068-31-9 460068-32-0
 460068-33-1 460068-36-4 460068-38-6 460068-42-2 460068-44-4
 460068-45-5 460068-48-8 460068-51-3 460068-55-7 460068-57-9
 460068-58-0 460068-59-1 460068-60-4 460068-62-6 460068-65-9
 460068-66-0 460068-68-2 460068-76-2 460068-77-3 460068-78-4
 460068-80-8 460068-86-4 460068-87-5 460068-93-3 460068-95-5
 460068-96-6 460068-97-7 460069-34-5 460069-38-9 460069-65-2
 460069-70-9 460069-96-9 460070-02-4 460070-03-5 460070-61-5
 460070-66-0 460070-73-9 460070-95-5 460071-09-4 460071-12-9
 460071-14-1 460071-33-4 460072-33-7 460072-47-3 460072-59-7
 460072-65-5 460073-05-6 460073-17-0 460073-22-7 460074-06-0
 460074-13-9 460074-19-5 460074-21-9 460075-62-1
 460082-77-3 460082-89-7 473972-91-7 473973-13-6
 473973-20-5 473973-34-1 473973-37-4 473973-41-0 473973-62-5
 473973-64-7 473973-69-2 473973-86-3

RL: PAC (Pharmacological activity); THU (Therapeutic
 use); BIOL (Biological study); USES (Uses)
 (Substituted tetracycline compds. for the treatment of malaria)

L56 ANSWER 10 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2002:716234 HCAPLUS Full-text
 DOCUMENT NUMBER: 137:247552
 TITLE: Preparation of 7, 9-substituted tetracycline
 derivatives for pharmaceutical use as antibacterial
 agents
 INVENTOR(S): Nelson, Mark L.; Frechette, Roger; Viski, Peter;
 Ismail, Mohamed; Bowser, Todd; McIntyre, Laura;
 Bhatia, Beena; Hawkins, Paul; Reddy, Laxma; Stapleton,
 Karen; Warchol, Tad; Sheahan, Paul
 PATENT ASSIGNEE(S): Paratek Pharmaceuticals, Inc., USA
 SOURCE: PCT Int. Appl., 54 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002072532	A1	20020919	WO 2001-US20722	20010629 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2440383	A1	20020919	CA 2001-2440383	20010629 <--
CA 2440383	C	20070130		
AU 2001271619	A1	20020924	AU 2001-271619	20010629 <--
US 2002193354	A1	20021219	US 2001-895797	20010629 <--
US 6683068	B2	20040127		
EP 1368305	A1	20031210	EP 2001-950651	20010629 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
HU 200402047	A2	20050128	HU 2004-2047	20010629 <--
JP 2005506291	T	20050303	JP 2002-571448	20010629 <--
BR 2001016935	A	20050412	BR 2001-16935	20010629 <--
ZA 2003007239	A	20041117	ZA 2003-7239	20030916 <--
IN 2003CN01594	A	20051125	IN 2003-CN1594	20031008 <--
US 2004138183	A1	20040715	US 2003-738862	20031216 <--
PRIORITY APPLN. INFO.:			US 2001-275620P	P 20010313 <--
			US 2001-895797	A1 20010629 <--
			WO 2001-US20722	W 20010629 <--

OTHER SOURCE(S): MARPAT 137:247552
 GI



AB 7,9-Substituted tetracycline derivs., such as I [X = CHC(R13Y'Y), CR6'R6, S, NR6, O; R2, R2', R4', R4" = H, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, arylalkyl, aryl, heterocyclic, heteroarom., prodrug; R4 = NR4'R4", alkyl, alkenyl, alkynyl, OH, halogen, H; R2', R3, R10, R11, R12 = H, prodrug; R5 = OH, H, thiol, alkanoyl, aroyl, aryl, alkoxy, alkylthio, carbonyloxy; R6, R6' = H, methylene, absent, OH, halogen, thiol, alkyl, alkenyl, alkynyl, alkoxy; R7 = NO2, alkyl, alkenyl, alkynyl, aryl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, amino, arylalkyl, arylalkenyl, arylalkynyl, aminoalkyl; R8 = H, OH, halogen, thiol, alkyl, alkenyl, alkynyl, aryl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl; R9 = NO2, alkyl, alkenyl, alkynyl, aryl, alkoxy; R13 = H, OH, alkyl, alkenyl, alkynyl, aryl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl; Y, Y' = H, halogen, OH, CN, sulfhydryl, amino, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino], and pharmaceutically acceptable salts thereof, were prepared to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline compds. in general, such as blocking tetracycline efflux and modulation of gene expression. Thus, reaction between N-iodosuccinimide and sancycline hydrochloride hemihydrate yielded 7,9-diiodosancycline II (R = I) which was reacted with 3,4-methylenedioxyphenyl boronic acid to afford 7,9-bis(3,4-methylenedioxyphenyl)-sancycline II (R = 3,4-methylenedioxyphenyl). The prepared tetracycline derivs. were tested for antibacterial activity against *Staphylococcus aureus*, *Enterococcus hirae* and *Escherichia coli*.

IT 459809-44-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation);

THU (Therapeutic use); BIOL (Biological study); PREP

(Preparation); USES (Uses)

(preparation of 7, 9-substituted tetracycline derivs. for pharmaceutical


use

as antibacterial agents)

RN 459809-44-0 HCAPLUS

CN 3-Pyridinecarboxamide, N-[[[(6aS,10S,10aS,11aR)-8-(aminocarbonyl)-10-(dimethylamino)-3-(1,1-dimethylethyl)-5,6a,7,10,10a,11,11a,12-octahydro-4,6,6a,9-tetrahydroxy-5,7-dioxo-1-naphthacenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IC ICM C07C237-26

ICS A61K031-65
 CC 26-6 (Biomolecules and Their Synthetic Analogs)
 Section cross-reference(s): 1, 10, 63
 IT 330627-26-4P 459809-42-8P 459809-43-9P 459809-44-0P
 459809-45-1P 459809-46-2P 459809-47-3P 459809-48-4P 459809-49-5P
 459809-50-8P 459809-51-9P 459809-52-0P 459809-53-1P 459809-54-2P
 459809-55-3P 459809-56-4P 459809-57-5P 459809-58-6P 459809-59-7P
 459809-61-1P 459809-63-3P 459809-65-5P 459809-66-6P 459809-67-7P
 459809-68-8P 459809-70-2P 459809-72-4P 459809-74-6P 459809-76-8P
 459809-77-9P 459809-79-1P 459809-81-5P 459809-82-6P 459809-84-8P
 459809-86-0P 459809-88-2P 459809-91-7P 459809-92-8P 459809-93-9P
 459809-94-0P 459809-95-1P 459809-96-2P 459809-97-3P 459809-98-4P
 459809-99-5P 459810-00-5P 459810-01-6P 459810-02-7P 459810-03-8P
 459810-05-0P 459810-06-1P 459810-07-2P 459810-09-4P 459810-11-8P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation);
 THU (Therapeutic use); BIOL (Biological study); PREP
 (Preparation); USES (Uses)
 (preparation of 7, 9-substituted tetracycline derivs. for pharmaceutical
 use
 as antibacterial agents)

RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Ashley, R	2000			WO 0028983 A	HCAPLUS
Farmaceutici Italia	1974			DE 2346535 A	HCAPLUS
Farmaceutici Italia	1976			DE 2527568 A	HCAPLUS
James, H	1967			US 3338963 A	HCAPLUS
Winterbottom, R	1969			US 3433834 A	HCAPLUS

L56 ANSWER 11 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:716035 HCAPLUS Full-text

DOCUMENT NUMBER: 137:244598

TITLE: Substituted tetracycline compounds as synergistic
antifungal agents

INVENTOR(S): Draper, Michael; Nelson, Mark L.

PATENT ASSIGNEE(S): Paratek Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 114 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002072031	A2	20020919	WO 2002-US7829	20020314 <--
WO 2002072031	A3	20031113		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2440757	A1	20020919	CA 2002-2440757	20020314 <--
US 2003166585	A1	20030904	US 2002-97634	20020314 <--

US 7045507 B2 20060516
 EP 1381372 A2 20040121 EP 2002-750617 20020314 <--
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
 JP 2005504722 T 20050217 JP 2002-570991 20020314 <--
 US 2005070510 A1 20050331 US 2004-943571 20040916 <--
 PRIORITY APPLN. INFO.: US 2001-275899P P 20010314 <--
 US 2002-97634 A1 20020314 <--
 WO 2002-US7829 W 20020314 <--

OTHER SOURCE(S): MARPAT 137:244598

AB Methods and compns. for treating for the synergistic treatment of fungal associated disorders are discussed. The method includes administering the antifungal agent with an effective amount of a substituted tetracycline compound, such that the antifungal activity of the antifungal agent is increased. Examples of antifungal agents include polyenes such as amphotericin B.

IT 389625-03-0 459809-44-0 460071-69-6
 460073-37-4 460073-70-5 460073-72-7
 460073-74-9 460074-19-5

RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study);


USES (Uses)

(substituted tetracycline compds. as synergistic antifungal agents in relation to cytotoxicity)

RN 389625-03-0 HCAPLUS

CN Carbamic acid, [[(6aS,10S,10aS,11aR)-8-(aminocarbonyl)-10-(dimethylamino)-5,6a,7,10,10a,11,11a,12-octahydro-4,6,6a,9-tetrahydroxy-5,7-dioxo-1-naphthacenyl]methyl]-, 2,2-dimethylpropyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 459809-44-0 HCAPLUS

CN 3-Pyridinecarboxamide, N-[[[(6aS,10S,10aS,11aR)-8-(aminocarbonyl)-10-(dimethylamino)-3-(1,1-dimethylethyl)-5,6a,7,10,10a,11,11a,12-octahydro-4,6,6a,9-tetrahydroxy-5,7-dioxo-1-naphthacenyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 460071-69-6 HCAPLUS

CN Carbamic acid, [[(6aS,10S,10aS,11aR)-8-(aminocarbonyl)-10-(dimethylamino)-5,6a,7,10,10a,11,11a,12-octahydro-4,6,6a,9-tetrahydroxy-5,7-dioxo-1-naphthacenyl]methyl]-, 2-methylpropyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 460073-37-4 HCAPLUS

CN 2-Naphthacenecarboxamide, 7-[[bis(2-methylpropyl)amino]methyl]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 460073-70-5 HCAPLUS

CN 2-Naphthacenecarboxamide, 7-[[bis(2,2-dimethoxyethyl)amino]methyl]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 460073-72-7 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-7-[[[(1-methyl-1H-pyrrol-2-yl)methyl]amino]methyl]-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 460073-74-9 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-7-[[[(1H-pyrrol-2-yl)methyl]amino]methyl]-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 460074-19-5 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-7,9-bis[[[2,2-dimethylpropyl)amino)methyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IC ICM A61K

CC 10-5 (Microbial, Algal, and Fungal Biochemistry)

Section cross-reference(s): 1, 5, 26

IT AIDS (disease)

Immunodeficiency

(fungal infections in; substituted tetracycline compds. as synergistic antifungal agents in relation to cytotoxicity)

IT	564-25-0	1397-89-3, Amphotericin B	5995-55-1	31642-30-5	35689-65-7
	113164-67-3	120793-45-5	146253-75-0	146278-03-7	151922-17-7
	161321-34-2	161452-36-4	186759-47-7	186759-51-3	186759-53-5
	186759-61-5	220620-09-7	233585-94-9	233585-95-0	233586-04-4
	233586-06-6	233586-11-3	233586-12-4	263760-96-9	263760-99-2
	263761-02-0	263761-08-6	295356-11-5	295356-12-6	330627-21-9
	330627-24-2	330627-27-5	365277-01-6	365277-03-8	365277-07-2
	365277-13-0	365277-14-1	365277-16-3	365277-23-2	365277-28-7
	365277-29-8	365277-35-6	365277-36-7	365277-38-9	365277-39-0
	365277-40-3	365277-42-5	365277-43-6	365277-46-9	365277-47-0
	365277-48-1	365277-49-2	365277-50-5	365277-51-6	365277-52-7
	365277-53-8	365277-54-9	365277-55-0	365277-56-1	365277-60-7
	365277-61-8	365277-62-9	365277-63-0	365277-65-2	374748-06-8
	380435-65-4	380435-74-5	380435-76-7	389081-56-5	389081-58-7
	389081-59-8	389081-61-2	389081-63-4	389081-67-8	389081-68-9
	389081-77-0	389081-78-1	389081-82-7	389081-85-0	389139-10-0
	389139-12-2	389139-16-6	389139-17-7	389139-19-9	389139-20-2
	389139-21-3	389139-22-4	389139-23-5	389139-24-6	389139-26-8
	389139-27-9	389139-28-0	389139-31-5	389139-32-6	389139-33-7
	389139-41-7	389139-43-9	389139-45-1	389139-46-2	389139-48-4
	389139-49-5	389139-50-8	389139-51-9	389139-53-1	389139-54-2
	389139-55-3	389139-56-4	389139-58-6	389139-59-7	389139-61-1
	389139-62-2	389139-63-3	389139-64-4	389139-65-5	389139-66-6
	389139-67-7	389139-68-8	389139-69-9	389139-70-2	389139-71-3
	389139-72-4	389139-73-5	389139-75-7	389139-76-8	389139-78-0
	389139-79-1	389139-81-5	389139-82-6	389139-83-7	389139-85-9
	389139-86-0	389139-87-1	389139-88-2	389139-89-3	389139-90-6
	389139-91-7	389139-92-8	389139-93-9	389139-94-0	389139-95-1
	389139-96-2	389139-97-3	389139-98-4	389139-99-5	389140-00-5
	389140-01-6	389140-02-7	389140-03-8	389570-51-8	389623-72-7
	389623-82-9	389623-84-1	389623-86-3	389623-88-5	389623-89-6
	389623-90-9	389623-91-0	389623-95-4	389623-97-6	389623-99-8
	389624-05-9	389624-06-0	389624-08-2	389624-09-3	389624-13-9

389624-14-0	389624-18-4	389624-19-5	389624-20-8	389624-21-9
389624-22-0	389624-24-2	389624-31-1	389624-32-2	389624-33-3
389624-34-4	389624-36-6	389624-38-8	389624-39-9	389624-40-2
389624-41-3	389624-42-4	389624-43-5	389624-47-9	389624-51-5
389624-52-6	389624-53-7	389624-54-8	389624-55-9	389624-56-0
389624-57-1	389624-59-3	389624-60-6	389624-61-7	389624-64-0
389624-65-1	389624-66-2	389624-68-4	389624-69-5	389624-70-8
389624-71-9	389624-72-0	389624-73-1	389624-74-2	389624-75-3
389624-76-4	389624-77-5	389624-78-6	389624-79-7	389624-80-0
389624-81-1	389624-82-2	389624-83-3	389624-85-5	389624-86-6
389624-87-7	389624-89-9	389624-90-2	389624-91-3	389624-92-4
389624-93-5	389624-94-6	389624-97-9	389624-98-0	389624-99-1
389625-01-8	389625-02-9	389625-03-0	389625-04-1	
389625-06-3	389625-07-4	389625-09-6	389625-09-6	389625-10-9
389625-11-0				

RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study);
USES (Uses)

(substituted tetracycline compds. as synergistic antifungal agents in relation to cytotoxicity)

IT	389625-12-1	459809-44-0	459809-45-1	459809-46-2	
	459809-47-3	459809-48-4	459809-49-5	459809-50-8	459809-51-9
	459809-52-0	459809-53-1	459809-54-2	459809-55-3	459809-56-4
	459809-57-5	459809-61-1	459809-63-3	459809-65-5	459809-66-6
	459809-67-7	459809-68-8	459809-70-2	459809-72-4	459809-74-6
	459809-76-8	459809-77-9	459809-82-6	459809-88-2	459809-91-7
	459809-93-9	459809-94-0	459809-95-1	459809-96-2	459809-97-3
	459809-98-4	459809-99-5	459810-00-5	459810-01-6	459810-02-7
	459810-04-9	459810-07-2	459810-08-3	460068-26-2	460068-28-4
	460068-29-5	460068-30-8	460068-31-9	460068-32-0	460068-33-1
	460068-34-2	460068-35-3	460068-36-4	460068-37-5	460068-38-6
	460068-39-7	460068-40-0	460068-41-1	460068-42-2	460068-43-3
	460068-44-4	460068-45-5	460068-46-6	460068-47-7	460068-48-8
	460068-49-9	460068-50-2	460068-51-3	460068-52-4	460068-53-5
	460068-54-6	460068-55-7	460068-56-8	460068-57-9	460068-58-0
	460068-59-1	460068-60-4	460068-61-5	460068-62-6	460068-63-7
	460068-64-8	460068-65-9	460068-66-0	460068-67-1	460068-68-2
	460068-69-3	460068-70-6	460068-71-7	460068-72-8	460068-73-9
	460068-74-0	460068-75-1	460068-76-2	460068-77-3	460068-78-4
	460068-79-5	460068-80-8	460068-81-9	460068-82-0	460068-83-1
	460068-84-2	460068-85-3	460068-86-4	460068-87-5	460068-88-6
	460068-89-7	460068-90-0	460068-91-1	460068-92-2	460068-93-3
	460068-94-4	460068-95-5	460068-96-6	460068-97-7	460068-99-9
	460069-25-4	460069-34-5	460069-38-9	460069-65-2	460069-70-9
	460069-76-5	460069-89-0	460069-96-9	460069-99-2	460070-02-4
	460070-03-5	460070-34-2	460070-44-4	460070-53-5	460070-61-5
	460070-66-0	460070-73-9	460070-76-2	460070-79-5	460070-83-1
	460070-92-2	460070-95-5	460071-02-7	460071-04-9	460071-06-1
	460071-09-4	460071-12-9	460071-14-1	460071-17-4	460071-19-6
	460071-23-2	460071-29-8	460071-31-2	460071-33-4	460071-37-8
	460071-66-3	460071-69-6	460071-80-1	460071-83-4	
	460071-87-8	460071-89-0	460071-91-4	460071-93-6	460071-95-8
	460071-97-0	460071-99-2	460072-01-9	460072-03-1	460072-05-3
	460072-07-5	460072-09-7	460072-10-0	460072-12-2	460072-15-5
	460072-17-7	460072-19-9	460072-25-7	460072-27-9	460072-28-0
	460072-29-1	460072-30-4	460072-31-5	460072-33-7	460072-36-0
	460072-38-2	460072-40-6	460072-43-9	460072-45-1	460072-47-3
	460072-49-5	460072-51-9	460072-53-1	460072-55-3	460072-57-5
	460072-59-7	460072-61-1	460072-63-3	460072-65-5	460072-68-8
	460072-70-2	460072-73-5	460072-75-7	460072-78-0	460072-80-4

460072-82-6 460072-86-0 460072-89-3 460072-91-7 460072-93-9
 460072-99-5 460073-01-2 460073-03-4 460073-07-8 460073-09-0
 460073-11-4 460073-15-8 460073-17-0 460073-21-6 460073-22-7
 460073-23-8 460073-25-0 460073-27-2 460073-29-4 460073-31-8
 460073-33-0 460073-35-2 460073-37-4 460073-40-9
 460073-41-0 460073-45-4 460073-47-6 460073-49-8 460073-51-2
 460073-53-4 460073-55-6 460073-58-9 460073-60-3 460073-64-7
 460073-66-9 460073-70-5 460073-72-7

RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study);

USES (Uses)

(substituted tetracycline compds. as synergistic antifungal agents in relation to cytotoxicity)

IT 460073-74-9 460073-76-1 460073-78-3 460073-80-7
 460073-84-1 460073-86-3 460073-88-5 460073-90-9 460073-92-1
 460073-94-3 460073-96-5 460073-98-7 460074-00-4 460074-02-6
 460074-04-8 460074-06-0 460074-09-3 460074-11-7 460074-15-1
 460074-17-3 460074-19-5 460074-21-9 460074-23-1
 460074-26-4 460074-28-6 460074-30-0 460074-32-2 460074-34-4
 460074-38-8 460074-40-2 460074-42-4 460074-44-6 460074-46-8
 460074-48-0 460074-50-4 460074-52-6 460074-54-8 460074-60-6
 460074-62-8 460074-64-0 460074-66-2 460074-68-4 460074-71-9
 460074-73-1 460074-75-3 460074-77-5 460074-79-7 460074-81-1
 460074-83-3 460074-85-5 460074-87-7 460074-89-9 460074-91-3
 460074-93-5 460074-95-7 460074-97-9 460074-99-1 460075-04-1
 460075-06-3 460075-08-5 460075-10-9 460075-12-1 460075-14-3
 460075-62-1 460076-23-7 460082-61-5 460082-62-6

RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study);

USES (Uses)

(substituted tetracycline compds. as synergistic antifungal agents in relation to cytotoxicity)

L56 ANSWER 12 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:716027 HCAPLUS Full-text

DOCUMENT NUMBER: 137:244597

TITLE: Substituted tetracycline compounds as antifungal agents

INVENTOR(S): Draper, Michael; Nelson, Mark L.

PATENT ASSIGNEE(S): Paratek Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 71 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002072022	A2	20020919	WO 2002-US7502	20020314 <--
WO 2002072022	A3	20031016		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA,

10692764

GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2457234	A1	20020919	CA 2002-2457234	20020314 <--
US 2003100017	A1	20030529	US 2002-97457	20020314 <--
US 6841546	B2	20050111		
EP 1379255	A2	20040114	EP 2002-721365	20020314 <--

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

JP 2004530661	T	20041007	JP 2002-570982	20020314 <--
US 2005020545	A1	20050127	US 2004-921580	20040818 <--

PRIORITY APPLN. INFO.:

US 2001-275948P	P	20010314 <--
US 2002-97457	A3	20020314 <--
WO 2002-US7502	W	20020314 <--

OTHER SOURCE(S): MARPAT 137:244597

AB Methods and compns. for treating fungal associated disorders in subjects are discussed. The method includes contacting the fungus with an effective amount of a substituted tetracycline compound, such that the growth of said fungus is inhibited.

IT 460073-37-4

RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study);


USES (Uses)

(substituted tetracycline compds. as antifungal agents in relation to cytotoxicity)

RN 460073-37-4 HCAPLUS

CN 2-Naphthacenecarboxamide, 7-[[bis(2-methylpropyl)amino]methyl]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IC ICM A61K

CC 10-5 (Microbial, Algal, and Fungal Biochemistry)

Section cross-reference(s): 1, 5, 26

IT AIDS (disease)

Immunodeficiency

(fungal infections in; substituted tetracycline compds. as antifungal agents in relation to cytotoxicity)

IT	31642-30-5	113164-67-3	161452-36-4	233585-94-9	233585-95-0
	233586-04-4	233586-06-6	233586-12-4	330627-29-7	351336-94-2
	365277-14-1	365277-36-7	365277-88-9	380435-74-5	380435-76-7
	389139-17-7	389139-27-9	389139-31-5	389139-33-7	389139-41-7
	389139-43-9	389139-45-1	389139-49-5	389139-56-4	389139-64-4
	389139-72-4	389139-73-5	389139-74-6	389139-75-7	389139-76-8
	389139-80-4	389139-87-1	389139-90-6	389139-91-7	389623-86-3
	389623-88-5	389623-89-6	389623-90-9	389623-96-5	389623-99-8
	389624-06-0	389624-08-2	389624-09-3	389624-13-9	389624-18-4
	389624-19-5	389624-20-8	389624-21-9	389624-33-3	389624-36-6
	389624-38-8	389624-39-9	389624-41-3	389624-42-4	389624-43-5

389624-48-0	389624-64-0	389624-65-1	389624-67-3	389624-75-3
389624-76-4	389624-77-5	389624-78-6	389624-96-8	389625-11-0
459809-54-2	459809-55-3	459809-63-3	459809-81-5	459809-94-0
459809-99-5	459810-05-0	459810-08-3	460068-29-5	460068-30-8
460068-39-7	460068-40-0	460068-43-3	460068-44-4	460068-48-8
460068-49-9	460068-60-4	460068-72-8	460068-80-8	460068-84-2
460068-85-3	460068-86-4	460068-87-5	460068-88-6	460068-90-0
460069-34-5	460069-38-9	460071-97-0	460071-99-2	460072-10-0
460072-78-0	460072-80-4	460073-29-4	460073-37-4	
460073-68-1	460074-28-6	460074-52-6	460074-60-6	460074-73-1
460082-75-1	460082-77-3	460082-81-9	460082-82-0	460082-83-1
460082-84-2	460082-85-3	460082-86-4	460082-87-5	460082-88-6
460082-89-7	460082-90-0	460082-91-1		

RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study);

USES (Uses)

(substituted tetracycline compds. as antifungal agents in relation to cytotoxicity)

L56 ANSWER 13 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:51420 HCAPLUS Full-text

DOCUMENT NUMBER: 136:102232

TITLE: Preparation of 7-substituted tetracycline derivatives for pharmaceutical use as antibacterial agents

INVENTOR(S): Nelson, Mark L.; Frechette, Roger; Viski, Peter; Ismail, Mohamed; Bowser, Todd; Bhatia, Beena; Messersmith, David; McIntyre, Laura; Koza, Darrell; Rennie, Glen; Sheahan, Paul; Hawkins, Paul; Verma, Atul; Warchol, Tad; Bandarage, Upul

PATENT ASSIGNEE(S): Trustees of Tufts College, USA; Paratek Pharmaceuticals, Inc.

SOURCE: PCT Int. Appl., 97 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2002004407	A2	20020117	WO 2001-US20766	20010629 <--
WO 2002004407	A3	20020404		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2415718	A1	20020117	CA 2001-2415718	20010629 <--
AU 200171642	A	20020121	AU 2001-71642	20010629 <--
AU 2001271642	B2	20060105		
US 2003055025	A1	20030320	US 2001-895812	20010629 <--
US 6818635	B2	20041116		
EP 1301466	A2	20030416	EP 2001-950674	20010629 <--
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
BR 2001012265	A	20030624	BR 2001-12265	20010629 <--

10692764

HU 200301163	A2	20030828	HU 2003-1163	20010629 <--
JP 2004502753	T	20040129	JP 2002-509075	20010629 <--
ZA 2003000750	A	20040211	ZA 2003-750	20030127 <--
IN 2003CN00162	A	20050408	IN 2003-CN162	20030127 <--
US 2004224928	A1	20041111	US 2004-853635	20040524 <--
AU 2006201433	A1	20060427	AU 2006-201433	20060405 <--
PRIORITY APPLN. INFO.:			US 2000-216760P	P 20000707 <--
			US 2001-275576P	P 20010313 <--
			AU 2001-71642	A3 20010629 <--
			US 2001-895812	A1 20010629 <--
			WO 2001-US20766	W 20010629 <--
OTHER SOURCE(S):		MARPAT 136:102232		
GI				



AB 7-Substituted tetracycline derivs., such as I [R7 = NO2, alkyl, alkenyl, alkynyl, aryl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, arylalkyl, amino, arylalkenyl, arylalkynyl, aminoalkyl, etc.], were prepared for therapeutic use as antibacterial agents. Thus, 7-phenylsancycline I (R7 = Ph) was prepared in 42% yield by aromatic coupling reaction of 7-iodosancycline I (R7 = iodo) with PhB(OH)2 using Pd(OAc)2 and Na2CO3 in MeOH under an argon atmosphere at r.t. for 2 h. The prepared tetracycline derivs. were tested for antibacterial activity against Escherichia coli, Enterococcus hirae, and Staphylococcus aureus.

IT 389625-03-OP 389625-13-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation);

THU (Therapeutic use); BIOL (Biological study); PREP

(Preparation); USES (Uses)

(preparation of 7-substituted tetracycline derivs. for pharmaceutical use


as

antibacterial agents)

RN 389625-03-0 HCAPLUS


CN Carbamic acid, [[[6aS,10S,10aS,11aR)-8-(aminocarbonyl)-10-(dimethylamino)-5,6a,7,10,10a,11,11a,12-octahydro-4,6,6a,9-tetrahydroxy-5,7-dioxo-1-naphthacenyl]methyl]-, 2,2-dimethylpropyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 389625-13-2 HCAPLUS
 CN Carbamic acid, [[[6aS,10S,10aS,11aR)-8-(aminocarbonyl)-10-(dimethylamino)-5,6a,7,10,10a,11,11a,12-octahydro-4,6,6a,9-tetrahydroxy-5,7-dioxo-1-naphthaceny]]methyl]-, propyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IC ICM C07C237-00
 CC 26-6 (Biomolecules and Their Synthetic Analogs)
 Section cross-reference(s): 10
 IT 263760-96-9P 263760-98-1P 263760-99-2P 263761-02-0P 365277-42-5P
 365277-44-7P 365277-45-8P 374748-06-8P 380435-62-1P 380435-63-2P
 380435-65-4P 380435-76-7P 389623-67-0P 389623-72-7P 389623-74-9P
 389623-77-2P 389623-80-7P 389623-82-9P 389623-84-1P 389623-86-3P
 389623-88-5P 389623-89-6P 389623-90-9P 389623-91-0P 389623-93-2P
 389623-95-4P 389623-96-5P 389623-97-6P 389623-98-7P 389623-99-8P
 389624-00-4P 389624-01-5P 389624-02-6P 389624-03-7P 389624-04-8P
 389624-05-9P 389624-06-0P 389624-07-1P 389624-08-2P 389624-09-3P
 389624-10-6P 389624-11-7P 389624-12-8P 389624-13-9P 389624-14-0P
 389624-15-1P 389624-16-2P 389624-17-3P 389624-18-4P 389624-19-5P
 389624-20-8P 389624-21-9P 389624-22-0P 389624-23-1P 389624-25-3P
 389624-26-4P 389624-27-5P 389624-28-6P 389624-29-7P 389624-30-0P
 389624-31-1P 389624-32-2P 389624-33-3P 389624-34-4P 389624-35-5P
 389624-37-7P 389624-38-8P 389624-39-9P 389624-40-2P 389624-41-3P
 389624-42-4P 389624-43-5P 389624-44-6P 389624-45-7P 389624-46-8P
 389624-47-9P 389624-48-0P 389624-49-1P 389624-50-4P 389624-51-5P
 389624-52-6P 389624-53-7P 389624-54-8P 389624-55-9P 389624-56-0P
 389624-57-1P 389624-58-2P 389624-59-3P 389624-60-6P 389624-61-7P
 389624-62-8P 389624-63-9P 389624-64-0P 389624-65-1P 389624-66-2P
 389624-67-3P 389624-68-4P 389624-69-5P 389624-70-8P 389624-71-9P
 389624-72-0P 389624-73-1P 389624-74-2P 389624-75-3P 389624-76-4P
 389624-77-5P 389624-78-6P 389624-79-7P 389624-80-0P 389624-81-1P
 389624-82-2P 389624-83-3P 389624-84-4P 389624-85-5P 389624-86-6P
 389624-87-7P 389624-88-8P 389624-89-9P 389624-90-2P 389624-91-3P
 389624-92-4P 389624-93-5P 389624-94-6P 389624-95-7P 389624-96-8P
 389624-97-9P 389624-98-0P 389624-99-1P 389625-00-7P 389625-01-8P
 389625-02-9P 389625-03-0P 389625-04-1P 389625-05-2P
 389625-06-3P 389625-07-4P 389625-08-5P 389625-09-6P 389625-10-9P
 389625-11-0P 389625-12-1P 389625-13-2P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation);
 THU (Therapeutic use); BIOL (Biological study); PREP
 (Preparation); USES (Uses)
 (preparation of 7-substituted tetracycline derivs. for pharmaceutical use
 as
 antibacterial agents)

L56 ANSWER 14 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1974:477746 HCAPLUS Full-text
 DOCUMENT NUMBER: 81:77746
 TITLE: Tetracycline derivatives
 INVENTOR(S): Bernardi, Luigi; Colonna, Vincenzo; De Castiglione, Roberto; Masi, Paolo
 PATENT ASSIGNEE(S): Societa Farmaceutici Italia
 SOURCE: Ger. Offen., 39 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2346535	A1	19740411	DE 1973-2346535	19730915 <--
DE 2346535	B2	19800911		
DE 2346535	C3	19810521		
NL 7312648	A	19740320	NL 1973-12648	19730913 <--
NL 158172	B	19781016		
CA 999855	A1	19761116	CA 1973-181034	19730913 <--
FR 2208885	A1	19740628	FR 1973-33067	19730914 <--
JP 49069653	A	19740705	JP 1973-104458	19730914 <--
JP 57041458	B	19820903		
ZA 7307317	A	19740925	ZA 1973-7317	19730914 <--
AU 7360333	A	19750320	AU 1973-60333	19730914 <--
BE 804913	A1	19740318	BE 1973-135695	19730917 <--
AT 7307996	A	19750615	AT 1973-7996	19730917 <--
AT 328613	B	19760325		
US 3901942	A	19750826	US 1973-397691	19730917 <--
GB 1413347	A	19751112	GB 1973-43564	19730917 <--
HU 167850	B	19751225	HU 1973-SO1098	19730917 <--
ES 418809	A1	19760316	ES 1973-418809	19730917 <--
SU 574145	A3	19770925	SU 1973-1957942	19730917 <--
PRIORITY APPLN. INFO.:			IT 1972-29328	A 19720918 <--

GI For diagram(s), see printed CA Issue.

AB Tetracycline derivs. I (R = H, R1 = e.g., Me, NH2, Me2NCH2, F3CCONHCH2; R2 = H, Me; R3 = H, OH) were prepared by the selective alkylation of a tetracycline derivative in the 9-position, followed by electrophilic substitution in the 7-position and dealkylation. Thus, I (R = R1 = R2 = R3 = H) was alkylated with Me2C:CH2 in (Me2N)3PO to give I (r = Me3C; R1 = R2 = R3 = H) which was nitrated with KNO3 and HF, then hydrogenated over PtO2 to give I (R = Me3C, R1 = NH2, R2 = R3 = H). Reaction of this product with HCHO in the presence of Pd-C followed by dealkylation with F3CSO3H in PhOMe gave I (R = R2 = R3 = H, R1 = Me2N). About 20 I were prepared

IT 53108-32-0P 53108-37-5P 53108-41-1P


53173-83-4P 53173-84-5P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)

RN 53108-32-0 HCAPLUS

CN Carbamic acid, [[8-(aminocarbonyl)-10-(dimethylamino)-3-(1,1-dimethylethyl)-5,6a,7,10,10a,11,11a,12-octahydro-4,6,6a,9-tetrahydroxy-5,7-dioxo-1-naphthacenyl]methyl]-, ethyl ester, [6aS-(6aα,10α,10aα,11aα)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 53108-37-5 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-9-(1,1-dimethylethyl)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-7-[[[(trichloroacetyl)amino]methyl]-, [4S-(4α,4α,5α,12α,12a,12b,12c,12d)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 53108-41-1 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-7-[(dimethylamino)methyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, [4S-(4α,4α,5α,12α,12a,12b,12c,12d)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 53173-83-4 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-9-(1,1-dimethylethyl)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-7-[[[(trifluoroacetyl)amino]methyl]-, [4S-(4α,4α,5α,12α,12a,12b,12c,12d)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10692764



RN 53173-84-5 HCAPLUS
 CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-7-[(dimethylamino)methyl]-9-(1,1-dimethylethyl)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, dihydrochloride, [4S-(4α,4αa,5αa,12αa)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

IC C07C
 CC 26-6 (Condensed Aromatic Compounds)
 IT 10118-90-8P 53108-30-8P 53108-31-9P 53108-32-0P
 53108-33-1P 53108-34-2P 53108-35-3P 53108-36-4P 53108-37-5P
 53108-38-6P 53108-39-7P 53108-40-0P 53108-41-1P
 53173-80-1P 53173-81-2P 53173-82-3P 53173-83-4P
 53173-84-5P 53203-06-8P 53209-23-7P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)

*****REFERENCES GEARED TOWARDS QUERY FOR CLAIM 54*****

=> d que 1109

L1 STR




G1 C,O,S,N

Structure attributes must be viewed using STN Express query preparation.

L3 9270 SEA FILE=REGISTRY SSS FUL L1


L5 STR



Structure attributes must be viewed using STN Express query preparation.

L7 66 SEA FILE=REGISTRY SUB=L3 SSS FUL L5

L8 STR




Structure attributes must be viewed using STN Express query preparation.

L10 1047 SEA FILE=REGISTRY SUB=L3 SSS FUL L8

L11 18 SEA FILE=HCAPLUS ABB=ON PLU=ON L7

L12 14 SEA FILE=HCAPLUS ABB=ON PLU=ON L11 AND (AY<2003 OR PY<2003 OR PRY<2003)

L13	28687	SEA FILE=HCAPLUS	ABB=ON	PLU=ON	L10
L14	1	SEA FILE=HCAPLUS	ABB=ON	PLU=ON	L12 AND ((RNA OR RIBONUCLEIC ACID?) (L) (MODULAT?))
L15	1	SEA FILE=HCAPLUS	ABB=ON	PLU=ON	L12 AND (RNA OR RIBONUCLEIC ACID?)
L16	1	SEA FILE=HCAPLUS	ABB=ON	PLU=ON	(L14 OR L15)
L17	14	SEA FILE=HCAPLUS	ABB=ON	PLU=ON	(L12 OR L16)
L18	15	SEA FILE=HCAPLUS	ABB=ON	PLU=ON	L7 (L) (THU OR PKT OR PAC OR BAC OR DMA)/RL
L19	13	SEA FILE=HCAPLUS	ABB=ON	PLU=ON	L18 AND (AY<2003 OR PY<2003 OR PRY<2003)
L20	14	SEA FILE=HCAPLUS	ABB=ON	PLU=ON	(L17 OR L19)
L21	18	SEA FILE=HCAPLUS	ABB=ON	PLU=ON	L13 AND ((RNA OR RIBONUCLEIC ACID?) (L) (MODULAT?))
L22	7	SEA FILE=HCAPLUS	ABB=ON	PLU=ON	L21 AND (AY<2003 OR PY<2003 OR PRY<2003)
L26		STR			



Structure attributes must be viewed using STN Express query preparation.

L28	493	SEA FILE=REGISTRY	SUB=L3	SSS FUL	L26
L30	5922	SEA FILE=HCAPLUS	ABB=ON	PLU=ON	L28 (L) (THU OR PKT OR PAC OR BAC OR DMA)/RL
L31	3	SEA FILE=HCAPLUS	ABB=ON	PLU=ON	L30 AND ((RNA OR RIBONUCLEIC ACID?) (L) (MODULAT?))
L32	155	SEA FILE=HCAPLUS	ABB=ON	PLU=ON	L30 AND (RNA OR RIBONUCLEIC ACID?)
L33	116	SEA FILE=HCAPLUS	ABB=ON	PLU=ON	L32 AND (AY<2003 OR PY<2003 OR PRY<2003)
L34	7	SEA FILE=HCAPLUS	ABB=ON	PLU=ON	(L22 OR L31)
L35	22	SEA FILE=HCAPLUS	ABB=ON	PLU=ON	L33 AND (?DISEASE? OR ?DISORDER? OR ?INFECTION? OR ?DYSFUNCTION?)
L36	28	SEA FILE=HCAPLUS	ABB=ON	PLU=ON	(L34 OR L35)
L37	28	SEA FILE=HCAPLUS	ABB=ON	PLU=ON	(L36 OR L22)
L38	5	SEA FILE=HCAPLUS	ABB=ON	PLU=ON	DTMR
L39	9535	SEA FILE=HCAPLUS	ABB=ON	PLU=ON	"NERVOUS SYSTEM, DISEASE (L) DEGENERATION"+OLD/CT
L40	54794	SEA FILE=HCAPLUS	ABB=ON	PLU=ON	"HUMAN IMMUNODEFICIENCY VIRUS"+OLD,NT/CT
L41	44073	SEA FILE=HCAPLUS	ABB=ON	PLU=ON	"HUMAN IMMUNODEFICIENCY VIRUS 1"+OLD/CT
L42	20700	SEA FILE=HCAPLUS	ABB=ON	PLU=ON	"AIDS (DISEASE)" +OLD/CT
L43	885	SEA FILE=HCAPLUS	ABB=ON	PLU=ON	"WEST NILE VIRUS"+OLD/CT
L44	271	SEA FILE=HCAPLUS	ABB=ON	PLU=ON	"POTATO LEAFROLL VIRUS"+OLD/CT

L45	13196	SEA FILE=HCAPLUS	ABB=ON	PLU=ON	"INFLUENZA VIRUS"+OLD,NT/CT
L46	5	SEA FILE=HCAPLUS	ABB=ON	PLU=ON	"INFECTION (L) MENINGOPNEUMONITIS"+OLD/CT
L47	5	SEA FILE=HCAPLUS	ABB=ON	PLU=ON	"LUNG, DISEASE (L) MENINGOPNEUMONITIS"+OLD/CT
L48	1669	SEA FILE=HCAPLUS	ABB=ON	PLU=ON	"RABIES VIRUS"+OLD/CT
L49	87393	SEA FILE=HCAPLUS	ABB=ON	PLU=ON	(L38 OR L39 OR L40 OR L41 OR L42 OR L43 OR L44 OR L45 OR L46 OR L47 OR L48)
L50	25	SEA FILE=HCAPLUS	ABB=ON	PLU=ON	L33 AND (CANCER? OR TUMOR? OR TUMOUR? OR LEUKEMIA? OR SARCOMA? OR MYELOMA? OR MELANOMA? OR ASTHMA? OR ARTHRITIS? OR ANEMIA? OR ALZHEIMER? OR HUNTINGTON? OR OARTIC ANEURYSM? OR DIABETES? OR ISCHEMIA? OR HYPERLIPIDEMIA ? OR OBESITY?)
L51	10	SEA FILE=HCAPLUS	ABB=ON	PLU=ON	L33 AND L49
L52	26	SEA FILE=HCAPLUS	ABB=ON	PLU=ON	(L50 OR L51)
L53	39	SEA FILE=HCAPLUS	ABB=ON	PLU=ON	(L52 OR L37)
L54	6	SEA FILE=HCAPLUS	ABB=ON	PLU=ON	L20 AND (CANCER? OR TUMOR? OR TUMOUR? OR LEUKEMIA? OR SARCOMA? OR MYELOMA? OR MELANOMA? OR ASTHMA? OR ARTHRITIS? OR ANEMIA? OR ALZHEIMER? OR HUNTINGTON? OR OARTIC ANEURYSM? OR DIABETES? OR ISCHEMIA? OR HYPERLIPIDEMIA ? OR OBESITY?)
L55	2	SEA FILE=HCAPLUS	ABB=ON	PLU=ON	L20 AND L49
L56	14	SEA FILE=HCAPLUS	ABB=ON	PLU=ON	(L54 OR L55 OR L20)
L57	9813	SEA FILE=HCAPLUS	ABB=ON	PLU=ON	L3 (L) (THU OR PKT OR PAC OR BAC OR DMA)/RL
L58	951	SEA FILE=HCAPLUS	ABB=ON	PLU=ON	L57 AND (CANCER? OR TUMOR? OR TUMOUR? OR LEUKEMIA? OR SARCOMA? OR MYELOMA? OR MELANOMA? OR ASTHMA? OR ARTHRITIS? OR ANEMIA? OR ALZHEIMER? OR HUNTINGTON? OR OARTIC ANEURYSM? OR DIABETES? OR ISCHEMIA? OR HYPERLIPIDEMIA ? OR OBESITY?)
L59	155	SEA FILE=HCAPLUS	ABB=ON	PLU=ON	L57 AND L49
L60	93	SEA FILE=HCAPLUS	ABB=ON	PLU=ON	L58 AND L59
L61	57	SEA FILE=HCAPLUS	ABB=ON	PLU=ON	L60 AND (AY<2003 OR PY<2003 OR PRY<2003)
L64	9	SEA FILE=HCAPLUS	ABB=ON	PLU=ON	L53 AND L61
L65	30	SEA FILE=HCAPLUS	ABB=ON	PLU=ON	L53 AND (AY<2002 OR PY<2002 OR PRY<2002)
L66	6	SEA FILE=HCAPLUS	ABB=ON	PLU=ON	L65 AND L61
L67	7	SEA FILE=HCAPLUS	ABB=ON	PLU=ON	L65 AND L49
L68	7	SEA FILE=HCAPLUS	ABB=ON	PLU=ON	(L66 OR L67)
L69	10	SEA FILE=HCAPLUS	ABB=ON	PLU=ON	(L64 OR L68)
L70	17	SEA FILE=HCAPLUS	ABB=ON	PLU=ON	(L34 OR L69)
L71	25	SEA FILE=HCAPLUS	ABB=ON	PLU=ON	L33 AND (CANCER? OR TUMOR? OR TUMOUR? OR LEUKEMIA? OR SARCOMA? OR MYELOMA? OR MELANOMA? OR ASTHMA? OR ARTHRITIS? OR ANEMIA? OR ALZHEIMER? OR HUNTINGTON? OR OARTIC ANEURYSM? OR DIABETES? OR ISCHEMIA? OR HYPERLIPIDEMIA ? OR OBESITY?)
L72	10	SEA FILE=HCAPLUS	ABB=ON	PLU=ON	L33 AND L49
L73	26	SEA FILE=HCAPLUS	ABB=ON	PLU=ON	(L71 OR L72)
L74	33	SEA FILE=HCAPLUS	ABB=ON	PLU=ON	(L70 OR L73)
L79	33	SEA FILE=HCAPLUS	ABB=ON	PLU=ON	(L31 OR L34 OR L74)
L80	10	SEA FILE=HCAPLUS	ABB=ON	PLU=ON	L79 AND L49
L81	26	SEA FILE=HCAPLUS	ABB=ON	PLU=ON	L79 AND (CANCER? OR TUMOR? OR TUMOUR? OR LEUKEMIA? OR SARCOMA? OR MYELOMA? OR MELANOMA? OR ASTHMA? OR ARTHRITIS? OR ANEMIA? OR ALZHEIMER? OR HUNTINGTON? OR OARTIC ANEURYSM? OR DIABETES? OR ISCHEMIA? OR HYPERLIPIDEMIA ? OR OBESITY?)
L82	27	SEA FILE=HCAPLUS	ABB=ON	PLU=ON	(L80 OR L81)
L83	33	SEA FILE=HCAPLUS	ABB=ON	PLU=ON	(L82 OR L31 OR L34)

L109 32 SEA FILE=HCAPLUS ABB=ON PLU=ON L83 NOT L56

=> d ibib abs hitstr hitind retable l109 tot

L109 ANSWER 1 OF 32 HCAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2006:100738 HCAPLUS Full-text
 DOCUMENT NUMBER: 144:198849
 TITLE: Novel dosage form comprising modified-release and
 immediate-release active ingredients
 INVENTOR(S): Vaya, Navin; Karan, Rajesh Singh; Sadanand, Sunil;
 Gupta, Vinod Kumar
 PATENT ASSIGNEE(S): India
 SOURCE: U.S. Pat. Appl. Publ., 49 pp., Cont.-in-part of U.S.
 Ser. No. 630,446.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006024365	A1	20060202	US 2005-134633	20050519 <--
IN 2002MU00697	A	20040529	IN 2002-MU697	20020805 <--
IN 193042	A1	20040626		
IN 2002MU00699	A	20040529	IN 2002-MU699	20020805 <--
IN 2003MU00080	A	20050204	IN 2003-MU80	20030122
IN 2003MU00082	A	20050204	IN 2003-MU82	20030122
US 2004096499	A1	20040520	US 2003-630446	20030729 <--
PRIORITY APPLN. INFO.:			IN 2002-MU697	A 20020805 <--
			IN 2002-MU699	A 20020805 <--
			IN 2003-MU80	A 20030122
			IN 2003-MU82	A 20030122
			US 2003-630446	A2 20030729

AB A dosage form comprising of a high dose, high solubility active ingredient as modified release and a low dose active ingredient as immediate release where the weight ratio of immediate release active ingredient and modified release active ingredient is from 1:10 to 1:15000 and the weight of modified release active ingredient per unit is from 500 mg to 1500 mg; a process for preparing the dosage form. Tablets containing 10 mg sodium pravastatin and 1000 mg niacin were prepared The release of sodium pravastatin after 24 h was 67.7%, and the release of niacin after 1 h was 84.1%.


IT 60-54-8, Tetracycline 23313-80-6, Epitetracycline hydrochloride

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (novel dosage form comprising modified-release and immediate-release active ingredients)

RN 60-54-8 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S,4aS,5aS,6S,12aS)-
 (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 23313-80-6 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, monohydrochloride, (4R,4aS,5aS,6S,12aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

INCL 424468000

CC 63-6 (Pharmaceuticals)

IT **Ischemia**

(cerebral, drugs for treatment of; novel dosage form comprising modified-release and immediate-release active ingredients)

IT Brain, disease

(**ischemia**, drugs for treatment of; novel dosage form comprising modified-release and immediate-release active ingredients)

IT Double stranded RNA

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(mismatched; novel dosage form comprising modified-release and immediate-release active ingredients)

IT 50-02-2, Dexamethasone 50-04-4, Cortisone acetate 50-06-6, Phenobarbital, biological studies 50-12-4, Mephentyoin 50-13-5, Meperidine hydrochloride 50-18-0, Cyclophosphamide 50-19-1, Hydroxyphenamate 50-23-7, Hydrocortisone 50-24-8, Prednisolone 50-27-1, Estriol 50-28-2, Estradiol, 1,3,5(10)-triene-3,17-diol (17β)-, biological studies 50-33-9, Phenylbutazone, biological studies 50-34-0, Propantheline bromide 50-35-1, Thalidomide 50-36-2, Cocaine 50-52-2, Thioridazine 50-53-3, Chlorpromazine, biological studies 50-55-5, Reserpine 50-56-6, Oxytocin, biological studies 50-57-7, Lypressin 50-58-8, Phendimetrazine tartrate 50-59-9, Cephaloridine 50-65-7, Niclosamide 50-76-0, Dactinomycin 50-78-2, Aspirin 50-91-9, Floxuridine 51-05-8, Procaine hydrochloride 51-15-0, Pralidoxime chloride 51-21-8, Fluorouracil 51-30-9, Isoproterenol hydrochloride 51-40-1, Norepinephrine bitartrate 51-43-4, Epinephrine 51-52-5, Propylthiouracil 51-55-8, Atropine, biological studies 51-56-9, Homatropine hydrobromide 51-57-0, Methamphetamine hydrochloride 51-64-9, Dextroamphetamine 51-83-2, Carbachol 52-01-7, Spironolactone

52-24-4, Thiotepa 52-49-3, Trihexyphenidyl hydrochloride 52-68-6,
 Metrifonate 52-76-6, Lynestrenol 52-86-8, Haloperidol 52-88-0,
 Methyldatropine nitrate 52-89-1, Cysteine hydrochloride 53-03-2,
 Prednisone 53-16-7D, Estrone, esters 53-19-0, Mitotane 53-34-9,
 Fluprednisolone 53-39-4, Oxandrolone 53-43-0, Dehydroepiandrosterone
 53-60-1, Promazine hydrochloride 53-73-6, Angiotensin amide 53-79-2,
 Puromycin 53-84-9, Nadide 53-86-1, Indometacin 54-03-5, Hexobendine
 54-05-7, Chloroquine 54-21-7, Sodium salicylate 54-31-9, Furosemide
 54-35-3, Penicillingprocaine 54-36-4, Metyrapone 54-42-2, Idoxuridine
 54-64-8, Thimerosal 54-84-2, Cinanserin hydrochloride 54-85-3,
 Isoniazid 54-91-1, Pipobroman 55-03-8, Levothyroxine sodium 55-06-1,
 Liothyronine sodium 55-63-0, Nitroglycerin 55-86-7, Mechlorethamine
 hydrochloride 55-91-4, Isoflurophate 55-98-1, Busulfan 56-45-1,
 Serine, biological studies 56-47-3, Desoxycorticosterone acetate
 56-53-1, Diethylstilbestrol 56-59-7, Felypressin 56-75-7,
 Chloramphenicol 56-84-8, Aspartic acid, biological studies 56-87-1,
 Lysine, biological studies 56-89-3, Cystine, biological studies
 56-94-0, Demecarium bromide 57-13-6, Urea, biological studies 57-41-0,
 Phenytoin 57-47-6, Physostigmine 57-53-4, Meproamate 57-63-6,
 Ethinyl estradiol 57-65-8, Thyromedan hydrochloride 57-66-9,
 Probenecid 57-68-1, Sulfamethazine 57-83-0, Progesterone, biological
 studies 57-91-0, 17- α Estradiol 57-94-3, Tubocurarine chloride
 57-96-5, Sulfinpyrazone 58-08-2, Caffeine, biological studies 58-14-0,
 Pyrimethamine 58-18-4, Methyltestosterone 58-22-0, Testosterone
 58-25-3, Chlordiazepoxide 58-28-6, Desipramine hydrochloride 58-32-2,
 Dipyrindamole 58-33-3, Promethazine hydrochloride 58-38-8,
 Prochlorperazine 58-39-9, Perphenazine 58-54-8, Ethacrynic acid
 58-55-9, Theophylline, biological studies 58-71-9, Cephalothin sodium
 58-86-6, Xylose, biological studies 58-93-5, Hydrochlorothiazide
 58-94-6, Chlorothiazide 59-05-2, Methotrexate 59-30-3, Folic acid,
 biological studies 59-33-6, Pyrillamine maleate 59-52-9, Dimercaprol
 59-63-2, Isocarboxazid 59-67-6, Niacin, biological studies 59-87-0,
 Nitrofurazone 59-92-7, Levodopa, biological studies 59-97-2,
 Tolazoline hydrochloride 60-13-9, Amphetamine sulfate 60-18-4,
 Tyrosine, biological studies 60-23-1, Cysteamine 60-29-7, Ether,
 biological studies 60-45-7, Fenimide 60-54-8, Tetracycline
 60-56-0, Methimazole 60-80-0, Antipyrine 60-99-1, Methotrimeprazine
 61-25-6, Papaverine hydrochloride 61-56-3, Sulthiame 61-57-4,
 Niridazole 61-68-7, Mefenamic acid 61-73-4, Methylene blue 61-75-6,
 Bretylum tosylate 61-76-7, Phenylephrine hydrochloride 61-90-5,
 Leucine, biological studies 62-51-1, Methacholine chloride 62-68-0,
 Proadifen hydrochloride 62-73-7, Dichlorvos 62-90-8, Nandrolone
 phenpropionate 63-05-8, Androstenedione 63-12-7, Benzquinamide
 63-39-8, Uridine triphosphate 63-45-6, Primaquine phosphate 63-68-3,
 Methionine, biological studies 63-89-8, Colfosceril palmitate 63-91-2,
 Phenylalanine, biological studies 63-92-3, Phenoxybenzamine
 hydrochloride 63-98-9, Phenacetamide 64-31-3, Morphine sulfate
 64-43-7, Amobarbital sodium 64-55-1, Mebutamate 64-77-7, Tolbutamide
 64-86-8, Colchicine 65-28-1, Phentolamine mesylate 65-29-2, Gallamine
 triethiodide 65-45-2, Salicylamide 66-75-1, Uracil mustard 66-76-2,
 Dicumarol 66-81-9, Cycloheximide 67-20-9, Nitrofurantoin 67-43-6,
 Pentetic acid 67-45-8, Furazolidone 67-63-0, Isopropyl alcohol,
 biological studies 67-68-5, Dimethyl sulfoxide, biological studies
 67-73-2, Fluocinolone acetonide 67-92-5, Dicyclomine hydrochloride
 67-95-8, Quingestron 67-96-9, Dihydrotachysterol 68-22-4,
 Norethindrone 68-23-5, Norethynodrel 68-35-9, Sulfadiazine 68-41-7,
 Cycloserine 68-89-3, Dipyrone 68-91-7, Trimethaphan camsylate
 68-96-2, 17 Hydroxy progesterone 69-44-3, Amodiaquine hydrochloride
 69-53-4, Ampicillin 69-57-8, Penicillingsodium 69-65-8, Mannitol
 69-72-7, Salicylic acid, biological studies 69-74-9, Cytarabine

hydrochloride 70-00-8, Trifluridine 70-10-0, Ticlatone 70-30-4, Hexachlorophene 71-00-1, Histidine, biological studies 71-27-2, Succinylcholine chloride 71-58-9, Medroxyprogesterone acetate 71-63-6, Digitoxin 71-68-1, Hydromorphone hydrochloride 71-73-8, Thiopental sodium 71-81-8, Isopropamide iodide 72-18-4, Valine, biological studies 72-19-5, Threonine, biological studies 72-33-3, Mestranol 72-44-6, Methaqualone 73-09-6, Etizolam 73-22-3, Tryptophan, biological studies 73-31-4, Melatonin 73-32-5, Isoleucine, biological studies 73-48-3, Bendroflumethiazide 74-79-3, Arginine, biological studies 75-00-3, Ethyl chloride 75-19-4, Cyclopropane 76-38-0, Methoxyflurane 76-42-6, Oxycodone 76-43-7, Fluoxymesterone 76-57-3, Codeine 76-73-3, Secobarbital 76-74-4, Pentobarbital 76-90-4, Mepenzolate bromide 77-21-4, Glutethimide 77-26-9, Butalbital 77-27-0, Thiamylal 77-36-1, Chlorthalidone 77-41-8, Methsuximide 77-46-3, Acedapsone 77-67-8, Ethosuximide 77-86-1, Trometamol 78-11-5, Pentaerythritol tetranitrate 78-44-4, Carisoprodol 79-09-4, Propionic acid, biological studies 79-17-4, Pimagedine 79-57-2, Oxytetracycline 79-64-1, Dimethisterone 80-08-0, Dapsone 80-50-2, Anisotropine methylbromide 81-04-9, 1,5-Naphthalenedisulfonic acid 81-13-0, Dexpanthenol 81-23-2, Dehydrocholic acid 81-54-9, Purpurin 82-92-8, Cyclizine 83-43-2, Methylprednisolone 83-73-8, Iodoquinol 83-74-9, Ibogaine 84-17-3, Dienestrol

RL: THU (*Therapeutic use*); BIOL (Biological study); USES (Uses)

(novel dosage form comprising modified-release and immediate-release active ingredients)

IT 11056-15-8, Mitosper 11056-18-1, Scopafungin 11056-20-5, Zorbamycin 11078-21-0, Filipin 11096-49-4, Partricin 11121-32-7, Mepartricin 12192-57-3, Aurothioglucose 12622-73-0, Coccidioidin 12629-01-5, Somatropin 12706-94-4, Anthelmecin 12713-07-4D, Verdin, derivs. 13010-47-4, Lomustine 13055-82-8, Reproterol hydrochloride 13060-14-5, Yangambin 13071-11-9, Dexpropranolol hydrochloride 13103-34-9, Boldenone undecylenate 13115-40-7, Fonazine mesylate 13292-46-1, Rifampin 13379-87-8, Tiprenolol hydrochloride 13392-18-2, Fenoterol 13392-28-4, Rimantadine 13408-29-2, Nitroxide 13411-16-0, Nifurpirinol 13422-16-7, Triflocin 13463-41-7, Pyrithione zinc 13494-90-1, Gallium nitrate 13523-86-9, Pindolol 13539-59-8, Apazone 13551-87-6, Misonidazole 13647-35-3, Trilostane 13665-88-8, Mopidamol 13698-49-2, Delmadinone acetate 13758-23-1, Quinterenol sulfate 13838-16-9, Enflurane 13909-09-6, Semustine 13958-40-2, Oxiramide 14008-44-7, Metopimazine 14008-46-9, Pinoxepin hydrochloride 14028-44-5, Amoxapine 14088-71-2, Proclonol 14176-10-4, Cetiedil 14176-50-2, Tiletamine hydrochloride 14188-82-0, Cytostatin 14255-87-9, Parbendazole 14265-71-5, Selenium 75, biological studies 14293-44-8, Xipamide 14402-89-2, Sodium nitroprusside 14437-41-3, Clioquinide 14484-47-0, Deflazacort 14561-42-3, Menoctone 14611-51-9, Selegiline 14611-52-0, Selegiline hydrochloride 14636-12-5, Terlipressin 14698-29-4, Oxolinic acid 14769-73-4, Levamisole 14769-74-5, Dexamisole 14796-24-8, Cinperene 14796-28-2, Clodanole 14816-67-2, Soterenol hydrochloride 14885-29-1, Iprnidazole 14930-96-2, Cytochalasin B 15037-55-5, Ethonam nitrate 15176-29-1, Edoxudine 15179-97-2, Estrazinol hydrobromide 15180-00-4, Prednival 15221-81-5, Fludorex 15256-58-3, Beloxamide 15307-79-6, Diclofenac sodium 15318-45-3, Thiamphenicol 15468-10-7, Oxidronic acid 15478-78-1, Iodamide 15500-66-0, Pancuronium bromide 15574-96-6, Pizotyline 15578-26-4, Stannous pyrophosphate 15622-65-8, Molindone hydrochloride 15639-50-6, Safingol 15663-27-1, Cisplatin 15676-16-1, sulphuride 15686-51-8, Clemastine 15686-68-7, Volazocine 15686-71-2, Cephalixin 15686-74-5, Cyclophenazine hydrochloride 15686-91-6, Propiram 15687-07-7, Cyprazepam 15687-27-1, Ibuprofen 15722-48-2, Olsalazine 15793-40-5, Terodiline 15826-37-6, Cromolyn sodium


15922-78-8, Pyrithione sodium 15992-13-9, Intrazole 16034-77-8,
 Iocetamic acid 16051-77-7, Isosorbide mononitrate 16231-75-7, Atolide
 16320-04-0, Gestrinone 16590-41-3, Naltrexone 16624-40-1 16662-47-8,
 Gallopamil 16676-27-0, Nalmexone hydrochloride 16679-58-6,
 Desmopressin 16773-42-5, Ornidazole 16816-67-4, Pantethine
 16846-24-5, Josamycin 16915-71-2, Cingestol 16915-78-9, Bolenol
 16915-79-0, Mequidox 16915-80-3, Oxogestone phenpropionate 16960-16-0,
 Cosyntropin 17021-26-0, Calusterone 17033-82-8, Iomethini125
 17090-79-8, Monensin 17196-88-2, Vincofos 17230-85-2, Amquinat
 17230-86-3, Carbenicillin potassium 17230-87-4, Seperidol hydrochloride
 17230-88-5, Danazol 17230-89-6, Nimazone 17243-32-2, Ketipramine
 fumarate 17243-64-0, Piprozolin 17289-49-5, Tetrydamine 17321-77-6,
 Clomipramine hydrochloride 17560-51-9, Metolazone 17598-65-1,
 Deslanoside 17605-73-1, Colterol mesylate 17650-98-5, Ceruletide
 17737-65-4, Clonixin 17784-12-2, Sulfacytine 17902-23-7, Tegafur
 18010-40-7, Bupivacaine hydrochloride 18046-21-4, Fentiazac
 18109-81-4, Butamirate citrate 18174-58-8, Pipoxolan hydrochloride
 18323-44-9, Clindamycin 18378-89-7, Plicamycin 18416-85-8, Lombricine
 18464-39-6, Caroxazone 18472-51-0, Chlorhexidine gluconate 18559-94-9,
 Salbutamol 18588-57-3, Etoprine 18641-57-1, Glyceryl behenate
 18694-40-1, Epirizole 18883-66-4, Streptozocin 18917-89-0, Magnesium
 salicylate 18965-97-4, Berlafenone 18984-80-0, Euprocine hydrochloride
 19216-56-9, Prazosin 19237-84-4, Prazosin hydrochloride 19291-69-1,
 Gestaclone 19356-17-3, Calcifediol 19561-70-7, Nifuratrone
 19825-63-9, Pirnabine 19863-06-0, Ioxotrizoic acid 19885-51-9,
 Aranotin 19888-56-3, Fluazacort 19916-73-5, O6-Benzylguanine
 19992-80-4, Butixirate 20064-19-1, Propionylcarnitine 20098-14-0,
 Idramantone 20187-55-7, Bendazac 20287-37-0, Fenquizone 20350-15-6,
 Brefeldin 20423-99-8, Deprodone 20554-84-1, Parthenolide 20559-55-1,
 Oxibendazole 20638-84-0, Retinamide 20684-06-4, Bamifylline
 hydrochloride 20830-75-5, Digoxin 21059-48-3, Veramine 21132-59-2,
 Pazoxide 21221-18-1, Flazalone 21256-18-8, Oxaprozin 21365-49-1,
 Tralonide 21434-91-3, Capobenice acid 21440-97-1, Brofoxine
 21498-08-8, Lofexidine hydrochloride 21535-47-7, Mianserin hydrochloride
 21626-89-1, Diftalone 21638-36-8, Nifurimide 21736-83-4, Spectinomycin
 hydrochloride 21738-42-1, Oxamniquine 21791-39-9, Letimide
 hydrochloride 21820-82-6, Fenpibalone 21829-22-1, Clonixeril
 21829-25-4, Nifedipine 21888-98-2, Dexetimide 21925-88-2, Tesicam
 22012-72-2, Zilantel 22071-15-4, Ketoprofen 22161-81-5, Dexketoprofen
 22195-34-2, Guanadrel sulfate 22199-46-8, Clomacran phosphate
 22204-24-6, Pyrantel Pamoate 22204-53-1, Naproxen 22204-91-7,
 Lofibrate 22232-71-9, Mazindol 22254-24-6, Ipratropium bromide
 22316-47-8, Clobazam 22365-40-8, Triflubazam 22461-13-8, Fantridone
 hydrochloride 22484-64-6, Sulfanilate zinc 22494-27-5, Flufenisal
 22494-42-4, Diflunisal 22632-06-0, Bupicomide 22662-39-1, Rafoxanide
 22664-55-7, Metipranolol 22668-01-5, Etanidazole 22737-01-5,
 Diflumidone sodium 22760-18-5, Proquazone 22916-38-7, Orconazole
 nitrate 22916-47-8, Miconazole 23031-32-5, Terbutaline sulfate
 23076-35-9, Xylazine hydrochloride 23092-17-3, Halazepam 23155-02-4,
 Fosfomycin 23163-51-1, Methynodiol diacetate 23226-37-1, Daledalin
 tosylate 23239-36-3, Deterenol hydrochloride 23239-37-4, Etoxadol
 hydrochloride 23239-41-0, Cephacetrile sodium 23239-78-3, Pridetine
 hydrochloride 23247-36-1, Nafomine malate 23256-09-9, Closiramine
 acetate 23256-26-0, Piquizil hydrochloride 23256-28-2, Hoquizil
 hydrochloride 23256-50-0, Guanabenz acetate 23257-58-1, Levoadrol
 hydrochloride 23277-43-2, Nalbuphine hydrochloride 23277-50-1,
 Salicylate meglumine 23288-49-5, Probucol 23313-80-6,
 Epitettracycline hydrochloride 23319-48-4, Megalomycin potassium
 phosphate 23327-57-3, Nefopam hydrochloride 23444-86-2, Suncillin
 sodium 23469-05-8, Diamocaine cyclamate 23478-02-6, 16- α -Gitoxin

23486-22-8, Esproquin hydrochloride 23541-50-6, Daunorubicin
hydrochloride 23593-75-1, Clotrimazole
RL: **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(novel dosage form comprising modified-release and immediate-release
active ingredients)

L109 ANSWER 2 OF 32 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:1262019 HCAPLUS Full-text
DOCUMENT NUMBER: 144:17190
TITLE: Methods, nucleic acid constructs and cells for
treating neurodegenerative **disorders**
INVENTOR(S): Melamed, Eldad; Offen, Daniel; Levy, Yosef; Green,
Pnina
PATENT ASSIGNEE(S): Israel
SOURCE: U.S. Pat. Appl. Publ., 107 pp., Cont.-in-part of Appl.
No. PCT/IL03/00972.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005265983	A1	20051201	US 2005-130197	20050517 <--
WO 2004046348	A1	20040603	WO 2003-IL972	20031117 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005202128	A1	20050602	AU 2005-202128	20050517
PRIORITY APPLN. INFO.:				
			IL 2002-152905	A 20021117 <--
			WO 2003-IL972	A2 20031117
			US 2005-651645P	P 20050211
			AU 2003-302134	A3 20031117
AB	A method of treating a neurodegenerative disorder is provided. The method is effected by administering to an individual in need thereof cells capable of exogenously regulatable neurotransmitter synthesis thereby treating the neurodegenerative disorder .			
IT	60-54-8, Tetracycline 564-25-0, Doxycycline RL: PAC (Pharmacological activity) ; THU (Therapeutic use) ; BIOL (Biological study); USES (Uses) (methods, nucleic acid constructs and cells for treating neurodegenerative disorders)			
RN	60-54-8 HCAPLUS			
CN	2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S,4aS,5aS,6S,12aS)- (CA INDEX NAME)			


Absolute stereochemistry. Rotation (-).



RN 564-25-0 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S,4aR,5S,5aR,6R,12aS)- (CA INDEX NAME)

Absolute stereochemistry.



IC ICM A61K048-00

INCL 424093210; 514044000

CC 1-11 (Pharmacology)

Section cross-reference(s): 2, 3

ST nucleic acid construct neuroprotectant neurodegenerative **disorder** neurotransmitter

IT Transcription factors

RL: BSU (Biological study, unclassified); BIOL (Biological study) (ARNT (aryl hydrocarbon receptor nuclear translocator); methods, nucleic acid constructs and cells for treating neurodegenerative **disorders**)

IT CD antigens

RL: BSU (Biological study, unclassified); BIOL (Biological study) (CD11B; methods, nucleic acid constructs and cells for treating neurodegenerative **disorders**)

IT Culture media

(DMEM; methods, nucleic acid constructs and cells for treating neurodegenerative **disorders**)

IT Dopamine receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study) (D2; methods, nucleic acid constructs and cells for treating neurodegenerative **disorders**)

IT Blood serum

(FCS (fecal calf serum); methods, nucleic acid constructs and cells for treating neurodegenerative **disorders**)

IT Culture media

(FCS; methods, nucleic acid constructs and cells for treating neurodegenerative **disorders**)

IT Transcription factors

RL: BSU (Biological study, unclassified); BIOL (Biological study) (HNF-3B (hepatocyte nuclear factor 3B); methods, nucleic acid constructs and cells for treating neurodegenerative **disorders**)

-)
- IT Nervous system, *disease*
(*Huntington's* chorea; methods, nucleic acid constructs and cells for treating neurodegenerative *disorders*)
- IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(MAP2 (microtubule-associated protein 2); methods, nucleic acid constructs and cells for treating neurodegenerative *disorders*)
- IT Neurofilament proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(NF-H, heavy; methods, nucleic acid constructs and cells for treating neurodegenerative *disorders*)
- IT Neurofilament proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(NF-L; methods, nucleic acid constructs and cells for treating neurodegenerative *disorders*)
- IT Neurofilament proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(NF-M; methods, nucleic acid constructs and cells for treating neurodegenerative *disorders*)
- IT Nuclear receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(NR4A2; methods, nucleic acid constructs and cells for treating neurodegenerative *disorders*)
- IT Transcription factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(NURR1 (Nur-related factor 1); methods, nucleic acid constructs and cells for treating neurodegenerative *disorders*)
- IT Gene, animal
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(PAX3; methods, nucleic acid constructs and cells for treating neurodegenerative *disorders*)
- IT Gene, animal
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(PAX6; methods, nucleic acid constructs and cells for treating neurodegenerative *disorders*)
- IT Transcription factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(PITX3 (paired-like homeodomain transcription factor 3); methods, nucleic acid constructs and cells for treating neurodegenerative *disorders*)
- IT Transcription factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(Pax3; methods, nucleic acid constructs and cells for treating neurodegenerative *disorders*)
- IT Transcription factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(Pax6; methods, nucleic acid constructs and cells for treating neurodegenerative *disorders*)
- IT Retinoic acid receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(RAR- α ; methods, nucleic acid constructs and cells for treating neurodegenerative *disorders*)
- IT Tyrosine kinase receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(ROR2 (receptor tyrosine kinase-like orphan receptor 2); methods, nucleic acid constructs and cells for treating neurodegenerative *disorders*)
- IT Gene, animal
RL: BSU (Biological study, unclassified); BIOL (Biological study)

- (SOD1; methods, nucleic acid constructs and cells for treating neurodegenerative *disorders*)
- IT Culture media
(SPN; methods, nucleic acid constructs and cells for treating neurodegenerative *disorders*)
- IT Receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(Smo (Smoothed); methods, nucleic acid constructs and cells for treating neurodegenerative *disorders*)
- IT Antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(Thy-1; methods, nucleic acid constructs and cells for treating neurodegenerative *disorders*)
- IT Transport proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(VMAT2 (vesicle monoamine transporter 2); methods, nucleic acid constructs and cells for treating neurodegenerative *disorders*)
- IT Genetic element
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(XRE (xenobiotic-responsive element); methods, nucleic acid constructs and cells for treating neurodegenerative *disorders*)
- IT Nervous system, *disease*
(amyotrophic lateral sclerosis; methods, nucleic acid constructs and cells for treating neurodegenerative *disorders*)
- IT Transplant and Transplantation
(bone marrow; methods, nucleic acid constructs and cells for treating neurodegenerative *disorders*)
- IT Neurotrophic factors
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(brain-derived; methods, nucleic acid constructs and cells for treating neurodegenerative *disorders*)
- IT Nervous system, *disease*
(*degeneration*; methods, nucleic acid constructs and cells for treating neurodegenerative *disorders*)
- IT Transport proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(dopamine transporter; methods, nucleic acid constructs and cells for treating neurodegenerative *disorders*)
- IT Neuron
Neurotransmission
(dopaminergic; methods, nucleic acid constructs and cells for treating neurodegenerative *disorders*)
- IT Polynucleotides
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(encoding an apoptosis inhibiting polypeptide; methods, nucleic acid constructs and cells for treating neurodegenerative *disorders*)
- IT Transcription factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(engrailed; methods, nucleic acid constructs and cells for treating neurodegenerative *disorders*)
- IT Autoimmune *disease*
(exptl. autoimmune encephalomyelitis; methods, nucleic acid constructs and cells for treating neurodegenerative *disorders*)
- IT Encephalomyelitis
(exptl. autoimmune; methods, nucleic acid constructs and cells for treating neurodegenerative *disorders*)

- IT Transcription factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(gene EVI1; methods, nucleic acid constructs and cells for treating neurodegenerative **disorders**)
- IT Myelin
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(gene expression factor-2 (MEF2); methods, nucleic acid constructs and cells for treating neurodegenerative **disorders**)
- IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(gene fork head; methods, nucleic acid constructs and cells for treating neurodegenerative **disorders**)
- IT Bone marrow
Neuron
(genetically modified cells; methods, nucleic acid constructs and cells for treating neurodegenerative **disorders**)
- IT Neurotrophic factors
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(glial-derived; methods, nucleic acid constructs and cells for treating neurodegenerative **disorders**)
- IT Proteoglycans, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(glypican, 4; methods, nucleic acid constructs and cells for treating neurodegenerative **disorders**)
- IT Drug delivery systems
(infusions; methods, nucleic acid constructs and cells for treating neurodegenerative **disorders**)
- IT **Alzheimer's disease**
Anti-**Alzheimer's** agents
Antiparkinsonian agents
Apoptosis
Cell proliferation
DNA microarray technology
Flow cytometry
Gene expression profiles, animal
Human
Human
Multiple sclerosis
Nerve regeneration
Parkinson's **disease**
Protein microarray technology
Transcriptional regulation
(methods, nucleic acid constructs and cells for treating neurodegenerative **disorders**)
- IT Aromatic hydrocarbon receptors
CD19 (antigen)
CD20 (antigen)
CD34 (antigen)
CD44 (antigen)
CD45 (antigen)
CD5 (antigen)
Glial fibrillary acidic protein
Glycosaminoglycans, biological studies
Neurotransmitters
Purine nucleotides
Tachykinins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(methods, nucleic acid constructs and cells for treating neurodegenerative **disorders**)

- IT Interleukin 1 β
 RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (methods, nucleic acid constructs and cells for treating neurodegenerative **disorders**)
- IT Fatty acids, biological studies
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (methods, nucleic acid constructs and cells for treating neurodegenerative **disorders**)
- IT Nucleic acids
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (methods, nucleic acid constructs and cells for treating neurodegenerative **disorders**)
- IT Polynucleotides
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (methods, nucleic acid constructs and cells for treating neurodegenerative **disorders**)
- IT Transcription factors
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (necdin; methods, nucleic acid constructs and cells for treating neurodegenerative **disorders**)
- IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (nestins; methods, nucleic acid constructs and cells for treating neurodegenerative **disorders**)
- IT Growth factors, animal
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (neurite extension factors, NEGF-2; methods, nucleic acid constructs and cells for treating neurodegenerative **disorders**)
- IT Cell nucleus
 (neuronal; methods, nucleic acid constructs and cells for treating neurodegenerative **disorders**)
- IT Cytoprotective agents
 Nervous system agents
 (neuroprotective agents; methods, nucleic acid constructs and cells for treating neurodegenerative **disorders**)
- IT Amino acids, biological studies
 RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (nonessential; methods, nucleic acid constructs and cells for treating neurodegenerative **disorders**)
- IT Transcription factors
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (nuclear factor Y; methods, nucleic acid constructs and cells for treating neurodegenerative **disorders**)
- IT Receptors
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (patched; methods, nucleic acid constructs and cells for treating neurodegenerative **disorders**)
- IT Opioids
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (peptide; methods, nucleic acid constructs and cells for treating neurodegenerative **disorders**)
- IT Fatty acids, biological studies
 RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (polyunsatd.; methods, nucleic acid constructs and cells for treating

- neurodegenerative *disorders*)
- IT Neurotransmission
(serotonergic; methods, nucleic acid constructs and cells for treating neurodegenerative *disorders*)
- IT Hedgehog protein
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(sonic, shh; methods, nucleic acid constructs and cells for treating neurodegenerative *disorders*)
- IT Brain, *disease*
(stroke; methods, nucleic acid constructs and cells for treating neurodegenerative *disorders*)
- IT Bone marrow
(stroma, genetically modified cells; methods, nucleic acid constructs and cells for treating neurodegenerative *disorders*)
- IT Brain
(substantia nigra; methods, nucleic acid constructs and cells for treating neurodegenerative *disorders*)
- IT *RNA* formation factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(tetracycline controlled; methods, nucleic acid constructs and cells for treating neurodegenerative *disorders*)
- IT Bone marrow
(transplant; methods, nucleic acid constructs and cells for treating neurodegenerative *disorders*)
- IT Spinal cord
(transplanting cell into; methods, nucleic acid constructs and cells for treating neurodegenerative *disorders*)
- IT Brain
(transplanting cells into; methods, nucleic acid constructs and cells for treating neurodegenerative *disorders*)
- IT Protein motifs
(zinc finger, NZF-3; methods, nucleic acid constructs and cells for treating neurodegenerative *disorders*)
- IT Integrins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(α M; methods, nucleic acid constructs and cells for treating neurodegenerative *disorders*)
- IT Transforming growth factors
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(β 3-; methods, nucleic acid constructs and cells for treating neurodegenerative *disorders*)
- IT Tubulins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(β 3-; methods, nucleic acid constructs and cells for treating neurodegenerative *disorders*)
- IT Integrins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(β 4; methods, nucleic acid constructs and cells for treating neurodegenerative *disorders*)
- IT 37340-61-7
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(1; methods, nucleic acid constructs and cells for treating neurodegenerative *disorders*)
- IT 9001-66-5
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(B; methods, nucleic acid constructs and cells for treating neurodegenerative *disorders*)

- IT 60-92-4, CAMP
 RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (dbc; methods, nucleic acid constructs and cells for treating neurodegenerative **disorders**)
- IT 50-56-6, Oxytocin, biological studies 50-67-9, Serotonin, biological studies 51-41-2, Norepinephrine 51-43-4, Epinephrine 51-45-6, Histamine, biological studies 51-61-6, Dopamine, biological studies 51-84-3, Acetylcholine, biological studies 54-16-0, 5HIAA, biological studies 56-12-2, biological studies 56-40-6, Glycine, biological studies 56-86-0, L-Glutamic acid, biological studies 86-01-1, 5'-GTP 102-32-9, DOPAC 9001-50-7, Glyceraldehyde 3-phosphate dehydrogenase 9011-97-6, Cholecystokinin 9012-25-3, Catechol-o-methyltransferase 9012-78-6, Choline acetyltransferase 9013-38-1, Dopamine β -hydroxylase 9024-58-2, Glutamate decarboxylase 9028-86-8, Aldehyde dehydrogenase 9036-22-0, Tyrosine hydroxylase 9037-21-2, Tryptophan-5 monooxygenase 9042-64-2, DOPA decarboxylase 9054-89-1, Superoxide dismutase 11000-17-2, Vasopressin 37289-19-3, GTP cyclohydrolase I 39379-15-2, Neurotensin 51110-01-1, Somatostatin 60098-35-3, 2',3'-Cyclic nucleotide 3'-phosphodiesterase 82785-45-3, Neuropeptide Y 146279-92-7, Gene ret protein tyrosine kinase 216864-07-2, α -Synuclein
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (methods, nucleic acid constructs and cells for treating neurodegenerative **disorders**)
- IT 50-81-7, L-Ascorbic acid, biological studies 1406-18-4, Vitamin E
 RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (methods, nucleic acid constructs and cells for treating neurodegenerative **disorders**)
- IT 56-85-9, L-Glutamine, biological studies 60-24-2 302-79-4, Retinoic acid 25013-16-5, BHA 62229-50-9, Epidermal growth factor 106096-93-9, BFGF 130939-66-1, Neurotrophic factor, 3 164003-41-2, FGF-8 185857-51-6, Neurturin
 RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (methods, nucleic acid constructs and cells for treating neurodegenerative **disorders**)
- IT 60-54-8, Tetracycline 564-25-0, Doxycycline
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (methods, nucleic acid constructs and cells for treating neurodegenerative **disorders**)
- IT 9014-08-8, Enolase
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (promoter human-specific; methods, nucleic acid constructs and cells for treating neurodegenerative **disorders**)

L109 ANSWER 3 OF 32 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:140662 HCAPLUS Full-text

DOCUMENT NUMBER: 142:214819

TITLE: Combined nanotechnology and sensor technologies for simultaneous diagnosis and treatment

INVENTOR(S): Melker, Richard J.; Dennis, Donn Michael

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 20 pp., Cont.-in-part of U.S. Ser. No. 345,532.

CODEN: USXXCO

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 9

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005037374	A1	20050217	US 2003-744789	20031223 <--
US 2002177232	A1	20021128	US 2002-154201	20020522 <--
US 2004076681	A1	20040422	US 2002-274829	20021021 <--
US 7195780	B2	20070327		
US 6974706	B1	20051213	US 2003-345532	20030116
US 2005054942	A1	20050310	US 2004-788501	20040226 <--
WO 2005098429	A2	20051020	WO 2005-US6355	20050228 <--
WO 2005098429	A3	20060526		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, US				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1718971	A2	20061108	EP 2005-756623	20050228
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU				
US 2006160134	A1	20060720	US 2005-296757	20051207 <--
PRIORITY APPLN. INFO.:				
			US 1999-164250P	P 19991108 <--
			US 2000-708789	B2 20001108 <--
			US 2001-292962P	P 20010523 <--
			US 2002-154201	A2 20020522 <--
			US 2002-274829	A2 20021021 <--
			US 2003-345532	A2 20030116
			US 2002-54619	A2 20020122 <--
			US 2002-178877	A2 20020624 <--
			US 2003-722620	A 20031126
			US 2003-744789	A 20031223
			US 2004-788501	A2 20040226
			WO 2005-US6355	W 20050228
AB	Systems and methods for diagnosing and/or treating conditions, diseases , or disorders . The present invention uses nanoparticle-based assemblies, which comprise a nanoparticle; a surrogate marker; and a means for detecting a specific chemical entity. Such nanoparticle-based assemblies combine nanotechnol. and sensor technol. to provide an efficient and accurate means for diagnosing a condition, disease , or disorder as well as for focused treatment regimens.			
IT	60-54-8, Tetracycline			
	RL: THU (Therapeutic use) ; BIOL (Biological study); USES (Uses) (combined nanotechnol. and sensor technol. for simultaneous diagnosis and treatment)			
RN	60-54-8 HCAPLUS			
CN	2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S,4aS,5aS,6S,12aS)-(CA INDEX NAME)			

Absolute stereochemistry. Rotation (-).



IC ICM C12Q001-68
 ICS G01N033-53
 INCL 435006000; 435007100
 CC 9-1 (Biochemical Methods)
 Section cross-reference(s): 2, 4, 63
 IT Amniotic fluid
 Analgesics
 Anti-AIDS agents
 Anti-inflammatory agents
 Antibiotics
 Anticonvulsants
 Antitumor agents
 Aptamers
 Arachis hypogaea
 Biomarkers
 Biosensors
 Blood
 Blood plasma
 Body fluid
 Bordetella bronchiseptica
 Carcinogens
 Cardiovascular agents
 Cerebrospinal fluid
 Citrobacter
 Contraceptives
 Diagnosis
 Drugs
 Drugs of abuse
 Egg, poultry
 Escherichia coli
 Feces
 Fungicides
 Hepatitis virus
 Human
 Human herpesvirus
Human immunodeficiency virus
 Hypolipemic agents
 Immunomodulators
Influenza virus
 Listeria
 Micrococcus
 Mucus
 Muscle relaxants
 Mycobacterium
 Nanoparticles
 Nanotubes
 Narcotics
 Nervous system agents
 Nervous system depressants

Nervous system stimulants

Pollen

Psychotomimetics

Rabies virus

Respiratory air

Rhinovirus

Rubella virus

Saliva

Salmonella

Semen

Sensors

Shellfish

Spore

Sputum

Sweat

Therapy

Urine

Yellow fever virus

(combined nanotechnol. and sensor technol. for simultaneous diagnosis and treatment)

IT Adrenoceptors

Alkaloids, biological studies

Bone morphogenetic proteins

Cholinergic receptors

Cytokines

Enzymes, biological studies

Glucocorticoids

Hemopoietins

Hormones, animal, biological studies

Interferons

Interleukins

Oligonucleotides

Pituitary hormones

RNA

Ribozymes

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(combined nanotechnol. and sensor technol. for simultaneous diagnosis and treatment)

IT 50-02-2, Dexamethasone 50-03-3 50-04-4, Cortisone acetate 50-13-5, Meperidine hydrochloride 50-23-7, Hydrocortisone 50-28-2, Estradiol, 17 β -estradiol, biological studies 50-44-2, 6-Mercaptopurine 50-48-6, Amitriptyline 50-49-7, Imipramine 50-53-3, biological studies 50-56-6, Oxytocin, biological studies 50-57-7, Lypressin 50-78-2, Aspirin 51-21-8, 5-Fluorouracil 51-43-4, Epinephrine 51-57-0, Methamphetamine hydrochloride 52-86-8, Haloperidol 53-86-1, Indomethacin 54-21-7, Sodium salicylate 54-71-7, Pilocarpine hydrochloride 55-48-1, Atropine sulfate 55-63-0, Nitroglycerin 55-91-4, Isoflurophate 55-98-1, Busulfan 57-22-7, Vincristine 57-63-6, Ethinyl estradiol 57-83-0, Progesterone, biological studies 58-18-4, Methyltestosterone 58-25-3, Chlorodiazepoxide 58-55-9, Theophylline, biological studies 58-93-5, Hydrochlorothiazide 59-05-2, Methotrexate 59-66-5, Acetazolamide 59-92-7, Levodopa, biological studies 59-96-1, Phenoxybenzamine 60-13-9, Amphetamine sulfate 60-54-8, Tetracycline 61-68-7, Mefenamic acid 62-51-1, Methacholine chloride 63-74-1, Sulfanilamide 64-77-7, Tolbutamide 64-86-8, Colchicine 65-49-6, p-Aminosalicylic acid 68-22-4, Norethindrone 68-23-5, Norethynodrel 68-35-9, Sulfadiazine 69-72-7, Salicylic acid, biological studies 71-81-8, Isopropamide iodide 72-33-3, Ethinyl estradiol 3-methyl ether 73-48-3, Bendroflumethiazide 76-57-3, Codeine 79-93-6, Phenaglycodol 80-74-0,

Acetylsulfisoxazole 82-66-6, Diphenadione 87-33-2, Isosorbide dinitrate 114-07-8, Erythromycin 114-49-8, Scopolamine bromide 117-37-3, Anisindione 124-94-7, Triamcinolone 127-07-1, Hydroxyurea 128-46-1, Dihydrostreptomycin 154-42-7, Thioguanine 154-93-8, BCNU 298-59-9, Methyl phenidate hydrochloride 299-28-5, Calcium gluconate 299-42-3, Ephedrine 299-95-6, Isoproterenol sulfate 302-22-7 302-23-8 305-03-3, Chlorambucil 315-30-0, Allopurinol 317-34-0, Aminophylline 378-44-9, Betamethasone 439-14-5, Diazepam 472-54-8, 19-Norprogesterone 511-13-7, Chlorthalidone hydrochloride 525-66-6, Propranolol 530-78-9, Flufenamic acid 554-57-4, Methazolamide 555-30-6, Methyldopa 590-63-6, Bethanechol chloride 614-39-1, Procainamide hydrochloride 616-91-1, Acetylcysteine 826-39-1, Mecamylamine hydrochloride 834-28-6, Phenformin hydrochloride 972-02-1, Diphenidol 1104-22-9, Meclizine hydrochloride 1156-19-0, Tolazamide 1179-69-7, Thiethylperazine maleate 1257-78-9, Prochlorperazine edisylate 1319-82-0, Aminocaproic acid 1617-90-9, Vincamine 1707-14-8, Phenmetrazine hydrochloride 3416-26-0, Lidoflazine 4205-90-7, Clonidine 4310-35-4, Tridihexethyl chloride 4499-40-5, Theophylline choline, biological studies 5051-62-7, Guanabenz 5104-49-4, Flurbiprofen 5905-52-2, Ferrous lactate 6533-00-2, Norgestrel 6998-60-3, Rifampin 7297-25-8, Erythrityl tetranitrate 7647-01-0, Hydrochloric acid, biological studies 7683-59-2, Isoproterenol 7689-03-4, Camptothecin 7720-78-7, Ferrous sulfate 9001-98-3, Rennin 9002-60-2, Corticotrophin, biological studies 9002-62-4, Prolactin, biological studies 9002-64-6, Parathyroid hormone 9002-67-9, Luteinizing hormone 9002-68-0, Follicle-stimulating hormone 9002-71-5, Thyroid stimulating hormone 9002-72-6, Somatotropin 9004-10-8, Insulin, biological studies 9007-12-9, Calcitonin 9007-92-5, Glucagon, biological studies 9011-97-6, Pancreozymin 9034-40-6, Gonadotropin-releasing hormone 11000-17-2, Vasopressin 13292-46-1, Rifampin 13563-60-5, Norgestrel 13655-52-2, Alprenolol 15663-27-1, Cisplatin 15686-71-2, Cephalexin 15687-27-1, Ibuprofen 15826-37-6, Disodium cromoglycate 16662-47-8, Gallopamil 17692-38-5, Fluprofen 18559-94-9, Salbutamol 20830-75-5, Digoxin 22071-15-4, Ketoprofen 22131-79-9, Alclofenac 22204-53-1, Naproxen 22494-42-4, Diflunisal 23031-25-6, Terbutaline 23413-80-1, Aluminum aspirin 26171-23-3, Tolmetin 26839-75-8, Timolol 29122-68-7, Atenolol 29679-58-1, Fenoprofen 31842-01-0, Indoprofen 33069-62-4, Paclitaxel 33369-31-2, Zomepirac 33419-42-0, Etoposide 36330-85-5, Fenbufen 38194-50-2, Sulindac 38304-91-5, Minoxidil 39562-70-4, Nitrendipine 41575-94-4, Carboplatin 42399-41-7, Diltiazem 42540-40-9, Mandol 51110-01-1, Somatostatin 51481-61-9, Cimetidine 53714-56-0, Leuprolide 54182-58-0, Sucralfate 55985-32-5, Nicardipine 57010-31-8, Tiapamil 59695-59-9, Cephalexin hydrochloride 62571-86-2, Captopril 63675-72-9, Nisoldipine 66085-59-4, Nimodipine 66357-35-5, Ranitidine 69539-53-3, Etomidate 72509-76-3, Felodipine 75847-73-3, Enalapril 76420-72-9, Enalaprilat 76547-98-3, Lisinopril 76824-35-6, Famotidine 76963-41-2, Nizatidine 78415-72-2, Milrinone 79467-23-5, Mioflazine 83688-84-0, Tertatolol 87333-19-5, Ramipril 88021-18-5, Prochlorperazine maleate 88150-42-9, Amlodipine

RL: **THU** (**Therapeutic use**); BIOL (Biological study); USES (Uses).
(combined nanotechnol. and sensor technol. for simultaneous diagnosis and treatment)

L109 ANSWER 4 OF 32 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:430756 HCAPLUS Full-text

DOCUMENT NUMBER: 140:429032

TITLE: Compositions containing peptide copper complexes and metalloproteinase inhibitors

INVENTOR(S): Patt, Leonard M.

PATENT ASSIGNEE(S): Procyte Corporation, USA
 SOURCE: PCT Int. Appl., 37 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004043481	A2	20040527	WO 2003-US35557	20031107 <--
WO 2004043481	A3	20041028		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004138103	A1	20040715	US 2003-696536	20031029 <--
CA 2505523	A1	20040527	CA 2003-2505523	20031107 <--
AU 2003290657	A1	20040603	AU 2003-290657	20031107 <--
EP 1560591	A2	20050810	EP 2003-783239	20031107 <--

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

PRIORITY APPLN. INFO.: US 2002-425203P P 20021107 <--
 WO 2003-US35557 W 20031107

AB Novel compns. capable of inhibiting the degradation of extracellular matrixes of warm-blooded animals, including humans, and promoting the production of proteins thereof, combine at least one metalloproteinase inhibitor, which may be a matrix metalloproteinase inhibitor, and at least one peptide copper complex. Also disclosed are methods that utilize the disclosed compns., by administering to warm-blooded animals effective amts. thereof orally, parenterally, or topically, for treating *arthritis* and other inflammatory conditions, enhancing wound and bone healing, treating skin diseases, treating cosmetic defects of the skin, or stimulating hair growth. A moisturizing lotion composition contained Gly-His-Lys copper complex and TIMP-1 (tissue inhibitor of metalloproteinase) in addition to many other excipients.

IT 60-54-8, Tetracycline


RL: MOA (Modifier or additive use); *THU* (Therapeutic use); BIOL (Biological study); USES (Uses)

(compns. containing peptide copper complexes and metalloproteinase inhibitors)

RN 60-54-8 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S,4aS,5aS,6S,12aS)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IC ICM A61K038-05
ICS A61K038-55; A61K038-57; A61K007-48; A61P007-02; A61P017-14
CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 62
IT **RNA**
Ribozymes
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(comps. containing peptide copper complexes and metalloproteinase inhibitors)
IT 57-83-0, Progesterone, biological studies 60-54-8, Tetracycline
564-25-0, Doxycycline 10118-90-8, Minocycline
RL: MOA (Modifier or additive use); **THU (Therapeutic use)**; BIOL
(Biological study); USES (Uses)
(comps. containing peptide copper complexes and metalloproteinase inhibitors)

L109 ANSWER 5 OF 32 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:41226 HCAPLUS Full-text
DOCUMENT NUMBER: 140:105321
TITLE: Methods and compositions relating to isoleucine
boroproline compounds
INVENTOR(S): Adams, Sharlene; Miller, Glenn T.; Jesson, Michael I.;
Jones, Barry
PATENT ASSIGNEE(S): Point Therapeutics, Inc., USA
SOURCE: PCT Int. Appl., 152 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004004658	A2	20040115	WO 2003-US21405	20030709 <--
WO 2004004658	A3	20050804		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2491466	A1	20040115	CA 2003-2491466	20030709 <--
AU 2003265264	A1	20040123	AU 2003-265264	20030709 <--
US 2004077601	A1	20040422	US 2003-616694	20030709 <--
US 2005084490	A1	20050421	US 2003-616409	20030709 <--

EP 1578434 A2 20050928 EP 2003-763380 20030709 <--
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
 JP 2006507352 T 20060302 JP 2004-562634 20030709 <--
 CN 1802090 A 20060712 CN 2003-821282 20030709 <--
 CN 1826129 A 20060830 CN 2003-821281 20030709 <--
 IN 2005KN00151 A 20050916 IN 2005-KN151 20050208 <--
 PRIORITY APPLN. INFO.: US 2002-394856P P 20020709 <--
 US 2002-414978P P 20021001 <--
 US 2003-466435P P 20030428
 WO 2003-US21405 W 20030709

OTHER SOURCE(S): MARPAT 140:105321

AB A method for treating subjects with, inter alia, abnormal cell proliferation or infectious *disease* using agents of formula (I, AmNHCH(CH(CH₃)CH₂CH₃)COAlR) (where Am and Al are amino acids and R = organo boronates, organo phosphonates, fluoroalkyl ketones, alphaketos, N-peptioly-O-(acylhydroxylamines), azapeptides, azetidines, fluoroolefins dipeptide isosteres, peptidyl (α-aminoalkyl) phosphonate esters, aminoacyl pyrrolidine-2-nitriles and 4-cyanothiazolidides) is claimed. Methods for stimulating an immune response using the compds. of the invention are also claimed. Compns. containing Ile-boroPro compds. are also provided as are kits containing the compns. The invention embraces the use of these compds. alone or in combination with other therapeutic agents.

IT 57-62-5, Chlortetracycline 60-54-8, Tetracycline
 64-72-2, Chlortetracycline hydrochloride 64-73-3,
 Demeclocycline hydrochloride 64-75-5, Tetracycline hydrochloride
 79-57-2, Oxytetracycline 127-33-3, Demeclocycline
 564-25-0, Doxycycline 751-97-3, Rolitetracycline
 808-26-4, Sancycline 914-00-1, Methacycline
 987-02-0, Demecycline 1336-20-5, Tetracycline phosphate
 complex 2013-58-3, Meclocycline 2058-46-0,
 Oxytetracycline hydrochloride 3963-95-9, Methacycline
 hydrochloride 5585-59-1, Nitrocycline 5874-95-3,
 Amicycline 7179-50-2, Oxytetracycline calcium 10118-90-8
 , Minocycline 13614-98-7, Minocycline hydrochloride
 20685-78-3, Rolitetracycline nitrate 23313-80-6,
 Epitetracycline hydrochloride 24390-14-5, Doxycycline hyclate
 27823-62-7, Chlortetracycline bisulfate 73816-42-9,
 Meclocycline sulfosalicylate 83038-87-3, Doxycycline fosfatex
 94088-85-4, Doxycycline calcium


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(therapeutic methods and compns. relating to isoleucine boroproline compds. alone or in combination with other drugs, antibodies, or antigens)

RN 57-62-5 HCAPLUS

CN 2-Naphthacenecarboxamide, 7-chloro-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S,4aS,5aS,6S,12aS) - (CA INDEX NAME)


Absolute stereochemistry.



RN 60-54-8 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S,4aS,5aS,6S,12aS)- (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 64-72-2 HCAPLUS

CN 2-Naphthacenecarboxamide, 7-chloro-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, hydrochloride (1:1), (4S,4aS,5aS,6S,12aS)- (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 64-73-3 HCAPLUS

CN 2-Naphthacenecarboxamide, 7-chloro-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-1,11-dioxo-, monohydrochloride, (4S,4aS,5aS,6S,12aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 64-75-5 HCAPLUS
 CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, hydrochloride (1:1), (4S,4aS,5aS,6S,12aS) - (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



● HCl


RN 79-57-2 HCAPLUS
 CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,6,10,12,12a-hexahydroxy-6-methyl-1,11-dioxo-, (4S,4aR,5S,5aR,6S,12aS) - (CA INDEX NAME)

Absolute stereochemistry.



RN 127-33-3 HCAPLUS
 CN 2-Naphthacenecarboxamide, 7-chloro-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-1,11-dioxo-, (4S,4aS,5aS,6S,12aS) - (CA INDEX NAME)

Absolute stereochemistry.




RN 564-25-0 HCAPLUS
 CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-

10692764


3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S,4aR,5S,5aR,6R,12aS) -
(CA INDEX NAME)

Absolute stereochemistry.




RN 751-97-3 HCAPLUS
CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-
3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-N-(1-pyrrolidinylmethyl)-,
(4S,4aS,5aS,6S,12aS) - (CA INDEX NAME)

Absolute stereochemistry.




RN 808-26-4 HCAPLUS
CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-
3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS) - (9CI) (CA INDEX
NAME)

Absolute stereochemistry.



RN 914-00-1 HCAPLUS
CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-
3,5,10,12,12a-pentahydroxy-6-methylene-1,11-dioxo-, (4S,4aR,5S,5aR,12aS) -
(CA INDEX NAME)


Absolute stereochemistry.



RN 987-02-0 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-1,11-dioxo-, (4S,4aS,5aS,6S,12aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1336-20-5 HCAPLUS

CN Metaphosphoric acid, sodium salt, compd. with (4S,4aS,5aS,6S,12aS)-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide (9CI) (CA INDEX NAME)

CM 1

CRN 50813-16-6

CMF Unspecified

CCI MAN


*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 60-54-8

CMF C22 H24 N2 O8

Absolute stereochemistry. Rotation (-).




RN 2013-58-3 HCAPLUS

CN 2-Naphthacenecarboxamide, 7-chloro-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-

10692764

octahydro-3,5,10,12,12a-pentahydroxy-6-methylene-1,11-dioxo-,
(4S,4aR,5S,5aR,12aS) - (CA INDEX NAME)


Absolute stereochemistry.



RN 2058-46-0 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,6,10,12,12a-hexahydroxy-6-methyl-1,11-dioxo-, monohydrochloride,
(4S,4aR,5S,5aR,6S,12aS) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 3963-95-9 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methylene-1,11-dioxo-, monohydrochloride,
(4S,4aR,5S,5aR,12aS) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 5585-59-1 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-7-nitro-1,11-dioxo-, (4S,4aS,5aR,12aS) - (9CI)

(CA INDEX NAME)


Absolute stereochemistry.



RN 5874-95-3 HCAPLUS

CN 2-Naphthacenecarboxamide, 9-amino-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS) - (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 7179-50-2 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,6,10,12,12a-hexahydroxy-6-methyl-1,11-dioxo-, calcium salt (1:1), (4S,4aR,5S,5aR,6S,12aS) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Ca

RN 10118-90-8 HCAPLUS

CN 2-Naphthacenecarboxamide, 4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS) - (CA INDEX NAME)


Absolute stereochemistry.



RN 13614-98-7 HCAPLUS

CN 2-Naphthacenecarboxamide, 4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, hydrochloride (1:1), (4S,4aS,5aR,12aS)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl


RN 20685-78-3 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-N-(1-pyrrolidinylmethyl)-, (4S,4aS,5aS,6S,12aS)-, mononitrate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 7697-37-2

CMF H N O3




CM 2

CRN 751-97-3

CMF C27 H33 N3 O8


Absolute stereochemistry.



RN 23313-80-6 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, monohydrochloride, (4R,4aS,5aS,6S,12aS) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 24390-14-5 HCAPLUS


CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, hydrochloride, (4S,4aR,5S,5aR,6R,12aS) -, compd. with ethanol, hydrate (2:2:1:1) (CA INDEX NAME)

CM 1

CRN 10592-13-9

CMF C22 H24 N2 O8 . Cl H


Absolute stereochemistry.



● HCl

CM 2


CRN 64-17-5
CMF C2 H6 O



RN 27823-62-7 HCAPLUS
CN 2-Naphthacenecarboxamide, 7-chloro-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, sulfate (1:1) (salt), (4S,4aS,5aS,6S,12aS) - (9CI) (CA INDEX NAME)

CM 1


CRN 7664-93-9
CMF H2 O4 S



CM 2

CRN 57-62-5
CMF C22 H23 Cl N2 O8

Absolute stereochemistry.




RN 73816-42-9 HCAPLUS
CN Benzoic acid, 2-hydroxy-5-sulfo-, compd. with (4S,4aR,5S,5aR,12aS)-7-chloro-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methylene-1,11-dioxo-2-naphthacenecarboxamide (1:1) (CA INDEX NAME)

CM 1

CRN 2013-58-3
CMF C22 H21 Cl N2 O8

Absolute stereochemistry.


10692764



CM 2

CRN 97-05-2

CMF C7 H6 O6 S




RN 83038-87-3 HCAPLUS

CN Metaphosphoric acid (H4P4O12), monosodium salt, compd. with
(4S,4aR,5S,5aR,6R,12aS)-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-
3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide
(1:3) (9CI) (CA INDEX NAME)

CM 1

CRN 13598-74-8

CMF H4 O12 P4




CM 2

CRN 564-25-0

CMF C22 H24 N2 O8


Absolute stereochemistry.



RN 94088-85-4 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, calcium salt (1:2), (4S,4aR,5S,5aR,6R,12aS) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● 2 Ca

IC ICM A61K

CC 1-12 (Pharmacology)

Section cross-reference(s): 15

IT Tumor antigens

RL: BSU (Biological study, unclassified); PAC (Pharmacological activity);

THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(17-1A; therapeutic methods and compns. relating to isoleucine boroproline compds. alone or in combination with other drugs, antibodies, or antigens)

IT Gene, animal

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(ALK, in relation to **cancer** treatment; therapeutic methods and compns. relating to isoleucine boroproline compds. alone or in combination with other drugs, antibodies, or antigens)

IT Gene, animal

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(BCL-6, in relation to **cancer** treatment; therapeutic methods and compns. relating to isoleucine boroproline compds. alone or in combination with other drugs, antibodies, or antigens)

IT Gene, animal

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(BCR, in relation to **cancer** treatment; therapeutic methods and compns. relating to isoleucine boroproline compds. alone or in combination with other drugs, antibodies, or antigens)

IT Gene, animal

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(Bcl-2, in relation to **cancer** treatment; therapeutic methods and compns. relating to isoleucine boroproline compds. alone or in combination with other drugs, antibodies, or antigens)

- IT Gene, animal
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (E2A, in relation to **cancer** treatment; therapeutic methods
 and compns. relating to isoleucine boroprolin compds. alone or in
 combination with other drugs, antibodies, or antigens)
- IT **Infection**
 (Epstein Barr Virus; therapeutic methods and compns. relating to
 isoleucine boroprolin compds. alone or in combination with other
 drugs, antibodies, or antigens)
- IT Gene, animal
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (HLF, in relation to **cancer** treatment; therapeutic methods
 and compns. relating to isoleucine boroprolin compds. alone or in
 combination with other drugs, antibodies, or antigens)
- IT Gene, animal
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (IRF4, in relation to **cancer** treatment; therapeutic methods
 and compns. relating to isoleucine boroprolin compds. alone or in
 combination with other drugs, antibodies, or antigens)
- IT Gene, animal
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (IgL, in relation to **cancer** treatment; therapeutic methods
 and compns. relating to isoleucine boroprolin compds. alone or in
 combination with other drugs, antibodies, or antigens)
- IT Gene, animal
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (Igh, in relation to **cancer** treatment; therapeutic methods
 and compns. relating to isoleucine boroprolin compds. alone or in
 combination with other drugs, antibodies, or antigens)
- IT **Melanoma-associated antigens**
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (MAGE-1 (**melanoma**-associated antigen-encoding gene 1);
 therapeutic methods and compns. relating to isoleucine boroprolin
 compds. alone or in combination with other drugs, antibodies, or
 antigens)
- IT **Melanoma-associated antigens**
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (MAGE-2 (**melanoma**-associated antigen-encoding gene 2);
 therapeutic methods and compns. relating to isoleucine boroprolin
 compds. alone or in combination with other drugs, antibodies, or
 antigens)
- IT **Melanoma-associated antigens**
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (MAGE-3 (**melanoma**-associated antigen-encoding gene 3);
 therapeutic methods and compns. relating to isoleucine boroprolin
 compds. alone or in combination with other drugs, antibodies, or
 antigens)
- IT Gene, animal
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (MLF-1, in relation to **cancer** treatment; therapeutic methods
 and compns. relating to isoleucine boroprolin compds. alone or in
 combination with other drugs, antibodies, or antigens)
- IT Gene, animal
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (MLL, in relation to **cancer** treatment; therapeutic methods
 and compns. relating to isoleucine boroprolin compds. alone or in
 combination with other drugs, antibodies, or antigens)

- IT Gene, animal
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(NPAM, in relation to **cancer** treatment; therapeutic methods
and compns. relating to isoleucine boroproline compds. alone or in
combination with other drugs, antibodies, or antigens)
- IT Gene, animal
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(NPM, in relation to **cancer** treatment; therapeutic methods
and compns. relating to isoleucine boroproline compds. alone or in
combination with other drugs, antibodies, or antigens)
- IT **Tumor** antigens
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity);
THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(NY-ESO-1; therapeutic methods and compns. relating to isoleucine
boroproline compds. alone or in combination with other drugs,
antibodies, or antigens)
- IT Gene, animal
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(NuMA, in relation to **cancer** treatment; therapeutic methods
and compns. relating to isoleucine boroproline compds. alone or in
combination with other drugs, antibodies, or antigens)
- IT Gene, animal
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(PAX-5, in relation to **cancer** treatment; therapeutic methods
and compns. relating to isoleucine boroproline compds. alone or in
combination with other drugs, antibodies, or antigens)
- IT Gene, animal
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(PBX, in relation to **cancer** treatment; therapeutic methods
and compns. relating to isoleucine boroproline compds. alone or in
combination with other drugs, antibodies, or antigens)
- IT Gene, animal
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(PLZF, in relation to **cancer** treatment; therapeutic methods
and compns. relating to isoleucine boroproline compds. alone or in
combination with other drugs, antibodies, or antigens)
- IT Gene, animal
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(PML, in relation to **cancer** treatment; therapeutic methods
and compns. relating to isoleucine boroproline compds. alone or in
combination with other drugs, antibodies, or antigens)
- IT Antigens
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity);
THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(PRAME (preferentially expressed antigen of **melanoma**);
therapeutic methods and compns. relating to isoleucine boroproline
compds. alone or in combination with other drugs, antibodies, or
antigens)
- IT Gene, animal
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(RAR α , in relation to **cancer** treatment; therapeutic
methods and compns. relating to isoleucine boroproline compds. alone or
in combination with other drugs, antibodies, or antigens)
- IT **Infection**
Respiratory system, **disease**
(SARS (severe acute respiratory syndrome); therapeutic methods and
compns. relating to isoleucine boroproline compds. alone or in
combination with other drugs, antibodies, or antigens)
- IT Gene, animal
RL: BSU (Biological study, unclassified); BIOL (Biological study)

(SIL, in relation to **cancer** treatment; therapeutic methods and compns. relating to isoleucine boroprolin compds. alone or in combination with other drugs, antibodies, or antigens)

IT Proteins

RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(SSX (synovial **sarcoma** X breakpoint), SSX-4; therapeutic methods and compns. relating to isoleucine boroprolin compds. alone or in combination with other drugs, antibodies, or antigens)

IT Proteins

RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(SSX (synovial **sarcoma** X breakpoint), SSX-5; therapeutic methods and compns. relating to isoleucine boroprolin compds. alone or in combination with other drugs, antibodies, or antigens)

IT Proteins

RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(SSX (synovial **sarcoma** X breakpoint), SSX-9; therapeutic methods and compns. relating to isoleucine boroprolin compds. alone or in combination with other drugs, antibodies, or antigens)

IT Proteins

RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(SSX1 (synovial **sarcoma** X breakpoint 1); therapeutic methods and compns. relating to isoleucine boroprolin compds. alone or in combination with other drugs, antibodies, or antigens)

IT Proteins

RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(SSX2 (synovial **sarcoma** X breakpoint 2); therapeutic methods and compns. relating to isoleucine boroprolin compds. alone or in combination with other drugs, antibodies, or antigens)

IT Transcription factors

RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Smad, Smad family of **tumor** antigens; therapeutic methods and compns. relating to isoleucine boroprolin compds. alone or in combination with other drugs, antibodies, or antigens)

IT **Tumor** antigens

RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(TAG-72 (**tumor**-associated glycoprotein 72); therapeutic methods and compns. relating to isoleucine boroprolin compds. alone or in combination with other drugs, antibodies, or antigens)

IT Gene, animal

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(TCR δ , in relation to **cancer** treatment; therapeutic methods and compns. relating to isoleucine boroprolin compds. alone or in combination with other drugs, antibodies, or antigens)

IT Heart, **disease**

(angina pectoris; therapeutic methods and compns. relating to isoleucine boroprolin compds. alone or in combination with other drugs, antibodies, or antigens)

IT **Infection**

(anthrax; therapeutic methods and compns. relating to isoleucine boroprolin compds. alone or in combination with other drugs, antibodies, or antigens)

IT **Infection**

(bacterial, mycobacterial **infection**; therapeutic methods and

- compns. relating to isoleucine boroproline compds. alone or in combination with other drugs, antibodies, or antigens)
- IT **Infection**
(bacterial; therapeutic methods and compns. relating to isoleucine boroproline compds. alone or in combination with other drugs, antibodies, or antigens)
- IT Gene, animal
RL: BSU (Biological study, unclassified); BIOL (Biological study) (bcl-1, in relation to **cancer** treatment; therapeutic methods and compns. relating to isoleucine boroproline compds. alone or in combination with other drugs, antibodies, or antigens)
- IT Gene, animal
RL: BSU (Biological study, unclassified); BIOL (Biological study) (c-abl, in relation to **cancer** treatment; therapeutic methods and compns. relating to isoleucine boroproline compds. alone or in combination with other drugs, antibodies, or antigens)
- IT Gene, animal
Transcription factors
RL: BSU (Biological study, unclassified); BIOL (Biological study) (c-myc, in relation to **cancer** treatment; therapeutic methods and compns. relating to isoleucine boroproline compds. alone or in combination with other drugs, antibodies, or antigens)
- IT Fusion proteins (chimeric proteins)
Proteins
RNA
RL: BSU (Biological study, unclassified); BIOL (Biological study) (**cancer** antigen; therapeutic methods and compns. relating to isoleucine boroproline compds. alone or in combination with other drugs, antibodies, or antigens)
- IT **Tumor** antigens
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (**cancer** testis (CT) antigen; therapeutic methods and compns. relating to isoleucine boroproline compds. alone or in combination with other drugs, antibodies, or antigens)
- IT Antigens
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (**cancer**; therapeutic methods and compns. relating to isoleucine boroproline compds. alone or in combination with other drugs, antibodies, or antigens)
- IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (cell surface-associated, as **cancer** antigen; therapeutic methods and compns. relating to isoleucine boroproline compds. alone or in combination with other drugs, antibodies, or antigens)
- IT Mycosis
Skin, **disease**
(chromoblastomycosis; therapeutic methods and compns. relating to isoleucine boroproline compds. alone or in combination with other drugs, antibodies, or antigens)
- IT Connective tissue, **disease**
(connective tissue **cancer**; therapeutic methods and compns. relating to isoleucine boroproline compds. alone or in combination with other drugs, antibodies, or antigens)
- IT **Infection**
(hepatitis A; therapeutic methods and compns. relating to isoleucine boroproline compds. alone or in combination with other drugs, antibodies, or antigens)
- IT **Infection**

(hepatitis B; therapeutic methods and compns. relating to isoleucine boroproline compds. alone or in combination with other drugs, antibodies, or antigens)

IT **Infection**

(hepatitis C; therapeutic methods and compns. relating to isoleucine boroproline compds. alone or in combination with other drugs, antibodies, or antigens)

IT **Antigens**

RL: BSU (Biological study, unclassified); PAC (Pharmacological activity);
THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(high Mr *melanoma* antigens recognized by antibody 9.2.27;
therapeutic methods and compns. relating to isoleucine boroproline
compds. alone or in combination with other drugs, antibodies, or
antigens)

IT

Actinomyces
Adenoviridae
Bacteroides
Borrelia
Campylobacter
Citrobacter
Clostridium difficile
Corynebacterium
Cytomegalovirus
Echinococcus
Enterobacter
Escherichia coli
Fasciola
Gardnerella
Haemophilus
Helicobacter pylori
Human herpesvirus 1
Human herpesvirus 2
Human herpesvirus 3
Human herpesvirus 4
Human immunodeficiency virus
Human papillomavirus
Hymenolepis
Klebsiella
Legionella
Listeria
Monkeypox virus
Necator americanus
Neisseria
Nocardia
Paragonimus
Pasteurella
Pneumocystis
Proteus (bacterium)
Pseudomonas
Respiratory syncytial virus
Rotavirus
Salmonella
Shigella
Spirillum
Spirochaeta
Streptobacillus
Streptococcus
Streptococcus pneumoniae
Taenia
Treponema

Trichomonas vaginalis

Trichuris trichiura

Trypanosoma brucei

Trypanosoma cruzi

(**infection**; therapeutic methods and compns. relating to isoleucine boroproline compds. alone or in combination with other drugs, antibodies, or antigens)

IT **Infection**

(leishmaniasis; therapeutic methods and compns. relating to isoleucine boroproline compds. alone or in combination with other drugs, antibodies, or antigens)

IT **Infection**

Nervous system, **disease**

(neurocysticercosis; therapeutic methods and compns. relating to isoleucine boroproline compds. alone or in combination with other drugs, antibodies, or antigens)

IT **Infection**

(onchocerciasis; therapeutic methods and compns. relating to isoleucine boroproline compds. alone or in combination with other drugs, antibodies, or antigens)

IT **Infection**

(parasitic **infection**; therapeutic methods and compns. relating to isoleucine boroproline compds. alone or in combination with other drugs, antibodies, or antigens)

IT **Sarcoma**

(rhabdomyosarcoma; therapeutic methods and compns. relating to isoleucine boroproline compds. alone or in combination with other drugs, antibodies, or antigens)

IT **Infection**

(schistosomiasis; therapeutic methods and compns. relating to isoleucine boroproline compds. alone or in combination with other drugs, antibodies, or antigens)

IT **Proteins**

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(secreted, as **cancer** antigen; therapeutic methods and compns. relating to isoleucine boroproline compds. alone or in combination with other drugs, antibodies, or antigens)

IT **Gene, animal**

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(tall, in relation to **cancer** treatment; therapeutic methods and compns. relating to isoleucine boroproline compds. alone or in combination with other drugs, antibodies, or antigens)

IT **Acute lymphocytic leukemia**

Acute myeloid **leukemia**

Angiogenesis inhibitors

Anti-infective agents

Antibacterial agents

Antibacterial agents

Antibiotics

Antiemetics

Antimicrobial agents

Antitumor agents

Antiviral agents

Biliary tract, neoplasm

Bladder, neoplasm

Bone, neoplasm

Brain, neoplasm

Central nervous system, neoplasm

Chronic lymphocytic **leukemia**

Chronic myeloid **leukemia**

Digestive tract, neoplasm
 Drug delivery systems
 Esophagus, neoplasm
 Eye, neoplasm
 Fungicides
 Head and Neck
 Head and Neck, neoplasm
 Hodgkin's *disease*
 Human
 Immunodeficiency
 Immunostimulants
 Infection
 Influenza A virus
 Kidney, neoplasm
 Larynx, neoplasm
 Leprosy
 Leukemia
 Liver, neoplasm
 Lymphoma
 Malaria
 Mammary gland, neoplasm
 Melanoma
 Mouth, neoplasm
 Multiple *myeloma*
 Multiple sclerosis
 Mycosis
 Nausea
 Neoplasm
 Ovary, neoplasm
 Pancreas, neoplasm
 Parasitocides
 Prostate gland, neoplasm
 Radiotherapy
 Respiratory system, neoplasm
 Sarcoma
 Skin, neoplasm
 Staphylococcus
 Stomach, neoplasm
 Testis, neoplasm
 Thyroid gland, neoplasm
 Tuberculosis
 Tuberculostatics
 Urinary system, neoplasm
 Uterus, neoplasm
 Vaccines

(therapeutic methods and compns. relating to isoleucine boroproline
 compds. alone or in combination with other drugs, antibodies, or
 antigens)

IT CD3 (antigen)
 Endoglins
 Epidermal growth factor receptors
 Phosphatidylethanolamines, biological studies
 Phosphatidylserines
 Tumor antigens
 p53 (protein)
 α -Fetoproteins

RL: BSU (Biological study, unclassified); PAC (Pharmacological activity);
 THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (therapeutic methods and compns. relating to isoleucine boroproline
 compds. alone or in combination with other drugs, antibodies, or

- antigens)
- IT Tinea (skin **disease**)
(tinea versicolor **infection**; therapeutic methods and compns. relating to isoleucine boroproline compds. alone or in combination with other drugs, antibodies, or antigens)
- IT Antigens
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**tumor** vasculature associated antigen; therapeutic methods and compns. relating to isoleucine boroproline compds. alone or in combination with other drugs, antibodies, or antigens)
- IT **Infection**
(variola; therapeutic methods and compns. relating to isoleucine boroproline compds. alone or in combination with other drugs, antibodies, or antigens)
- IT **Infection**
(viral; therapeutic methods and compns. relating to isoleucine boroproline compds. alone or in combination with other drugs, antibodies, or antigens)
- IT 50-18-0, Cyclophosphamide 50-44-2 50-59-9, Cephaloridine 50-63-5, Chloroquine phosphate 50-65-7, Niclosamide 50-76-0, Dactinomycin 50-91-9, Floxuridine 51-21-8, Fluorouracil 52-68-6, Metrifonate 53-03-2, Prednisone 54-42-2, Idoxuridine 54-85-3, Isoniazid 55-86-7, Mechlorethamine hydrochloride 56-75-7, Chloramphenicol 57-62-5, Chlortetracycline 57-68-1, Sulfamethazine 57-92-1, Streptomycin, biological studies 58-71-9, Cephalothin sodium 59-05-2, Methotrexate 60-54-8, Tetracycline 61-32-5, Methicillin 63-45-6, Primaquine phosphate 64-72-2, Chlortetracycline hydrochloride 64-73-3, Demeclocycline hydrochloride 64-75-5, Tetracycline hydrochloride 66-79-5, Oxacillin 67-20-9, Nitrofurantoin 67-45-8, Furazolidone 68-35-9, Sulfadiazine 68-41-7, Cycloserine 69-05-6, Quinacrine hydrochloride 69-52-3, Ampicillin sodium 69-53-4, Ampicillin 69-57-8, Penicillin g sodium 69-74-9, Cytarabine hydrochloride 70-00-8, Trifluridine 70-10-0, Ticlatone 72-14-0, Sulfathiazole 74-55-5, Ethambutol 77-46-3, Acedapsone 79-57-2, Oxytetracycline 80-08-0, Dapsone 80-74-0, Sulfisoxazole acetyl 83-73-8, Iodoquinol 87-08-1, Penicillin v 88-04-0, Chloroxylonol 90-89-1, Diethylcarbamazine 97-18-7, Bithionol 98-96-4, Pyrazinamide 100-97-0, Methenamine, biological studies 102-76-1, Triacetin 106-48-9 110-85-0, Piperazine, biological studies 112-38-9, Undecylenic acid 113-98-4, Penicillin g potassium 114-07-8, Erythromycin 115-02-6, Azaserine 121-19-7, Roxarsone 121-81-3, Nitromide 122-16-7, Sulfanitran 124-07-2, Octanoic acid, biological studies 126-07-8, Griseofulvin 127-07-1, Hydroxyurea 127-33-3, Demeclocycline 127-56-0, Sulfacetamide sodium 127-69-5, Gantrisin 127-71-9, Sulfabenzamide 127-77-5, Sulfabenz 127-79-7, Sulfamerazine 128-12-1, Acetosulfone sodium 130-16-5, Cloxyquin 132-92-3, Methicillin sodium 132-98-9, Penicillin v potassium 133-10-8, p-Aminosalicylate sodium 133-11-9, Phenyl aminosalicylate 133-51-7, Meglumine antimoniate 134-36-1, Erythromycin propionate 137-26-8, Thiram 138-39-6, Mafenide 140-64-7, Pentamidine isethionate 143-67-9, Vinblastine sulfate 144-80-9, Sulfacetamide 144-82-1, Sulfamethizole 145-63-1, Suramin 147-52-4, Nafcillin 147-94-4, Cytarabine 148-79-8, Thiabendazole 148-82-3, Melphalan 152-47-6, Sulfalene 153-61-7, Cephalothin 154-21-2, Lincomycin 288-32-4, Imidazole, biological studies 288-32-4D, Imidazole, derivs. 305-03-3, Chlorambucil 343-55-5, Dicloxacillin sodium 366-70-1, Procarbazine hydrochloride 389-08-2, Nalidixic acid 443-48-1, Metronidazole 494-79-1, Melarsoprol 500-92-5, Proguanil 527-75-3, Berythromycin 528-96-1, Benzoylpas calcium 530-43-8, Chloramphenicol palmitate 536-33-4, Ethionamide

547-32-0, Sulfadiazine sodium 554-72-3, Tryparsamide 555-84-0, Nifuradene 557-08-4, Zinc undecyl enate 564-25-0, Doxycycline 575-54-2, Penicillins 587-23-5, Methenamine mandelate 599-79-1, Sulfasalazine 632-00-8, Sulfasomizole 642-78-4, Cloxacillin sodium 643-22-1, Erythromycin stearate 651-06-9, Sulfameter 665-66-7, Amantadine hydrochloride 723-46-6, Sulfamethoxazole 729-99-7, Sulfamoxole 735-52-4, Cetophenicol 738-70-5, Trimethoprim 751-94-0, Fusidate sodium 751-97-3, Rolitetracycline 768-94-5, Amantadine 777-11-7, Haloproglin 801-52-5, Porfiromycin 804-63-7, Quinine sulfate 808-26-4, Sancycline 847-25-6, Racephenicol 852-19-7, Sulfazamet 859-18-7, Lincomycin hydrochloride 909-14-8 914-00-1, Methacycline 982-57-0, Chloramphenicol sodium succinate 983-85-7, Penamecillin 985-16-0, Nafcillin sodium 987-02-0, Demecycline 1018-71-9, Pyrrolnitrin 1070-11-7, Ethambutol hydrochloride 1173-88-2, Oxacillin sodium 1220-83-3, Sulfamonomethoxine 1264-62-6, Erythromycin ethyl succinate 1264-72-8, Colistin sulfate 1322-14-1, Calcium undecylenate 1336-20-5, Tetracycline phosphate complex 1392-21-8, Kitasamycin 1397-89-3, Amphotericin B 1400-61-9, Nystatin 1402-82-0, Amphomycin 1403-17-4, Candicidin 1403-66-3, Gentamicin 1403-71-0, Hamycin 1404-00-8, Mitomycin 1404-08-6, Neutramycin 1404-48-4, Relomycin 1404-59-7, Rutamycin 1404-88-2, Tyrothricin 1404-90-6, Vancomycin 1404-93-9, Vancomycin hydrochloride 1405-00-1, Viridofulvin 1405-10-3, Neomycin sulfate 1405-20-5, Polymyxin b sulfate 1405-37-4, Capreomycin sulfate 1405-41-0, Gentamicin sulfate 1405-52-3, Sulfomycin 1405-87-4, Bacitracin 1405-89-6, Bacitracin zinc 1405-97-6, Gramicidin 1406-04-8, Neomycin undecyl enate 1406-11-7, Polymyxin 1432-75-3, Nitralamine hydrochloride 1476-53-5, Novobiocin sodium 1501-84-4, Rimantadine hydrochloride 1538-09-6 1617-53-4, Amentoflavone 1910-68-5, Methisazone 2013-58-3, Meclocycline 2022-85-7, Flucytosine 2030-63-9, Clofazimine 2058-46-0, Oxytetracycline hydrochloride 2068-78-2, Vincristine sulfate 2398-96-1, Tolnaftate 2447-57-6, Sulfadoxine 2750-76-7, Rifamide 2751-09-9, Troleandomycin 3056-17-5, Stavudine 3116-76-5, Dicloxacillin 3270-71-1, Nifuraldezone 3374-05-8, Nalidixate sodium 3424-98-4 3485-14-1, Cyclacillin 3511-16-8, Hetacillin 3521-62-8, Erythromycin estolate 3545-67-3, Chloroquine hydrochloride 3570-75-0, Nifurthiazole 3577-01-3, Cephaloglycin 3696-28-4, Dipyrithione 3736-81-0, Diloxanide furoate 3778-73-2, Ifosfamide 3795-88-8, Levofuraltadone 3810-74-0, Streptomycin sulfate 3847-29-8, Erythromycin lactobionate 3922-90-5, Oleandomycin 3963-95-9, Methacycline hydrochloride 4117-65-1, Aspartocin 4197-24-4, Carbol-fuchsin 4291-63-8, Cladribine 4299-60-9, Sulfisoxazole diolamine 4342-03-4, Dacarbazine 4375-07-9D, Epipodophyllotoxin, antibody conjugates 4428-95-9 4575-42-2, Coumermycin sodium 4697-36-3, Carbenicillin 4800-94-6, Carbenicillin disodium 4803-44-5, Levopropylcillin potassium 4803-45-6, Thiphencillin potassium 4914-30-1, Dehydroemetine 4936-47-4, Nifuratel 5036-03-3, Nifurdazil 5055-20-9, Nifurquinazol 5118-17-2, Furazolium chloride 5250-39-5, Floxacillin 5321-32-4, Hetacillin potassium 5355-16-8, Diaveridine 5490-27-7, Dihydrostreptomycin sulfate 5536-17-4, Vidarabine 5560-62-3, Biphenamine hydrochloride 5578-73-4, Sanguinarium chloride 5579-95-3, Nifurmerone 5585-59-1, Nitrocyline 5588-20-5, Chlordantoin 5667-71-0, Streptonicozid 5714-05-6, Quindecamine acetate 5714-73-8, Methenamine hippurate 5874-95-3, Amicycline 5928-84-7, Penicillin v benzathine

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(therapeutic methods and compns. relating to isoleucine boroproline compds. alone or in combination with other drugs, antibodies, or antigens)

IT 5980-31-4, Hexedine 6576-51-8, Stallimycin hydrochloride 6591-72-6, Penicillin v hydrabamine 6804-07-5, Carbadox 6981-18-6, Ormetoprim 6990-06-3, Fusidic acid 7054-25-3, Quinidine gluconate 7179-50-2, Oxytetracycline calcium 7481-89-2, Zalcitabine 7527-91-5, Acrisorcin 7542-37-2, Paromomycin 7681-11-0, Potassium iodide, biological studies 7681-93-8, Natamycin 8017-57-0D, Trisulfapyrimidine, derivs. 8025-81-8, Spiramycin 8063-07-8, Kanamycin 8063-91-0, Mirincamycin hydrochloride 8064-90-2 8068-28-8, Colistimethate sodium 9001-06-3, Chitinase 9015-68-3, Asparaginase 9041-93-4, Bleomycin sulfate 10118-85-1, Lydimycin 10118-90-8, Minocycline 10500-82-0, Famotidine hydrochloride 10540-97-3, Memotidine hydrochloride 11006-76-1, Virginiamycin 11006-77-2, Statolon 11015-37-5, Bambermycin 11016-07-2, Fungimycin 11033-34-4, Steffimycin 11048-13-8, Nebramycin 11048-15-0, Kalafungin 11051-71-1, Avilamycin 11056-09-0, Ranimycin 11056-11-4, Biniramycin 11056-12-5, Cirolemycin 11056-13-6, Denofungin 11056-18-1, Scopafungin 11056-20-5, Zorbamycin 11078-21-0, Filipin 11096-49-4, Partricin 11096-79-0, Alamecin 11111-12-9, Cephalosporin 11121-32-7, Mepartricin 13292-46-1, Rifampin 13292-46-1D, Rifampin, derivs. 13392-28-4, Rimantadine 13411-16-0, Nifurpirinol 13463-41-7, Pyrithione zinc 13614-98-7, Minocycline hydrochloride 14088-71-2, Proclonol 14698-29-4, Oxolinic acid 15037-55-5, Ethonam nitrate 15176-29-1, Edoxudine 15318-45-3, Thiamphenicol 15475-56-6, Methotrexate sodium 15663-27-1, Cisplatin 15686-71-2, Cephalixin 16037-91-5, Stibogluconate sodium 16846-24-5, Josamycin 16915-79-0, Mequidox 17090-79-8, Monensin 17230-86-3, Carbenicillin potassium 17692-15-8, Furazolum tartrate 17784-12-2, Sulfacytine 18323-44-9, Clindamycin 19387-91-8, Tinidazole 19561-70-7, Nifuratrone 19885-51-9, Aranotin 20685-78-3, Rolitetracycline nitrate 21462-39-5, Clindamycin hydrochloride 21593-23-7, Cephapirin 21638-36-8, Nifurimide 21649-57-0, Carbenicillin phenylsodium 21679-14-1, Fludarabine 21736-83-4, Spectinomycin hydrochloride 21738-42-1, Oxamniquine 22204-24-6, Pyrantel pamoate 22373-78-0, Monensin sodium 22484-64-6, Sulfanilate zinc 22573-93-9, Alexidine 22832-87-7, Miconazole nitrate 22916-38-7, Orconazole nitrate 22916-47-8, Miconazole 22994-85-0, Benznidazole 23067-13-2, Erythromycin gluceptate 23155-02-4, Fosfomycin 23214-92-8, Doxorubicin 23239-41-0, Cephacetrile sodium 23256-30-6, Nifurtimox 23313-80-6, Eptitetracycline hydrochloride 23319-48-4, Megalomycin potassium phosphate 23444-86-2, Suncillin sodium 23541-50-6, Daunorubicin hydrochloride 23593-75-1, Clotrimazole 23736-58-5, Cloxacillin benzathine 24169-02-6, Econazole nitrate 24356-60-3, Cephapirin sodium 24390-14-5, Doxycycline hyclate 24729-96-2, Clindamycin phosphate 25316-40-9, Doxorubicin hydrochloride 25389-94-0, Kanamycin sulfate 25507-04-4, Clindamycin palmitate hydrochloride 25526-93-6, Alovudine 25953-19-9, Cefazolin 26309-95-5, Pivampicillin hydrochloride 26605-69-6, Carbenicillinindanylsodium 26774-90-3, Epicillin 26786-84-5, Lomofungin 26787-78-0, Amoxicillin 27164-46-1, Cefazolin sodium 27220-47-9, Econazole 27523-40-6, Isoconazole 27591-69-1, Tilorone hydrochloride 27762-78-3, Kethoxal 27823-62-7, Chlortetracycline bisulfate 27877-51-6, Tolindate 28069-65-0, Cuprimyxin 28088-64-4, Aminosalicic acid 28657-80-9, Cinoxacin 29342-05-0, Ciclopirox 29457-07-6, Ticarcillin disodium 29767-20-2, Teniposide 29984-33-6, Vidarabine phosphate 30034-03-8, Cefamandole sodium 30516-87-1, Zidovudine 31342-36-6, Chloramphenicol pantothenate complex 31431-39-7, Mebendazole 32385-11-8, Sisomicin 32886-97-8, Amdinocillin pivoxil 32887-01-7, Amdinocillin 32986-56-4, Tobramycin 33069-62-4, Taxol 33419-42-0, Etoposide 33564-30-6, Cefoxitin sodium 34444-01-4, Cefamandole 35523-45-6, Fludalanine 35554-44-0, Enilconazole 35607-20-6, Avridine 35607-66-0, Cefoxitin 35834-26-5,

Rosaramicin 36791-04-5, Ribavirin 36983-81-0, Fosfonet sodium 37091-65-9, Azlocillin sodium 37091-66-0, Azlocillin 37321-09-8, Apramycin 37332-99-3, Avoparcin 37338-39-9 37517-28-5, Amikacin 37661-08-8, Bacampicillin hydrochloride 38070-41-6, Tiodonium chloride 38821-53-3, Cephradine 39030-72-3, Pivampicillin pamoate 39809-25-1, Penciclovir 39831-55-5, Amikacin sulfate 39878-70-1, Talampicillin hydrochloride 40034-42-2, Rosoxacin 40966-79-8, Sarpicillin 41575-94-4, Carboplatin 41621-49-2, Ciclopirox olamine 42057-22-7, Mezlocillin sodium 42190-91-0, Pivampicillin probenatate 42540-40-9, Cefamandole nafate 42835-25-6, Flumequine 43143-11-9, Bispyrithione magsulfex 43169-50-2, Betamycin sulfate 49620-13-5, Robustaflavone 49842-07-1, Tobramycin sulfate 50370-12-2, Cefadroxil 50838-36-3, Tolciclate 51022-98-1, Butirosin sulfate 51481-64-2, Rosaramicin propionate 51481-65-3, Mezlocillin 51547-64-9, Rosaramicin stearate 51627-14-6, Cefatrizine 51627-20-4, Cefaparole 51762-05-1, Cefroxadine 52123-49-6, Cefazafur sodium 52152-93-9, Cefsulodin sodium 53066-26-5, Lexithromycin 53179-09-2, Sisomicin sulfate 53230-10-7, Mefloquine 53678-77-6, Muramyl dipeptide 53808-87-0, Tetroxoprim 53910-25-1, Pentostatin 53994-73-3, Cefaclor 54965-21-8, Albendazole 55103-30-5, Rosaramicin butyrate 55162-26-0, Pirbenicillin sodium 55242-74-5, Oxifungin hydrochloride 55242-77-8, Triafungin 55268-74-1, Praziquantel 55268-75-2, Cefuroxime 55298-68-5, Neomycin palmitate 55694-87-6, Pentizidone sodium 55852-84-1, Bacitracin methylene disalicylate 56093-45-9, Selenium sulfide 56219-57-9, Arildone 56238-63-2, Cefuroxime sodium 56390-09-1, Epirubicin hydrochloride 56391-57-2, Netilmicin sulfate 56433-46-6, Cetocycline hydrochloride 56585-33-2, Trimethoprim sulfate 56689-42-0, Repromicin 56796-20-4, Cefmetazole 56796-39-5, Cefmetazole sodium 57363-13-0, Droxacillin sodium 57852-57-0, Idarubicin hydrochloride 58001-44-8, Clavulanic acid 58152-03-7, Isepamicin 58795-03-2, Apalcillin sodium 58857-02-6, Ambruticin 58944-73-3, Sinefungin 59070-06-3, Ticarcillin cresylsodium 59277-89-3, Acyclovir 59695-59-9, Cephalixin hydrochloride 59703-84-3, Piperacillin sodium 59733-86-7, Butikacin 59794-18-2, Paulomycin 59831-63-9, Doconazole 60207-31-0, Azaconazole 60628-96-8, Bifonazole 60802-40-6, Rosaramicin sodium phosphate 60925-61-3, Ceforanide 61036-62-2, Teicoplanin 61270-78-8, Cefonicid sodium 61318-91-0, Sulconazole nitrate 61379-65-5, Rifapentine 61477-96-1, Piperacillin 62013-04-1, Dirithromycin 62587-73-9, Cefsulodin 62893-19-0, Cefoperazone 62893-20-3, Cefoperazone sodium 62973-77-7, Parconazole hydrochloride 63198-97-0, Viroxime

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(therapeutic methods and compns. relating to isoleucine boroproline compds. alone or in combination with other drugs, antibodies, or antigens)

IT 63527-52-6, Cefotaxime 63585-09-1, Foscarnet sodium 64211-46-7, Oxiconazole nitrate 64221-86-9, Imipenem 64221-86-9D, Imipenem, derivs. 64485-93-4, Cefotaxime sodium 64544-07-6, Cefuroxime axetil 64872-77-1, Butoconazole nitrate 64952-97-2, Moxalactam 65025-62-9, (-)-Soulattrolide 65052-63-3, Cefetamet 65271-80-9, Mitoxantrone 65277-42-1, Ketoconazole 65473-14-5, Naftifine hydrochloride 65899-73-2, Tioconazole 66148-78-5, Temocillin 66309-69-1, Cefotiam hydrochloride 66887-96-5, Propikacin 67337-44-4, Sarmoxicillin 67915-31-5, Terconazole 68401-82-1, Ceftizoxime sodium 68693-30-1, Somantadine hydrochloride 68902-57-8, Metioprime 69123-90-6, Fiacitabine 69123-98-4, Fialuridine 69198-10-3, Metronidazole hydrochloride 69402-03-5, Piridicillin sodium 69521-94-4, Thymosin α -1 69655-05-6, Didanosine 69657-51-8, Acyclovir sodium 69712-56-7, Cefotetan 69756-53-2, Halofantrine 70052-12-9, Eflornithine 70288-86-7, Ivermectin 70458-92-3, Pefloxacin

70458-95-6, Pefloxacin mesylate 70458-96-7, Norfloxacin 70797-11-4, Cefpiramide 71002-10-3, Vidarabine sodium phosphate 71420-79-6 72275-67-3, Astromicin sulfate 72301-78-1, Zinviroxime 72301-79-2, Enviroxime 72558-82-8, Ceftazidime 72559-06-9, Rifabutin 73334-05-1, Metronidazole phosphate 73384-59-5, Ceftriaxone 73514-87-1, Fosarilate 73816-42-9, Meclocycline sulfosalicylate 74011-58-8, Enoxacin 74356-00-6, Cefotetan disodium 74578-69-1, Ceftriaxone sodium 74682-62-5, Ticarcillin monosodium 74849-93-7, Cefpiramide sodium 75738-58-8, Cefmenoxime hydrochloride 76168-82-6, Ramoplanin 76470-66-1, Loracarbef 76497-13-7, Sultamicillin 76610-84-9, Cefbuperazone 77146-42-0, Chlorhexidine phosphanilate 77181-69-2, Sorivudine 78040-85-4, Coumermycin 78110-38-0, Aztreonam 78186-33-1, Fumoxicillin 78613-35-1, Amorolfine 78822-40-9, Pirlimycin hydrochloride 78964-85-9, Fosfomycin tromethamine 79350-37-1, Cefixime 79404-91-4, Cilofungin 79660-72-3, Fleroxacin 80168-44-1, Zinoconazole hydrochloride 80214-83-1, Roxithromycin 80621-81-4, Rifaximin 80883-55-2, Enviradene 81103-11-9, Clarithromycin 82410-32-0, Ganciclovir 82419-36-1, Ofloxacin 83038-87-3, Doxycycline fosfatex 83200-96-8D, Carbapenem, derivs. 83905-01-5, Azithromycin 84408-37-7, Desciclovir 84625-61-6, Itraconazole 84880-03-5, Cefpimizole 85287-61-2, Cefpimizole sodium 85721-33-1, Ciprofloxacin 86386-73-4, Fluconazole 86393-37-5, Amifloxacin 86832-68-0, Carumonam sodium 87239-81-4, Cefpodoxime proxetil 87495-31-6, Disoxaril 87806-31-3, Porfimer sodium 88036-80-0, Amifloxacin mesylate 88040-23-7, Cefepime 90849-08-4, Oximonam sodium 90850-05-8, Gloximonam 90898-90-1, Oximonam 91161-71-6, Terbinafine 91618-36-9, Ibafloxacin 91832-40-5, Cefdinir 92562-88-4 92665-29-7, Cefprozil 93107-08-5, Ciprofloxacin hydrochloride 94088-85-4, Doxycycline calcium 94168-98-6, Rifametan 95058-81-4, Gemcitabine 96036-03-2, Meropenem 96128-89-1, Erythromycin acistrate 97519-39-6, Ceftibuten 97673-66-0, Trospectomycin sulfate 97682-44-5, Irinotecan 98079-51-7, Lomefloxacin 98079-52-8, Lomefloxacin hydrochloride 98753-19-6, Cefpirome sulfate 100234-70-6, Resorcinomycin A 100490-36-6, Tosufloxacin 100680-33-9, Cefuroxime pivoxetil 101828-21-1, Butenafine 102426-96-0, Paldimycin 103060-53-3, Daptomycin 104227-87-4, Famciclovir 104456-95-3, Ciconazole 105784-61-0, Temafloxacin hydrochloride 105956-99-8, Clinafloxacin hydrochloride 106941-25-7, Adefovir 107648-80-6, Cefepime hydrochloride 107910-75-8, Ganciclovir sodium 108319-06-8, Temafloxacin 110042-95-0, Acemannan 110588-57-3, Saperconazole 110871-86-8, Sparfloxacin 110942-02-4, Aldesleukin 112362-50-2, Dalfopristin 113102-19-5, Rifamexil 113852-37-2, Cidofovir 114394-67-1, Lomefloxacin mesylate 114977-28-5, Taxotere 117091-64-2, Etoposide phosphate 117211-03-7, Cefetecol 119413-54-6, Topotecan hydrochloride 120138-50-3, Quinupristin 120410-24-4, Biapenem 120788-07-0, Sulopenem 122111-03-9, Gemcitabine hydrochloride 124436-59-5, Pirodavis 124832-27-5, Valacyclovir hydrochloride 125317-39-7, Vinorelbine tartrate 127464-60-2, Vascular endothelial growth factor 127759-89-1, Lobucavir 127779-20-8, Saquinavir 127785-64-2, Basifungin 129618-40-2, Nevirapine 130167-69-0, Pegaspargase 132210-43-6, Cipamfylline 134678-17-4, Lamivudine 136817-59-9, Delavirdine 137487-62-8, Alvircept sudotox 138540-32-6, Ateviridine mesylate 139442-47-0, LFM-A 12 141611-76-9, Sanfetrinem sodium 142217-69-4, Entecavir 142340-99-6, Adefovir dipivoxil 142632-32-4, (+)Calanolide A 143491-57-0, Emtricitabine 147221-93-0, Delavirdine mesylate 149845-06-7, Saquinavir mesylate 150378-17-9, Indinavir 150572-30-8 151581-81-6, Pradimicin 152121-44-3 152923-56-3, Daclizumab 154598-52-4, Efavirenz 155213-67-5, Ritonavir 156586-89-9, Panorex 159989-64-7, Nelfinavir 163252-36-6, Clevudine 163661-45-8, (-)-Calanolide A 164301-51-3, CNI-1493 167869-21-8, PD98059 170277-31-3, Infliximab 174722-31-7, Rituxan 179463-17-3, MK

991 180288-69-1, Herceptin 183319-69-9, Tarceva 184475-35-2, Iressa
 185243-69-0, Etanercept 187029-72-7, (-)-7,8-Dihydrosoulattrolide
 188039-54-5, Palivizumab 205923-56-4, IMC-C225 206181-63-7, Zevalin
 208538-73-2, FK 463 208921-02-2, Tositumomab 211555-05-4, WHI-P97
 213327-37-8, Oregovomab 216503-57-0, Campath 216503-58-1, Mitumomab
 216974-75-3, Avastin 220578-59-6, Mylotarg 339150-51-5, CeaVac
 339150-82-2, LymphoCide 339151-95-0, MDX-22 339151-96-1, MDX-447
 339152-71-5, MDX-210 339286-23-6, Gliomab-H 339286-24-7, GNI-250
 339526-30-6, MDX-220 478159-64-7, 2C3 645405-72-7 645405-73-8
 645416-54-2, AG 1458 645417-10-3, UK 292 645417-21-6, BAY 38-9502
 646031-42-7, Celogovab 646032-07-7, Zamy1

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(therapeutic methods and compns. relating to isoleucine boroproline compds. alone or in combination with other drugs, antibodies, or antigens)

L109 ANSWER 6 OF 32 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:610643 HCAPLUS Full-text

DOCUMENT NUMBER: 139:160800

TITLE: Viral vector

INVENTOR(S): Radcliffe, Philippa; Miskin, James E.; Wilkes, Fraser J.; Mitrophanous, Kyriacos A.

PATENT ASSIGNEE(S): Oxford Biomedica (UK) Limited, UK

SOURCE: PCT Int. Appl., 193 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003064665	A2	20030807	WO 2003-GB418	20030203 <--
WO 2003064665	A3	20041202		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
EP 1504108	A2	20050209	EP 2003-734767	20030203 <--
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
JP 2005515783	T	20050602	JP 2003-564256	20030203 <--
US 2005106559	A1	20050519	US 2004-841603	20040507 <--
PRIORITY APPLN. INFO.:			GB 2002-2403	A 20020201 <--
			GB 2002-12768	A 20020531 <--
			WO 2003-GB418	W 20030203

AB A multicistronic retroviral vector genome comprising a first nucleic acid sequence upstream of an internal regulatory element, such that the level of genomic RNA available for packaging in the absence of rev, or a functional equivalent thereof, is increased.

IT 60-54-8, Tetracycline

RL: BSU (Biological study, unclassified); THU (Therapeutic use);


BIOL (Biological study); USES (Uses)

(mol. cloning of viral vector and its therapeutic uses)

RN 60-54-8 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S,4aS,5aS,6S,12aS)-
(CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IC ICM C12N015-86

CC 3-2 (Biochemical Genetics)

Section cross-reference(s): 1, 10

IT RNA

RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(I; mol. cloning of viral vector and its therapeutic uses)

IT RNA

RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(U3; mol. cloning of viral vector and its therapeutic uses)

IT Adeno-associated virus

Adenoviridae

Baculoviridae

Bovine immunodeficiency virus

Caprine arthritis encephalitis virus

Cell immortalization

Disease, animal

Drug screening

Drugs

Equine infectious anemia virus

Feline immunodeficiency virus

Fluorescence

Gene targeting

Gene therapy

Human herpesvirus

Human immunodeficiency virus 1

Human immunodeficiency virus 2

Molecular cloning

Nucleic acid library

Parvovirus

Peptide library

Phenotypes

Poxviridae

Retroviridae

Simian immunodeficiency virus

Transcription, genetic

Viral vectors

Visna-Maedi virus

cDNA library

(mol. cloning of viral vector and its therapeutic uses)

IT Envelope proteins
 Nucleic acids
 Promoter (genetic element)
 Viral DNA
 Viral **RNA**
 gag proteins
 RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (mol. cloning of viral vector and its therapeutic uses)

IT 60-54-8, Tetracycline
 RL: BSU (Biological study, unclassified); **THU (Therapeutic use)**;
 BIOL (Biological study); USES (Uses)
 (mol. cloning of viral vector and its therapeutic uses)

L109 ANSWER 7 OF 32 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:609843 HCAPLUS Full-text

DOCUMENT NUMBER: 139:169326

TITLE: Device and methods for initiating chemical reactions
 and for the targeted delivery of drugs or other agents

INVENTOR(S): Ueberle, Friedrich

PATENT ASSIGNEE(S): Germany

SOURCE: U.S. Pat. Appl. Publ., 19 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003147812	A1	20030807	US 2002-316273	20021211 <--
EP 1319423	A2	20030618	EP 2002-27643	20021211 <--
EP 1319423	A3	20031008		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK

PRIORITY APPLN. INFO.: US 2001-339285P P 20011211 <--


AB The present invention is directed to methods and apparatus for the targeted
 initiation or deactivation of chemical reactions by an acoustic energy source
 in a host. Methods and apparatus for the targeted delivery of drugs,
 diagnostic agents and other compds. using an acoustic energy source are also
 provided.

IT 60-54-8, Tetracycline
 RL: **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
 (device and methods for initiating chemical reactions and for targeted
 delivery of drugs or other agents)

RN 60-54-8 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-
 3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S,4aS,5aS,6S,12aS)-
 (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IC ICM A61N001-30
 INCL 424009520; 604020000
 CC 63-6 (Pharmaceuticals)
 IT Agglutinins and Lectins
 Antibodies and Immunoglobulins
 Collagens, biological studies
 DNA
 Elastins
 Glycoproteins
 Hormones, animal, biological studies
 Integrins
 Interferons
 Interleukin 1
 Interleukin 10
 Interleukin 11
 Interleukin 12
 Interleukin 2
 Interleukin 3
 Interleukin 4
 Interleukin 5
 Interleukin 6
 Interleukin 7
 Interleukin 8
 Interleukin 9
 Lymphokines
 Lymphotoxin
 Monosaccharides
 Nucleosides, biological studies
 Nucleotides, biological studies
 Peptides, biological studies
 Platelet-derived growth factors
 Polymers, biological studies
 Polynucleotides
 Polysaccharides, biological studies
 Porphyrins
 Prostaglandins
 Proteins
 RNA
 Retinoids
 Ricins
 Steroids, biological studies
 Transforming growth factors
 Tumor necrosis factors
 Vitamins
 cDNA
 mRNA
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (device and methods for initiating chemical reactions and for targeted
 delivery of drugs or other agents)
 IT 50-02-2, Dexamethasone 50-03-3, Hydrocortisone acetate 50-04-4,
 Cortisone acetate 50-23-7, Hydrocortisone 50-24-8, Prednisolone
 50-28-2, Estradiol, biological studies 50-33-9, Phenylbutazone,
 biological studies 50-56-6, Oxytocin, biological studies 50-78-2,
 Aspirin 51-05-8, Procaine hydrochloride 51-61-6, Dopamine, biological
 studies 52-21-1, Prednisolone acetate 52-53-9, Verapamil 52-67-5,
 Penicillamine 53-03-2, Prednisone 53-36-1, Methylprednisolone acetate
 53-86-1, Indomethacin 54-05-7, Chloroquine 54-85-3, Isoniazid

55-63-0, Nitroglycerin 56-75-7, Chloramphenicol 57-27-2, Morphine, biological studies 57-30-7, Phenobarbital sodium 57-43-2, Amobarbital 57-83-0, Progesterone, biological studies 57-94-3, Tubocurarine chloride 58-22-0, Testosterone 58-82-2, Bradykinin 59-02-9, α -Tocopherol 59-30-3, Folic acid, biological studies 60-54-8, Tetracycline 61-32-5, Methicillin 61-33-6, Penicillin G, biological studies 61-68-7, Mefenamic acid 64-43-7, Amobarbital sodium 65-29-2, Gallamine triethiodide 65-49-6, Para-aminosalicylic acid 66-79-5, Oxacillin 67-78-7, Triamcinolone diacetate 67-97-0, Cholecalciferol 68-19-9, Cyanocobalamine 68-41-7, Cycloserine 69-53-4, Ampicillin 69-72-7D, Salicylic acid, derivs. 70-18-8, Glutathione, biological studies 71-27-2, Succinylcholine chloride 71-63-6, Digitoxin 71-73-8, Thiopental sodium 73-78-9, Lidocaine hydrochloride 76-25-5, Triamcinolone acetonide 76-57-3, Codeine 76-74-4, Pentobarbital 76-99-3, Methadone 77-02-1, Aprobarbital 77-21-4, Glutethimide 78-11-5, Pentaerythritol tetranitrate 79-81-2, Retinol palmitate 80-08-0, Dapsone 83-43-2, Methylprednisolone 87-08-1, Penicillin V 87-33-2, Isosorbide dinitrate 98-96-4, Pyrazinamide 113-18-8, Ethchlorvynol 114-07-8, Erythromycin 115-44-6, Talbutal 118-42-3, Hydroxychloroquine 123-63-7, Paraldehyde 124-94-7, Triamcinolone 125-02-0, Prednisolone sodium phosphate 125-04-2, Hydrocortisone sodium succinate 125-64-4, Methypylon 126-07-8, Griseofulvin 126-52-3, Ethinamate 129-20-4, Oxyphenbutazone 130-15-4, 1,4-Naphthalenedione 130-95-0, Quinine 135-16-0 136-47-0, Tetracaine hydrochloride 143-81-7, Butabarbital sodium 147-52-4, Nafcillin 151-73-5, Betamethasone sodium phosphate 154-21-2, Lincomycin 302-17-0, Chloral hydrate 309-36-4, Methohexital sodium 309-43-3, Secobarbital sodium 317-52-2, Hexafluorenum bromide 378-44-9, Betamethasone 443-48-1, Metronidazole 508-99-6, Hydrocortisone cypionate 514-36-3, Fludrocortisone acetate 525-66-6, Propranolol 536-33-4, Ethionamide 548-73-2, Droperidol 561-27-3, Heroin 644-62-2 752-61-4, Digitalin 768-94-5, Amantadine 846-50-4, Temazepam 987-24-6, Betamethasone acetate 990-73-8, Fentanyl citrate 1070-11-7, Ethambutol hydrochloride 1172-18-5, Flurazepam hydrochloride 1177-87-3, Dexamethasone acetate 1397-89-3, Amphotericin B 1400-61-9, Nystatin 1404-04-2, Neomycin 1405-37-4, Capreomycin sulfate 1597-82-6, Paramethasone acetate 1722-62-9, Mepivacaine hydrochloride 1867-66-9, Ketamine hydrochloride 2022-85-7, Flucytosine 2375-03-3, Methylprednisolone sodium succinate 2392-39-4, Dexamethasone sodium phosphate 3116-76-5, Dicloxacillin 3385-03-3, Flunisolide 3485-14-1, Cyclacillin 3511-16-8, Hetacillin 3810-74-0, Streptomycin sulfate 3858-89-7, Chloroprocaine hydrochloride 4185-80-2, Methotrimeprazine hydrochloride 4697-36-3, Carbenicillin 5534-09-8, Beclomethasone dipropionate 5536-17-4, Vidarabine 5611-51-8, Triamcinolone hexacetonide 6000-74-4, Hydrocortisone sodium phosphate 6284-40-8D, Meglumine, antimonite complexes 7297-25-8, Erythrityl tetranitrate 7440-15-5, Rhenium, biological studies 7440-24-6, Strontium, biological studies 7440-26-8, Technetium, biological studies 7440-48-4, Cobalt, biological studies 7440-65-5, Yttrium, biological studies 7601-55-0, Metocurine iodide 7681-14-3, Prednisolone tebutate 8029-99-0, Paregoric 9001-12-1, Collagenase 9001-75-6, Pepsin 9001-78-9, Alkaline phosphatase 9002-01-1, Streptokinase 9002-04-4, Thrombin 9002-60-2, Adrenocorticotrophic hormone, biological studies 9002-61-3, Human chorionic gonadotropin 9002-72-6, Growth hormone 9002-79-3, Melanocyte stimulating hormone 9004-10-8, Insulin, biological studies 9007-12-9, Calcitonin 9007-92-5, Glucagon, biological studies 9011-97-6, Cholecystokinin 9015-71-8, Corticotropin releasing factor 9039-53-6, Urokinase 9061-61-4, Nerve growth factor 11000-17-2, Vasopressin 11096-26-7, Erythropoietin 13292-46-1, Rifampin 15500-66-0, Pancuronium bromide 15686-71-2, Cephalixin 15687-27-1, Ibuprofen 16009-13-5, Hemin

17598-65-1, Deslanoside 18010-40-7, Bupivacaine hydrochloride
 18323-44-9, Clindamycin 20461-54-5, Iodide, biological studies
 20830-75-5, Digoxin 21829-25-4, Nifedipine 22204-53-1, Naproxen
 22494-42-4, Diflunisal 22916-47-8, Miconazole 24356-66-9 26171-23-3,
 Tolmetin 26787-78-0, Amoxicillin 28911-01-5, Triazolam 30516-87-1,
 Azidothymidine 33125-97-2, Etomidate 33507-63-0, Substance P
 34787-01-4, Ticarcillin 36322-90-4, Piroxicam 36637-19-1, Etidocaine
 hydrochloride 36791-04-5, Ribavirin 38194-50-2, Sulindac 38821-53-3,
 Cephadrine 39391-18-9, Cyclooxygenase 42399-41-7, Diltiazem
 50370-12-2, Cefadroxil 50700-72-6, Vecuronium bromide 50972-17-3,
 Bacampicillin 53678-77-6, Muramyl dipeptide 53994-73-3, Cefaclor
 59277-89-3, Acyclovir 59467-96-8, Midazolam hydrochloride 62031-54-3,
 Fibroblast growth factor 62229-50-9, Epidermal growth factor
 62571-86-2, Captopril 64228-81-5, Atracurium besylate 65277-42-1,
 Ketoconazole 75847-73-3, Enalapril 76547-98-3, Lisinopril
 83869-56-1, Granulocyte-macrophage colony stimulating factor 86090-08-6,
 Angiostatin 102577-23-1, Neurokinin B 106128-89-6, Senktide
 106956-32-5, Oncostatin M 124389-07-7, Muramyl tripeptide 127464-60-2,
 Vascular endothelial growth factor 139639-23-9, Tissue plasminogen
 activator 141436-78-4, Protein kinase C 143011-72-7, Granulocyte
 colony stimulating factor

RL: **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
 (device and methods for initiating chemical reactions and for targeted
 delivery of drugs or other agents)

L109 ANSWER 8 OF 32 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:532776 HCAPLUS Full-text

DOCUMENT NUMBER: 139:96338

TITLE: Use of non-primate lentiviral vectors encoding
 inhibitory RNA molecules in gene therapy

INVENTOR(S): Radcliffe, Philippa; Mitrophanous, Kyriacos; Themis,
 Michael

PATENT ASSIGNEE(S): Oxford Biomedica (UK) Limited, UK

SOURCE: PCT Int. Appl., 117 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003056022	A2	20030710	WO 2002-GB5901	20021223 <--
WO 2003056022	A3	20031231		
WO 2003056022	B1	20040212		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,				
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,				
PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,				
UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,				
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,				
FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ,				
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003121062	A1	20030626	US 2002-82122	20020226 <--
AU 2002353231	A1	20030715	AU 2002-353231	20021223 <--
EP 1458879	A2	20040922	EP 2002-788249	20021223 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				

JP 2005512598	T	20050512	JP 2003-556539	20021223 <--
US 2004040052	A1	20040226	US 2003-421947	20030424 <--
PRIORITY APPLN. INFO.:			GB 2001-30797	A 20011221 <--
			GB 2002-1140	A 20020118 <--
			US 2002-82122	A 20020226 <--
			GB 2002-11409	A 20020517 <--
			WO 2002-GB5901	W 20021223 <--

AB A method of producing a transgenic cell comprising into a cell a non-primate lentiviral expression vector comprising a nucleotide of interest (NOI). Also described is a method of producing a transgenic cell comprising introducing into a cell a lentiviral expression vector comprising a NOI capable of generating an antisense oligonucleotide; a ribozyme, an siRNA, a short hairpin RNA, a micro-RNA, a micro-RNA or a group 1 intron. Also described is a viral vector comprising a first nucleotide sequence, wherein said first nucleotide sequence comprises: (a) a second nucleotide sequence comprising an aptazyme; and (b) a third nucleotide sequence capable of generating a polynucleotide; wherein (a) and (b) are operably linked and wherein the aptazyme is activatable to cleave a transcript of the first nucleotide sequence such that said polynucleotide is generated.


IT 60-54-8, Tetracycline 564-25-0, Doxycycline

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(as ligands for aptazyme activation or deactivation; use of non-primate lentiviral vectors encoding inhibitory RNA mols. in gene therapy)

RN 60-54-8 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S,4aS,5aS,6S,12aS)-(CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 564-25-0 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S,4aR,5S,5aR,6R,12aS)-(CA INDEX NAME)

Absolute stereochemistry.



IC ICM C12N015-867

ICS A01K067-027

CC 3-2 (Biochemical Genetics)
Section cross-reference(s): 1, 10

ST viral vector ribozyme antisense **RNA** gene therapy

IT Hemophilia
(A; use of non-primate lentiviral vectors encoding inhibitory **RNA** mols. in gene therapy)

IT Hemophilia
(B; use of non-primate lentiviral vectors encoding inhibitory **RNA** mols. in gene therapy)

IT Promoter (genetic element)
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**RNA** polymerase II or III, constitutive, inducible, tissue-specific, for transgene; use of non-primate lentiviral vectors encoding inhibitory **RNA** mols. in gene therapy)

IT Enzymes, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(aptazyme, vector for synthesis of; use of non-primate lentiviral vectors encoding inhibitory **RNA** mols. in gene therapy)

IT Antibodies and Immunoglobulins
Inorganic compounds
Nucleic acids
Organic compounds, biological studies
Peptides, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(as ligands for aptazyme activation or deactivation; use of non-primate lentiviral vectors encoding inhibitory **RNA** mols. in gene therapy)

IT Embryo, animal
(blastoderm, transgenic; use of non-primate lentiviral vectors encoding inhibitory **RNA** mols. in gene therapy)

IT Embryo, animal
(blastomere, transgenic; use of non-primate lentiviral vectors encoding inhibitory **RNA** mols. in gene therapy)

IT Gamete and Germ cell
(cell, gametogenesis, transgenic; use of non-primate lentiviral vectors encoding inhibitory **RNA** mols. in gene therapy)

IT Anas domesticus
Aves
Embryo, animal
Epithelium
Fibroblast
Gallus domesticus
Goose
Heart
Kidney
Liver
Lung
Mammary gland
Muscle
Neoplasm
Neuron
Poultry
(cell, transgenic; use of non-primate lentiviral vectors encoding inhibitory **RNA** mols. in gene therapy)

IT Peptides, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cyclic, as ligands for aptazyme activation or deactivation; use of non-primate lentiviral vectors encoding inhibitory **RNA** mols. in gene therapy)

- IT Stem cell
(embryo, transgenic; use of non-primate lentiviral vectors encoding inhibitory *RNA* mols. in gene therapy)
- IT Blood vessel
(endothelium, cell, transgenic; use of non-primate lentiviral vectors encoding inhibitory *RNA* mols. in gene therapy)
- IT Embryo, animal
(fetus, cell, transgenic; use of non-primate lentiviral vectors encoding inhibitory *RNA* mols. in gene therapy)
- IT Ligands
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(for aptazyme activation or deactivation; use of non-primate lentiviral vectors encoding inhibitory *RNA* mols. in gene therapy)
- IT Conformation
(hairpin loop, *RNA*; use of non-primate lentiviral vectors encoding inhibitory *RNA* mols. in gene therapy)
- IT Liver
(hepatocyte, cell, transgenic; use of non-primate lentiviral vectors encoding inhibitory *RNA* mols. in gene therapy)
- IT Drug delivery systems
(injections, i.m., lentiviral vectors in; use of non-primate lentiviral vectors encoding inhibitory *RNA* mols. in gene therapy)
- IT Drug delivery systems
(injections, i.v., lentiviral vectors in; use of non-primate lentiviral vectors encoding inhibitory *RNA* mols. in gene therapy)
- IT Post-transcriptional processing
(interference; use of non-primate lentiviral vectors encoding inhibitory *RNA* mols. in gene therapy)
- IT Genetic element
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(intron, group 1; use of non-primate lentiviral vectors encoding inhibitory *RNA* mols. in gene therapy)
- IT Ascitic fluid
Brain
Digestive tract
Respiratory system
Spinal column
(lentiviral vectors delivery to; use of non-primate lentiviral vectors encoding inhibitory *RNA* mols. in gene therapy)
- IT *RNA*
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(micro; use of non-primate lentiviral vectors encoding inhibitory *RNA* mols. in gene therapy)
- IT Antibodies and Immunoglobulins
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(monoclonal, as ligands for aptazyme activation or deactivation; use of non-primate lentiviral vectors encoding inhibitory *RNA* mols. in gene therapy)
- IT Egg
(oocyte, transgenic; use of non-primate lentiviral vectors encoding inhibitory *RNA* mols. in gene therapy)
- IT Egg
(oogonium, transgenic; use of non-primate lentiviral vectors encoding inhibitory *RNA* mols. in gene therapy)
- IT Sperm
(spermatid, transgenic; use of non-primate lentiviral vectors encoding inhibitory *RNA* mols. in gene therapy)
- IT Sperm
(spermatocyte, transgenic; use of non-primate lentiviral vectors encoding inhibitory *RNA* mols. in gene therapy)

- IT · Sperm
(spermatogonium, transgenic; use of non-primate lentiviral vectors encoding inhibitory *RNA* mols. in gene therapy)
- IT Cell
(stromal, transgenic; use of non-primate lentiviral vectors encoding inhibitory *RNA* mols. in gene therapy)
- IT Chemical compounds
(synthetic, natural, low mol. weight, as ligands for aptazyme activation or deactivation; use of non-primate lentiviral vectors encoding inhibitory *RNA* mols. in gene therapy)
- IT Genetic element
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tetracycline responsive element; use of non-primate lentiviral vectors encoding inhibitory *RNA* mols. in gene therapy)
- IT Amniotic fluid
- Animal cell
- Animals
- Astrocyte
- Bos taurus
- Caenorhabditis elegans
- Drosophila
- Equus caballus
- Fish
- Hematopoietic precursor cell
- Insecta
- Lymphocyte
- Macrophage
- Mammalia
- Monkey
- Monocyte
- Mus
- Neuroglia
- Ovary
- Ovis aries
- Placenta
- Polymorphonuclear leukocyte
- Reproductive system
- Reptilia
- Sperm
- Sus scrofa domestica
- Umbilical cord
- Uterus
- Yeast
(transgenic; use of non-primate lentiviral vectors encoding inhibitory *RNA* mols. in gene therapy)
- IT Adenoviral vectors
- Angiogenesis
- Bovine immunodeficiency virus
- Caprine *arthritis* encephalitis virus
- Cystic fibrosis
- Equine infectious *anemia* virus
- Feline immunodeficiency virus
- Gene therapy
- Human
Human immunodeficiency virus 1
- Lentivirus
- Molecular cloning
- Muscular dystrophy
- Parkinson's *disease*
- Retroviral vectors

Viral vectors
 Visna-Maedi virus
 (use of non-primate lentiviral vectors encoding inhibitory *RNA* mols. in gene therapy)

IT Antisense oligonucleotides
 Ribozymes
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (use of non-primate lentiviral vectors encoding inhibitory *RNA* mols. in gene therapy)

IT Endothelium
 (vascular, cell, transgenic; use of non-primate lentiviral vectors encoding inhibitory *RNA* mols. in gene therapy)

IT Proteins
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (vector for synthesis of; use of non-primate lentiviral vectors encoding inhibitory *RNA* mols. in gene therapy)

IT Adeno-associated virus
 Baculoviridae
 Herpesviridae
 Parvovirus
 Poxviridae
 (vectors; use of non-primate lentiviral vectors encoding inhibitory *RNA* mols. in gene therapy)

IT Embryo, animal
 (zygote, transgenic; use of non-primate lentiviral vectors encoding inhibitory *RNA* mols. in gene therapy)

IT 9014-24-8
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (II, III, promoter for transgene expression; use of non-primate lentiviral vectors encoding inhibitory *RNA* mols. in gene therapy)

IT 50-99-7, Glucose, biological studies 60-54-8, Tetracycline 146-17-8, Fmn 564-25-0, Doxycycline 127464-60-2, Vascular endothelial growth factor
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (as ligands for aptazyme activation or deactivation; use of non-primate lentiviral vectors encoding inhibitory *RNA* mols. in gene therapy)

IT 556842-47-8 556842-48-9 556842-49-0 556842-50-3 556842-51-4, 5:
 PN: WO03056022 SEQID: 5 unclaimed DNA 556842-52-5, 6: PN: WO03056022
 SEQID: 6 unclaimed DNA 556842-53-6, 7: PN: WO03056022 SEQID: 7 unclaimed
 DNA 556842-54-7 556842-55-8 556842-56-9 556842-57-0 556842-58-1
 556842-59-2 556842-60-5 556842-61-6 556842-62-7 556842-63-8
 556842-64-9 556842-65-0 556842-66-1 556842-67-2 556842-68-3
 RL: PRP (Properties)
 (unclaimed nucleotide sequence; use of non-primate lentiviral vectors encoding inhibitory *RNA* mols. in gene therapy)

L109 ANSWER 9 OF 32 HCAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2003:241921 HCAPLUS Full-text
 DOCUMENT NUMBER: 138:260539
 TITLE: Apparatus and method for flow electroporation of biological samples
 INVENTOR(S): Dzekunov, Sergey M.; Lee, Hyung J.; Li, Linhong; Singh, Vininder; Liu, Linda; Holaday, John W.
 PATENT ASSIGNEE(S): Maxcyte, Inc., USA
 SOURCE: U.S. Pat. Appl. Publ., 59 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003059945	A1	20030327	US 2002-80272	20020221 <--
US 7029916	B2	20060418		

PRIORITY APPLN. INFO.:

US 2001-269867P	P	20010221 <--
US 2001-269868P	P	20010221 <--

AB The present invention relates to methods and apparatus for the encapsulation of biol.-active substances in various cell populations. More particularly, the present invention relates to a method and apparatus for the encapsulation of biol.-active substances in various cell populations in blood by electroporation to achieve therapeutically desirable changes in the phys. characteristics of the various cell populations in blood. Primary lymphocytes were suspended in B and K buffer (125 mM KCl, 15 mM NaCl, 1.2 mM MgCl₂, 3 mM glucose, 25 mM Hepes, pH 7.4) and cell concentration was set from 1x10⁷ cells/mL to 6x10⁸ cells/mL together with DNA plasmid from 50 to 1 mg/mL. Electroporation, 2.3 kV/cm, 400 μ s, 4 pulses for small volume expts. (15 μ l) or 2.2 kV/cm, 1.6 ms, 1 pulse for large volume expts. (0.5 mL-2 mL) was performed at room temperature. Following electroporation, cells were incubated in B&K buffer for 20 min at 37° C. for small volume expts., or diluted by 10+ volume of culture medium (RPMI-1640+10% fetal bovine serum+1% Pen-strep+2 mM L-glutamine) for large volume expts. Cells were cultured in culture medium for various periods (up to 72 h) and the transfection efficiency was analyzed. Primary quiescence lymphocytes were shown refractory to retrovirus based gene transfer. HIV-based vector could transduce primary lymphocytes, but the efficiency is extremely low in the absence of HIV accessory genes. Other non-viral transfection methods also gave very low transfection efficiency. This is the first demonstration of high efficiency of transfection of primary lymphocytes by a non-viral method.


IT 60-54-8D, Tetracycline, derivs.

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(apparatus and method for flow electroporation of biol. samples)

RN 60-54-8 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S,4aS,5aS,6S,12aS)-
(CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IC ICM C12M001-42

ICS C12N015-87

INCL 435461000; X43-528.52

CC 63-7 (Pharmaceuticals)

Section cross-reference(s): 3, 9

IT DNA

RNA

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(DNA/RNA oligomer; apparatus and method for flow electroporation of biol. samples)

IT Proteins

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(TRAIL (tumor necrosis factor-related apoptosis-inducing ligand); apparatus and method for flow electroporation of biol. samples)

IT Angiogenic factors

Cadherins

Heat-shock proteins

Integrins

Interleukin 1

Interleukin 10

Interleukin 11

Interleukin 12

Interleukin 13

Interleukin 14

Interleukin 15

Interleukin 16

Interleukin 17

Interleukin 18

Interleukin 1 α

Interleukin 1 β

Interleukin 2

Interleukin 3

Interleukin 4

Interleukin 5

Interleukin 6

Interleukin 7

Interleukin 8

Interleukin 9

Leukemia inhibitory factor

Lymphotoxin

Melanoma growth-stimulating activity- α

Platelet-derived growth factors

Protamines

Proteins

Selectins

Thrombospondins

Transcription factors

Tumor necrosis factors

mRNA

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(apparatus and method for flow electroporation of biol. samples)

- IT 50-35-1D, Thalidomide, derivs. 50-81-7D, Ascorbic acid, ethers, biological studies 52-01-7, Spironolactone 53-05-4, Tetrahydrocortisone 60-33-3, Linoleic acid, biological studies 60-54-8D, Tetracycline, derivs. 68-96-2, 17 α -Hydroxyprogesterone 128-13-2, Ursodeoxycholic acid 145-63-1, Suramin 152-58-9, Cortisolone 302-79-4, Retinoic acid 362-07-2, 2-Methoxyestradiol 446-72-0, Genistein 465-21-4, Bufalin 566-35-8 1406-16-2D, Vitamin D, derivs. 2609-46-3, Amiloride 4431-00-9, Aurintricarboxylic acid 9001-91-6, Plasminogen 9061-61-4, NGF 10118-90-8, Minocycline 11096-26-7, Erythropoietin 12772-57-5, Radicicol 19545-26-7, Wortmannin 33069-62-4, Taxol 34031-32-8, Auranoftin 37270-94-3, Platelet factor 4 37300-21-3, Pentosan polysulfate 38096-31-0, Diaminoanthraquinone 50903-99-6, L-NAME 57381-26-7, Irsogladine 62031-54-3, Fibroblast growth factor 62571-86-2, Captopril 62683-29-8, Colony stimulating factor 62996-74-1, Staurosporine 65646-68-6, Fenretinide 70563-58-5,

Herbimycin A 79831-76-8, Castanospermine 81627-83-0, M-CSF
 83869-56-1, GM-CSF 86090-08-6, Angiostatin 86102-31-0, TIMP
 98724-27-7, Proliferin-related protein 99519-84-3 100827-28-9,
 Erbstatin 103909-75-7, 22-Oxa-1 α ,25-dihydroxyvitamin D3
 105219-56-5, WEB 2086 106096-93-9, Basic fibroblast growth factor
 110124-55-5, MDL 27032 125697-92-9, Lavendustin A 126509-46-4,
 Eponemycin 127464-60-2, Vascular endothelial growth factor
 129298-91-5, AGM-1470 130370-60-4, Batimastat 134633-29-7, Tecogalan
 sodium 142186-14-9, FR-118487 143011-72-7, G-CSF 148717-90-2,
 Squalamine 154039-60-8, Marimastat 169494-85-3, Leptin 171784-03-5,
 Louisianine A 171784-05-7, Louisianine C 171784-06-8, Louisianine D
 187888-07-9, Endostatin 188417-67-6, CM101 204005-46-9, SU5416
 271597-12-7, Myostatin

RL: *THU (Therapeutic use)*; BIOL (Biological study); USES (Uses)
 (apparatus and method for flow electroporation of biol. samples)

RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Abatti	1992	39	43	IEEE Trans. Biomed.	MEDLINE
Achelpohl	1984			US 4440386 A	
Andal Corp				Multi-Arc Scientific	
Anon	1975			DE 2405119	HCAPLUS
Anon	1985			EP 0137504	HCAPLUS
Anon	1987			DE 3603029	HCAPLUS
Anon	1987			JP 62151174	
Anon	1987			JP 62171687	HCAPLUS
Anon	1987			JP 62228277	HCAPLUS
Anon	1987			JP 62265975	
Anon	1988			JP 63141587	
Anon	1988			WO 8804322	
Anon	1989			EP 0343783	HCAPLUS
Anon	1989			JP 1141582	
Anon	1989			WO 8902464	HCAPLUS
Anon	1989			WO 8903426	HCAPLUS
Anon	1990			EP 0362758	HCAPLUS
Anon	1990			JP 2131584	
Anon	1990			JP 2131585	
Anon	1990			JP 2186993	
Anon	1991			JP 3195485	HCAPLUS
Anon	1991			WO 9118103	HCAPLUS
Anon	1992			EP 0472772	HCAPLUS
Anon	1992			JP 4027393	
Anon	1994			JP 6349068	
Anon	1994			AT 680890	
Anon	1994			WO 9421117	HCAPLUS
Anon	1995			JP 7180029	
Anon	1995			JP 7320720	
Anon	1996			DE 4440386	HCAPLUS
Anon	1996			WO 9628199	HCAPLUS
Anon	1997			EP 0798309	HCAPLUS
Anon	1998			CN 1195997	HCAPLUS
Anon	1998			WO 9824490	HCAPLUS
Anon	2001			WO 0124830	HCAPLUS
Anon	2002			CA 2214800	HCAPLUS
Anon	1975		598	Preparation of certa	
Asakami	1990	9	892	J. Mater. Sci. Lett.	HCAPLUS
Baer	1992			US 5128257 A	HCAPLUS
Barsoum	1990			US 4956288 A	HCAPLUS
Behrndt	1991	A139	58	Materials Sciences a	HCAPLUS

Bertoncini	1992			US 5114681 A	HCAPLUS
Boulton	1981			US 4252628 A	HCAPLUS
Buican	1992			US 5100627 A	HCAPLUS
Busta	1992			US 5137817 A	HCAPLUS
CRC Press	1995		1650	Biological Buffers,	
Calvin	1992			US 5098843 A	HCAPLUS
Capizzi	1993	72	3495	Cancer	HCAPLUS
Casnig	1992			US 5134070 A	
Chang	1989			US 4822470 A	HCAPLUS
Chang	1990			US 4970154 A	HCAPLUS
Chassy	1988	6	303	Trends in Biotechnol	HCAPLUS
Coll	1992			Metallurgical and Tr	
Dower	1990			US 4910140 A	HCAPLUS
Dunican	1998	7	1067	BIO/Technology	
Dzekunov	2003			US 20030073238 A1	
Dzekunov	2004			US 20040197883 A1	
Egorov	1991	29	705	Sov. Powder Metall M	
Einck	1998		357	Tissue Oxygenation i	HCAPLUS
Firth	1993			US 5232856 A	HCAPLUS
Franco	1984			US 4478824 A	HCAPLUS
Franco	1990			US 4931276 A	HCAPLUS
Gersonde	1980	46	81	Bibltthca Haemat.	
Gersonde	1979	39	1	Blut, Improvement of	MEDLINE
Gersonde	1982		277	Origins of Cooperati	HCAPLUS
Gersonde	1982	22	279	Toxicology	HCAPLUS
Goodrich	1989			US 4874690 A	HCAPLUS
Goodrich	1991			US 5043261 A	HCAPLUS
Gossling	1960			US 2955076 A	
Hibi	1989			US 4800163 A	
Hilliard	1987			US 4695547 A	HCAPLUS
Hilliard	1989			US 4882281 A	HCAPLUS
Hirai	1987	40	607	J. of Antibiotics	HCAPLUS
Hofmann	1996			US 5501662 A	
Hofmann	1996			US 5545130 A	
Hofmann	1997			US 5676646 A	
Hofmann	1986		6	IEEE Engineering in	HCAPLUS
Holaday	2001			US 20010001064 A1	HCAPLUS
Holmstrm	1998			US 5728281 A	HCAPLUS
Kaali	1992			US 5139684 A	HCAPLUS
Kearney	1995			US 5424209 A	
Kinosita	1979	554	479	Biochimica et Biophy	HCAPLUS
Kobayashi	1989	97	1189	J. Ceram. Soc. Jpn.	HCAPLUS
Kullmann	1993	8	83	Am. J. Respir. Cell	HCAPLUS
Kurtz	1987	15	229	Sol. Energy Mater.	HCAPLUS
Lehninger	1982		181	Principles of Bioche	
Littlehales	1989			US 4840714 A	
Marshall	1989			US 4849089 A	HCAPLUS
Marshall	1990			US 4906576 A	HCAPLUS
Marshall	1990			US 4923814 A	HCAPLUS
Marshall	1990			US 4946793 A	HCAPLUS
Matschke	1987			US 4699881 A	HCAPLUS
Matschke	1988			US 4764473 A	HCAPLUS
Maurer	1993	11	865	J. Orthop. Res.	HCAPLUS
Merz	1991	941	47	Unfallchirurg, Deter	
Meserol	1998			US 5720921 A	HCAPLUS
Meserol	2000			US 6074605 A	HCAPLUS
Meserol	2000			US 6090617 A	HCAPLUS
Meserol	2002			US 6485961 B1	HCAPLUS
Mochizuki	1989			US 4804450 A	HCAPLUS
Mouneimne	1990	275	117	FEBS Letters	HCAPLUS

Multi-Arc, Inc	1996			Ion Bond 16 Zirconiu	
Multi-Arc, Inc	1995			Ion Bond 17 Titanium	
Multi-Arc, Inc	1995			Ion Bond 19 Chromium	
Multi-Arc, Inc	1995			Ion Bond Coatings fo	
Multi-Arc, Inc	1995			Ion Bond Coatings fo	
Multi-Arc, Inc	1995			The Ion Bond Network	
Narayan	1994	B25	5	Materials Sciences a	
Nicolau	1980			US 4192869 A	HCAPLUS
Nicolau	1982			US 4321259 A	HCAPLUS
Nicolau	1984			US 4473563 A	HCAPLUS
Nicolau	1997			US 5612207 A	HCAPLUS
Nicolau	1985	51	92	Biblthca haemat.	HCAPLUS
Nicolau	1986		265	Phytic Acid: Chemist	HCAPLUS
Pietra	1990	115	1025	Analyst	HCAPLUS
Pohl	1984			US 4476004 A	
Ray	1988			US 4784737 A	HCAPLUS
Ropars	1987			US 4652449 A	HCAPLUS
Ropars	1988			US 4752586 A	HCAPLUS
Ropars	1985	445	304	Improved oxygen deli	MEDLINE
Sanford	1990			US 4945050 A	
Sanford	1991			US 5036006 A	
Sanford	1992			US 5100792 A	
Satomi	1988	15	339	Annals Rehab.	HCAPLUS
Schaldach	1989	34	185	Biomed. Technik.	MEDLINE
Schoendorfer	1992			US 5135667 A	HCAPLUS
Shoji	1982	41	1097	Appl. Phys. Lett.	HCAPLUS
Smith	1972			US 3676325 A	HCAPLUS
Sowers	1986			US 4622302 A	
Susuki	1981	19	114	Jpn. J. Med. Electro	MEDLINE
Tada	1992			US 5124259 A	HCAPLUS
Taheri	1994	90	376	Electroencephalograp	MEDLINE
Tait	1991	7	327	Surf. Eng.	HCAPLUS
Takahashi	1991			US 5007995 A	HCAPLUS
Teisseire	1985	58	1810	J. Appl. Phys.	MEDLINE
Teisseire			153	Significance of low	
Teissere	1987	84	6894	Proc. Natl. Acad. Sc	
Therin	1991	2	1	J. Materials Science	
Vasilenko	1973	13	39	Poroshkovaia Metallu	HCAPLUS
Weiner	1983	47	65	Biol. of the Cell	HCAPLUS
Weisel	1978	83	682	Surgery	MEDLINE
Wisbey	1987	8	477	Biomaterials	HCAPLUS
Wisbey	1989	C384/	9	ImechE	
Wong	1987			US 4663292 A	HCAPLUS
Wong	1989			US 4849355 A	HCAPLUS
Xylander	1978			US 4075076 A	
Zhao	1991	42	1109	Vacuum	HCAPLUS
Zhu	1994	9	295	Biosensors and Bioel	HCAPLUS
Ziegler	1991			US 4995957 A	HCAPLUS
Zimmermann	1978			US 4081340 A	HCAPLUS

L109 ANSWER 10 OF 32 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:675868 HCAPLUS Full-text

DOCUMENT NUMBER: 137:200279

TITLE: Composition comprising cytokine, adjuvant and antibiotic for improving farm animal growth and meat production

INVENTOR(S): Strom, Alan David Greve; Knowles, Aleta Gai; Andrew, Marion Elizabeth

PATENT ASSIGNEE(S): The University of Sydney, Australia

SOURCE: PCT Int. Appl., 228 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002067979	A1	20020906	WO 2002-AU209	20020226 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2439116	A1	20020906	CA 2002-2439116	20020226 <--
AU 2002233045	A1	20020912	AU 2002-233045	20020226 <--
EP 1372699	A1	20040102	EP 2002-700034	20020226 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2002007585	A	20040629	BR 2002-7585	20020226 <--
JP 2004528026	T	20040916	JP 2002-567344	20020226 <--
US 2004170601	A1	20040902	US 2004-468891	20040405 <--
PRIORITY APPLN. INFO.:				
			AU 2001-3354	A 20010226 <--
			AU 2001-3532	A 20010305 <--
			AU 2001-9596	A 20011218 <--
			WO 2002-AU209	W 20020226 <--

AB A method of, and compns. for improving the growth performance of an animal by administration of a cytokine or biol. active fragment, optionally with an antibiotic. The cytokine or active fragment may be administered as coded by a suitable nucleic acid sequence.

IT 60-54-8, Tetracycline

RL: FFD (Food or feed use); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)

(composition comprising cytokine, adjuvant and antibiotic for improving


farm

animal growth and meat production)

RN 60-54-8 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S,4aS,5aS,6S,12aS) - (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IC ICM A61K038-19

ICS A61K038-20; A61K048-00; A23K001-16; A23K001-165; A23K001-17

CC 15-5 (Immunochemistry)
 Section cross-reference(s): 1, 3, 5, 17, 63
 IT Cytokines
 DNA
 Interleukin 1
 Interleukin 10
 Interleukin 11
 Interleukin 12
 Interleukin 13
 Interleukin 2
 Interleukin 3
 Interleukin 4
 Interleukin 5
 Interleukin 6
 Interleukin 7
Leukemia inhibitory factor
 Nucleic acids
 RNA
 Stem cell factor
 Tumor necrosis factors
 cDNA
 RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (composition comprising cytokine, adjuvant and antibiotic for improving

farm

animal growth and meat production)

IT 57-62-5, Chlortetracycline 57-92-1, Streptomycin, biological studies
 59-46-1, Procaine 60-54-8, Tetracycline 61-33-6, Penicillin G,
 biological studies 61-72-3, Cloxacillin 63-74-1D, Sulfonamide, derivs.
 69-53-4, Ampicillin 79-57-2, Oxytetracycline 114-07-8, Erythromycin
 140-28-3, Benzathine 154-21-2, Lincomycin 551-92-8, Dimetridazole
 738-70-5, Trimethoprim 751-84-8, Benethamine penicillin 1392-21-8,
 Kitasamycin 1401-69-0, Tylosin 1404-04-2, Neomycin 1405-87-4,
 Bacitracin 1406-05-9, Penicillin 1695-77-8, Spectinomycin 3922-90-5,
 Oleandomycin 5355-16-8, Diaveridine 5575-21-3, Cephalonium
 7732-18-5, Water, biological studies 11006-76-1, Virginiamycin
 11054-70-9, Lasalocid 11096-26-7, Erythropoietin 17090-79-8, Monensin
 23696-28-8, Olaquinox 26787-78-0, Amoxycillin 37321-09-8, Apramycin
 37332-99-3, Avoparcin 53003-10-4, Salinomycin 55134-13-9, Narasin
 55268-75-2, Cefuroxime 80370-57-6, Ceftiofur 81627-83-0, M-CSF
 83869-56-1, GM-CSF 108050-54-0, Tilmicosin 143011-72-7, G-CSF
 RL: FFD (Food or feed use); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)

(composition comprising cytokine, adjuvant and antibiotic for improving

farm

animal growth and meat production)

RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Cetus Corporation	1990			EP 400762 A1	HCAPLUS
Cetus Corporation	1992			EP 219979 B1	HCAPLUS
Dovetail Technologies I	1997			WO 9714306 A1	HCAPLUS
Dovetail Technologies I	1999			WO 9942098 A1	HCAPLUS
Dovetail Technologies I	2000			US 6166086 A	HCAPLUS
Embrex Inc	1990			WO 9014099 A2	HCAPLUS
University Of Georgia R	1989			WO 8909065 A1	HCAPLUS

L109 ANSWER 11 OF 32 HCAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2002:638224 HCAPLUS Full-text

DOCUMENT NUMBER: 137:163779
 TITLE: Methods for discovering therapeutic compounds, particularly antimicrobials, and identifying their cellular targets using whole cell assay
 INVENTOR(S): Fan, Frank; Ji, Yinduo; Kallender, Howard; Li, Tong; McDevitt, Damien
 PATENT ASSIGNEE(S): SmithKline Beecham Corporation, USA
 SOURCE: U.S. Pat. Appl. Publ., 8 pp., Cont.-in-part of U.S. Ser. No. 509,723, abandoned.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
US 2002115217	A1	20020822	US 2001-981121	20011017 <--
WO 9918239	A1	19990415	WO 1998-US20582	19981001 <--
W: CA, JP, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
WO 2003034027	A2	20030424	WO 2002-US32849	20021015 <--
WO 2003034027	A3	20031120		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002347898	A1	20030428	AU 2002-347898	20021015 <--
US 2004197767	A1	20041007	US 2004-492565	20040414 <--
US 2006141448	A1	20060629	US 2006-354387	20060215 <--
PRIORITY APPLN. INFO.:			US 1997-60767P	P 19971002 <--
			WO 1998-US20582	W 19981001 <--
			US 1999-361318	B2 19990727 <--
			US 2000-509723	B2 20000330 <--
			US 2001-981121	A 20011017 <--
			WO 2002-US32849	W 20021015 <--
			US 2004-492565	A1 20040414

AB This invention relates to newly developed methods for discovering therapeutic compds. using a cell-based assay system. This invention also relates to compns. of matter useful in carrying out the methods of the invention as well as therapeutic compds. developed using such methods. In one of the examples provided a RAT gene-based whole cell assay in *S. aureus* for discovery of antimicrobial compds. is described. The RAT operon encodes tRNA-dependent amidotransferase which can be titrated by varying levels of IPTG inducer. The natural promoter of the RAT operon was replaced with a heterologous, regulatable promoter plus a constitutively expressed lacI gene in the chromosome of *S. aureus*.


IT 60-54-8, Tetracycline

RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses).

(downregulation of α -toxin expression in *S. aureus* after induction transcription of antisense RNA using tetracycline or anhydrotetracycline)

RN 60-54-8 HCAPLUS
 CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S,4aS,5aS,6S,12aS)-(CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IC ICM C12Q001-00
 ICS C12Q001-68; C12N015-87
 INCL 435455000
 CC 1-1 (Pharmacology)
 Section cross-reference(s): 3, 10
 ST drug screening metab **modulation** gene induction; antimicrobial screening Staphylococcus amidotransferase IPTG inducer; polypeptide deformylase Staphylococcus antimicrobial screening IPTG inducer; alpha toxin antisense **RNA** tetracycline anhydrotetracycline inducer Staphylococcus
 IT 60-54-8, Tetracycline 1665-56-1, Anhydrotetracycline
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (downregulation of α -toxin expression in *S. aureus* after induction transcription of antisense RNA using tetracycline or anhydrotetracycline)

L109 ANSWER 12 OF 32 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:521462 HCAPLUS Full-text

DOCUMENT NUMBER: 137:88442

TITLE: Incensole and furanogermacrene and compounds in treatment for inhibiting neoplastic lesions and microorganisms

INVENTOR(S): Shanahan-Pendergast, Elisabeth

PATENT ASSIGNEE(S): Ire.

SOURCE: PCT Int. Appl., 68 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002053138	A2	20020711	WO 2002-IE1	20020102 <--
WO 2002053138	A3	20020919		
W: AE, AG, AT, AU, BB, BG, CA, CH, CN, CO, CU, CZ, LU, LV, MA, MD, UA, UG, US, VN, YU, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, AT, BE, CH, CY, DE, ES, FI, ML, MR, NE, SN, TD, TG				
AU 2002219472	A1	20020716	AU 2002-219472	20020102 <--
EP 1351678	A2	20031015	EP 2002-727007	20020102 <--

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

US 2004092583 A1 20040513 US 2004-250535 20040102 <--
PRIORITY APPLN. INFO.: IE 2001-2 A 20010102 <--
WO 2002-IE1 W 20020102 <--

OTHER SOURCE(S): MARPAT 137:88442

AB The invention discloses the use of incensole and/or furanogermacrens, derivs. metabolites and precursors thereof in the treatment of neoplasia, particularly resistant neoplasia and immunodysregulatory **disorders**. These compds. can be administered alone or in combination with conventional chemotherapeutic, antiviral, antiparasite agents, radiation and/or surgery. Incensole and furanogermacren and their mixture showed antitumor activity against various human carcinomas and **melanomas** and antimicrobial activity against *Staphylococcus aureus* and *Enterococcus faecalis*.

IT 60-54-8, Tetracycline


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(pharmaceutical formulation further containing; incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)

RN 60-54-8 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S,4aS,5aS,6S,12aS) - (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IC ICM A61K031-00

CC 1-6 (Pharmacology)

Section cross-reference(s): 10, 63

IT Inflammation

(Crohn's **disease**, treatment of; incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)

IT Intestine, **disease**

(Crohn's, treatment of; incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)

IT Transcription factors

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(WT1 (Wilms' **tumor** suppressor 1), therapy based on; incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)

IT **Melanoma**

(amelanotic; incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)

IT Lung, **disease**

(aspergillosis, treatment of immunodysregulation condition caused by; incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)

IT **Infection**

(bacterial, intracellular or extracellular, treatment of

immunodysregulation condition caused by; incensole and furanogermacrene and compds. as antitumor and antimicrobial agents)

IT Uterus, **disease**
(cervix, dysplasia; incensole and furanogermacrene and compds. as antitumor and antimicrobial agents)

IT Tumor antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(drug targeting with monoclonal antibody to; incensole and furanogermacrene and compds. as antitumor and antimicrobial agents)

IT Bronchi, **disease**
Prostate gland, **disease**
(dysplasia; incensole and furanogermacrene and compds. as antitumor and antimicrobial agents)

IT Escherichia coli
(enterohemorrhagic, treatment of immunodysregulation condition caused by **infection** with; incensole and furanogermacrene and compds. as antitumor and antimicrobial agents)

IT Escherichia coli
(enteroinvasive, treatment of immunodysregulation condition caused by **infection** with; incensole and furanogermacrene and compds. as antitumor and antimicrobial agents)

IT Escherichia coli
(enteropathogenic, treatment of immunodysregulation condition caused by **infection** with; incensole and furanogermacrene and compds. as antitumor and antimicrobial agents)

IT Escherichia coli
(enterotoxigenic, treatment of immunodysregulation condition caused by **infection** with; incensole and furanogermacrene and compds. as antitumor and antimicrobial agents)

IT Adrenal gland, neoplasm
Anti-AIDS agents
Anti-infective agents
Antiarthritics
Antiasthmatics
Antidiabetic agents
Antidiarrheals
Antitumor agents
B-cell **leukemia**
Bladder, neoplasm
Brain, neoplasm
Burn
Central nervous system, neoplasm
Drug delivery systems
Enterococcus faecalis
Hairy cell **leukemia**
Hematopoietic neoplasm
Hodgkin's **disease**
Human
 Leukemia
 Leukemia
Lymphoma
Mammary gland, neoplasm
 Melanoma
Monocytic **leukemia**
Mouth, neoplasm
Multiple **myeloma**
Myeloid **leukemia**
Myelomonocytic **leukemia**
Neoplasm
Newborn

Ovary, neoplasm
 Pancreas, neoplasm
 Prostate gland, neoplasm
 Sarcoma
 Staphylococcus aureus
 Stomach, neoplasm
 T-cell *leukemia*
 Testis, neoplasm
 (incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)
 IT Yeast
 (*infection* with, treatment of immunodysregulation condition caused by; incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)
 IT Intestine, *disease*
 (inflammatory, treatment of; incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)
 IT Parasite
 (intracellular or extracellular *infection* with, treatment of immunodysregulation condition caused by; incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)
 IT Intestine, *disease*
 (irritable bowel syndrome, treatment of; incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)
 IT Bladder, *disease*
 Skin, *disease*
 (lesions; incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)
 IT Virus
 (lipid envelope, treatment of immunodysregulation condition caused by *infection* with; incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)
 IT Double stranded *RNA*
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (mismatched, pharmaceutical formulation further including; incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)
 IT Antibodies and Immunoglobulins
 RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (monoclonal, conjugates, with liposome or carbohydrate vehicles, to *tumor*-associated antigen; incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)
 IT Nerve, *disease*
 (motor, treatment of; incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)
 IT Lymphocyte
 (null cell, *leukemia*; incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)
 IT Antisense oligonucleotides
 Estrogens
 Hormones, animal, biological studies
 Interleukins
 Leukemia inhibitory factor
 Neuregulin 1
 Oligonucleotides
 Polyamines
 Ribozymes
 Steroids, biological studies
 Taxanes

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(pharmaceutical formulation further including; incensole and
furanogermacrens and compds. as antitumor and antimicrobial agents)

- IT **Disease**, animal
(polyposis syndrome; incensole and furanogermacrens and compds. as
antitumor and antimicrobial agents)
- IT Central nervous system, **disease**
Kidney, **disease**
Lung, **disease**
Mammary gland, **disease**
Stomach, **disease**
(precancerous lesion in; incensole and furanogermacrens and compds. as
antitumor and antimicrobial agents)
- IT **Leukemia**
(small cell; incensole and furanogermacrens and compds. as antitumor
and antimicrobial agents)
- IT **Human immunodeficiency virus**
(targeting to cells infected with; incensole and furanogermacrens and
compds. as antitumor and antimicrobial agents)
- IT Adeno-associated virus
Balantidium
Balantidium coli
Borrelia
Campylobacter
Candida
Coronavirus
Cryptococcus (fungus)
Cryptosporidium
DNA viruses
Entamoeba
Entamoeba histolytica
Filovirus
Flavivirus
Haemophilus
Hantavirus
Human papillomavirus
Human parainfluenza virus
Human poliovirus
Influenza virus
Legionella
Leishmania
Leishmania braziliensis
Leishmania donovani
Leishmania mexicana
Leishmania tropica
Listeria
Measles virus
Mycoplasma
Papillomavirus
Pestivirus
Picornaviridae
Plasmodium berghei
Plasmodium falciparum
Plasmodium malariae
Plasmodium ovale
Plasmodium vivax
Pneumocystis
Pneumocystis carinii
Poxviridae

Pseudomonas
 RNA viruses
 Respiratory syncytial virus
 Retroviridae
 Rhinovirus
 Rubivirus
 Salmonella
 Shigella
 Staphylococcus
 Streptococcus
 Togaviridae
 Toxoplasma
 Toxoplasma gondii
 Trichomonas
 Trichomonas vaginalis
 Trypanosoma
 Trypanosoma brucei
 Trypanosoma cruzi
 Trypanosoma gambiense
 Trypanosoma rhodesiense
 Vibrio
 Yersinia
 (treatment of immunodysregulation condition caused by **infection**
 with; incensole and furanogermacrens and compds. as antitumor and
 antimicrobial agents)

IT **Arthritis**

Asthma
 Autoimmune **disease**
 Cachexia
 Cirrhosis
 Diabetes mellitus
 Diarrhea
 Immune **disease**
 Multiple sclerosis
 Respiratory distress syndrome
 (treatment of; incensole and furanogermacrens and compds. as antitumor
 and antimicrobial agents)

IT **Infection**

 (viral, treatment of immunodysregulation condition caused by; incensole
 and furanogermacrens and compds. as antitumor and antimicrobial agents)

IT **Disease, animal**

 (wasting, treatment of; incensole and furanogermacrens and compds. as
 antitumor and antimicrobial agents)

IT 54-05-7, Chloroquine 54-42-2, Idoxuridine 60-54-8,
 Tetracycline 69-74-9, Cytarabine Hydrochloride 70-00-8, Trifluridine
 80-08-0, Dapsone 90-34-6, Primaquine 100-33-4, Pentamidine 130-95-0,
 Quinine 443-48-1, Metronidazole 494-79-1, Melarsoprol 665-66-7,
 Amantadine Hydrochloride 1501-84-4, Rimantadine Hydrochloride
 1910-68-5, Methisazone 3056-17-5, d4T 3736-81-0, Diloxanide furoate
 5536-17-4, Vidarabine 7481-89-2, DdC 8064-90-2 9004-70-0, HE-2000
 10500-82-0, Famotidine Hydrochloride 10540-97-3, Memotidine Hydrochloride
 11006-77-2, Statolon 15176-29-1, Edoxudine 15185-43-0, DOTC
 19387-91-8, Tinidazole 19885-51-9, Aranotin 22994-85-0, Benznidazole
 23256-30-6, Nifurtimox 25526-93-6, Alovudine 27591-69-1, Tilorone
 Hydrochloride 27762-78-3, Kethoxal 29984-33-6, Vidarabine Phosphate
 30516-87-1, AZT 35607-20-6, Avridine 36791-04-5, Ribavirin
 36983-81-0, Fosfonet Sodium 37338-39-9 39809-25-1, Penciclovir
 51867-87-9 53230-10-7, Mefloquine 56219-57-9, Arildone 59277-89-3,
 Acyclovir 63198-97-0, Viroxime 63585-09-1, Foscarnet Sodium
 63968-64-9D, Artemisinin, derivs. 68693-30-1, Somantadine Hydrochloride

69123-90-6, Fiacitabine 69123-98-4, Fialuridine 69655-05-6, DdI
 69657-51-8, Acyclovir Sodium 69756-53-2, Halofantrine 72301-78-1,
 Zinviroxime 72301-79-2, Enviroxime 73514-87-1, Fosarilate
 77181-69-2, Sorivudine 80883-55-2, Envirodene 82410-32-0, Ganciclovir
 84408-37-7, Desciclovir 85087-20-3, Doxycycline 87495-31-6, Disoxaril
 95233-18-4, Atovaquone 100817-46-7, Stibogluconic acid 104227-87-4,
 Famciclovir 106362-32-7, Peptide T 106941-25-7, PMEA 107910-75-8,
 Ganciclovir Sodium 110042-95-0, Acemannan 110143-10-7, Lodenosine
 113852-37-2, Cidofovir 124436-59-5, Pirodavis 124832-27-5,
 Valacyclovir Hydrochloride 127759-89-1, Lobucavir 127779-20-8,
 Saquinavir 129618-40-2, Nevirapine 132210-43-6, Cipamfylline
 134678-17-4, 3TC 136470-78-5, Abacavir 136817-59-9, Delavirdine
 137487-62-8, Alvircept Sudotox 138540-32-6, Ateviridine Mesylate
 141204-94-6, Co-artemether 142340-99-6 142632-32-4, Calanolide A
 143491-57-0, Coviracil 145514-04-1, DAPD 147127-20-6, Tenofovir
 147221-93-0, Delavirdine Mesylate 147318-81-8, KNI-272 147362-57-0,
 Loviride 149845-06-7, Saquinavir Mesylate 149950-60-7, Emivirine
 150378-17-9, Indinavir 153127-49-2, ALX40-4C 154598-52-4, DMP 266
 155148-31-5, AMD 3100 155213-67-5, Ritonavir 156879-70-8
 159519-65-0, Pentafuside 159989-64-7, Nelfinavir 163451-80-7
 170020-61-8, FP-21399 174484-41-4, Tipranavir 177932-89-7, DMP-450
 178979-85-6, AG 1549 185220-03-5, PNU142721 192725-17-0, ABT-378
 214287-88-4, DPC961 216863-66-0, L-756423 251562-00-2, T-1249
 383198-56-9, BW 141 383198-57-0, BMS-232630 383198-58-1, PRO 542
 RL: PAC (Pharmacological activity); THU (Therapeutic
 use); BIOL (Biological study); USES (Uses)
 (pharmaceutical formulation further containing; incensole and
 furanogermacrens and compds. as antitumor and antimicrobial agents)

L109 ANSWER 13 OF 32 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:762228 HCAPLUS Full-text

DOCUMENT NUMBER: 135:300664

TITLE: In vivo method for characterizing *modulators*
 of RNA splicing and for disease diagnosis

INVENTOR(S): Bauer, Bettina; Simandi, Claus; Huels, Christoph

PATENT ASSIGNEE(S): Aventis Research and Technologies GmbH and Co. KG,
 Germany

SOURCE: Ger. Offen., 8 pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent

LANGUAGE: German


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 10018464	A1	20011018	DE 2000-10018464	20000414 <--
WO 2001079853	A2	20011025	WO 2001-EP2235	20010228 <--
WO 2001079853	A3	20021219		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2001042439	A5	20011030	AU 2001-42439	20010228 <--
PRIORITY APPLN. INFO.:			DE 2000-10018464	A 20000414 <--

- AB The title method comprises a cell containing a spliceable **RNA** containing at least two exons and an intron and splicing and translation of the pre- **RNA** thus giving rise to a detectable signal. The splicing reaction may occur in the presence of a **modulator** of the process. Thus, pre-mRNA constructs comprising GFP exon 1-actin intron/MINX intron-GFP exon 2, or cell surface protein exon 1-actin/MINX intron-cell surface protein exon 2, or Ras (G12V) exon 1-actin/MINX intro-Ras (G12V) exon 2 were prepared and introduced into *Saccharomyces cerevisiae* or HeLa cells. Formation of the GFP could be detected by fluorescence, morphol. alteration of the cytoskeleton could be determined by rhodamine-phalloidin staining, and neurite outgrowth of NGF-treated Ras (G12V)-producing cells could be observed by phase-contrast microscopy.
- IT 60-54-8, Tetracycline
 RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses)
 (in vivo method for characterizing **modulators** of **RNA** splicing and for disease diagnosis)
- RN 60-54-8 HCAPLUS
- CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S,4aS,5aS,6S,12aS)-(CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



- IC ICM C12Q001-68
 ICS C12N015-79
- CC 9-2 (Biochemical Methods)
- ST **RNA** splicing **modulator** yeast GFP Ras protein
- IT Ras proteins
 RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses)
 (G12V, mRNA for; in vivo method for characterizing **modulators** of **RNA** splicing and for disease diagnosis)
- IT Gene, animal
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (MINX, intron of; in vivo method for characterizing **modulators** of **RNA** splicing and for disease diagnosis)
- IT Diagnosis
 (**cancer**; in vivo method for characterizing **modulators** of **RNA** splicing and for disease diagnosis)
- IT Proteins, specific or class
 RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses)
 (cell-surface, mRNA for; in vivo method for characterizing **modulators** of **RNA** splicing and for disease diagnosis)
- IT Neoplasm
 (diagnosis; in vivo method for characterizing **modulators** of **RNA** splicing and for disease diagnosis)
- IT mRNA
 RL: ARG (Analytical reagent use); BSU (Biological study, unclassified);
 MFM (Metabolic formation); ANST (Analytical study); BIOL (Biological

- study); FORM (Formation, nonpreparative); USES (Uses)
(for GFP, cell surface protein, or Ras; in vivo method for characterizing *modulators* of RNA splicing and for disease diagnosis)
- IT Acts
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(gene for, intron of; in vivo method for characterizing *modulators* of RNA splicing and for disease diagnosis)
- IT Proteins, specific or class
RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses)
(green fluorescent, mRNA for; in vivo method for characterizing *modulators* of RNA splicing and for disease diagnosis)
- IT Graves' disease
HeLa cell
RNA splicing
Saccharomyces cerevisiae
Spinal muscular atrophy
(in vivo method for characterizing *modulators* of RNA splicing and for disease diagnosis)
- IT Hepatitis C virus
Human herpesvirus
(infection by; in vivo method for characterizing *modulators* of RNA splicing and for disease diagnosis)
- IT Combinatorial library
(members of, splicing *modulator*; in vivo method for characterizing *modulators* of RNA splicing and for disease diagnosis)
- IT Diagnosis
(mol.; in vivo method for characterizing *modulators* of RNA splicing and for disease diagnosis)
- IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(oncogene, c-erb, cancer caused by; in vivo method for characterizing *modulators* of RNA splicing and for disease diagnosis)
- IT Antibiotics
Drugs
Herbicides
Insecticides
Pesticides
(splicing *modulator*; in vivo method for characterizing *modulators* of RNA splicing and for disease diagnosis)
- IT Thalassemia
(β -; in vivo method for characterizing *modulators* of RNA splicing and for disease diagnosis)
- IT 50-99-7, Glucose, uses 56-65-5, ATP, uses 60-54-8, Tetracycline 13408-56-5
RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses)
(in vivo method for characterizing *modulators* of RNA splicing and for disease diagnosis)

L109 ANSWER 14 OF 32 HCAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2001:338762 HCAPLUS Full-text
 DOCUMENT NUMBER: 134:362292
 TITLE: Methods of determining individual hypersensitivity to a pharmaceutical agent from gene expression profile
 INVENTOR(S): Farr, Spencer
 PATENT ASSIGNEE(S): Phase-1 Molecular Toxicology, USA
 SOURCE: PCT Int. Appl., 222 pp.
 CODEN: PIXXD2

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001032928	A2	20010510	WO 2000-US30474	20001103 <--
WO 2001032928	A3	20020725		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 1999-165398P P 19991105 <--
 US 2000-196571P P 20000411 <--

AB The invention discloses methods, gene databases, gene arrays, protein arrays, and devices that may be used to determine the hypersensitivity of individuals to a given agent, such as drug or other chemical, in order to prevent toxic side effects. In one embodiment, methods of identifying hypersensitivity in a subject by obtaining a gene expression profile of multiple genes associated with hypersensitivity of the subject suspected to be hypersensitive, and identifying in the gene expression profile of the subject a pattern of gene expression of the genes associated with hypersensitivity are disclosed. The gene expression profile of the subject may be compared with the gene expression profile of a normal individual and a hypersensitive individual. The gene expression profile of the subject that is obtained may comprise a profile of levels of mRNA or cDNA. The gene expression profile may be obtained by using an array of nucleic acid probes for the plurality of genes associated with hypersensitivity. The expression of the genes predetd. to be associated with hypersensitivity is directly related to prevention or repair of toxic damage at the tissue, organ or system level. Gene databases arrays and apparatus useful for identifying hypersensitivity in a subject are also disclosed.

IT 60-54-8, Tetracycline 64-75-5, Tetracycline hydrochloride


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)

(methods of determining individual hypersensitivity to a pharmaceutical agent from gene expression profile)

RN 60-54-8 HCAPLUS


CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S,4aS,5aS,6S,12aS)-(CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 64-75-5 HCAPLUS
 CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, hydrochloride (1:1), (4S,4aS,5aS,6S,12aS)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● HCl

IC ICM C12Q001-68
 ICS G01N033-50
 CC 3-4 (Biochemical Genetics)
 Section cross-reference(s): 1, 6, 7, 13, 15
 IT Multidrug resistance proteins
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (BCRP (breast **cancer** resistance protein); methods of determining individual hypersensitivity to a pharmaceutical agent from gene expression profile)
 IT Proteins, specific or class
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (DCC (deleted in colorectal **cancer**); methods of determining individual hypersensitivity to a pharmaceutical agent from gene expression profile)
 IT Phosphoproteins
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (IκB-α (inhibitor of **RNA** formation factor NF-κB, α); methods of determining individual hypersensitivity to a pharmaceutical agent from gene expression profile)
 IT Proteins, specific or class
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (Mcl-1 (myeloid cell **leukemia** sequence-1); methods of determining individual hypersensitivity to a pharmaceutical agent from gene expression profile)
 IT Ribonucleoproteins
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (**RNA** U1-containing, C; methods of determining individual hypersensitivity to a pharmaceutical agent from gene expression profile)
 IT Enzymes, biological studies
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL

(Biological study); PROC (Process)

(RNA-unwinding, helicases; methods of determining individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Proteins, specific or class

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(TRAF2 (tumor necrosis factor receptor-associated factor 2);

methods of determining individual hypersensitivity to a pharmaceutical

agent

from gene expression profile)

IT Gene, animal

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(leukemia inhibitory factor; methods of determining individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Aging, animal

Allergy

Apparatus

Astrocyte

Bone

Brain

Bronchodilators

Computer program

DNA microarray technology

Digestive tract

Dione

Drugs

Eye

Fibroblast

Gallbladder

Hepatitis

Hyperplasia

Hypertension

Hypotension

Immunosuppression

Inflammation

Intestine

Jaundice

Kidney

Leukemia

Leukocyte

Liver

Macrophage

Mast cell

Muscle

Mutagenesis

Necrosis

Nucleic acid hybridization

Oligodendrocyte

Ovary

Pancreas

Plantago psyllium

Podophyllum (plant)

Sex

Skin

Spleen

Statistical analysis

Stomach

Testis

Thyroid gland

(methods of determining individual hypersensitivity to a pharmaceutical

agent

from gene expression profile)

IT *Leukemia* inhibitory factor

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(methods of determining individual hypersensitivity to a pharmaceutical

agent.

from gene expression profile)

IT *Tumor* necrosis factors

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(methods of determining individual hypersensitivity to a pharmaceutical

agent

from gene expression profile)

IT *Tumor* necrosis factor receptors

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(p55; methods of determining individual hypersensitivity to a

pharmaceutical

agent from gene expression profile)

IT *Tumor* necrosis factor receptors

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(p75; methods of determining individual hypersensitivity to a

pharmaceutical

agent from gene expression profile)

IT Ribonucleoproteins

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(small nuclear *RNA*-containing, B; methods of determining individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT 50-02-2, Dexamethasone 50-06-6, Phenobarbital, biological studies

50-18-0, Cyclophosphamide 50-23-7, Hydrocortisone 50-24-8,

Prednisolone 50-28-2, Estradiol, biological studies 50-44-2,

6-Thiopurine 50-48-6, Amitriptyline 50-55-5, Reserpine 50-76-0,

Actinomycin D 50-78-2, Aspirin 51-06-9, Procainamide 51-21-8,

Fluorouracil 51-34-3, Scopolamine 51-48-9, Levothyroxine, biological

studies 51-49-0, Dextrothyroxine 51-55-8, Atropine, biological studies

51-75-2, Mechlorethamine 52-01-7, Spironolactone 52-53-9, Verapamil

52-67-5, Penicillamine 52-86-8, Haloperidol 53-03-2, Prednisone

53-06-5, Cortisone 53-19-0, Mitotane 53-33-8, Paramethasone 53-86-1,

Indomethacin 54-05-7, Chloroquine 54-11-5, Nicotine 54-31-9,

Furosemide 54-36-4, Metirapone 54-85-3, Isoniazid 55-63-0,

Nitroglycerin 55-65-2, Guanethidine 55-98-1, Busulfan 56-54-2,

Quinidine 56-75-7, Chloramphenicol 57-22-7, Vincristine 57-41-0,

Phenytoin 57-53-4, Meprobamate 57-63-6, Ethinyl estradiol 57-66-9,

Probenecid 57-83-0, Progestin, biological studies 57-96-5,

Sulfinpyrazone 58-05-9, Leucovorin 58-14-0, Pyrimethamine 58-32-2,

Dipyridamole 58-39-9, Perphenazine 58-54-8, Ethacrynic acid 58-55-9,

Theophylline, biological studies 58-61-7, Adenosine, biological studies

58-74-2, Papaverine 58-93-5, Hydrochlorothiazide 58-94-6, Thiazide

59-05-2, Methotrexate 59-42-7, Phenylephrine 59-43-8, Thiamine,

biological studies 59-92-7, Levodopa, biological studies 59-99-4,

Neostigmine 60-40-2, Mecamylamine 60-54-8, Tetracycline

60-79-7, Ergonovine 60-87-7, Promethazine 61-32-5, Methicillin

61-72-3, Cloxacillin 64-75-5, Tetracycline hydrochloride

64-77-7, Tolbutamide 64-86-8, Colchicine 65-23-6, Pyridoxine
 66-79-5, Oxacillin 66-97-7, Psoralen 67-20-9, Nitrofurantoin
 67-45-8, Furazolidone 67-68-5, Dimethyl sulfoxide, biological studies
 68-22-4D, Norethindrone, mixture with ethinyl estradiol 68-41-7,
 Cycloserine 68-88-2, Hydroxyzine 69-53-4, Ampicillin 69-72-7,
 biological studies 69-89-6, Xanthine 73-24-5, 6-Aminopurine,
 biological studies 73-31-4, Melatonin 76-42-6, Oxycodone 76-57-3,
 Codeine 77-09-8, Phenolphthalein 77-19-0, Dicyclomine 77-36-1,
 Chlorthalidone 78-44-4, Carisoprodol 80-08-0, Dapsone 81-23-2,
 Dehydrocholic acid 81-81-2, Warfarin 82-92-8, Cyclizine 82-95-1,
 Buclizine 83-43-2, Methylprednisolone 83-73-8, Iodoquinol 83-89-6,
 Quinacrine 83-98-7, Orphenadrine 86-54-4, Hydralazine 89-57-6,
 Mesalamine 90-34-6, Primaquine 90-82-4, Pseudoephedrine 91-64-5,
 Coumarin 92-13-7, Pilocarpine 92-84-2, Phenothiazine 93-14-1,
 Guaifenesin 94-20-2, Chlorpropamide 94-36-0, Benzoyl peroxide,
 biological studies 94-78-0, Phenazopyridine 95-25-0, Chlorzoxazone
 96-64-0, Soman 97-77-8, Disulfiram 99-66-1, Valproic acid 100-33-4,
 Pentamidine 100-97-0, Methenamine, biological studies 101-31-5,
 Hyoscyamine 103-90-2, Acetaminophen 113-18-8, Ethchlorvynol
 113-42-8, Methylergonovine 113-45-1, Methylphenidate 114-07-8,
 Erythromycin 114-86-3, Phenformin 118-42-3, Hydroxychloroquine
 122-09-8, Phentermine 123-56-8, Succinimide 123-63-7, Paraldehyde
 124-94-7, Triamcinolone 125-29-1, Hydrocodone 125-33-7, Primidone
 125-64-4, Methypylon 125-71-3, Dextromethorphan 125-84-8,
 Aminogluthethimide 126-07-8, Griseofulvin 126-52-3, Ethinamate
 127-07-1, Hydroxyurea 127-69-5, Sulfisoxazole 128-13-2, Ursodiol
 130-95-0, Quinine 132-17-2, Benztropine 133-10-8, Sodium
 p-aminosalicylate 137-58-6, Lidocaine 138-56-7, Trimethobenzamide
 144-11-6, Trihexyphenidyl 147-52-4, Nafcillin 147-94-4, AraC
 148-82-3, Melphalan 154-21-2, Lincomycin 154-42-7, Thioguanine
 154-93-8, Carmustine 155-97-5, Pyridostigmine 298-46-4,
 5H-Dibenz[b,f]azepine-5-carboxamide 298-50-0, Propantheline 299-42-3,
 Ephedrine 300-62-9D, Amphetamine, mixed 300-62-9D, Amphetamine, mixed
 salts 302-17-0, Chloral hydrate 302-79-4, Tretinoin 303-53-7,
 Cyclobenzaprine 305-03-3, Chlorambucil 315-30-0, Allopurinol
 321-64-2, Tacrine 346-18-9, Polythiazide 361-37-5, Methysergide
 363-24-6, Dinoprostone 364-62-5, Metoclopramide 378-44-9,
 Betamethasone 389-08-2, Nalidixic acid 395-28-8, Isoxsuprine
 439-14-5, Diazepam 443-48-1, Metronidazole 446-86-6, Azathioprine
 456-59-7, Cycloandelate 461-72-3, Hydantoin 463-04-7, Amyl nitrite
 469-62-5, Propoxyphene 474-25-9, Chenodiol 480-30-8,
 Dichloralphenazone 484-23-1, Dihydralazine 503-01-5, Isometheptene
 512-15-2, Cyclopentolate 520-85-4, Medroxyprogesterone 525-66-6,
 Propranolol 526-36-3, Xylometazoline 536-33-4, Ethionamide 541-15-1,
 Levocarnitine 546-88-3, Acetohydroxamic acid 555-30-6, Methyl dopa
 564-25-0, Doxycycline 569-65-3, Meclizine 577-11-7, Docusate sodium
 596-51-0, Glycopyrrolate 599-79-1, Sulfasalazine 603-50-9, Bisacodyl
 634-03-7, Phendimetrazine 637-07-0, Clofibrate 657-24-9, Metformin
 671-16-9, Procarbazine 672-87-7, Metyrosine 674-38-4, Bethanechol
 723-46-6, Sulfamethoxazole 738-70-5, Trimethoprim 745-65-3,
 Alprostadil 791-35-5, Chlophedianol 797-63-7, Levonorgestrel
 797-64-8D, L-Norgestrel, ethinyl estradiol mixture 846-49-1, Lorazepam
 846-50-4, Temazepam 911-45-5, Clomiphene 915-30-0, Diphenoxylate
 962-58-3, Diazoxon 968-93-4, Testolactone 972-02-1, Diphenidol
 990-73-8, Fentanyl citrate 1134-47-0, Baclofen 1143-38-0, Anthralin
 1321-13-7, Potassium aminobenzoate 1397-89-3, Amphotericin B
 1400-61-9, Nystatin 1404-04-2, Neomycin 1404-04-2D, Neomycin, mixture
 with polymyx/HC 1404-90-6, Vancomycin 1406-05-9, Penicillin
 1491-59-4, Oxymetazoline 1622-61-3, Clonazepam 1953-02-2, Tiopronin
 1977-10-2, Loxapine 2152-34-3, Pemoline 2152-44-5, Betamethasone

valerate 2447-57-6, Sulfadoxine 2451-01-6, Terpin hydrate 2609-46-3,
 Amiloride 2809-21-4 2998-57-4, Estramustine 3116-76-5, Dicloxacillin
 3313-26-6, Thiothixene 3385-03-3, Flunisolide 3485-14-1, Cyclacillin
 3737-09-5, Disopyramide

RL: **BAC** (*Biological activity or effector, except adverse*); BSU

(Biological study, unclassified); BIOL (Biological study)

(methods of determining individual hypersensitivity to a pharmaceutical
 agent
 from gene expression profile)

L109 ANSWER 15 OF 32 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:37554 HCAPLUS Full-text

DOCUMENT NUMBER: 134:248657

TITLE: Rapid identification and characterization of
 hammerhead-ribozyme inhibitors using
 fluorescence-based technology

AUTHOR(S): Jenne, Andreas; Hartig, Jorg S.; Piganeau, Nicolas;
 Tauer, Andreas; Samarsky, Dmitry A.; Green, Michael
 R.; Davies, Julian; Famulok, Michael

CORPORATE SOURCE: Kekule-Institut fur Organische Chemie und Biochemie,
 Bonn, 35121, Germany

SOURCE: Nature Biotechnology (2001), 19(1), 56-61
 CODEN: NABIF9; ISSN: 1087-0156

PUBLISHER: Nature America Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The ability to rapidly identify small mols. that interact with **RNA** would have
 significant clin. and research applications. Low-mol.-weight mols. that bind
 to **RNA** have the potential to be used as drugs. Therefore, technologies
 facilitating the rapid and reliable identification of such activities become
 increasingly important. We have applied a fluorescence-based assay to screen
 for **modulators** of hammerhead ribozyme (HHR) catalysis from a small library of
 antibiotic compds. Several unknown potent inhibitors of the hammerhead
 cleavage reaction were identified and further characterized. Tuberactinomycin
 A, for which pos. cooperativity of inhibition in vitro was found, also reduced
 ribozyme cleavage in vivo. The assay is applicable to the screening of mixts.
 of compds., as inhibitory activities were detected within a collection of
 2,000 exts. from different actinomycete strains. This approach allows the
 rapid, reliable, and convenient identification and characterization of
 ribozyme **modulators** leading to insights difficult to obtain by classical
 methodol.

IT 60-54-8, Tetracycline


RL: ANT (Analyte); **BAC** (*Biological activity or effector, except
 adverse*); BSU (Biological study, unclassified); ANST (Analytical
 study); BIOL (Biological study)

(rapid identification and characterization of hammerhead-ribozyme
 inhibitors using fluorescence-based technol.)

RN 60-54-8 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-
 3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S,4aS,5aS,6S,12aS)-
 (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



CC 7-1 (Enzymes)

IT 60-54-8, Tetracycline 119-04-0, Neomycin B 908-54-3,
 Diminazene aceturate 1405-10-3, Neomycin sulfate 1405-41-0, Gentamicin
 sulfate 3947-65-7, Neamine 11097-82-8, Gentamicin C 25316-40-9,
 Adriamycin 29144-42-1, Chelocardin 32988-50-4, Tuberactinomycin B
 33103-21-8, Tuberactinomycin A 37713-04-5, Gentamicin C1A sulfate
 55870-64-9, 5-epi-Sisomicin 57572-76-6, Gramicidin S hydrochloride
 84420-34-8, Paromomycin

RL: ANT (Analyte); BAC (Biological activity or effector, except
 adverse); BSU (Biological study, unclassified); ANST (Analytical
 study); BIOL (Biological study)

(rapid identification and characterization of hammerhead-ribozyme
 inhibitors using fluorescence-based technol.)

RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Afshar, M	1999	10	59	Curr Opin Biotechnol	HCAPLUS
Baily, C	1996	24	1460	Nucleic Acids Res	
Clouet-d'Orval, B	1995	34	11186	Biochemistry	HCAPLUS
Dassonneville, L	1997	25	4487	Nucleic Acids Res	HCAPLUS
Davies, J	1994	264	375	Science	HCAPLUS
Davies, J	1997	5	234	Trends Microbiol	MEDLINE
Earnshaw, D	1998	26	5551	Nucleic Acids Res	HCAPLUS
Ecker, D	1999	4	420	Drug Discovery Today	HCAPLUS
Gait, M	1993	18	255	Trends Biochem Sci	HCAPLUS
Hermann, T	1998	9	66	Curr Opin Biotechnol	HCAPLUS
Hermann, T	1998	276	903	J Mol Biol	HCAPLUS
Hoch, I	1998	282	557	J Mol Biol	HCAPLUS
Jenne, A	1999	38	1300	Angew Chem Int Edn	HCAPLUS
Mestre, B	1999	1445	86	Biochim Biophys Acta	HCAPLUS
Michael, K	1998	4	2091	Chemistry Eur J	HCAPLUS
Mikkelsen, N	1999	96	6155	Proc Natl Acad Sci U	HCAPLUS
Murray, J	1996	317	855	Biochem J	HCAPLUS
Neu, H	1992	257	1064	Science	HCAPLUS
Noller, H	1991	353	302	Nature	MEDLINE
Pearson, N	1997	4	409	Chem Biol	HCAPLUS
Pilch, D	1995	34	9962	Biochemistry	HCAPLUS
Rogers, J	1996	259	916	J Mol Biol	HCAPLUS
Rossi, J	1999	285	1685	Science	HCAPLUS
Samarsky, D	1998	17	3747	EMBO J	HCAPLUS
Samarsky, D	1999	96	6609	Proc Natl Acad Sci U	HCAPLUS
Schroeder, R	2000	19	1	EMBO J	HCAPLUS
Scott, W	1996	274	2065	Science	HCAPLUS
Singh, K	1999	5	1348	RNA	HCAPLUS
Stage, T	1995	1	95	RNA	HCAPLUS
Stage-Zimmermann, T	1998	4	875	RNA	HCAPLUS
Tor, Y	1999	38	1579	Angew Chem Int Edn	HCAPLUS
von Ahsen, U	1992	226	935	J Mol Biol	HCAPLUS

Walter, F	1999	3	694	Curr Opin Chem Biol	HCAPLUS
Wang, S	1998	37	5549	Biochemistry	HCAPLUS
Wang, Y	1997	36	768	Biochemistry	HCAPLUS
Werstuck, G	1998	282	296	Science	HCAPLUS
Woodcock, J	1991	10	3099	EMBO J	HCAPLUS
Zapp, M	1993	74	969	Cell	HCAPLUS
Zhu, K	1999	266	361	Biochem Biophys Res	HCAPLUS

L109 ANSWER 16 OF 32 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2000:742369 HCAPLUS Full-text

DOCUMENT NUMBER: 133:325618

TITLE: Novel transduction molecules and methods for using same

INVENTOR(S): Dowdy, Steven F.

PATENT ASSIGNEE(S): Washington University, USA

SOURCE: PCT Int. Appl., 191 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000062067	A1	20001019	WO 2000-US5097	20000228 <--
WO 2000062067	A9	20020711		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2364690	A1	20001019	CA 2000-2364690	20000228 <--
AU 2000074970	A	20001114	AU 2000-74970	20000228 <--
EP 1157275	A1	20011128	EP 2000-962058	20000228 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2003514765	T	20030422	JP 2000-611079	20000228 <--
PRIORITY APPLN. INFO.:			US 1999-122757P	P 19990228 <--
			US 1999-151291P	P 19990829 <--
			WO 2000-US5097	W 20000228 <--

OTHER SOURCE(S): MARPAT 133:325618

AB The invention relates to novel fusion mols. and methods for introducing the fusion mols. into a desired cell, tissue or organ. A fusion mol. is claimed comprising at least one protein transduction domain and at least one linked mol, wherein the linked mol. is suspected of having or has recognized capacity to treat or prevent a medical or veterinary condition in a subject mammal. The mol. linked to the fusion mol. may be a vaccine, anti-infective drug, cardiovascular drug, antitumor drug, analgesic, anti-inflammatory, diagnostic marker, or a drug for treatment or prevention of a nervous system **disorder**.

IT 60-54-8D, Tetracycline, derivs.


RL: **BAC (Biological activity or effector, except adverse)**; BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); **THU (Therapeutic use)**; BIOL (Biological study); PROC (Process); USES (Uses)

(genetic and pharmaceutical transduction mols. for therapeutic use)

RN 60-54-8 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S,4aS,5aS,6S,12aS)-(CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IC ICM G01N033-567
 CC 63-5 (Pharmaceuticals)
 Section cross-reference(s): 1, 2, 3, 9, 15
 IT Nervous system
 (*Huntington's* chorea; genetic and pharmaceutical transduction
 mols. for therapeutic use)
 IT Nervous system
 (central, **disease**; genetic and pharmaceutical transduction
 mols. for therapeutic use)
 IT Cytomegalovirus
 Hepatitis virus
 Herpesviridae
 Human immunodeficiency virus
 Papillomavirus
 (coat proteins; genetic and pharmaceutical transduction mols. for
 therapeutic use)
 IT Behavior
 (**disorder**, dyslexia; genetic and pharmaceutical transduction
 mols. for therapeutic use)
 IT **AIDS (disease)**
 Alzheimer's disease
 Amebicides
 Amnesia
 Analgesics
 Anthelmintics
 Anti-AIDS agents
 Anti-**Alzheimer's** agents
 Anti-infective agents
 Anti-inflammatory agents
 Antibiotics
 Anticonvulsants
 Antiparkinsonian agents
 Antitumor agents
 Antiviral agents
 Blood-brain barrier
 Brain, **disease**
 Cardiovascular agents
 Chimpanzee
 Circulation
 Disulfide group
 Drug bioavailability
 Encephalitis
 Epilepsy

Fungicides
 Gene therapy
 Hepatitis C virus
 Human herpesvirus 1
 Human herpesvirus 8
 Human immunodeficiency virus 1
 Human immunodeficiency virus 2
 Hydrophilicity
 Immunity
 Ischemia
 Leprosy
 Lipophilicity
 Lymphatic system
 Molecular cloning
 Molecular weight distribution
 Monkey
 Mouse
 Mutation
 Nervous system agents
 Parkinson's *disease*
 Plasmodium falciparum
 Primate
 Protozoacides
 Rabbit
 Rat
 Rodent
 Solubility
 Syringes
 Transduction, genetic
 Vaccines
 α -Helix
 (genetic and pharmaceutical transduction mols. for therapeutic use)
 IT DNA
 Proteins, general, biological studies
 RNA
 RL: BOC (Biological occurrence); BSU (Biological study; unclassified);
 BIOL (Biological study); OCCU (Occurrence)
 (genetic and pharmaceutical transduction mols. for therapeutic use)
 IT Retroviridae
 (*infection*; genetic and pharmaceutical transduction mols. for
 therapeutic use)
 IT Mental *disorder*
 (obsession-compulsion, compulsion; genetic and pharmaceutical
 transduction mols. for therapeutic use)
 IT Nervous system
 (peripheral, *disease*; genetic and pharmaceutical transduction
 mols. for therapeutic use)
 IT DNA viruses
 RNA viruses
 (proteins of human; genetic and pharmaceutical transduction mols. for
 therapeutic use)
 IT Brain, *disease*
 Prion *diseases*
 (scrapie; genetic and pharmaceutical transduction mols. for therapeutic
 use)
 IT 60-54-8D, Tetracycline, derivs. 61-33-6, biological studies
 63-74-1D, Sulfanilamide, derivs. 69-53-4, Ampicillin 114-07-8,
 Erythromycin 120-73-0D, Purine, analogs 289-95-2D, Pyrimidine, analogs
 738-70-5, Trimethoprim 1405-87-4, Bacitracin 11111-12-9, Cephalosporin
 26787-78-0, Amoxicillin

RL: **BAC** (*Biological activity or effector, except adverse*); BSU
 (Biological study, unclassified); PEP (Physical, engineering or chemical
 process); **THU** (*Therapeutic use*); BIOL (Biological study); PROC
 (Process); USES (Uses)
 (genetic and pharmaceutical transduction mols. for therapeutic use)

RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Cytogen Corporation	1998			WO 9851325 A2	HCAPLUS
Donnelly	1993	90	3530	Proc Nat Acad Sci US	HCAPLUS
Elliott	1997	88	223	Cell	HCAPLUS
Ezhevsky	1997	94	10699	Proc Nat Acad Sci US	HCAPLUS
Fawell	1994	91	664	Proc Nat Acad Sci US	HCAPLUS
Friden	1997			US 5672683 A	HCAPLUS
Pastan	1994			US 5328984 A	HCAPLUS
Vocero-Akbani	1999	5	29	Nature Medicine	HCAPLUS

L109 ANSWER 17 OF 32 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2000:553677 HCAPLUS Full-text

DOCUMENT NUMBER: 133:144909

TITLE: Screening assay for antagonists of FGFR-mediated
 malignant cell transformation and **tumor**
 formation

INVENTOR(S): Yayon, Avner; Reznitsky, Dalya; Ben-Levy, Rachel

PATENT ASSIGNEE(S): Yeda Research and Development Co. Ltd., Israel;
 Prochon Biotech Ltd.

SOURCE: PCT Int. Appl., 55 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000046343	A2	20000810	WO 2000-IL71	20000203 <--
WO 2000046343	A3	20001228		
W: CA, IL, JP, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2360745	A1	20000810	CA 2000-2360745	20000203 <--
EP 1164838	A2	20020102	EP 2000-901885	20000203 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
US 2004014024	A1	20040122	US 2001-921279	20010802 <--
PRIORITY APPLN. INFO.:			IL 1999-128380	A 19990204 <--
			WO 2000-IL71	W 20000203 <--

AB In vitro and in vivo screening assays for antagonists of fibroblast growth
 factor receptor (FGFR)-mediated malignant cell transformation are provided
 using stable cell lines genetically engineered to express a recombinant wild
 type or constitutively active mutant FGFR selected from FGFR1, FGFR2 and
 FGFR3, the malignant potential of said cell lines being modulated by said
 FGFR.

IT 60-54-8, Tetracycline

RL: **BAC** (*Biological activity or effector, except adverse*); BPR
 (Biological process); BSU (Biological study, unclassified); BIOL
 (Biological study); PROC (Process)


(tetracycline-responsive or -repressible promoter; screening assay for
 antagonists of FGFR-mediated malignant cell transformation and

tumor formation)

RN 60-54-8 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S,4aS,5aS,6S,12aS)-
(CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IC ICM C12N

CC 1-6 (Pharmacology)

ST screening antagonist FGFR mediated malignant transformation; tumor formation FGFR mediated screening antagonist

IT Receptors

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(4-1BB; screening assay for antagonists of FGFR-mediated malignant cell transformation and tumor formation)

IT Sialoglycoproteins

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(BSP II (bone sialoglycoprotein II); screening assay for antagonists of FGFR-mediated malignant cell transformation and tumor formation)

IT Proteins, specific or class

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(FRS2; screening assay for antagonists of FGFR-mediated malignant cell transformation and tumor formation)

IT Proteins, specific or class

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(Grb-2; screening assay for antagonists of FGFR-mediated malignant cell transformation and tumor formation)

IT Proteins, specific or class

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(ILA; screening assay for antagonists of FGFR-mediated malignant cell transformation and tumor formation)

IT Animal cell line

(L8-hAChR3; screening assay for antagonists of FGFR-mediated malignant cell transformation and tumor formation)

IT Animal cell line

(L8; screening assay for antagonists of FGFR-mediated malignant cell transformation and tumor formation)

IT Proteins, specific or class

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(MGP (matrix γ -carboxyglutamic acid-containing protein); screening assay for antagonists of FGFR-mediated malignant cell transformation)

and **tumor** formation)

IT Animal cell line
(RCJ-13 M14; screening assay for antagonists of FGFR-mediated malignant cell transformation and **tumor** formation)

IT Animal cell line
(RCJ-13 R1-1; screening assay for antagonists of FGFR-mediated malignant cell transformation and **tumor** formation)

IT Animal cell line
(RCJ-13 R2-2; screening assay for antagonists of FGFR-mediated malignant cell transformation and **tumor** formation)

IT Animal cell line
(RCJ-13 W11; screening assay for antagonists of FGFR-mediated malignant cell transformation and **tumor** formation)

IT Animal cell line
(RCJ; screening assay for antagonists of FGFR-mediated malignant cell transformation and **tumor** formation)

IT Transcription factors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(STAT1; screening assay for antagonists of FGFR-mediated malignant cell transformation and **tumor** formation)

IT Transcription factors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(STAT5; screening assay for antagonists of FGFR-mediated malignant cell transformation and **tumor** formation)

IT Cell aggregation
(and nodule formation; screening assay for antagonists of FGFR-mediated malignant cell transformation and **tumor** formation)

IT Cytometry
(flow; screening assay for antagonists of FGFR-mediated malignant cell transformation and **tumor** formation)

IT Cartilage
(formation; screening assay for antagonists of FGFR-mediated malignant cell transformation and **tumor** formation)

IT Neoplasm
(malignant phenotype; screening assay for antagonists of FGFR-mediated malignant cell transformation and **tumor** formation)

IT Phenotypes
(malignant; screening assay for antagonists of FGFR-mediated malignant cell transformation and **tumor** formation)

IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(matrilin-3; screening assay for antagonists of FGFR-mediated malignant cell transformation and **tumor** formation)

IT Phosphorylation, biological
(protein; screening assay for antagonists of FGFR-mediated malignant cell transformation and **tumor** formation)

IT Animal cell line
Antitumor agents
Cell differentiation
Chondrocyte
Disease models
Drug screening
Genetic vectors
Immunodeficiency
Microscopy
Mouse
Muscle

Mutation
 Myoblast
 Retroviral vectors
 Signal transduction, biological
 Transformation, neoplastic
 Turbidimetry
 (screening assay for antagonists of FGFR-mediated malignant cell transformation and **tumor** formation)

IT DNA
 Fibroblast growth factor receptors
 Promoter (genetic element)
 Proteins, general, biological studies
RNA
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (screening assay for antagonists of FGFR-mediated malignant cell transformation and **tumor** formation)

IT Immunodeficiency
 (severe combined, SCID or nude mouse; screening assay for antagonists of FGFR-mediated malignant cell transformation and **tumor** formation)

IT Genetic element
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (tetracycline tet-off transactivator; screening assay for antagonists of FGFR-mediated malignant cell transformation and **tumor** formation)

IT Tetracyclines
 RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (tetracycline-responsive or -repressible promoter; screening assay for antagonists of FGFR-mediated malignant cell transformation and **tumor** formation)

IT Collagens, biological studies
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (type II; screening assay for antagonists of FGFR-mediated malignant cell transformation and **tumor** formation)

IT Collagens, biological studies
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (type X; screening assay for antagonists of FGFR-mediated malignant cell transformation and **tumor** formation)

IT 62031-54-3, Fibroblast growth factor
 RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (screening assay for antagonists of FGFR-mediated malignant cell transformation and **tumor** formation)

IT 564-25-0, Doxycycline 151185-16-9, Fibroblast growth factor 9
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
 (screening assay for antagonists of FGFR-mediated malignant cell transformation and **tumor** formation)

IT 115926-52-8 127407-08-3, Receptor tyrosine kinase 141436-78-4, Protein kinase C 142243-02-5, Erk kinase 155215-87-5, Jnk kinase 192230-91-4, p38 SAPK
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(screening assay for antagonists of FGFR-mediated malignant cell transformation and **tumor** formation)

IT 60-54-8, Tetracycline

RL: BAC (*Biological activity or effector, except adverse*); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(tetracycline-responsive or -repressible promoter; screening assay for antagonists of FGFR-mediated malignant cell transformation and **tumor** formation)

IT 287215-60-5, 1: PN: WO0046343 PAGE: 22 unclaimed DNA

RL: PRP (Properties)

(unclaimed nucleotide sequence; screening assay for antagonists of FGFR-mediated malignant cell transformation and **tumor** formation)

IT 9001-86-9, Phospholipase C

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(γ ; screening assay for antagonists of FGFR-mediated malignant cell transformation and **tumor** formation)

L109 ANSWER 18 OF 32 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2000:475560 HCAPLUS Full-text

DOCUMENT NUMBER: 133:109949

TITLE: Pharmaceutical compositions for treatment of diseased tissues

INVENTOR(S): Lee, Clarence C.; Lee, Feng-Min

PATENT ASSIGNEE(S): USA

SOURCE: PCT Int. Appl., 26 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000040269	A2	20000713	WO 2000-US191	20000105 <--
WO 2000040269	A3	20001130		
W: AU, CA, CN, JP				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				

PRIORITY APPLN. INFO.: US 1999-114906P P 19990105 <--

AB A method to treat diseased tissue is provided where a cytotoxic compound is administered to a patient in need of treatment in combination with an immunostimulant. Diseased cells and/or infectious microbes/viruses are killed by the cytotoxic compound in the presence of the immunostimulant. The cell components including cellular contents and cell membrane fragments are presented by the immunostimulant to the host animal as antigens to stimulate the immune responses toward other diseased cells of the same type(s), that either remain in the vicinity or reside in distant tissues or organs. The cytotoxic mol. and immunostimulant are preferably applied locally at high concns., either sequentially or, preferably, simultaneously. For example, the composition can be administered directly to a target **cancer**. The composition can be prepared in various forms, such as a paste, a time release molded solid shape, a solution, a mixture with emulsifier, etc. Alternatively, the cytotoxic mol. and immunostimulant are applied in sequence.

IT 60-54-8D, Tetracycline, derivs.

RL: BAC (*Biological activity or effector, except adverse*); BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); THU (*Therapeutic use*); BIOL (Biological study); PROC


(Process); USES (Uses)

(pharmaceutical compns. for treatment of diseased tissues)

RN 60-54-8 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S,4aS,5aS,6S,12aS)-
(CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IC ICM A61K045-06

CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 2, 15

IT Cytokines

DNA

Mucopolysaccharides, biological studies

RNA

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses) (immunostimulants; pharmaceutical compns. for treatment of diseased tissues)

IT 50-35-1, Thalidomide 50-76-0, Dactinomycin 50-81-7, Ascorbic acid, biological studies 51-21-8, 5-Fluorouracil 51-79-6, Urethan 52-67-5, Penicillamine 53-19-0, Mitotane 54-42-2, Idoxuridine 54-62-6, Aminopterin 55-86-7, Nitrogen mustard 56-53-1, Diethylstilbestrol 56-75-7D, Amphenicol, derivs. 58-40-2, Prazine 59-14-3, Budr 59-30-3D, Folic acid, analogs 60-00-4, Edta, biological studies 60-54-8D, Tetracycline, derivs. 62-33-9, Calcium disodium edetate 64-02-8, Sodium edetate 64-18-6, Formic acid, biological studies 64-19-7, Acetic acid, biological studies 67-43-6, Pentetic acid 67-63-0, Isopropanol, biological studies 67-68-5, Dmsol, biological studies 68-76-8, Triaziquone 69-33-0, Tubercidin 70-51-9, Deferoxamine 73-03-0, Cordycepin 75-75-2D, Methanesulfonic acid, derivs. 112-24-3 120-73-0D, Purine, analogs 121-76-6 122-79-2, Phenylacetate 127-07-1, Hydroxyurea 127-07-1D, Hydroxyurea, derivs. 139-33-3, Disodium edetate 150-38-9, Trisodium edetate 151-56-4, Aziridine, biological studies 289-95-2D, Pyrimidine, analogs 302-79-4, Tretinoin 304-55-2, Succimer 320-67-2, 5-Azacytidine 366-70-1, Matulane 459-86-9, Mitoguazone 477-30-5, Demecolcine 518-28-5, Podophyllotoxin 569-57-3, Chlorotrianisene 636-47-5, Stallimycin 642-83-1, Aceglatone 645-05-6, Altretamine 671-16-9, Procarbazine 768-94-5, Amantadine 801-52-5, Porfiromycin 1174-11-4, Xenazoic acid 1310-73-2, Sodium hydroxide, biological studies 1402-44-4, Actinomycin F1 1404-00-8D, Mitomycin, derivs. 1508-45-8, Podophyllinic acid 2-ethylhydrazide 1910-68-5, Methisazone 1954-28-5, Etoglucid 2353-33-5 3572-60-9, Amidinomycin 3731-59-7, Moroxydine 3733-81-1, Defosfamide 3819-34-9, Phenamet 3930-19-6, Streptonigrin 4533-39-5, Nitracrine 4803-27-4, Anthramycin 5300-03-8, 9-cis-Retinoic acid 7440-06-4D, Platinum, complexes, biological studies 7647-01-0,

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000012741	A2	20000309	WO 1999-FR2051	19990827 <--
WO 2000012741	A3	20000504		
W: AU, CA, JP, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
FR 2782732	A1	20000303	FR 1998-10842	19980828 <--
CA 2341775	A1	20000309	CA 1999-2341775	19990827 <--
AU 9954262	A1	20000321	AU 1999-54262	19990827 <--
EP 1108051	A2	20010620	EP 1999-940240	19990827 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002523106	T	20020730	JP 2000-567726	19990827 <--
PRIORITY APPLN. INFO.:			FR 1998-10842	A 19980828 <--
			WO 1999-FR2051	W 19990827 <--

AB The invention concerns an inducible expression system using nucleotide sequences coding for a transcriptional activator of eukaryotic or viral origin and a recombinant adenoviral vector comprising a gene of interest placed under the control of a promoter inducible in trans by said transcriptional activator. The invention also concerns a recombinant adenoviral vector bearing a first expression cassette coding for a transcriptional activator and a second cassette bearing a gene of interest placed under the control of a promoter inducible in trans by said transcriptional activator. The invention further concerns an infectious viral particle, its preparation method, a eukaryotic cell and a pharmaceutical composition comprising such a vector or expression system as well as their use for therapeutic or prophylactic purposes. Thus, an adenoviral vector containing genes for glucocorticoid receptor GRDEX and for blood-coagulation factor IX regulated by GRE sequences was prepared. Factor IX gene expression was induced in vitro and in vivo by dexamethasone.

IT 60-54-8, Tetracycline

RL: **BAC (Biological activity or effector, except adverse);** BSU


(Biological study, unclassified); BIOL (Biological study)

(inducer; adenoviral vectors and inducible expression system for gene expression and therapy)

RN 60-54-8 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S,4aS,5aS,6S,12aS) - (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IC ICM C12N015-861

ICS C12N015-62; C12N005-10; A61K048-00

CC 3-1 (Biochemical Genetics)

IT Antisense **RNA**

Apolipoproteins

Blood-coagulation factors

Hydrochloric acid, biological studies 7647-17-8, Cesium chloride, biological studies 7664-93-9, Sulfuric acid, biological studies 7761-88-8, Silver nitrate, biological studies 9001-63-2, Lysozyme 9014-02-2, Zinostatin 9015-68-3, Asparaginase 10318-26-0, Mitolactol 11006-77-2, Statolon 11056-06-7D, Bleomycin, derivs. 12111-24-9, Calcium trisodium pentetate 13010-20-3D, Nitrosourea, derivs. 13311-84-7, Flutamide 13392-28-4, Rimantadine 13494-90-1, Gallium nitrate 13665-88-8, Mopidamol 15663-27-1, Cisplatin 18378-89-7, Plicamycin 20537-88-6, Amifostine 20830-81-3, Daunorubicin 21416-67-1, Razoxane 22668-01-5, Radinyl 23214-92-8, Doxorubicin 24967-93-9, Chondroitin sulfate A 26657-95-4, Dipalmitoylglycerol 26833-87-4, Homoharringtonine 27314-97-2, Tirapazamine 27762-78-3, Kethoxal 27778-66-1, Tenuazonic acid 29767-20-2, Teniposide 33069-62-4, Paclitaxel 33419-42-0, Etoposide 36703-88-5, Isoprinosine 36791-04-5, Ribavirin 38819-10-2, Guanine arabinoside 39389-47-4, Distamycin 41992-23-8, Spirogermanium 50264-69-2, Lonidamine 51264-14-3, Amsacrine 52205-73-9, Estramustine phosphate sodium 53678-77-6, Muramyl dipeptide 53783-83-8, Tromantadine 53910-25-1, Pentostatin 56741-95-8, Bropirimine 57998-68-2, Diaziquone 58066-85-6, Miltefosine 58337-35-2, Elliptinium acetate 58957-92-9, Idarubicin 61825-94-3, Oxaliplatin 63585-09-1, Foscarnet sodium 63612-50-0, Nilutamide 65271-80-9, Mitoxantrone 65646-68-6, Fenretinide 66676-88-8D, Aclacinomycin, derivs. 70052-12-9, Eflornithine 72732-56-0, Piritrexim 74853-75-1 74913-06-7D, Chromomycin, derivs. 75706-12-6, SU101 78186-34-2, Bisantrene 80738-43-8D, Lincosamide, derivs. 82413-20-5, Droloxifene 82952-64-5, Trimetrexate glucuronate 83314-01-6, Bryostatins 1 84088-42-6, Linomide 85622-93-1, Temozolomide 89778-26-7, Toremifene 95058-81-4, Gemcitabine 96389-68-3, Crisnatol 97682-44-5, Irinotecan 97919-22-7 98631-95-9, Sobuzoxane 98930-34-8 107868-30-4, Exemestane 110042-95-0, Acemannan 110314-48-2, Adozelesin 112809-51-5, Letrozole 114977-28-5, Docetaxel 115575-11-6, Liarozole 116057-75-1, Idoxifene 120511-73-1, Anastrozole 121181-53-1, Filgrastim 123948-87-8, Topotecan 125317-39-7, Navelbine 126268-81-3, CI-980 127779-20-8, Saquinavir 129618-40-2, Nevirapine 129655-21-6, Bizelesin 133432-71-0, Peldesine 135467-16-2, Octreotide pamoate 136817-59-9, Delavirdine 144849-63-8, Bisnafide 150378-17-9, Indinavir 154361-50-9, Capecitabine 155213-67-5, Ritonavir 159768-75-9, RMP-7 159997-94-1, VX-710 282102-49-2 282102-50-5 282527-39-3 282527-40-6

RL: **BAC** (**Biological activity or effector, except adverse**); BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); **THU** (**Therapeutic use**); BIOL (Biological study); PROC (Process); USES (Uses)
(pharmaceutical compns. for treatment of diseased tissues)

L109 ANSWER 19 OF 32 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2000:161479 HCAPLUS Full-text

DOCUMENT NUMBER: 132:204016

TITLE: Adenoviral vectors and inducible expression system for gene expression and therapy

INVENTOR(S): Mehtali, Majid; Sorg-guss, Tania

PATENT ASSIGNEE(S): Transgene S.A., Fr.

SOURCE: PCT Int. Appl., 75 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

CFTR (cystic fibrosis transmembrane conductance regulator)

Chemokines

Cytokines

Dystrophin

Enzymes, biological studies

Growth factors, animal

Immunoglobulins

Interleukin 10

Ligands

Receptors

Ribozymes

RL: BPN (Biosynthetic preparation); THU (Therapeutic use); BIOL

(Biological study); PREP (Preparation); USES (Uses)

(adenoviral vectors and inducible expression system for gene expression and therapy)

IT Gene, animal

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL

(Biological study); PROC (Process)

(*tumor* suppressor, products of; adenoviral vectors and inducible expression system for gene expression and therapy)

IT Antigens

RL: BPN (Biosynthetic preparation); THU (Therapeutic use); BIOL

(Biological study); PREP (Preparation); USES (Uses)

(*tumor*-associated; adenoviral vectors and inducible expression system for gene expression and therapy)

IT 50-02-2, Dexamethasone 60-54-8, Tetracycline 564-25-0

1746-01-6, 2,3,7,8-Tetrachlorodibenzo-p-dioxin 10540-29-1, Tamoxifen

38778-30-2, Muristerone A 53123-88-9, Rapamycin

RL: BAC (*Biological activity or effector, except adverse*); BSU

(Biological study, unclassified); BIOL (Biological study)

(inducer; adenoviral vectors and inducible expression system for gene expression and therapy)

L109 ANSWER 20 OF 32 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1999:691109 HCAPLUS Full-text

DOCUMENT NUMBER: 131:335805

TITLE: Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity

INVENTOR(S): Umana, Pablo; Jean-Mairet, Joel; Bailey, James E.

PATENT ASSIGNEE(S): Switz.

SOURCE: PCT Int. Appl., 79 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9954342	A1	19991028	WO 1999-US8711	19990420 <--
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
AU 9936578	A	19991108	AU 1999-36578	19990420 <--
EP 1071700	A1	20010131	EP 1999-918731	19990420 <--

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, FI

JP 2002512014	T	20020423	JP 2000-544680	19990420 <--
US 6602684	B1	20030805	US 1999-294584	19990420 <--
US 2004072290	A1	20040415	US 2003-437388	20030514 <--
US 2005074843	A1	20050407	US 2003-633699	20030805 <--
PRIORITY APPLN. INFO.:			US 1998-82581P	P 19980420 <--
			US 1999-294584	A1 19990420 <--
			WO 1999-US8711	W 19990420 <--

AB The present invention relates to the field of glycosylation engineering of proteins. More particularly, the present invention is directed to the glycosylation engineering of proteins to provide proteins with improved therapeutic properties, e.g., antibodies, antibody fragments, or a fusion protein that includes a region equivalent to the Fc region of an Ig, with enhanced Fc-mediated cellular cytotoxicity. The antibodies or fusion proteins with enhanced Fc-mediated cellular cytotoxicity are expressed in host cells engineered to also express a glycoprotein-modifying glycosyl transferase, e.g. $\beta(1,4)$ -N-acetylglucosaminyltransferase III or V, $\beta(1,4)$ -N-galactosyltransferase, and mannosidase II.


IT 60-54-8, Tetracycline

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study) (co-expression of glycosyltransferase and chimeric antibody for engineering glycosylated antibodies with improved antibody-dependent cellular cytotoxicity)

RN 60-54-8 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S,4aS,5aS,6S,12aS)-(CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IC ICM C07H021-04

ICS A61K039-395; A61K038-43; C12N015-00

CC 15-3 (Immunochemistry)

Section cross-reference(s): 3, 7

IT RNA

Reporter gene

mRNA

RL: ARU (Analytical role, unclassified); BUU (Biological use, unclassified); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(co-expression of glycosyltransferase and chimeric antibody for engineering glycosylated antibodies with improved antibody-dependent cellular cytotoxicity)

IT Melanoma

(human; co-expression of glycosyltransferase and chimeric antibody for engineering glycosylated antibodies with improved antibody-dependent cellular cytotoxicity)

IT 60-54-8, Tetracycline

RL: BAC (*Biological activity or effector, except adverse*); BSU
 (Biological study, unclassified); BIOL (Biological study)
 (co-expression of glycosyltransferase and chimeric antibody for
 engineering glycosylated antibodies with improved antibody-dependent
 cellular cytotoxicity)

RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Amstutz	1993	53	147	Int J Cancer	HCAPLUS
Durr	1993	20	858	Eur J Nucl Med	
Sburlati	1998	14	189	Biotechnology Progre	HCAPLUS
Sburlati	1997	14	781	Glycoconjugate Journ	
Trill			558	Current Opinion in B	
Trill	1995	6	553	Current Opinion in B	HCAPLUS
Umana	1999	17	176	Nature Biotechnology	HCAPLUS
Wright	1997	15	26	Tibtech	HCAPLUS

L109 ANSWER 21 OF 32 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1999:599268 HCAPLUS Full-text

DOCUMENT NUMBER: 132:120595

TITLE: Regulation of nitric oxide and inflammatory mediators
 in human osteoarthritis-affected cartilage:
 Implication for pharmacological intervention

AUTHOR(S): Amin, Ashok R.; Attur, Mukundan G.; Abramson, Steven
 B.

CORPORATE SOURCE: Department of Rheumatology and Medicine, Hospital for
 Joint Diseases, New York, NY, 10003, USA

SOURCE: Endothelial Cell Research Series (1999),
 5(Pathophysiology and Clinical Applications of Nitric
 Oxide, Pt. B), 397-412
 CODEN: ECRSFY; ISSN: 1384-1270

PUBLISHER: Harwood Academic Publishers

DOCUMENT TYPE: Journal; General Review

LANGUAGE: English

AB A review, with 68 refs. Human OA-affected cartilage demonstrates spontaneous
 superinduction of NO and PGE2 production in ex vivo conditions which is
 sensitive to inhibitors of RNA transcription and protein translation. Human
 OA-affected cartilage expresses NOS that has properties similar to ncNOS and
 iNOS. The spontaneous release of NO is regulated by autocrine IL-1 β or
 paracrine IL-17. Intra-articular NO downregulates PGE2 production in OA-
 affected cartilage, whereas increases in intracellular cAMP or PKC activation
 downregulates the spontaneous (or cytokine induced) NO production. The OA-
 affected cartilage also releases several other inflammatory mediators which
 include TNF α , IL-6 and IL-8. Various anti-inflammatory drugs used in the
 treatment of arthritis including aspirin, sodium salicylate, tetracyclines,
 cyclosporine and rapamycin inhibit NO production in OA-affected cartilage.
 Thus, OA cartilage is a rich source of inflammatory mediators, a site of
 activated cytokine production and of prodigious amts. of both NO and PGE2. So
 conceived, OA cartilage is a tissue "inflamed", brimming with phlogistic
 products that can serve as targets of future pharmacol. intervention.

IT 60-54-8, Tetracycline


RL: BAC (*Biological activity or effector, except adverse*); BSU
 (Biological study, unclassified); THU (*Therapeutic use*); BIOL
 (Biological study); USES (Uses)
 (nitric oxide and inflammatory mediators in human osteoarthritis-
 affected cartilage)

RN 60-54-8 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-

3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S,4aS,5aS,6S,12aS) -
(CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



CC 14-0 (Mammalian Pathological Biochemistry)

Section cross-reference(s): 1, 2

IT Interleukin 17

Interleukin 1 β

Interleukin 6

Interleukin 8

Tumor necrosis factors

RL: BOC (Biological occurrence); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence); PROC (Process)

(nitric oxide and inflammatory mediators in human osteoarthritis-affected cartilage)

IT 50-78-2, Aspirin 60-54-8, Tetracycline 53123-88-9, Rapamycin 59865-13-3, Cyclosporine A

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(nitric oxide and inflammatory mediators in human osteoarthritis-affected cartilage)

RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Abramson, S	1994	47	563	Biochem Pharmac	HCAPLUS
Abramson, S	1985	82	7227	Nat Acad Sci USA	HCAPLUS
Amin, A	1998	41	1141	Arthritis & Rheum	
Amin, A	1997	410	59	FEBS Letters	
Amin, A	1997	99	1231	J Clin Invest	HCAPLUS
Amin, A	1995	183	2097	J Exp Med	
Amin, A	1995	92	1926	Proc Natl Acad Sci U	
Amin, A	1996	93	14014	Proc Natl Acad Sci U	HCAPLUS
Attur, M	1997	40	1050	Arthritis & Rheum	HCAPLUS
Attur, M	1998			Manuscript in prepar	
Attur, M	1998	6	269	Osteoarthritis & Car	MEDLINE
Attur, M	1998	110	1	Proc of Assoc of Ame	
Bandara, G	1992		205	Biological Regulatio	HCAPLUS
Belmont, M	1997	40	1810	Arthritis & Rheum	
Black, R	1997	385	729	Nature	HCAPLUS
Blanco, F	1995	146	75	Amer J Pathol	HCAPLUS
Blanco, F	1995	218	319	Expt Cell Res	HCAPLUS
Blanco, F	1995	154	4018	Journal of Immunol	HCAPLUS
Bombardier, S	1981	73	893	Br J Pharmacol	
Broxmeyer, H	1996	183	2411	J Exp Med	HCAPLUS
Davies, P	1984	2	335	Annual Rev Immunol	HCAPLUS

Davies, P	1992		123	Inflammation: Basic	
DeClerck, Y	1994	732	222	Ann NY Acad Sci	MEDLINE
DiCesare, P	1998			J of Orthropaedics	
Dower, S	1989	142	4314	J Immunol	HCAPLUS
Evans, C	1996	10	38	Methods	HCAPLUS
Farivar, R	1996	271	31585	J Biol Chem	HCAPLUS
Fossiez, F	1996	183	2593	J Exp Med	HCAPLUS
Frantz, B	1995	270	2017	Science	HCAPLUS
Frenkel, S	1996	39	1905	Arthritis & Rheum	HCAPLUS
Furst, D	1994	37	1	Arthritis & Rheum	MEDLINE
Geng, Y	1995	163	545	J Cell Physiol	HCAPLUS
Gilliam, M	1993	212	359	Anal Biochem	HCAPLUS
Goldring, M	1993		281	Joint Cartilage Degr	HCAPLUS
Golub, L	1991	2	297	Crit Rev Oral Biol M	MEDLINE
Golub, L	1992	2	80	Curr Opin Dent	MEDLINE
Hough, A	1993		1699	Arthritis and Allied	
Kasten, T	1994	91	3567	Proc Natl Acad Sci U	
Kopp, E	1994	265	956	Science	MEDLINE
Lu, X	1995	92	7961	Proc Natl Acad Sci U	HCAPLUS
Maier, R	1994	1208	145	Biochim Biophys Acta	HCAPLUS
Maragoudakis, M	1994	732	280	Ann NY Acad Sci	HCAPLUS
Mills, P	1996	52	119	British Vet Journal	
Moss, M	1997	385	733	Nature	HCAPLUS
Murrel, G	1995	206	15	Biochem Biophys Res	
Nathan, C	1994	78	915	Cell	HCAPLUS
Palmer, R	1992	188	209	Biochem Biophys Res	HCAPLUS
Palmer, R	1993	193	398	Biochem Biophys Res	HCAPLUS
Patel, R	1998	160	4570	J Immunol	
Pelletier, J	1996	4	77	Osteoarthritis & Car	MEDLINE
Pelletier, J	1991	20	12	Semin Arthritis & Re	MEDLINE
Peunova, N	1995	375	68	Science	HCAPLUS
Ramamurthy, N	1994	732	427	Ann NY Acad Sci	HCAPLUS
Recklies, A	1992	35	1510	Arthritis & Rheum	HCAPLUS
Rifkin, B	1994	732	165	Ann NY Acad Sci	HCAPLUS
Robinson, D	1975	56	1181	J Clin Inv	HCAPLUS
Sakurai, H	1995	96	2357	J Clin Invest	HCAPLUS
Schlaak, J	1996	14	155	Clin Exp Rheumatol	MEDLINE
Schmidt, H	1994	78	919	Cell	HCAPLUS
Taskiran, D	1994	200	142	Biochem Biophys Res	HCAPLUS
Togashi, H	1997	94	2676	Proc Natl Acad Sci U	HCAPLUS
Trachman, H	1996	229	243	Biochem Biophys Comm	
Tsujii, M	1995	83	493	Cell	HCAPLUS
Uitto, V	1994	732	140	Ann NY Acad Sci	HCAPLUS
Vane, J	1994	367	215	Nature	MEDLINE
Venn, G	1993	36	819	Arthritis & Rehum	HCAPLUS
Yao, Z	1995	3	811	Immunity	HCAPLUS
Yu, L	1992	35	1150	Arthritis & Rheum	

L109 ANSWER 22 OF 32 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1999:393034 HCAPLUS Full-text

DOCUMENT NUMBER: 131:40554

TITLE: Oncogene or virus induced multistep expression systems for gene therapy

INVENTOR(S): Muller, Rolf; Sedlacek, Hans-Harald

PATENT ASSIGNEE(S): Hoechst Marion Roussel Deutschland GmbH, Germany

SOURCE: Eur. Pat. Appl., 44 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 922768	A2	19990616	EP 1998-121471	19981111 <--
EP 922768	A3	20000105		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
DE 19751587	A1	19990729	DE 1997-19751587	19971121 <--
CA 2251257	A1	19990521	CA 1998-2251257	19981119 <--
AU 9893256	A	19990610	AU 1998-93256	19981119 <--
AU 745614	B2	20020328		
HU 9802681	A1	20001028	HU 1998-2681	19981119 <--
CN 1221033	A	19990630	CN 1998-122537	19981120 <--
BR 9804720	A	20000328	BR 1998-4720	19981120 <--
US 6465246	B1	20021015	US 1998-196099	19981120 <--
JP 2000106886	A	20000418	JP 1998-333200	19981124 <--
PRIORITY APPLN. INFO.:		DE 1997-19751587	A	19971121 <--
<p>AB The invention concerns a DNA construct for the expression of an effector gene containing promoter I (component a) that regulates the expression of the transcription factor gene (component b); promoter II (component c) that is specifically bound by the product of the transcription factor gene and that regulates the expression of the effector gene (component d); all components are part of the same DNA construct; the activity of the gene product of the transcription factor gene is dependent on one or more cellular regulatory protein(s), that bind specifically to the gene product and influence its activity. The invention also concerns cells hosting the construct and the application for gene therapy and production of gene therapeutics. Effector genes are coding for pharmacol. active substances, pharmacons, enzymes or their precursors, or fusion proteins with signal proteins; and are used for therapy or prophylaxis. In one of the versions the component b consists of the b1 activation domain, the b2 regulatory protein binding sequence, and the b3 DNA-binding domain for a transcription factor. The b2 sequence is a viral or bacterial binding protein sequence; this ensures that in healthy cells the function of the transcription factor gene is inhibited; regulatory proteins that are produced in infected cells bind to the sequence; thus the transcription factor becomes activated. In a specific version b2 represents an antibody or antibody fragment with VH or VL binding sequences for a regulatory protein; humanized murine antibodies, recombinant antibody fragments produced in hybridoma cells, or isolates from libraries are used. DNA expressing the antibody fragments are ligated to b1 and b3 components. Examples of activation domains (component b1) are: cDNA for the acidic transactivation domain of HSV1-VP16, activation domain of Oct-2, SP1, NFY etc. Examples of DNA-binding domains (component b2) are: cDNA for the DNA-binding domains of Gal4 protein, LEXA protein, lac-repressor protein, etc. In another version the construct consist of promoter I (component a'), the repressor (component b'); the activation sequence (component c1) induced by b'; the DNA binding sequence for the repressor protein (component c2). The promoter I (component a') consists of a DNA-binding sequence for a regulatory protein (component a1), and a basal promoter (component a2). Examples for component a1 are: the DNA binding sequences of p53 protein, Wt-1 protein, NF-Kappa B protein, E2f/DP1 complex, and Myc/Max protein. Examples for component a2 are: the basal promoter of SV40, c-fos, U2 sn RNA-promoter, HSV TK promoter. Activation sequences are (component a or component c1): non-constitutive activation promoters, e.g. promoters of RNA polymerase II and III, CMV promoter and enhancer, SV40 promoter; viral promoters and activation sequences, e.g. HBV, HCV, HIV, etc.; promoters with metabolic activation, e.g. hypoxia induced enhancer; promoters that are activated cell cycle-specific, e.g. promoters of the genes cdc25c, Cyclin A etc.; tetracyclin induced promoters; cell specific promoters, e.g. promoters and activation sequences of</p>				

endothelial cells, or of contiguous cells, smooth muscle cells, glial cells etc. The effector genes are for **tumor** therapy, with the following target cells: endothelium, stroma cells, muscle cells, **tumor** cells, **leukemia** cells. The effector genes include cell specific promoters, inhibitors for cell proliferation, blood activation factor inducing genes, angiogenesis inhibitors, cytostatics, cytotoxics, cytokines, growth factors, etc. also in form of fusion proteins.

IT 60-54-8, Tetracycline

RL: BPR (Biological process); BSU (Biological study, unclassified);

THU (Therapeutic use); BIOL (Biological study); PROC (Process);


USES (Uses)

(induced promoter; oncogene or virus induced multistep expression systems for gene therapy)

RN 60-54-8 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S,4aS,5aS,6S,12aS)-(CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IC ICM C12N015-85

ICS C12N015-63; A61K031-70; A61K048-00; A61K038-17; C12N005-10; C07K014-47

CC 3-2 (Biochemical Genetics)

Section cross-reference(s): 14

IT Proteins, specific or class

RL: BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses) (LMP-2A (latent-**infection** membrane protein 2A), from EBV; oncogene or virus induced multistep expression systems for gene therapy)

IT Proteins, specific or class

RL: BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses) (LMP-2B (latent-**infection** membrane protein 2B), from EBV; oncogene or virus induced multistep expression systems for gene therapy)

IT Genetic element

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (RNA formation factor E2F-responsive element, promoters using; oncogene or virus induced multistep expression systems for gene therapy)

IT Nervous system

(central, **disease**; oncogene or virus induced multistep expression systems for gene therapy)

IT Blood

(**disease**; oncogene or virus induced multistep expression

systems for gene therapy)

IT Adenoviridae
 Allergy
 Anemia (disease)
 Animal virus
 Anticoagulants
 Arthritis
 Autoimmune **disease**
 Cell proliferation
 Connective tissue
 Digestive tract
 Drug delivery systems
 Gene therapy
 Hematopoietic precursor cell
 Human papillomavirus 16
 Human papillomavirus 18
 Immune tolerance
 Infection
 Inflammation
 Kidney
 Leukemia
 Lung
 Lymphocyte
 Macrophage
 Neoplasm
 Skin
 Transcriptional regulation
 Transplant and Transplantation
 (oncogene or virus induced multistep expression systems for gene therapy)


IT Cytomegalovirus
 Hepatitis B virus
 Hepatitis C virus
 Human T-lymphotropic virus
 Human herpesvirus
 Human herpesvirus 4
 Human immunodeficiency virus
 Human papillomavirus
 (promoter sequences of; oncogene or virus induced multistep expression systems for gene therapy)

IT 60-54-8, Tetracycline
 RL: BPR (Biological process); BSU (Biological study, unclassified);
THU (Therapeutic use); BIOL (Biological study); PROC (Process);
 USES (Uses)
 (induced promoter; oncogene or virus induced multistep expression systems for gene therapy)

L109 ANSWER 23 OF 32 HCAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1999:53462 HCAPLUS Full-text
 DOCUMENT NUMBER: 130:76154
 TITLE: P53 as a regulator of cell differentiation, and method
 of screening for differentiation agents
 INVENTOR(S): Vize, Peter D.; Wallingford, John B.
 PATENT ASSIGNEE(S): Board of Regents, the University of Texas System, USA
 SOURCE: PCT Int. Appl., 71 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9901763	A2	19990114	WO 1998-US13797	19980701 <--
WO 9901763	A3	19990325		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9882841	A	19990125	AU 1998-82841	19980701 <--
US 6479285	B1	20021112	US 1998-108843	19980701 <--
ZA 9805833	A	19990114	ZA 1998-5833	19980702 <--
PRIORITY APPLN. INFO.:			US 1997-51549P	P 19970702 <--
			US 1997-515494P	P 19970702 <--
			WO 1998-US13797	W 19980701 <--
AB The invention involves the role of p53 in the differentiation of embryonic tissues. More particularly, the invention provides methods of the blocking of p53 function in embryonic tissues, and the use of these tissues as screening tools for substances that are capable of overcoming the p53-related block in differentiation, both in vitro and in vivo. The similarities between undifferentiated embryonic cells and <i>tumor</i> cells is evident, and thus these assays serve as a model for possible <i>cancer</i> therapeutics. In addition, methods for identifying addnl. cellular components that interact p53 or p53-related pathways are provided.				
IT 60-54-8, Tetracycline				
RL: BAC (<i>Biological activity or effector, except adverse</i>); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)				
(and tetracycline promoter; identification of genes involved in p53-mediated embryonic cell differentiation)				
RN 60-54-8 HCAPLUS				
CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S,4aS,5aS,6S,12aS)-(CA INDEX NAME)				

Absolute stereochemistry. Rotation (-).



IC ICM G01N033-50
 CC 1-1 (Pharmacology)
 Section cross-reference(s): 13
 IT Antisense DNA
 Antisense *RNA*
 RL: BAC (*Biological activity or effector, except adverse*); BSU (Biological study, unclassified); BIOL (Biological study)
 (P53 as a regulator of cell differentiation, and method of screening

for differentiation agents)

IT DNA
Nucleic acids
RNA
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(p53 mutant-encoding; P53 as a regulator of cell differentiation, and method of screening for differentiation agents)

IT 60-54-8, Tetracycline
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(and tetracycline promoter; identification of genes involved in p53-mediated embryonic cell differentiation)

L109 ANSWER 24 OF 32 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1998:147346 HCAPLUS Full-text

DOCUMENT NUMBER: 128:213381

TITLE: Compositions and methods for treating
infections using analogs of indolicidinINVENTOR(S): Fraser, Janet R.; West, Michael H. P.; Krieger,
Timothy J.; Taylor, Robert; Erfle, Douglas

PATENT ASSIGNEE(S): Micrologix Biotech, Inc., Can.

SOURCE: PCT Int. Appl., 130 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9807745	A2	19980226	WO 1997-US14779	19970821 <--
WO 9807745	A3	19980709		
W: AL, AM, AT, AU, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, AZ				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2263799	A1	19980226	CA 1997-2263799	19970821 <--
AU 9743279	A	19980306	AU 1997-43279	19970821 <--
EP 925308	A2	19990630	EP 1997-941352	19970821 <--
EP 925308	B1	20020605		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2001500477	T	20010116	JP 1998-510994	19970821 <--
EP 1174439	A2	20020123	EP 2001-119148	19970821 <--
EP 1174439	A3	20030326		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
AT 218579	T	20020615	AT 1997-941352	19970821 <--
ES 2178000	T3	20021216	ES 1997-941352	19970821 <--
HK 1021824	A1	20030221	HK 1999-106212	19991230 <--
US 2004009910	A1	20040115	US 2003-351985	20030124 <--
JP 2005225857	A	20050825	JP 2004-242925	20040823 <--
PRIORITY APPLN. INFO.:			US 1996-24754P	P 19960821 <--
			US 1997-34949P	P 19970113 <--

10692764

US 1997-915314	A1 19970820 <--
EP 1997-941352	A3 19970821 <--
JP 1998-510994	A3 19970821 <--
WO 1997-US14779	W 19970821 <--
US 2000-667486	A1 20000922 <--

OTHER SOURCE(S): MARPAT 128:213381

AB Compns. and methods for treating *infections*, especially bacterial *infections*, are provided. Indolicidin peptide analogs containing at least two basic amino acids are prepared. The analogs are administered as modified peptides, preferably containing photo-oxidized solubilizer.

IT 60-54-8, Tetracycline 60-54-8D, Tetracycline, derivs.
564-25-0, Doxycycline 564-25-0D, Doxycycline, derivs.
13614-98-7, Minocycline hydrochloride 13614-98-7D,
Minocycline hydrochloride, derivs.


RL: BAC (Biological activity or effector, except adverse); BSU
(Biological study, unclassified); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)

(indolicidin analogs, and combinations with other agents, for treating
infections)

RN 60-54-8 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-
3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S,4aS,5aS,6S,12aS) -
(CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 60-54-8 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-
3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S,4aS,5aS,6S,12aS) -
(CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 564-25-0 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-
3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S,4aR,5S,5aR,6R,12aS) -
(CA INDEX NAME)


Absolute stereochemistry.



RN 564-25-0 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S,4aR,5S,5aR,6R,12aS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 13614-98-7 HCAPLUS

CN 2-Naphthacenecarboxamide, 4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, hydrochloride (1:1), (4S,4aS,5aR,12aS)- (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 13614-98-7 HCAPLUS

CN 2-Naphthacenecarboxamide, 4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, hydrochloride (1:1), (4S,4aS,5aR,12aS)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

- IC ICM C07K007-06
ICS C07K007-08; C07K014-00; C07K016-44; C12N015-11; A61K038-16;
A61K038-08; A61K038-10; A61K047-48
- CC 1-5 (Pharmacology)
Section cross-reference(s): 34, 63
- IT Streptococcus
(Viridans-group; indolicidin analogs, and combinations with other agents, for treating *infections*)
- IT Antibiotics
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(aminoglycoside; indolicidin analogs, and combinations with other agents, for treating *infections*)
- IT Structure-activity relationship
(bactericidal; indolicidin analogs, and combinations with other agents, for treating *infections*)
- IT Alkaloids, biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cinchonane; indolicidin analogs, and combinations with other agents, for treating *infections*)
- IT Proteins, specific or class
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conjugates, with polyoxyalkylene glycol and fatty acid; indolicidin analogs, and combinations with other agents, for treating *infections*)
- IT Fatty acids, biological studies
Polyoxyalkylenes, biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conjugates; indolicidin analogs, and combinations with other agents, for treating *infections*)
- IT Bacteria (Eubacteria)
(diphtheroid; indolicidin analogs, and combinations with other agents, for treating *infections*)
- IT Drug delivery systems
(drops; indolicidin analogs, and combinations with other agents, for treating *infections*)
- IT Drug delivery systems
(enteric; indolicidin analogs, and combinations with other agents, for treating *infections*)

IT Drug delivery systems
 (implants; indolicidin analogs, and combinations with other agents, for treating *infections*)

IT Polyoxyalkylenes, biological studies
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (indolicidin analog conjugates; indolicidin analogs for treating *infections*)

IT Acinetobacter
 Acinetobacter calcoaceticus
 Adenoviridae
 Alphavirus
 Anaerobic bacteria
 Anti-infective agents
 Antibacterial agents
 Antimalarials
 Antimicrobial agents
 Antiviral agents
 Arenavirus
 Ascaris lumbricoides
 Babesia
 Bacillus (bacterium genus)
 Bacteroides
 Balantidium coli
 Blastocystis hominis
 Bordetella pertussis
 Borrelia
 Bovine *leukemia* virus
 Brucella
 Bunyavirus
 Campylobacter
 Chlamydia
 Clonorchis sinensis
 Clostridium
 Coagulase-negative Staphylococcus
 Coronavirus
 Corynebacterium
 Cryptosporidium parvum
 Cytomegalovirus
 Drug delivery systems
 Echinococcus
 Encephalitozoon
 Entamoeba
 Enterobacter
 Enterobacter cloacae
 Enterococcus faecalis
 Enterococcus faecium
 Enterovirus
 Escherichia coli
 Fasciola hepatica
 Fasciolopsis buski
 Filovirus
 Flavivirus
 Fungicides
 Genetic vectors
 Giardia lamblia
 Gram-negative bacteria
 Gram-positive bacteria (Firmicutes)
 Haemophilus ducreyi

Haemophilus influenzae
 Hantavirus
 Helicobacter pylori
 Hemolysis
 Hepadnaviridae
 Heterophyes heterophyes
 Human T-lymphotropic virus
 Hymenolepis
 Influenza virus
 Klebsiella pneumoniae
 Legionella
 Leishmania
 Lentivirus
 Listeria
 Lyssavirus
 Medical goods
 Mold (fungus)
 Molecular structure
 Molluscipoxvirus
 Moraxella catarrhalis
 Mycobacterium
 Mycoplasma
 Neisseria
 Nematode (Nematoda)
 Orthopoxvirus
 Papillomavirus
 Paramyxovirus
 Parasitocides
 Parvovirus
 Peptostreptococcus
 Pharmacokinetics
 Plasmodium (malarial genus)
 Polyomavirus
 Propionibacterium acnes
 Protozoacides
 Pseudomonas aeruginosa
 RNA viruses
 Reoviridae
 Rhinovirus
 Rickettsia
 Rotavirus
 Salmonella
 Schistosoma
 Serratia marcescens
 Shigella
 Simplexvirus
 Staphylococcus aureus
 Staphylococcus epidermidis
 Stenotrophomonas maltophilia
 Streptococcus pneumoniae
 Streptococcus pyogenes
 Taenia
 Tapeworm (Cestoda)
 Toxicity
 Toxoplasma gondii
 Trematode (Trematoda)
 Treponema
 Trichinella
 Trichomonas
 Trypanosoma

Ureaplasma
 Varicellovirus
 Yeast
 Yersinia
 (indolicidin analogs, and combinations with other agents, for treating
 infections)

IT Antibiotics
 Glycopeptides
 Interferons
 Peptides, biological studies
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
 (Uses)
 (indolicidin analogs, and combinations with other agents, for treating
 infections)

IT Nucleic acids
 RL: BPR (Biological process); BSU (Biological study, unclassified); THU
 (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
 (indolicidin analogs, and combinations with other agents, for treating
 infections)

IT Antibodies
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (indolicidin analogs, and combinations with other agents, for treating
 infections)

IT Drug delivery systems
 (inhalants; indolicidin analogs, and combinations with other agents,
 for treating *infections*)

IT Drug delivery systems
 (injections, i.m.; indolicidin analogs, and combinations with other
 agents, for treating *infections*)

IT Drug delivery systems
 (injections, i.p.; indolicidin analogs, and combinations with other
 agents, for treating *infections*)

IT Drug delivery systems
 (injections, i.v.; indolicidin analogs, and combinations with other
 agents, for treating *infections*)

IT Drug delivery systems
 (injections, s.c.; indolicidin analogs, and combinations with other
 agents, for treating *infections*)

IT Drug delivery systems
 (injections; indolicidin analogs, and combinations with other agents,
 for treating *infections*)

IT Drug delivery systems
 (liposomes; indolicidin analogs, and combinations with other agents,
 for treating *infections*)

IT Antibiotics
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
 (Uses)
 (macrolide; indolicidin analogs, and combinations with other agents,
 for treating *infections*)

IT Antibodies
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (monoclonal; indolicidin analogs, and combinations with other agents,
 for treating *infections*)

IT Drug delivery systems
 Drug delivery systems
 (nasal sprays; indolicidin analogs, and combinations with other agents,
 for treating *infections*)

IT Drug delivery systems

- (oral; indolicidin analogs, and combinations with other agents, for treating *infections*)
- IT Membranes, nonbiological
(permeabilization; indolicidin analogs, and combinations with other agents, for treating *infections*)
- IT UV radiation
(polyoxyalkylene glycol activation with; indolicidin analogs, and combinations with other agents, for treating *infections*)
- IT Antibodies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(single chain; indolicidin analogs, and combinations with other agents, for treating *infections*)
- IT Drug delivery systems
(slow-release; indolicidin analogs, and combinations with other agents, for treating *infections*)
- IT Drug delivery systems
(sprays; indolicidin analogs, and combinations with other agents, for treating *infections*)
- IT Drug delivery systems
(suppositories, vaginal; indolicidin analogs, and combinations with other agents, for treating *infections*)
- IT Drug delivery systems
(suppositories; indolicidin analogs, and combinations with other agents, for treating *infections*)
- IT Drug interactions
(synergistic; indolicidin analogs, and combinations with other agents, for treating *infections*)
- IT Drug delivery systems
(topical; indolicidin analogs, and combinations with other agents, for treating *infections*)
- IT Amino acids, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(D-; indolicidin analogs, and combinations with other agents, for treating *infections*)
- IT 13721-01-2
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(derivs., antibiotics; indolicidin analogs, and combinations with other agents, for treating *infections*)
- IT 140896-21-5D, Indolicidin, analogs 204244-86-0 204244-86-0D, branched peptide and other derivs. 204244-87-1 204244-87-1D, branched peptide and other derivs. 204244-88-2 204244-88-2D, branched peptide and other derivs. 204244-89-3 204244-89-3D, branched peptide and other derivs. 204244-90-6 204244-90-6D, branched peptide and other derivs. 204244-91-7 204244-91-7D, branched peptide and other derivs. 204244-92-8 204244-92-8D, branched peptide and other derivs. 204244-93-9 204244-93-9D, branched peptide and other derivs. 204244-94-0 204244-94-0D, branched peptide and other derivs. 204244-95-1 204244-95-1D, branched peptide and other derivs. 204244-96-2 204244-96-2D, branched peptide and other derivs. 204244-97-3 204244-97-3D, branched peptide and other derivs. 204244-98-4 204244-98-4D, branched peptide and other derivs. 204244-99-5 204244-99-5D, branched peptide and other derivs. 204245-00-1 204245-00-1D, branched peptide and other derivs. 204245-01-2 204245-01-2D, branched peptide and other derivs. 204245-02-3 204245-02-3D, branched peptide and other derivs. 204245-03-4 204245-03-4D, branched peptide and other derivs. 204245-04-5 204245-04-5D, branched peptide and other derivs. 204245-05-6 204245-05-6D, branched peptide and other derivs. 204245-06-7 204245-06-7D, branched peptide and other derivs. 204245-07-8 204245-07-8D, branched peptide and other derivs.

204245-08-9	204245-08-9D, branched peptide and other derivs.			
204245-09-0	204245-09-0D, branched peptide and other derivs.			
204245-10-3	204245-10-3D, branched peptide and other derivs.			
204245-11-4	204245-11-4D, branched peptide and other derivs.			
204245-12-5	204245-12-5D, branched peptide and other derivs.			
204245-13-6	204245-13-6D, branched peptide and other derivs.			
204245-14-7	204245-14-7D, branched peptide and other derivs.			
204245-15-8	204245-15-8D, branched peptide and other derivs.			
204245-16-9	204245-16-9D, branched peptide and other derivs.			
204245-17-0	204245-17-0D, branched peptide and other derivs.			
204245-18-1	204245-18-1D, branched peptide and other derivs.			
204245-19-2	204245-19-2D, branched peptide and other derivs.			
204245-20-5	204245-20-5D, branched peptide and other derivs.			
204245-21-6	204245-21-6D, branched peptide and other derivs.			
204245-22-7	204245-22-7D, branched peptide and other derivs.			
204245-23-8	204245-23-8D, branched peptide and other derivs.			
204245-24-9	204245-24-9D, branched peptide and other derivs.			
204245-25-0	204245-25-0D, branched peptide and other derivs.			
204245-26-1	204245-26-1D, branched peptide and other derivs.			
204245-27-2	204245-27-2D, branched peptide and other derivs.			
204245-28-3	204245-28-3D, branched peptide and other derivs.			
204245-29-4	204245-29-4D, branched peptide and other derivs.			
204245-30-7	204245-30-7D, branched peptide and other derivs.			
204245-31-8	204245-31-8D, branched peptide and other derivs.			
204245-32-9	204245-32-9D, branched peptide and other derivs.			
204245-33-0	204245-33-0D, branched peptide and other derivs.			
204245-34-1	204245-34-1D, branched peptide and other derivs.			
204245-35-2	204245-35-2D, branched peptide and other derivs.			
204245-36-3	204245-36-3D, branched peptide and other derivs.			
204245-37-4	204245-37-4D, branched peptide and other derivs.			
204245-38-5	204245-38-5D, branched peptide and other derivs.			
204245-39-6	204245-39-6D, branched peptide and other derivs.			
204245-40-9	204245-40-9D, branched peptide and other derivs.			
204245-41-0	204245-41-0D, branched peptide and other derivs.			
204245-42-1	204245-42-1D, branched peptide and other derivs.			
204245-43-2	204245-43-2D, branched peptide and other derivs.			
204245-44-3	204245-44-3D, branched peptide and other derivs.			
204245-45-4	204245-45-4D, branched peptide and other derivs.			
204245-46-5	204245-46-5D, branched peptide and other derivs.			
204245-47-6	204245-47-6D, branched peptide and other derivs.			
204245-48-7	204245-48-7D, branched peptide and other derivs.			
204245-49-8	204245-49-8D, branched peptide and other derivs.			
204245-50-1	204245-50-1D, branched peptide and other derivs.			
204245-51-2	204245-51-2D, branched peptide and other derivs.			
204245-59-0	204245-59-0D, branched peptide and other derivs.			
204245-71-6	204245-72-7	204245-73-8	204245-74-9	204245-75-0
204245-76-1	204245-78-3	204245-79-4	204245-80-7	204245-81-8
204245-82-9	204245-83-0	204245-84-1	204245-85-2	204245-86-3
204245-88-5	204245-90-9	204245-91-0	204245-92-1	204245-93-2
204245-94-3	204245-95-4	204245-96-5	204245-97-6	204245-98-7
204246-99-8	204246-00-4	204246-01-5	204246-02-6	204246-03-7
204246-04-8	204246-05-9	204246-06-0	204246-07-1	204246-08-2
204246-09-3	204246-10-6	204246-11-7	204246-12-8	204246-13-9
204246-14-0	204246-15-1	204246-16-2	204246-18-4	204246-19-5
204246-20-8	204246-21-9	204246-22-0	204246-23-1	204246-24-2
204246-25-3	204246-26-4	204246-27-5	204246-28-6	204246-29-7
204246-30-0	204246-31-1	204246-32-2	204246-33-3	204246-34-4
204246-35-5	204246-36-6	204246-37-7	204246-38-8	204246-39-9
204246-40-2	204246-41-3	204246-42-4	204246-43-5	204246-44-6
204246-45-7	204246-46-8	204246-47-9	204246-48-0	204246-49-1

204246-50-4	204246-51-5	204246-52-6	204246-53-7	204246-54-8
204246-55-9	204246-56-0	204246-57-1	204246-58-2	204246-59-3
204246-60-6	204246-61-7	204246-62-8	204246-63-9	204246-64-0
204246-65-1	204246-66-2	204246-67-3	204246-68-4	204246-69-5
204246-70-8	204246-71-9	204246-72-0		

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); DEV (Device component use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(indolicidin analogs for treating infections)

IT	204246-73-1	204246-74-2	204246-75-3	204246-76-4	204246-78-6
	204246-79-7	204246-81-1	204246-82-2	204246-84-4	204246-86-6
	204246-87-7	204246-88-8	204246-89-9	204246-90-2	204246-91-3
	204246-92-4	204246-93-5	204246-94-6	204246-95-7	204246-96-8
	204246-97-9	204246-98-0	204246-99-1	204247-00-7	204247-01-8
	204247-03-0	204247-04-1	204247-06-3	204247-08-5	204247-09-6
	204247-10-9	204247-11-0	204247-12-1	204247-13-2	204247-14-3
	204247-15-4	204247-16-5	204247-17-6	204247-18-7	204247-19-8
	204247-20-1	204247-21-2	204247-22-3	204247-23-4	204247-24-5
	204247-25-6	204247-26-7	204247-27-8	204247-28-9	204247-29-0
	204247-30-3	204247-31-4	204247-32-5	204247-33-6	204247-34-7
	204247-35-8	204247-36-9	204247-37-0	204247-38-1	204247-39-2
	204247-40-5	204247-41-6	204247-42-7	204247-43-8	204247-45-0
	204247-46-1	204247-47-2	204247-48-3	204247-49-4	204247-50-7
	204247-51-8	204247-52-9	204247-53-0	204247-54-1	204247-55-2
	204247-56-3	204247-57-4	204247-58-5	204247-59-6	204247-60-9
	204247-61-0	204247-62-1	204247-63-2	204247-64-3	204247-65-4
	204247-66-5	204247-67-6	204247-68-7	204247-69-8	204247-70-1
	204247-71-2	204247-72-3	204247-73-4	204247-74-5	204247-75-6
	204247-76-7	204247-77-8	204247-78-9	204247-79-0	204247-81-4
	204247-83-6	204247-85-8	204247-87-0	204247-89-2	204247-91-6
	204247-93-8	204247-95-0	204247-97-2	204247-99-4	204248-01-1
	204248-03-3	204248-04-4	204248-05-5	204248-06-6	204248-07-7
	204248-09-9	204248-10-2	204248-11-3	204248-12-4	204248-13-5
	204248-14-6	204248-15-7	204248-16-8	204248-17-9	204248-18-0
	204248-19-1	204248-20-4	204248-21-5	204248-22-6	204248-23-7
	204248-24-8	204248-25-9	204248-26-0	204248-27-1	204248-28-2
	204248-29-3	204248-30-6	204248-32-8	204248-33-9	204248-34-0
	204248-35-1	204248-36-2	204248-37-3	204248-38-4	204248-39-5
	204248-40-8	204248-41-9	204248-42-0	204248-43-1	204248-44-2
	204248-45-3	204248-46-4	204248-47-5	204248-48-6	204248-49-7
	204248-50-0	204248-51-1	204248-52-2	204248-53-3	204248-54-4
	204248-55-5	204248-56-6	204248-57-7	204248-59-9	204248-61-3
	204248-62-4	204248-63-5	204248-64-6	204248-65-7	204248-66-8
	204248-67-9	204248-68-0	204248-69-1	204248-70-4	204248-71-5
	204248-72-6	204248-73-7	204248-74-8	204248-75-9	204248-76-0
	204248-77-1	204248-78-2	204248-79-3	204248-80-6	204248-81-7
	204248-82-8	204248-83-9	204248-84-0	204248-85-1	204248-86-2
	204248-87-3	204248-88-4	204248-89-5	204248-91-9	204248-93-1
	204248-95-3	204248-97-5	204248-98-6	204249-00-3	204249-02-5
	204249-04-7	204249-06-9	204249-08-1	204249-09-2	204249-10-5
	204249-11-6	204249-12-7	204249-14-9	204249-16-1	204249-17-2
	204249-19-4	204249-21-8	204249-24-1	204249-27-4	204249-28-5
	204249-29-6	204249-30-9	204249-31-0	204249-32-1	204249-33-2
	204249-34-3	204249-35-4	204249-36-5	204249-37-6	204249-38-7
	204249-39-8	204249-40-1	204249-41-2	204249-42-3	204249-43-4
	204249-44-5	204249-45-6	204249-46-7		

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); DEV (Device component use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(indolicidin analogs for treating infections)

IT 204249-47-8 204249-48-9 204249-49-0 204249-50-3 204249-51-4
 204249-52-5 204249-53-6 204249-54-7 204249-55-8 204249-56-9
 204249-57-0 204249-58-1 204249-59-2 204249-60-5 204249-61-6
 204249-62-7 204249-63-8 204249-64-9 204249-65-0 204249-66-1
 204249-68-3 204249-69-4 204249-70-7 204249-71-8 204249-72-9
 204249-73-0 204249-74-1 204249-75-2 204249-76-3 204249-77-4
 204249-78-5 204249-79-6 204249-80-9 204249-81-0 204249-82-1
 204249-83-2 204249-84-3 204249-85-4 204249-86-5 204249-87-6
 204249-88-7 204249-89-8 204249-90-1 204249-91-2 204249-92-3
 204249-93-4 204249-94-5 204249-95-6 204249-96-7 204249-97-8
 204249-98-9 204249-99-0 204250-00-0 204250-01-1 204250-02-2
 204250-03-3 204250-04-4 204250-05-5 204250-06-6 204250-07-7
 204250-08-8 204250-09-9 204250-10-2 204250-11-3 204250-12-4
 204250-13-5 204250-14-6 204250-15-7 204250-16-8 204250-17-9
 204250-18-0 204250-19-1 204250-20-4 204250-21-5 204250-22-6
 204250-23-7 204250-24-8 204250-25-9 204250-26-0 204250-27-1
 204250-28-2 204250-29-3 204250-30-6 204250-31-7 204250-32-8
 204250-33-9 204250-34-0 204250-35-1 204250-36-2 204250-37-3
 204250-38-4 204250-39-5 204250-40-8 204250-41-9 204250-42-0
 204250-43-1 204250-44-2 204250-45-3 204250-46-4 204250-47-5
 204250-48-6 204250-49-7 204250-50-0 204250-51-1 204250-52-2
 204250-53-3 204250-54-4 204250-55-5 204250-56-6 204250-57-7
 204250-58-8 204250-59-9 204250-60-2 204250-61-3 204250-62-4
 204250-63-5 204250-64-6 204250-65-7 204250-66-8 204250-67-9
 204250-68-0 204250-69-1 204250-70-4 204250-71-5 204250-72-6
 204250-73-7 204250-74-8 204250-75-9 204250-76-0 204250-77-1
 204250-78-2 204250-79-3 204250-80-6 204250-81-7 204250-82-8
 204250-83-9 204250-84-0
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); DEV (Device component use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (indolicidin analogs for treating *infections*)

IT 25322-68-3D, indolicidin analog conjugates
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (indolicidin analogs for treating *infections*)

IT 204250-85-1D, conjugates with polyalkylene glycol and fatty acid
 204250-86-2D, conjugates with polyalkylene glycol and fatty acid
 204250-87-3D, conjugates with polyalkylene glycol and fatty acid
 204250-88-4D, conjugates with polyalkylene glycol and fatty acid
 204250-89-5D, conjugates with polyalkylene glycol and fatty acid
 204250-90-8D, conjugates with polyalkylene glycol and fatty acid
 204250-91-9D, conjugates with polyalkylene glycol and fatty acid
 204250-92-0D, conjugates with polyalkylene glycol and fatty acid
 204250-93-1D, conjugates with polyalkylene glycol and fatty acid
 204250-94-2D, conjugates with polyalkylene glycol and fatty acid
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (indolicidin analogs, and combinations with other agents, for treating *infections*)

IT 9005-65-6DP, Polysorbate 80, activated, conjugates
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (indolicidin analogs, and combinations with other agents, for treating *infections*)

IT 50-63-5, Chloroquine phosphate 50-65-7, Niclosamide 54-42-2, Idoxuridine 54-85-3, Isoniazid 54-85-3D, Isoniazid, deriys. 56-75-7,

Chloramphenicol 56-75-7D, Chloramphenicol, derivs. 57-92-1, Streptomycin, biological studies 57-92-1D, Streptomycin, derivs. 58-14-0, Pyrimethamine 60-54-8, Tetracycline 60-54-8D, Tetracycline, derivs. 61-32-5, Methicillin 61-32-5D, Methicillin, derivs. 61-33-6, Penicillin G, biological studies 61-33-6D, Penicillin G, derivs. 61-72-3, Cloxacillin 61-72-3D, Cloxacillin, derivs. 63-45-6, Primaquine phosphate 66-79-5, Oxacillin 66-79-5D, Oxacillin, derivs. 67-20-9, Nitrofurantoin 67-20-9D, Nitrofurantoin, derivs. 69-53-4, Ampicillin 69-53-4D, Ampicillin, derivs. 70-00-8, Trifluridine 74-55-5, Ethambutol 74-55-5D, Ethambutol, derivs. 83-73-8, Iodoquinol 91-22-5D, Quinoline, derivs., biological studies 98-96-4, Pyrazinamide 98-96-4D, Pyrazinamide, derivs. 104-29-0, Chlorphenesin 107-11-9D, Allylamine, derivs. 110-85-0, Piperazine, biological studies 110-85-0D, Piperazine, derivs., biological studies 112-38-9, 10-Undecenoic acid 114-07-8, Erythromycin 114-07-8D, Erythromycin, derivs. 126-07-8, Griseofulvin 130-26-7, Clioquinol 140-64-7, Pentamidine isethionate 145-63-1, Suramin 147-52-4, Nafcillin 147-52-4D, Nafcillin, derivs. 148-24-3D, 8-Hydroxyquinoline, derivs. 148-79-8, Thiabendazole 153-61-7, Cephalothin 153-61-7D, Cephalothin, derivs. 288-32-4D, Imidazole, derivs. 289-95-2D, Pyrimidine, derivs. 389-08-2, Nalidixic acid 389-08-2D, Nalidixic acid, derivs. 443-48-1, Metronidazole 443-48-1D, Metronidazole, derivs. 494-79-1 500-92-5, Proguanil 518-28-5, Podophyllotoxin 564-25-0, Doxycycline 564-25-0D, Doxycycline, derivs. 643-22-1, Erythromycin stearate 643-22-1D, Erythromycin stearate, derivs. 665-66-7, Amantadine hydrochloride 723-46-6, Sulfamethoxazole 723-46-6D, Sulfamethoxazole, derivs. 738-70-5 738-70-5D, derivs. 804-63-7, Quinine sulfate 1264-62-6, Erythromycin ethyl succinate 1264-62-6D, Erythromycin ethyl succinate, derivs. 1397-89-3, Amphotericin B 1400-61-9, Nystatin 1403-66-3, Gentamicin 1403-66-3D, Gentamicin, derivs. 1404-90-6, Vancomycin 1404-90-6D, Vancomycin, derivs. 1406-05-9, Penicillin 1642-54-2, Diethyl carbamazepine citrate 2022-85-7, 5-Fluorocytosine 2398-96-1, Tolnaftate 3056-17-5, Stavudine 3116-76-5, Dicloxacillin 3116-76-5D, Dicloxacillin, derivs. 3521-62-8, Erythromycin estolate 3521-62-8D, Erythromycin estolate, derivs. 3546-41-6, Pyrvinium pamoate 3847-29-8, Erythromycin lactobionate 3847-29-8D, Erythromycin lactobionate, derivs. 4428-95-9, Foscarnet 4697-36-3, Carbenicillin 4697-36-3D, Carbenicillin, derivs. 5536-17-4, Vidarabine 7054-25-3, Quinidine gluconate 7481-89-2, Zalcitabine 7542-37-2, Paromomycin 8063-07-8, Kanamycin 8063-07-8D, Kanamycin, derivs. 9005-64-5D, conjugates 11111-12-9, Cephalosporin 12441-09-7D, Sorbitan, reaction products with polyoxyalkylene glycol and fatty acid, conjugates 12650-69-0, Mupirocin 12650-69-0D, Mupirocin, derivs. 13292-46-1, Rifampicin 13292-46-1D, Rifampicin, derivs. 13392-28-4, Rimantadine 13614-98-7, Minocycline hydrochloride 13614-98-7D, Minocycline hydrochloride, derivs. 15176-29-1, Edoxudine 15686-71-2, Cephalixin 15686-71-2D, Cephalixin, derivs. 16037-91-5, Sodium stibogluconate 18323-44-9, Clindamycin 18323-44-9D, Clindamycin, derivs. 22204-24-6, Pyrantel pamoate 22916-47-8, Miconazole 23067-13-2, Erythromycin glucoheptonate 23067-13-2D, Erythromycin glucoheptonate, derivs. 23256-30-6, Nifurtimox 23593-75-1, Clotrimazole 25953-19-9, Cefazolin 25953-19-9D, Cefazolin, derivs. 26787-78-0, Amoxicillin 26787-78-0D, Amoxicillin, derivs. 27220-47-9, Econazole 28657-80-9, Cinoxacin 28657-80-9D, Cinoxacin, derivs. 29342-05-0, Ciclopriox 30516-87-1, Zidovudine 31431-39-7, Mebendazole 32986-56-4, Tobramycin 32986-56-4D, Tobramycin, derivs. 34787-01-4, Ticarcillin 34787-01-4D, Ticarcillin, derivs. 35607-66-0, Cefoxitin 35607-66-0D, Cefoxitin, derivs. 36791-04-5, Ribavirin 36877-68-6D, Nitroimidazole, derivs. 37091-66-0, Azlocillin 37091-66-0D, Azlocillin, derivs. 37231-28-0D, Melittin, cecropin fusion

products 37306-44-8D, Triazole, derivs. 37517-28-5, Amikacin
 37517-28-5D, Amikacin, derivs. 39809-25-1, Penciclovir 42540-40-9,
 Cefamandole formate sodium 42540-40-9D, Cefamandole formate sodium,
 derivs. 51481-65-3, Mezlocillin 51481-65-3D, Mezlocillin, derivs.
 51773-92-3, Mefloquine hydrochloride 53994-73-3, Cefaclor 53994-73-3D,
 Cefaclor, derivs. 54965-21-8, Albendazole 55268-74-1, Praziquantel
 55268-75-2, Cefuroxime 55268-75-2D, Cefuroxime, derivs. 56093-45-9,
 Selenium sulfide 56391-56-1, Netilmicin 56391-56-1D, Netilmicin,
 derivs. 56796-20-4, Cefmetazole 56796-20-4D, Cefmetazole, derivs.
 59277-89-3, Acyclovir 61036-62-2, Teicoplanin 61036-62-2D,
 Teicoplanin, derivs. 61270-58-4, Cefonicid 61270-58-4D, Cefonicid,
 derivs. 61318-90-9, Sulconazole 61477-96-1, Piperacillin
 61477-96-1D, Piperacillin, derivs. 62587-73-9, Cefsulodin 62587-73-9D,
 Cefsulodin, derivs. 62893-19-0, Cefoperazone 62893-19-0D,
 Cefoperazone, derivs. 63527-52-6 63527-52-6D, derivs. 63744-80-9,
 Cephamycin 64221-86-9, Imipenem 64221-86-9D, Imipenem, derivs.
 64872-76-0, Butoconazole 65052-63-3, Cefetamet 65052-63-3D, Cefetamet,
 derivs. 65277-42-1, Ketoconazole 65473-14-5, Naftifine hydrochloride
 65899-73-2, Tioconazole 67915-31-5, Terconazole 68401-81-0,
 Ceftizoxime 68401-81-0D, Ceftizoxime, derivs. 69655-05-6, Didanosine
 69712-56-7, Cefotetan 69712-56-7D, Cefotetan, derivs. 69756-53-2,
 Halofantrine 70052-12-9, Eflornithine 70288-86-7, Ivermectin
 70458-96-7, Norfloxacin 70458-96-7D, Norfloxacin, derivs. 72558-82-8,
 Ceftazidime 72558-82-8D, Ceftazidime, derivs. 72559-06-9, Rifabutin
 72559-06-9D, Rifabutin, derivs. 73384-59-5, Ceftriaxone 73384-59-5D,
 Ceftriaxone, derivs. 74011-58-8, Enoxacin 74011-58-8D, Enoxacin,
 derivs. 76470-66-1, Loracarbef 76470-66-1D, Loracarbef, derivs.
 77181-69-2, Sorivudine 78110-38-0, Monobactam 78110-38-0D, Aztreonam,
 derivs. 78628-80-5, Terbinafine hydrochloride 79198-29-1
 79198-29-1D, derivs. 79350-37-1, Cefixime 79350-37-1D, Cefixime,
 derivs. 79660-72-3, Fleroxacin 79660-72-3D, Fleroxacin, derivs.
 80210-62-4, Cefpodoxime 80210-62-4D, Cefpodoxime, derivs. 80214-83-1,
 Roxithromycin 80214-83-1D, Roxithromycin, derivs. 80802-79-5D,
 Cecropin, mellitin fusion products 81103-11-9, Clarithromycin
 81103-11-9D, Clarithromycin, derivs. 82410-32-0, Ganciclovir
 82419-36-1, Ofloxacin 82419-36-1D, Ofloxacin, derivs. 83200-96-8,
 Carbapenem 83905-01-5, Azithromycin 83905-01-5D, Azithromycin, derivs.
 84625-61-6, Itraconazole 85721-33-1, Ciprofloxacin 85721-33-1D,
 Ciprofloxacin, derivs. 86386-73-4, Fluconazole 88040-23-7, Cefepime
 88040-23-7D, Cefepime, derivs. 92665-29-7, Cefprozil 92665-29-7D,
 Cefprozil, derivs.

RL: BAC (Biological activity or effector, except adverse); BSU

(Biological study, unclassified); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)

(indolicidin analogs, and combinations with other agents, for treating
infections)

IT 95233-18-4, Atovaquone 96036-03-2, Meropenem 96036-03-2D, Meropenem,
 derivs. 98079-51-7, Lomefloxacin 98079-51-7D, Lomefloxacin, derivs.
 104227-87-4, Famciclovir 123683-33-0, Piperacillin-tazobactam-mixture
 123683-33-0D, Piperacillin-tazobactam-mixture, derivs. 126602-89-9,
 Synercid 126602-89-9D, Synercid, derivs. 129618-40-2, Nevirapine
 134678-17-4, Lamivudine 140896-21-5, Indolicidin 204250-85-1
 204250-86-2 204250-87-3 204250-88-4 204250-89-5 204250-90-8
 204250-91-9 204250-92-0 204250-93-1 204250-94-2

RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
 (Uses)

(indolicidin analogs, and combinations with other agents, for treating
infections)

L109 ANSWER 25 OF 32 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1996:382806 HCAPLUS Full-text

DOCUMENT NUMBER: 125:52523

TITLE: Transfer of molecules into the cytosol of cells

INVENTOR(S): Berg, Kristian; Sandvik, Kirsten; Moan, Johan

PATENT ASSIGNEE(S): Radiumhospitalets Forskningsstiftelse, Norway

SOURCE: PCT Int. Appl., 33 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9607432	A1	19960314	WO 1995-NO149	19950904 <--
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT				
RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
NO 9403327	A	19960311	NO 1994-3327	19940908 <--
NO 180167	B	19961118		
NO 180167	C	19970226		
CA 2199290	A1	19960314	CA 1995-2199290	19950904 <--
AU 9535347	A	19960327	AU 1995-35347	19950904 <--
AU 700797	B2	19990114		
EP 783323	A1	19970716	EP 1995-932244	19950904 <--
EP 783323	B1	20011128		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
CN 1164829	A	19971112	CN 1995-196065	19950904 <--
BR 9508825	A	19980106	BR 1995-8825	19950904 <--
HU 77469	A2	19980528	HU 1998-153	19950904 <--
HU 222984	B1	20040128		
JP 10508295	T	19980818	JP 1996-509404	19950904 <--
NZ 293008	A	20010427	NZ 1995-293008	19950904 <--
AT 209507	T	20011215	AT 1995-932244	19950904 <--
ES 2163527	T3	20020201	ES 1995-932244	19950904 <--
PT 783323	T	20020328	PT 1995-932244	19950904 <--
NZ 509519	A	20041029	NZ 1995-509519	19950904 <--
FI 9700983	A	19970307	FI 1997-983	19970307 <--
US 5876989	A	19990302	US 1997-793794	19970328 <--
HK 1004110	A1	20060714	HK 1998-103468	19980424 <--
US 2002155099	A1	20021024	US 1998-144750	19980901 <--
US 6680301	B2	20040120		
US 2003134813	A1	20030717	US 2002-286632	20021101 <--
PRIORITY APPLN. INFO.:			NO 1994-3327	A 19940908 <--
			WO 1995-NO149	W 19950904 <--
			US 1997-793794	A2 19970328 <--
			US 1998-144750	A1 19980901 <--
AB	A method is described for releasing mols. into the cytosol of cells without killing the majority of the cells by allowing the mols. to be taken up in endosomes, lysosomes or other cell compartments and use light activation of photosensitizing compds. to rupture the membranes of the endosomes, lysosomes or other cell compartments. Transport into NHIK 3025 cells of the toxin agrostin using the photosensitizer TPPS2A was demonstrated.			
IT	60-54-8D, Tetracycline, derivs.			
	RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)			

W: CA, JP, MX

RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE

US 5667987 A 19970916 US 1994-274318 19940712 <--

EP 804609 A1 19971105 EP 1995-926643 19950710 <--

EP 804609 B1 20060104

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE

AT 315087 T 20060215 AT 1995-926643 19950710 <--

ES 2256847 T3 20060716 ES 1995-926643 19950710 <--

PRIORITY APPLN. INFO.:

US 1994-274318 A 19940712 <--

WO 1995-US8597 W 19950710 <--

AB Nucleic acid sequences, particularly DNA sequences, coding for all or part of p53 response protein PIGI-1, expression vectors containing the DNA sequences, host cells containing the expression vectors, and methods utilizing these materials. The invention also concerns polypeptide mols. comprising all or part of p53 response protein PIGI-1, and methods for producing these polypeptide mols.

IT 60-54-8, Tetracycline

RL: BAC (Biological activity or effector, except adverse); BSU

(Biological study, unclassified); THU (Therapeutic use); BIOL


(Biological study); USES (Uses)

(human brain p53 induced growth inhibitor protein PIGI-1 cDNA sequence and production using expression vector and usefulness as **cancer** inhibitor)

RN 60-54-8 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S,4aS,5aS,6S,12aS)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IC ICM C12P021-06

ICS C12N015-63; C12N001-20; C12N005-10; C07H021-04; C12Q001-68; C07K014-00

CC 3-2 (Biochemical Genetics)

Section cross-reference(s): 1, 13, 14

ST protein PIGI1 cDNA sequence human **cancer**; p53 induced growth inhibitor recombinant anticancer

IT Ribonucleic acid formation factors

RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(Tet activator; human brain p53 induced growth inhibitor protein PIGI-1 cDNA sequence and production using expression vector and usefulness as **cancer** inhibitor)

IT Gene, animal

RL: ANT (Analyte); BPR (Biological process); BSU (Biological study, unclassified); BUU (Biological use, unclassified); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PROC (Process); USES (Uses)


(for p53 induced growth inhibitor protein PIGI-1; human brain p53

(transfer of mols. into the cytosol of cells using photodynamic treatment)

RN 60-54-8 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S,4aS,5aS,6S,12aS)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IC ICM A61K047-48

ICS A61K047-00

CC 8-9 (Radiation Biochemistry)

Section cross-reference(s): 1

ST toxin transport cell cytosol photosensitizer; photodynamic therapy
cancer toxin transport; gene therapy toxin transport
photosensitizer

IT Carbohydrates and Sugars, biological studies

Deoxyribonucleic acids

Peptides, biological studies

Proteins, biological studies

Ribonucleic acids, messenger

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(transfer of mols. into the cytosol of cells using photodynamic treatment)

IT 60-54-8D, Tetracycline, derivs. 574-93-6D, Phthalocyanine,
derivs. 23627-89-6D, Naphthalocyanine, derivs.

RL: **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(transfer of mols. into the cytosol of cells using photodynamic treatment)

L109 ANSWER 26 OF 32 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1996:177968 HCAPLUS Full-text

DOCUMENT NUMBER: 124:222854

TITLE: human brain p53 induced growth inhibitor protein
PIGI-1 cDNA sequence and production using expression
vector and usefulness as **cancer** inhibitor

INVENTOR(S): Buckbinder, Leonard; Talbott, Randy; Seizinger, Bernd
R.; Kley, Nikolai

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA

SOURCE: PCT Int. Appl., 59 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9601907	A1	19960125	WO 1995-US8597	19950710 <--

induced growth inhibitor protein PIGI-1 cDNA sequence and production using expression vector and usefulness as **cancer** inhibitor)

IT Deoxyribonucleic acids

Ribonucleic acids

RL: BPR (Biological process); BSU (Biological study, unclassified); BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

(for p53 induced growth inhibitor protein PIGI-1; human brain p53 induced growth inhibitor protein PIGI-1 cDNA sequence and production using expression vector and usefulness as **cancer** inhibitor)

IT Eukaryote

Prokaryote

(host cell for expression plasmid; human brain p53 induced growth inhibitor protein PIGI-1 cDNA sequence and production using expression vector and usefulness as **cancer** inhibitor)

IT Apoptosis

Neoplasm inhibitors

Protein sequences

(human brain p53 induced growth inhibitor protein PIGI-1 cDNA sequence and production using expression vector and usefulness as **cancer** inhibitor)

IT Plasmid and Episome

(pUHG10-3, expression vector; human brain p53 induced growth inhibitor protein PIGI-1 cDNA sequence and production using expression vector and usefulness as **cancer** inhibitor)

IT **Ribonucleic acids**

RL: BPR (Biological process); BSU (Biological study, unclassified); BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

(antisense, for p53 induced growth inhibitor protein PIGI-1; human brain p53 induced growth inhibitor protein PIGI-1 cDNA sequence and production using expression vector and usefulness as **cancer** inhibitor)

IT Deoxyribonucleic acids

RL: BPR (Biological process); BSU (Biological study, unclassified); BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

(complementary, for p53 induced growth inhibitor protein PIGI-1; human brain p53 induced growth inhibitor protein PIGI-1 cDNA sequence and production using expression vector and usefulness as **cancer** inhibitor)

IT Deoxyribonucleic acid sequences

(complementary, human brain p53 induced growth inhibitor protein PIGI-1 cDNA sequence and production using expression vector and usefulness as **cancer** inhibitor)

IT Nucleotides, biological studies

RL: ARG (Analytical reagent use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(oligo-, labeled, radio-; human brain p53 induced growth inhibitor protein PIGI-1 cDNA sequence and production using expression vector and usefulness as **cancer** inhibitor)

IT 174723-59-2P

RL: BPN (Biosynthetic preparation); BUU (Biological use, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(amino acid sequence; human brain p53 induced growth inhibitor protein PIGI-1 cDNA sequence and production using expression vector and usefulness as **cancer** inhibitor)

IT 60-54-8, Tetracycline

RL: BAC (Biological activity or effector, except adverse); BSU

(Biological study, unclassified); *THU (Therapeutic use)*; BIOL
 (Biological study); USES (Uses)
 (human brain p53 induced growth inhibitor protein PIGI-1 cDNA sequence
 and production using expression vector and usefulness as **cancer**
 inhibitor)

IT 174723-58-1 174723-60-5

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
 (Biological study)

(nucleotide sequence; human brain p53 induced growth inhibitor protein
 PIGI-1 cDNA sequence and production using expression vector and usefulness
 as **cancer** inhibitor)

L109 ANSWER 27 OF 32 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1996:161307 HCAPLUS Full-text

DOCUMENT NUMBER: 124:195986

TITLE: Tetracycline-regulated transcriptional modulators and
 their use in regulating gene expression in transgenic
 eukaryotic cells and animals

INVENTOR(S): Bujard, Hermann; Gossen, Manfred

PATENT ASSIGNEE(S): Germany

SOURCE: PCT Int. Appl., 112 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 12

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9601313	A1	19960118	WO 1995-US8179	19950629 <--
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT				
RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 5654168	A	19970805	US 1994-275876	19940715 <--
US 5789156	A	19980804	US 1995-383754	19950203 <--
US 5866755	A	19990202	US 1995-486814	19950607 <--
AU 9530923	A	19960125	AU 1995-30923	19950629 <--
EP 804565	A1	19971105	EP 1995-926605	19950629 <--
EP 804565	B1	20050921		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
JP 11506901	T	19990622	JP 1996-503915	19950629 <--
AT 305034	T	20051015	AT 1995-926605	19950629 <--
NO 9605623	A	19970228	NO 1996-5623	19961230 <--
NO 315375	B1	20030825		
FI 9605287	A	19970228	FI 1996-5287	19961231 <--

PRIORITY APPLN. INFO.:

US 1994-270637	A2	19940701 <--
US 1994-275876	A2	19940715 <--
US 1995-383754	A2	19950203 <--
US 1995-486814	A2	19950607 <--
US 1993-76327	B2	19930614 <--
US 1993-76726	A2	19930614 <--
US 1994-260452	A2	19940614 <--
WO 1995-US8179	W	19950629 <--

AB Nucleic acid mols. and proteins useful for regulating the expression of genes in eukaryotic cells and organisms are disclosed. The invention provides a transcriptional activator fusion protein which binds to tet operator sequences

and stimulates transcription of a tet operator-linked gene in the presence, but not the absence, of tetracycline (or analog thereof). The invention further provides transcriptional inhibitor fusion proteins which inhibit transcription of a tet operator-linked gene in a regulated manner. In one embodiment, the inhibitor fusion protein binds to tet operator sequences in the absence, but not the presence, of tetracycline (or analog). In another embodiment, the inhibitor fusion protein binds to tet operator sequences in the presence, but not the absence, of tetracycline (or analog). The transcriptional activator and inhibitor fusion proteins of the invention can be used in combination to regulate expression of one of multiple tet operator-linked genes. Novel tet operator-containing transcription units which allow for coordinate or independent tetracycline-regulated expression of two or more genes by the transcriptional modulators of the invention are also disclosed. Kits including the components of the regulatory system are also encompassed by the invention. A gene for a tet repressor which binds to its target DNA in the presence rather than the absence of tetracycline was prepared by mutagenesis. This gene was fused to a sequence encoding the C-terminal 130 amino acids of herpes simplex virus VP16 to create a chimeric gene encoding a tetracycline-inducible transactivator. This transactivator was shown to function in HeLa cells and in transgenic mice. Activation by 3-5 orders of magnitude was observed upon addition of tetracycline (or tetracycline analog). Genes for tetracycline-regulated transcriptional inhibitors comprising TetR fused to a v-erbA or Krueppel silencer domain were also prepared.

IT 60-54-8, Tetracycline


RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(tetracycline-regulated transcriptional modulators and their use in regulating gene expression in transgenic eukaryotic cells and animals)

RN 60-54-8 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S,4aS,5aS,6S,12aS)-(CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IC ICM C12N015-00

ICS C12N015-12; C12N015-62; C12N015-63; C12N015-67; C12N015-85; C12N005-10; C12N001-15; C12N001-19; C07K014-245; A01K067-027

CC 3-2 (Biochemical Genetics)

IT Ribonucleic acid formation factors

RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(E4BP4, silencer domain of, fusion products with TetR; tetracycline-regulated transcriptional **modulators** and their use in regulating gene expression in transgenic eukaryotic cells and animals)

IT Ribonucleic acid formation factors

RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(Oct2.1, silencer domain of, fusion products with TetR; tetracycline-regulated transcriptional **modulators** and their use in regulating gene expression in transgenic eukaryotic cells and animals)

IT **Ribonucleic acid** formation factors

RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(TSF3, silencer domain of, fusion products with TetR; tetracycline-regulated transcriptional **modulators** and their use in regulating gene expression in transgenic eukaryotic cells and animals)

IT **Ribonucleic acid** formation factors

RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(WT1, silencer domain of, fusion products with TetR; tetracycline-regulated transcriptional **modulators** and their use in regulating gene expression in transgenic eukaryotic cells and animals)

IT **Ribonucleic acid** formation factors

RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(ZF5, silencer domain of, fusion products with TetR; tetracycline-regulated transcriptional **modulators** and their use in regulating gene expression in transgenic eukaryotic cells and animals)

IT **Ribonucleic acid** formation factors

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(tetO-binding; tetracycline-regulated transcriptional **modulators** and their use in regulating gene expression in transgenic eukaryotic cells and animals)

IT **Ribonucleic acid** formation factors

RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(NeP1 (neg. protein 1), silencer domain of, fusion products with TetR; tetracycline-regulated transcriptional **modulators** and their use in regulating gene expression in transgenic eukaryotic cells and animals)

IT **Ribonucleic acid** formation factors

RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(Vmw65 (virion-associated stimulatory protein, 65,000-mol.-weight), transactivator domain of, fusion products with TetR; tetracycline-regulated transcriptional **modulators** and their use in regulating gene expression in transgenic eukaryotic cells and animals)

IT **Ribonucleic acid** formation factors

RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(gene Krueppel, silencer domain of, fusion products with TetR; tetracycline-regulated transcriptional **modulators** and their use in regulating gene expression in transgenic eukaryotic cells and animals)

IT **Ribonucleic acid** formation factors

RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(gene dorsal, silencer domain of, fusion products with TetR; tetracycline-regulated transcriptional **modulators** and their use in regulating gene expression in transgenic eukaryotic cells and animals)

- animals)
- IT **Ribonucleic acid** formation factors
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES
 (Uses)
 (gene even-skipped, silencer domain of, fusion products with TetR;
 tetracycline-regulated transcriptional **modulators** and their
 use in regulating gene expression in transgenic eukaryotic cells and
 animals)
- IT **Ribonucleic acid** formation factors
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES
 (Uses)
 (gene hunchback, silencer domain of, fusion products with TetR;
 tetracycline-regulated transcriptional **modulators** and their
 use in regulating gene expression in transgenic eukaryotic cells and
 animals)
- IT **Ribonucleic acid** formation factors
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES
 (Uses)
 (gene knirps, silencer domain of, fusion products with TetR;
 tetracycline-regulated transcriptional **modulators** and their
 use in regulating gene expression in transgenic eukaryotic cells and
 animals)
- IT **Ribonucleic acid** formation factors
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES
 (Uses)
 (gene tetR, tetracycline-regulated transcriptional **modulators**
 and their use in regulating gene expression in transgenic eukaryotic
 cells and animals)
- IT **60-54-8**, Tetracycline 564-25-0, Doxycycline 1665-56-1,
 Anhydrotetracycline 4199-33-1, 2-Cyanotetracycline
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES
 (Uses)
 (tetracycline-regulated transcriptional modulators and their use in
 regulating gene expression in transgenic eukaryotic cells and animals)

L109 ANSWER 28 OF 32 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1995:947082 HCAPLUS Full-text

DOCUMENT NUMBER: 124:23328

TITLE: Cloning restriction endonuclease genes using methyl
 donor cofactor to modulate DNA methyltransferase which
 in turn regulates DNA accessibility to damage by
 endonuclease

INVENTOR(S): Collier, Gordon B.; Connaughton, John F.; Chirikjian,
 Jack G.

PATENT ASSIGNEE(S): Georgetown University, USA

SOURCE: U.S., 19 pp.
 CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5451519	A	19950919	US 1993-68678	19930528 <--
PRIORITY APPLN. INFO.:			US 1993-68678	19930528 <--

AB The present invention relates to a method for cloning genes that encode
 restriction endonucleases by altering the level of a Me donor co-factor of a
 DNA methyltransferase that protects the DNA of a host cell from damage by a
 restriction endonuclease. The method can be used to screen entire DNA

libraries en masse to identify clones that encode restriction enzymes by growing one library replicate under high or normal Me donor conditions to protect host DNA and a second library replicate under low Me donor conditions allowing DNA damage from the active restriction endonuclease. Clones that encode a restriction enzyme are identified by decreased growth or color produced in response to double stranded DNA damage under the low Me donor conditions. Colorimetric methods useful in the invention can use SOS-sensitive promoters operably linked to β -galactosidase, which detect DNA damage.


IT 57-62-5, ChlorTetracycline 60-54-8, Tetracycline

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(cloning restriction endonuclease genes using Me donor cofactor to modulate DNA methyltransferase which in turn regulates DNA accessibility to damage by endonuclease)

RN 57-62-5 HCAPLUS

CN 2-Naphthacenecarboxamide, 7-chloro-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S,4aS,5aS,6S,12aS) - (CA INDEX NAME)


Absolute stereochemistry.



RN 60-54-8 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S,4aS,5aS,6S,12aS) - (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IC ICM C12N009-22

ICS C12N015-55

INCL 435199000

CC 3-2 (Biochemical Genetics)

Section cross-reference(s): 7, 10

IT. Ribonucleic acid formation factors

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(gene tetR, cloning restriction endonuclease genes using Me donor cofactor to **modulate** DNA methyltransferase which in turn regulates DNA accessibility to damage by endonuclease)

IT 57-62-5, ChlorTetracycline 60-54-8, Tetracycline
13422-55-4, Methylcobalamin 29908-03-0, S-Adenosyl-L-methionine
RL: BAC (*Biological activity or effector, except adverse*); BSU
(Biological study, unclassified); BUU (Biological use, unclassified); BIOL
(Biological study); USES (Uses)
(cloning restriction endonuclease genes using Me donor cofactor to
modulate DNA methyltransferase which in turn regulates DNA
accessibility to damage by endonuclease)

L109 ANSWER 29 OF 32 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1995:550240 HCAPLUS Full-text

DOCUMENT NUMBER: 123:2629

TITLE: The function of inducible promoter systems in F9
embryonal carcinoma cells

AUTHOR(S): Miller, Keith; Rizzino, Angie

CORPORATE SOURCE: Dep. Pathol. Microbiol., Univ. Nebraska Med. Cent.,
Omaha, NE, 68198-6805, USA

SOURCE: Experimental Cell Research (1995), 218(1),
144-50

CODEN: ECREAL; ISSN: 0014-4827

PUBLISHER: Academic

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Embryonal carcinoma (EC) cells represent an important model for studying the regulation of cellular differentiation during embryonic development and **tumor** formation. The differentiation of EC cells is associated with changes in the expression of a number of cellular genes, some of which have been implicated directly in the regulation of differentiation. To facilitate further studies of the possible roles of cellular gene products during the differentiation of EC cells, we have used transient transfection assays to compare the function of three promoter systems that direct the conditional expression of recombinant gene constructs. One system employs the mouse mammary **tumor** virus (MMTV) promoter, which is induced by glucocorticoid hormones. The other two systems are based on chimeric transactivator proteins consisting of the bacterial lac repressor or tet repressor, resp., fused with a viral transactivation domain. The chimeric proteins function in mammalian cells as sequence-specific activators of transcription that are regulated by either lactose analogs or tetracycline. Transient transfections of mouse F9 EC cells and their differentiated cells with an MMTV promoter-reporter gene construct and a second plasmid encoding the rat glucocorticoid receptor resulted in a dramatic induction of reporter gene expression by glucocorticoid hormone of approx. 200-fold. The conditional expression system based on the tetracycline-responsive transactivator exhibited a similar range of reporter gene expression in response to tetracycline. In contrast, the system based on the lac repressor exhibited a much more limited range of conditional reporter gene expression in our studies. These findings and others discussed in this report suggest that the tetracycline-responsive promoter system may be useful for the conditional expression of recombinant gene constructs in F9 EC cells. Furthermore, data are presented indicating that the human β -actin promoter should be suitable for stable expression of conditional transactivators, such as the tetracycline-responsive transactivator, in F9 cells before and after differentiation.

IT 60-54-8, Tetracycline

RL: BAC (*Biological activity or effector, except adverse*); BSU

(Biological study, unclassified); BIOL (Biological study)


(the conditional expression system based on the tetracycline-responsive transactivator exhibited a similar range of reporter gene expression as

an MMTV promoter-reporter gene construct in response to tetracycline)

RN 60-54-8 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S,4aS,5aS,6S,12aS)-(CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



CC 3-4 (Biochemical Genetics)

Section cross-reference(s): 13

IT **Ribonucleic acid** formation factors

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(lactose repressors, 2 inducible promoter systems in F9 embryonal carcinoma cells based on chimeric transactivator proteins consist of the bacterial lac repressor or tet repressor, resp., fused with a viral transactivation domain)

IT Virus, animal

(murine mammary **tumor**, one promoter system in F9 embryonal carcinoma cells employs the mouse mammary **tumor** virus (MMTV) promoter, which is induced by glucocorticoid hormones)

IT **Ribonucleic acid** formation factors

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(repressors, tet; 2 inducible promoter systems in F9 embryonal carcinoma cells based on chimeric transactivator proteins consist of the bacterial lac repressor or tet repressor, resp., fused with a viral transactivation domain)

IT 60-54-8, Tetracycline

RL: **BAC (Biological activity or effector, except adverse)**; BSU (Biological study, unclassified); BIOL (Biological study)

(the conditional expression system based on the tetracycline-responsive transactivator exhibited a similar range of reporter gene expression as an MMTV promoter-reporter gene construct in response to tetracycline)

L109 ANSWER 30 OF 32 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1995:541403 HCAPLUS Full-text

DOCUMENT NUMBER: 122:283855

TITLE: Regulated apoptosis by chimeric proteins binding to FK506-type and cyclosporin-type ligands

INVENTOR(S): Crabtree, Gerald R.; Schreiber, Stuart L.; Spencer, David M.; Wandless, Thomas J.; Belshaw, Peter

PATENT ASSIGNEE(S): Board of Trustees of the Leland Stanford Junior University, USA; President and Fellows of Harvard College

SOURCE: PCT Int. Appl., 134 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 6
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9502684	A1	19950126	WO 1994-US8008	19940718 <--
W: AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, LV, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, UZ, VN				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
WO 9418317	A1	19940818	WO 1994-US1617	19940214 <--
W: AT, AU, BB, BG, BR, CA, CH, CN, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MG, MN, MW, NL, NO, PL, RO, RU, SD, SE, SK				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9473363	A	19950213	AU 1994-73363	19940718 <--
AU 696991	B2	19980924		
CN 1130401	A	19960904	CN 1994-193251	19940718 <--
JP 09503645	T	19970415	JP 1995-504752	19940718 <--
EP 776359	A1	19970604	EP 1994-923515	19940718 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
FI 9600165	A	19960126	FI 1996-165	19960115 <--
US 6063625	A	20000516	US 1998-156855	19980916 <--
US 6140120	A	20001031	US 1998-158010	19980916 <--
US 2006035325	A1	20060216	US 2005-38326	20050118 <--
PRIORITY APPLN. INFO.:			US 1993-93499	A 19930716 <--
			US 1994-179143	A 19940107 <--
			WO 1994-US1617	A 19940214 <--
			US 1993-17931	A 19930212 <--
			US 1993-92977	A 19930716 <--
			US 1994-179748	A 19940107 <--
			US 1994-196043	B1 19940211 <--
			WO 1994-US8008	W 19940718 <--
			US 1994-292597	A1 19940818 <--
			US 1998-87811	A1 19980529 <--
			US 1999-302629	A1 19990430 <--
			US 2001-54712	A1 20011113 <--

AB A general procedure is described for the regulated (inducible) dimerization or oligomerization of intracellular proteins and methods and materials are presented for using that procedure to regulatably initiate cell-specific apoptosis (programmed cell death) in genetically engineered cells. The procedure involves chimeric (or fused) proteins, DNA constructs encoding them, and ligand mols. capable of oligomerizing the chimeric proteins. The chimeric proteins contain at least one ligand-binding (or receptor) domain fused to an action domain capable of initiating apoptosis within a cell, and may also contain addnl. domains for (1) the regulatable or constitutive expression of desired genes and (2) intracellular targeting. The chimeric proteins are capable of binding to an FK506-type ligand, a cyclosporin A-type ligand, tetracycline, or a steroid ligand. One such chimeric protein is myristoylated CD3/FKBP12 (MZBF3E) receptor consisting of (1) a c-src fragment sufficient for myristoylation, (2) the cytoplasmic tail of ζ (a component of the B cell receptor), (3) 3 consecutive domains of the FKBP12 immunophilin, and (4) a flu epitope tag; oligomerization/apoptosis is induced by a dimeric derivative of FK506. Syntheses are reported for the preparation of dimeric and "bumped" (containing steric bulky groups) derivs. of FK506 and cyclosporin A. The overall procedures allows ligand-mediated oligomerization for regulated gene therapy.

IT 60-54-8P, Tetracycline


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(regulated apoptosis by chimeric proteins binding to FK506-type and cyclosporin-type ligands)

RN 60-54-8 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S,4aS,5aS,6S,12aS)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IC ICM C12N005-00

ICS C12N015-00; C07H015-12; C07K015-00; A61K031-70

CC 3-2 (Biochemical Genetics)

Section cross-reference(s): 1, 13, 64

IT Ribonucleic acid formation factors

RL: BAC (Biological activity or effector, except adverse); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(HNF-1 (hepatocyte nuclear factor 1), fusion products with apoptosis-inducing protein domains and ligand-binding receptors; regulated apoptosis by chimeric proteins binding to FK506-type and cyclosporin-type ligands)

IT Ribonucleic acid formation factors

RL: BAC (Biological activity or effector, except adverse); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(Vmw65 (virion-associated stimulatory protein, 65,000-mol.-weight), fusion products with apoptosis-inducing protein domains and ligand-binding receptors; regulated apoptosis by chimeric proteins binding to FK506-type and cyclosporin-type ligands)

IT Ribonucleic acid formation factors

RL: BAC (Biological activity or effector, except adverse); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(gene GAL4, fusion products with apoptosis-inducing protein domains and ligand-binding receptors; regulated apoptosis by chimeric proteins binding to FK506-type and cyclosporin-type ligands)

IT Lymphokine and cytokine receptors

Receptors

RL: BAC (Biological activity or effector, except adverse); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(Uses)

(**tumor** necrosis factor- α , fusion products with ligand-binding receptors; regulated apoptosis by chimeric proteins binding to FK506-type and cyclosporin-type ligands)

IT 60-54-8P, Tetracycline 53123-88-9P, Rapamycin 59865-13-3DP, Cyclosporin A, derivs. 104987-11-3DP, FK506, derivs. 104987-12-4P, FK520

RL: BAC (**Biological activity or effector, except adverse**); BSU (Biological study, unclassified); SPN (Synthetic preparation); **THU** (**Therapeutic use**); BIOL (Biological study); PREP (Preparation); USES (Uses)

(regulated apoptosis by chimeric proteins binding to FK506-type and cyclosporin-type ligands)

L109 ANSWER 31 OF 32 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1994:646338 HCAPLUS Full-text

DOCUMENT NUMBER: 121:246338

TITLE: Superoxide dismutase gene mutations as causes of neurodegenerative **diseases** and compounds and methods for the diagnosis, treatment, and prevention of the **diseases**

INVENTOR(S): Brown, Robert; Horvitz, H. Robert; Rosen, Daniel R.

PATENT ASSIGNEE(S): General Hospital Corp., USA; Massachusetts Institute of Technology

SOURCE: PCT Int. Appl., 98 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9419493	A1	19940901	WO 1994-US2089	19940228 <--
W: CA, JP				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 5843641	A	19981201	US 1993-23980	19930226 <--
CA 2157041	A1	19940901	CA 1994-2157041	19940228 <--
EP 686203	A1	19951213	EP 1994-910183	19940228 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 08510377	T	19961105	JP 1994-519309	19940228 <--
PRIORITY APPLN. INFO.:			US 1993-23980	A 19930226 <--
			WO 1994-US2089	W 19940228 <--


AB Disclosed is the family of genes responsible for the neurodegenerative **diseases**, particularly amyotrophic lateral sclerosis (ALS). Methods and compds. for the diagnosis, prevention, and therapy of the **disease** are also disclosed. Uses of the compds. in the preparation of diagnostic and therapeutic medicaments are also provided. Fourteen different SOD1 missense mutations in 16 different familial ALS families were identified. The mutations were identified by PCR followed by single-strand conformational polymorphism anal. The most common single mutation was an Ala-4 to Val substitution in exon 1. This mutation reduced the total SOD activity by 50% compared to normal controls. Addnl. polymorphisms were identified in exons 3 and 4 as well as in intron 3. Some of these mutations are detectable by restriction fragment length polymorphism.

IT 60-54-8, Tetracycline

RL: **THU** (**Therapeutic use**); BIOL (Biological study); USES (Uses)
(superoxide dismutase gene mutations as causes of neurodegenerative **diseases** and compds. and methods for diagnosis, treatment, and prevention of the **diseases**)

RN 60-54-8 HCAPLUS
 CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S,4aS,5aS,6S,12aS)-(CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IC ICM C12Q001-68
 ICS C12P019-34; C07H021-04
 CC 1-11 (Pharmacology)
 Section cross-reference(s): 3, 9, 14
 ST superoxide dismutase gene mutation neurodegenerative **disease**;
 amyotrophic lateral sclerosis diagnosis treatment
 IT Antibodies
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (anti-SOD; superoxide dismutase gene mutations as causes of
 neurodegenerative **diseases** and compds. and methods for
 diagnosis, treatment, and prevention of the **diseases**)
 IT Bacteria
 Yeast
 (cells producing **disease**-causing mutant superoxide dismutase)
 IT Enzymes
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (free radical-producing, inhibitors of; superoxide dismutase gene
 mutations as causes of neurodegenerative **diseases** and compds.
 and methods for diagnosis, treatment, and prevention of the
diseases)
 IT Genetic polymorphism
 (intron 3; superoxide dismutase gene mutations as causes of
 neurodegenerative **diseases** and compds. and methods for
 diagnosis, treatment, and prevention of the **diseases**)
 IT Genetic methods
 (single-strand conformational polymorphism; superoxide dismutase gene
 mutations as causes of neurodegenerative **diseases** and compds.
 and methods for diagnosis, treatment, and prevention of the
diseases)
 IT Antioxidants
 Chelating agents
 Deoxyribonucleic acid sequence determination
 Mutation
 Parkinsonism
 Polymerase chain reaction
 (superoxide dismutase gene mutations as causes of neurodegenerative
diseases and compds. and methods for diagnosis, treatment, and
 prevention of the **diseases**)
 IT Albumins, biological studies
 Ferritins
 Lazaroids
 Metallothioneins

Sulfonamides

Thiols, biological studies

Transferrins

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(superoxide dismutase gene mutations as causes of neurodegenerative **diseases** and compds. and methods for diagnosis, treatment, and prevention of the **diseases**)

IT Animal

Mouse

Worm

(transgenic nonhuman animals containing cells producing **disease**-causing mutant superoxide dismutase)

IT Mental **disorder**

(**Alzheimer's disease**, superoxide dismutase gene mutations as causes of neurodegenerative **diseases** and compds. and methods for diagnosis, treatment, and prevention of the **diseases**)

IT **Ribonucleic acids**

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antisense, to wild-type SOD mRNA; superoxide dismutase gene mutations as causes of neurodegenerative **diseases** and compds. and methods for diagnosis, treatment, and prevention of the **diseases**)

IT Hemoglobins

Myoglobins

Plastocyanins

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(apo-, superoxide dismutase gene mutations as causes of neurodegenerative **diseases** and compds. and methods for diagnosis, treatment, and prevention of the **diseases**)

IT Deoxyribonucleic acids

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(complementary, antisense, to mutant SOD gene; superoxide dismutase gene mutations as causes of neurodegenerative **diseases** and compds. and methods for diagnosis, treatment, and prevention of the **diseases**)

IT Nervous system

(**disease**, Hallervorden-Spatz, superoxide dismutase gene mutations as causes of neurodegenerative **diseases** and compds. and methods for diagnosis, treatment, and prevention of the **diseases**)

IT Nervous system

(**disease**, **Huntington's chorea**, superoxide dismutase gene mutations as causes of neurodegenerative **diseases** and compds. and methods for diagnosis, treatment, and prevention of the **diseases**)

IT Nervous system

(**disease**, amyotrophic lateral sclerosis, superoxide dismutase gene mutations as causes of neurodegenerative **diseases** and compds. and methods for diagnosis, treatment, and prevention of the **diseases**)

IT **Nervous system**

(**disease**, **degeneration**, superoxide dismutase gene mutations as causes of neurodegenerative **diseases** and compds. and methods for diagnosis, treatment, and prevention of the **diseases**)

IT Embryo

(fetus, superoxide dismutase gene mutations as causes of neurodegenerative **diseases** and compds. and methods for diagnosis, treatment, and prevention of the **diseases**)

- IT Proteins, specific or class
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(mercapto-containing, superoxide dismutase gene mutations as causes of neurodegenerative *diseases* and compds. and methods for diagnosis, treatment, and prevention of the *diseases*)
- IT Proteins, specific or class
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(metal-binding, apo-; superoxide dismutase gene mutations as causes of neurodegenerative *diseases* and compds. and methods for diagnosis, treatment, and prevention of the *diseases*)
- IT Antibodies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(monoclonal, anti-SOD; superoxide dismutase gene mutations as causes of neurodegenerative *diseases* and compds. and methods for diagnosis, treatment, and prevention of the *diseases*)
- IT Brain, *disease*
(olivopontocerebellar degeneration, superoxide dismutase gene mutations as causes of neurodegenerative *diseases* and compds. and methods for diagnosis, treatment, and prevention of the *diseases*)
- IT Genetic polymorphism
(restriction fragment length, superoxide dismutase gene mutations as causes of neurodegenerative *diseases* and compds. and methods for diagnosis, treatment, and prevention of the *diseases*)
- IT 158492-64-9 158492-65-0 158492-66-1 158492-67-2 158492-68-3
158492-69-4 158492-70-7 158492-71-8 158492-72-9 158492-73-0
158492-74-1 158492-75-2 158492-76-3 158492-77-4
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(PCR primer; superoxide dismutase gene mutations as causes of neurodegenerative *diseases* and compds. and methods for diagnosis, treatment, and prevention of the *diseases*)
- IT 623-80-3 86399-42-0, BCDA
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(SOD inhibitor; superoxide dismutase gene mutations as causes of neurodegenerative *diseases* and compds. and methods for diagnosis, treatment, and prevention of the *diseases*)
- IT 158371-98-3, Superoxide dismutase (human exon 2) 158371-99-4, Superoxide dismutase (human exon 2) 158372-00-0, Superoxide dismutase (human exon 2) 158372-01-1, Superoxide dismutase (human exon 2) 158372-02-2, Superoxide dismutase (human exon 1) 158405-33-5, Superoxide dismutase (human exon 2) 158484-33-4, Superoxide dismutase (human exon 4) 158484-34-5, Superoxide dismutase (human exon 4) 158484-35-6, Superoxide dismutase (human exon 4) 158484-37-8, Superoxide dismutase (human exon 4) 158484-38-9, Superoxide dismutase (human exon 4) 158484-39-0, Superoxide dismutase (human exon 4)
RL: PRP (Properties)
(amino acid sequence; superoxide dismutase gene mutations as causes of neurodegenerative *diseases* and compds. and methods for diagnosis, treatment, and prevention of the *diseases*)
- IT 9001-05-2, Catalase 9013-66-5, Glutathione peroxidase 125978-95-2, Nitric oxide synthase
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(enzyme gene mutations as predictor of risk of neurodegenerative *disease*)
- IT 9054-89-1, Superoxide dismutase
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(superoxide dismutase gene mutations as causes of neurodegenerative *diseases* and compds. and methods for diagnosis, treatment, and

prevention of the *diseases*)

IT 50-81-7, Vitamin C, biological studies 52-67-5, Penicillamine 52-90-4, Cysteine, biological studies 59-52-9, Dimercaprol 60-00-4, EDTA, biological studies 60-24-2, Mercaptoethanol 60-54-8, Tetracycline 63-68-3, Methionine, biological studies 67-42-5, EGTA 69-93-2, Urate, biological studies 70-18-8, Glutathione, biological studies 70-51-9, Desferoxamine 127-40-2, Lutein 128-37-0, BHT, biological studies 147-84-2, biological studies 502-65-8, Lycopene 616-91-1, N-Acetylcysteine 635-65-4, Bilirubin, biological studies 1406-18-4, Vitamin E 2323-36-6, Deprenyl 3483-12-3, Dithiothreitol 5677-55-4, Ubiquinol-10 7235-40-7, β -Carotene 9003-99-0, Guaiacol peroxidase 9029-26-9, Dehydroascorbate reductase 9029-51-0, NAD(P)H peroxidase 9029-53-2, Cytochrome c peroxidase 9031-37-2, Ceruloplasmin 9037-80-3, Reductase 25013-16-5, BHA 72906-87-7, Ascorbate peroxidase 97089-70-8, Phospholipid hydroperoxide glutathione peroxidase

RL: **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(superoxide dismutase gene mutations as causes of neurodegenerative *diseases* and compds. and methods for diagnosis, treatment, and prevention of the *diseases*)

L109 ANSWER 32 OF 32 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1992:606288 HCAPLUS Full-text

DOCUMENT NUMBER: 117:206288

TITLE: Activity of a plasmid-borne leu-500 promoter depends on the transcription and translation of an adjacent gene

AUTHOR(S): Chen, Dongrong; Bowater, Richard; Dorman, Charles J.; Lilley, David M. J.

CORPORATE SOURCE: Dep. Biochem., Univ. Dundee, Dundee, DD1 4HN, UK

SOURCE: Proceedings of the National Academy of Sciences of the United States of America (1992), 89(18), 8784-8

CODEN: PNASA6; ISSN: 0027-8424

DOCUMENT TYPE: Journal

LANGUAGE: English

AB leu-500 is a chromosomal promoter mutation in *Salmonella typhimurium* that normally causes the promoter to be inactive in the initiation of **RNA** synthesis. In a strain that has mutations in topA (coding for DNA topoisomerase I), however, the mutant promoter becomes active. The leu-500 promoter can function on a plasmid when it is adjacent to the tetracycline-resistance gene tetA. Activation of the leu-500 promoter requires that the tetA gene is transcribed and translated and that the host cell is topA. The authors propose that the A \rightarrow G mutation in the -10 region of the leu-500 promoter is compensated by local neg. supercoiling arising from transcription of the tetA gene, which may reach elevated levels in a topA background, provided that diffusional dissipation is reduced due to anchoring of the TetA peptide in the membrane. This is a clear example of the *modulation* of the activity of a promoter by the activity of another promoter in cis, when they can be coupled through the topol. of the template.

IT 60-54-8, Tetracycline


RL: BIOL (Biological study)

(gene tetA for resistance to, leu-500 mutant promoter activity response to, in *Salmonella typhimurium*)

RN 60-54-8 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S,4aS,5aS,6S,12aS)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



CC 3-4 (Biochemical Genetics)
 IT 60-54-8, Tetracycline
 RL: BIOL (Biological study)
 (gene tetA for resistance to, leu-500 mutant promoter activity response
 to, in Salmonella typhimurium)

=> d his full

(FILE 'HOME' ENTERED AT 15:59:31 ON 11 APR 2007)

FILE 'REGISTRY' ENTERED AT 15:59:36 ON 11 APR 2007

L1 STRUCTURE UPLOADED
 L2 50 SEA SSS SAM L1
 L3 9270 SEA SSS FUL L1
 SAVE L3 MAKAR764/A TEMP

FILE 'HCAPLUS' ENTERED AT 16:01:05 ON 11 APR 2007

E US2003-692764/APPS
 L4 1 SEA ABB=ON PLU=ON US2003-692764/AP
 D SCAN
 SEL RN L4
 DELETE SELECT
 SEL RN L4
 D SCAN

FILE 'STNGUIDE' ENTERED AT 16:02:35 ON 11 APR 2007

FILE 'REGISTRY' ENTERED AT 16:14:02 ON 11 APR 2007

L5 STRUCTURE UPLOADED
 L6 5 SEA SUB=L3 SSS SAM L5
 L7 66 SEA SUB=L3 SSS FUL L5
 SAVE L7 MARKARSPECI/A TEMP

FILE 'STNGUIDE' ENTERED AT 16:14:54 ON 11 APR 2007

FILE 'REGISTRY' ENTERED AT 16:16:00 ON 11 APR 2007

L8 STRUCTURE UPLOADED
 L9 49 SEA SUB=L3 SSS SAM L8
 L10 1047 SEA SUB=L3 SSS FUL L8
 SAVE L10 MARKARTETRA/A TEMP

FILE 'HCAPLUS' ENTERED AT 16:17:11 ON 11 APR 2007

L11 18 SEA ABB=ON PLU=ON L7
 L12 14 SEA ABB=ON PLU=ON L11 AND (AY<2003 OR PY<2003 OR PRY<2003)
 L13 28687 SEA ABB=ON PLU=ON L10

FILE 'STNGUIDE' ENTERED AT 16:17:56 ON 11 APR 2007

FILE 'HCAPLUS' ENTERED AT 16:20:04 ON 11 APR 2007

L14 1 SEA ABB=ON PLU=ON L12 AND ((RNA OR RIBONUCLEIC ACID?) (L) (MODU
LAT?))
D HIT

L15 1 SEA ABB=ON PLU=ON L12 AND (RNA OR RIBONUCLEIC ACID?)

L16 1 SEA ABB=ON PLU=ON (L14 OR L15)

L17 14 SEA ABB=ON PLU=ON (L12 OR L16)

L18 15 SEA ABB=ON PLU=ON L7 (L) (THU OR PKT OR PAC OR BAC OR DMA)/RL

L19 13 SEA ABB=ON PLU=ON L18 AND (AY<2003 OR PY<2003 OR PRY<2003)

L20 14 SEA ABB=ON PLU=ON (L17 OR L19)
E RNA MODULATION/CT

L21 18 SEA ABB=ON PLU=ON L13 AND ((RNA OR RIBONUCLEIC ACID?) (L) (MODU
LAT?))
D HIT
D HIT 5

L22 7 SEA ABB=ON PLU=ON L21 AND (AY<2003 OR PY<2003 OR PRY<2003)

L23 7056 SEA ABB=ON PLU=ON L10 (L) (THU OR PKT OR PAC OR BAC OR
DMA)/RL

L24 166 SEA ABB=ON PLU=ON L23 AND (RNA OR RIBONUCLEIC ACID?)

L25 125 SEA ABB=ON PLU=ON L24 AND (AY<2003 OR PY<2003 OR PRY<2003)
D HIT
D HIT 5
D HIT 8
D HIT 50

FILE 'STNGUIDE' ENTERED AT 16:23:25 ON 11 APR 2007

FILE 'REGISTRY' ENTERED AT 16:29:48 ON 11 APR 2007

L26 STRUCTURE UPLOADED

L27 21 SEA SUB=L3 SSS SAM L26

L28 493 SEA SUB=L3 SSS FUL L26

FILE 'HCAPLUS' ENTERED AT 16:30:18 ON 11 APR 2007

L29 18962 SEA ABB=ON PLU=ON L28

L30 5922 SEA ABB=ON PLU=ON L28 (L) (THU OR PKT OR PAC OR BAC OR
DMA)/RL

L31 3 SEA ABB=ON PLU=ON L30 AND ((RNA OR RIBONUCLEIC ACID?) (L) (MODU
LAT?))
D HIT

L32 155 SEA ABB=ON PLU=ON L30 AND (RNA OR RIBONUCLEIC ACID?)

L33 116 SEA ABB=ON PLU=ON L32 AND (AY<2003 OR PY<2003 OR PRY<2003)

L34 7 SEA ABB=ON PLU=ON (L22 OR L31)

L35 22 SEA ABB=ON PLU=ON L33 AND (?DISEASE? OR ?DISORDER? OR
?INFECTION? OR ?DYSFUNCTION?)
D HIT
D HIT

L36 28 SEA ABB=ON PLU=ON (L34 OR L35)

L37 28 SEA ABB=ON PLU=ON (L36 OR L22)

FILE 'STNGUIDE' ENTERED AT 16:33:34 ON 11 APR 2007

FILE 'HCAPLUS' ENTERED AT 16:36:47 ON 11 APR 2007

E DTMR/CT

L38 5 SEA ABB=ON PLU=ON DTMR
D HIT
D HIT 2
D HIT 3
E NEURODEGENRATIVE DISEASES/CT
E E1+ALL

L39 9535 SEA ABB=ON PLU=ON "NERVOUS SYSTEM, DISEASE (L) DEGENERATION"+
 OLD/CT
 E NEURODEGENRATIVE DISEASES/CT
 E E2+ALL
 E VIRAL DISEASES/CT
 E HIV/CT
 E E3+ALL
 E E2+ALL
 L40 54794 SEA ABB=ON PLU=ON "HUMAN IMMUNODEFICIENCY VIRUS"+OLD,NT/CT
 E HIV/CT
 E E3+ALL
 E E3+ALL
 L41 44073 SEA ABB=ON PLU=ON "HUMAN IMMUNODEFICIENCY VIRUS 1"+OLD/CT
 E HIV/CT
 E E4+ALL
 E E2+ALL
 L42 20700 SEA ABB=ON PLU=ON "AIDS (DISEASE)"+OLD/CT
 E VEE VIRUS/CT
 E VEEVIRUS/CT
 E VEE-VIRUS/CT
 E VEE/CT
 E WEST NILE VIRUS/CT
 E E3+ALL
 L43 885 SEA ABB=ON PLU=ON "WEST NILE VIRUS"+OLD/CT
 E CAMEPLOX VIRUS/CT
 E POTATO LEAFROLL VI/CT
 E E4+ALL
 L44 271 SEA ABB=ON PLU=ON "POTATO LEAFROLL VIRUS"+OLD/CT
 E YELLOW VIRUS/CT
 E RATOON STUNTING DISEASE/CT
 E INCLUSION CONJUNCTIVITIS/CT
 E INFLUENZA VIRUS/CT
 E E3+ALL
 L45 13196 SEA ABB=ON PLU=ON "INFLUENZA VIRUS"+OLD,NT/CT
 E MANINGOPNUEM/CT
 E MENINGOPNEU/CT
 E E4+ALL
 E E2+ALL
 L46 5 SEA ABB=ON PLU=ON "INFECTION (L) MENINGOPNEUMONITIS"+OLD/CT
 E LUNG, DISEASE (L) MENINGOPNEUMONITIS/CT
 E E3+ALL
 L47 5 SEA ABB=ON PLU=ON "LUNG, DISEASE (L) MENINGOPNEUMONITIS"+OLD/
 CT
 E TRACHOMA VIRUS/CT
 E HOG PLAGUE/CT
 E ORNITHOSIS VIRUS/CT
 E RABIES VIRUS/CT
 E E3+ALL
 L48 1669 SEA ABB=ON PLU=ON "RABIES VIRUS"+OLD/CT
 L49 87393 SEA ABB=ON PLU=ON (L38 OR L39 OR L40 OR L41 OR L42 OR L43 OR
 L44 OR L45 OR L46 OR L47 OR L48)
 L50 25 SEA ABB=ON PLU=ON L33 AND (CANCER? OR TUMOR? OR TUMOUR? OR
 LEUKEMIA? OR SARCOMA? OR MYELOMA? OR MELANOMA? OR ASTHMA? OR
 ARTHRITIS? OR ANEMIA? OR ALZHEIMER? OR HUNTINGTON? OR OARTIC
 ANEURYSM? OR DIABETES? OR ISCHEMIA? OR HYPERLIPIDEMIA? OR
 OBESITY?)
 L51 10 SEA ABB=ON PLU=ON L33 AND L49
 L52 26 SEA ABB=ON PLU=ON (L50 OR L51)
 D HIT

D HIT 5

L53 39 SEA ABB=ON PLU=ON (L52 OR L37)

L54 6 SEA ABB=ON PLU=ON L20 AND (CANCER? OR TUMOR? OR TUMOUR? OR LEUKEMIA? OR SARCOMA? OR MYELOMA? OR MELANOMA? OR ASTHMA? OR ARTHRITIS? OR ANEMIA? OR ALZHEIMER? OR HUNTINGTON? OR OARTIC ANEURYSM? OR DIABETES? OR ISCHEMIA? OR HYPERLIPIDEMIA? OR OBESITY?)

L55 2 SEA ABB=ON PLU=ON L20 AND L49

L56 14 SEA ABB=ON PLU=ON (L54 OR L55 OR L20)

L57 9813 SEA ABB=ON PLU=ON L3 (L) (THU OR PKT OR PAC OR BAC OR DMA) /RL

L58 951 SEA ABB=ON PLU=ON L57 AND (CANCER? OR TUMOR? OR TUMOUR? OR LEUKEMIA? OR SARCOMA? OR MYELOMA? OR MELANOMA? OR ASTHMA? OR ARTHRITIS? OR ANEMIA? OR ALZHEIMER? OR HUNTINGTON? OR OARTIC ANEURYSM? OR DIABETES? OR ISCHEMIA? OR HYPERLIPIDEMIA? OR OBESITY?)

L59 155 SEA ABB=ON PLU=ON L57 AND L49

L60 93 SEA ABB=ON PLU=ON L58 AND L59

L61 57 SEA ABB=ON PLU=ON L60 AND (AY<2003 OR PY<2003 OR PRY<2003)

D HIT

D HIT 5

L62 100 SEA ABB=ON PLU=ON (L61 OR L56 OR L53)

L63 87 SEA ABB=ON PLU=ON (L53 OR L61)

L64 9 SEA ABB=ON PLU=ON L53 AND L61

L65 30 SEA ABB=ON PLU=ON L53 AND (AY<2002 OR PY<2002 OR PRY<2002)

L66 6 SEA ABB=ON PLU=ON L65 AND L61

L67 7 SEA ABB=ON PLU=ON L65 AND L49

L68 7 SEA ABB=ON PLU=ON (L66 OR L67)

L69 10 SEA ABB=ON PLU=ON (L64 OR L68)

L70 17 SEA ABB=ON PLU=ON (L34 OR L69)

L71 25 SEA ABB=ON PLU=ON L33 AND (CANCER? OR TUMOR? OR TUMOUR? OR LEUKEMIA? OR SARCOMA? OR MYELOMA? OR MELANOMA? OR ASTHMA? OR ARTHRITIS? OR ANEMIA? OR ALZHEIMER? OR HUNTINGTON? OR OARTIC ANEURYSM? OR DIABETES? OR ISCHEMIA? OR HYPERLIPIDEMIA? OR OBESITY?)

L72 10 SEA ABB=ON PLU=ON L33 AND L49

L73 26 SEA ABB=ON PLU=ON (L71 OR L72)

L74 33 SEA ABB=ON PLU=ON (L70 OR L73)

L75 39 SEA ABB=ON PLU=ON (L37 OR L22 OR L53)

L76 0 SEA ABB=ON PLU=ON L74 NOT L75

L77 6 SEA ABB=ON PLU=ON L75 NOT L74

D HIT

L78 6 SEA ABB=ON PLU=ON L77 AND RNA?

L79 33 SEA ABB=ON PLU=ON (L31 OR L34 OR L74)

L80 10 SEA ABB=ON PLU=ON L79 AND L49

L81 26 SEA ABB=ON PLU=ON L79 AND (CANCER? OR TUMOR? OR TUMOUR? OR LEUKEMIA? OR SARCOMA? OR MYELOMA? OR MELANOMA? OR ASTHMA? OR ARTHRITIS? OR ANEMIA? OR ALZHEIMER? OR HUNTINGTON? OR OARTIC ANEURYSM? OR DIABETES? OR ISCHEMIA? OR HYPERLIPIDEMIA? OR OBESITY?)

L82 27 SEA ABB=ON PLU=ON (L80 OR L81)

L83 33 SEA ABB=ON PLU=ON (L82 OR L31 OR L34)

E LEVY S/AU

L84 536 SEA ABB=ON PLU=ON ("LEVY S"/AU OR "LEVY S B"/AU OR "LEVY STUARD B"/AU OR "LEVY STUART"/AU OR "LEVY STUART B"/AU)

E DRAPER M/AU

L85 93 SEA ABB=ON PLU=ON ("DRAPER M"/AU OR "DRAPER M A"/AU OR "DRAPER M D"/AU OR "DRAPER M H"/AU OR "DRAPER M P"/AU OR "DRAPER M R"/AU OR "DRAPER M S"/AU OR "DRAPER M W"/AU OR "DRAPER MICHAEL"/AU OR "DRAPER MICHAEL D"/AU OR "DRAPER MICHAEL DAVID"/AU OR "DRAPER MICHAEL L"/AU OR "DRAPER MICHAEL

P"/AU OR "DRAPER MICHAEL PRESTON"/AU OR "DRAPER MICHAEL W"/AU
OR "DRAPER MICHAEL WILLIAM"/AU)
E NELSON M/AU

L86 282 SEA ABB=ON PLU=ON ("NELSON M"/AU OR "NELSON M L"/AU OR
"NELSON MARC"/AU OR "NELSON MARK"/AU OR "NELSON MARK L"/AU OR
"NELSON MARK LESLIE"/AU OR "NELSON MARK LOGE"/AU OR "NELSON
MARK LOUIS"/AU)
E JONES G/AU

L87 2640 SEA ABB=ON PLU=ON ("JONES FUNIYO ICHII"/AU OR "JONES FURMAN
M JR"/AU OR "JONES G"/AU OR "JONES G A"/AU OR "JONES G A C"/AU
OR "JONES G A D"/AU OR "JONES G ALEXANDER"/AU OR "JONES G
ALUN"/AU OR "JONES G ARNOLD"/AU OR "JONES G B"/AU OR "JONES G
C"/AU OR "JONES G C H"/AU OR "JONES G C JR"/AU OR "JONES G C
W"/AU OR "JONES G CARLETON"/AU OR "JONES G CECIL"/AU OR "JONES
G D"/AU OR "JONES G D D"/AU OR "JONES G D GLYNNE"/AU OR "JONES
G D O"/AU OR "JONES G DENYS GLYNNE"/AU OR "JONES G DOUGLAS"/AU
OR "JONES G E"/AU OR "JONES G E G"/AU OR "JONES G E JR"/AU OR
"JONES G E M"/AU OR "JONES G E S"/AU OR "JONES G E SEEGAR"/AU
OR "JONES G F"/AU OR "JONES G F C"/AU OR "JONES G G"/AU OR
"JONES G GARY"/AU OR "JONES G H"/AU OR "JONES G H G"/AU OR
"JONES G H GETHIN"/AU OR "JONES G H S"/AU OR "JONES G HOWARD"/A
U OR "JONES G I"/AU OR "JONES G I L"/AU OR "JONES G II"/AU OR
"JONES G IVOR"/AU OR "JONES G J"/AU OR "JONES G J L"/AU OR
"JONES G J R"/AU OR "JONES G JR"/AU OR "JONES G K"/AU OR
"JONES G KEMPSON"/AU OR "JONES G L"/AU OR "JONES G LL"/AU OR
"JONES G LLOYD"/AU OR "JONES G M"/AU OR "JONES G M D B"/AU OR
"JONES G M JR"/AU OR "JONES G M M"/AU OR "JONES G M T"/AU OR
"JONES G M THELWALL"/AU OR "JONES G MARK"/AU OR "JONES G
MARY"/AU OR "JONES G MELVILL"/AU OR "JONES G NELSON"/AU OR
"JONES G O"/AU OR "JONES G O L"/AU OR "JONES G P"/AU OR "JONES
G P D"/AU OR "JONES G P GLYNNE"/AU OR "JONES G PARRY"/AU OR
"JONES G PAUL"/AU OR "JONES G R"/AU OR "JONES G R D"/AU OR
"JONES G R F"/AU OR "JONES G R H"/AU OR "JONES G R JR"/AU OR
"JONES G R N"/AU OR "JONES G ROBERT N"/AU OR "JONES G S"/AU OR
"JONES G S JR"/AU OR "JONES G SANFORD"/AU OR "JONES G SCOTT"/AU
OR "JONES G T"/AU OR "JONES G V"/AU OR "JONES G W"/AU OR
"JONES G WENDELL"/AU)
E JONES GRAHAM/AU

L88 381 SEA ABB=ON PLU=ON ("JONES GRAHAM"/AU OR "JONES GRAHAM A"/AU
OR "JONES GRAHAM ALFRED"/AU OR "JONES GRAHAM ANTHONY"/AU OR
"JONES GRAHAM B"/AU OR "JONES GRAHAM C"/AU OR "JONES GRAHAM
D"/AU OR "JONES GRAHAM E"/AU OR "JONES GRAHAM ELGIN"/AU OR
"JONES GRAHAM H"/AU OR "JONES GRAHAM HARRIES"/AU OR "JONES
GRAHAM HOWARD"/AU OR "JONES GRAHAM HUGH"/AU OR "JONES GRAHAM
J"/AU OR "JONES GRAHAM K"/AU OR "JONES GRAHAM L"/AU OR "JONES
GRAHAM LLOYD"/AU OR "JONES GRAHAM LONGDEN"/AU OR "JONES GRAHAM
P"/AU OR "JONES GRAHAM PETER"/AU OR "JONES GRAHAM R"/AU OR
"JONES GRAHAM R D"/AU OR "JONES GRAHAM ROGER"/AU OR "JONES
GRAHAM ROSS DALLAS"/AU OR "JONES GRAHAM STEWART"/AU OR "JONES
GRAHAM TREVOR"/AU)

L89 3 SEA ABB=ON PLU=ON L84 AND L85 AND L86 AND (L87 OR L88)

L90 113 SEA ABB=ON PLU=ON (L84 OR L85 OR L86 OR L87 OR L88) AND L3

L91 94 SEA ABB=ON PLU=ON (L84 OR L85 OR L86 OR L87 OR L88) AND (L7
OR L10)

L92 3 SEA ABB=ON PLU=ON (L90 OR L91) AND L49

L93 11 SEA ABB=ON PLU=ON (L90 OR L91) AND (CANCER? OR TUMOR? OR
TUMOUR? OR LEUKEMIA? OR SARCOMA? OR MYELOMA? OR MELANOMA? OR
ASTHMA? OR ARTHRITIS? OR ANEMIA? OR ALZHEIMER? OR HUNTINGTON?
OR OARTIC ANEURYSM? OR DIABETES? OR ISCHEMIA? OR HYPERLIPIDEMIA
? OR OBESITY?)

10692764

L94 15 SEA ABB=ON PLU=ON (L89 OR L92 OR L93)
L95 6 SEA ABB=ON PLU=ON L94 NOT (L56 OR L83)

FILE 'HCAPLUS, MEDLINE, EMBASE, BIOSIS, WPIX' ENTERED AT 16:59:28 ON 11 APR 2007

L96 6383 SEA ABB=ON PLU=ON LEVY S?/AU
L97 480 SEA ABB=ON PLU=ON DRAPER M?/AU
L98 8358 SEA ABB=ON PLU=ON NELSON M?/AU
L99 16184 SEA ABB=ON PLU=ON JONES G?/AU
L100 7 SEA ABB=ON PLU=ON L96 AND L97 AND L98 AND L99
L101 544 SEA ABB=ON PLU=ON (L96 OR L97 OR L98 OR L99) AND TETRACYCL?
L102 536 SEA ABB=ON PLU=ON (L96 OR L97 OR L98 OR L99) AND TETRACYCLINE
?
L103 40 SEA ABB=ON PLU=ON L102 AND (RNA OR RIBONUCLEIC ACID?)
L104 43 SEA ABB=ON PLU=ON (L100 OR L103) AND (AY<2003 OR PY<2003 OR
PRY<2003)
L105 26 DUP REM L104 (17 DUPLICATES REMOVED)
ANSWERS '1-11' FROM FILE HCAPLUS
ANSWERS '12-15' FROM FILE MEDLINE
ANSWERS '16-18' FROM FILE EMBASE
ANSWERS '19-23' FROM FILE BIOSIS
ANSWERS '24-26' FROM FILE WPIX
L106 6 SEA ABB=ON PLU=ON L105 AND (CANCER? OR TUMOR? OR TUMOUR? OR
LEUKEMIA? OR SARCOMA? OR MYELOMA? OR MELANOMA? OR ASTHMA? OR
ARTHRITIS? OR ANEMIA? OR ALZHEIMER? OR HUNTINGTON? OR OARTIC
ANEURYSM? OR DIABETES? OR ISCHEMIA? OR HYPERLIPIDEMIA? OR
OBESITY? OR VIRUS?)
L107 9 SEA ABB=ON PLU=ON (L100 OR L106)

FILE 'STNGUIDE' ENTERED AT 17:03:12 ON 11 APR 2007

D QUE L95
D QUE L107

FILE 'HCAPLUS, BIOSIS, WPIX' ENTERED AT 17:03:22 ON 11 APR 2007

L108 12 DUP REM L95 L107 (3 DUPLICATES REMOVED)
ANSWERS '1-9' FROM FILE HCAPLUS
ANSWERS '10-11' FROM FILE BIOSIS
ANSWER '12' FROM FILE WPIX
D IBIB ABS RETABLE L108 TOT
D QUE L56
D IBIB ABS HITSTR HITIND RETABLE L56 TOT
D QUE L83

FILE 'HCAPLUS' ENTERED AT 17:04:45 ON 11 APR 2007

L109 32 SEA ABB=ON PLU=ON L83 NOT L56
D QUE L109
D IBIB ABS HITSTR HITIND RETABLE L109 TOT

FILE HOME

FILE REGISTRY

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 10 APR 2007 HIGHEST RN 929680-66-0
DICTIONARY FILE UPDATES: 10 APR 2007 HIGHEST RN 929680-66-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

FILE HCAPLUS

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 11 Apr 2007 VOL 146 ISS 16
FILE LAST UPDATED: 10 Apr 2007 (20070410/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE STNGUIDE
FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Apr 6, 2007 (20070406/UP).

FILE MEDLINE
FILE LAST UPDATED: 10 Apr 2007 (20070410/UP). FILE COVERS 1950 TO DATE.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE EMBASE
FILE COVERS 1974 TO 11 Apr 2007 (20070411/ED)

EMBASE is now updated daily. SDI frequency remains weekly (default) and biweekly.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE BIOSIS
FILE COVERS 1969 TO DATE.
CAS REGISTRY NUMBERS AND CHEMICAL NAMES (CNs) PRESENT
FROM JANUARY 1969 TO DATE.

RECORDS LAST ADDED: 4 April 2007 (20070404/ED)

FILE WPIX

10692764

FILE LAST UPDATED: 4 APR 2007 <20070404/UP>
MOST RECENT THOMSON SCIENTIFIC UPDATE: 200723 <200723/DW>
DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE

>>> New reloaded DWPI Learn File (LWPI) available as well <<<

>>> YOU ARE IN THE NEW AND ENHANCED DERWENT WORLD PATENTS INDEX <<<

>>> New display format FRAGHITSTR available <<<

SEE ONLINE NEWS and

http://www.stn-international.de/archive/stn_online_news/fraghitstr_ex.pdf

>>> IPC Reform backfile reclassification has been loaded to 31 December 2006. No update date (UP) has been created for the reclassified documents, but they can be identified by 20060101/UPIC and 20061231/UPIC. <<<

FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE,
PLEASE VISIT:

http://www.stn-international.de/training_center/patents/stn_guide.pdf

FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES, SEE

<http://scientific.thomson.com/support/patents/coverage/latestupdates/>

PLEASE BE AWARE OF THE NEW IPC REFORM IN 2006, SEE

http://www.stn-international.de/stndatabases/details/ipc_reform.html and

<http://scientific.thomson.com/media/scpdf/ipcrdwpi.pdf>

>>> FOR DETAILS ON THE NEW AND ENHANCED DERWENT WORLD PATENTS INDEX
PLEASE SEE

http://www.stn-international.de/stndatabases/details/dwpi_r.html <<<